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Cardiovascular disease (CVD) is the leading cause of morbidity and mortality in 
many countries around the world
1
. CVD is caused by disorders of the heart and the 
blood vessels. The most common types of CVD include coronary heart disease 
(CHD; affecting the heart), cerebrovascular disease (affecting the brain) and 
peripheral artery disease (affecting the limbs). Many CVD cases can be prevented 
by addressing unhealthy diets and lifestyles thereby managing cardiovascular risk 
factors such as raised blood lipids, blood pressure and blood glucose. Efforts should 
be undertaken to manage and reduce the risk of CVD. This thesis aims to advance 
insights in the role of phytosterols, lipid-like compounds found in foods of plant 
origin, in the management of blood lipid risk factors for CVD. 
 
Phytosterols 
Chemical structure and function 
Phytosterols have a chemical structure comparable to that of cholesterol
2,3
. Both 
compounds are characterized by having a steroid nucleus containing four 
cycloalkane rings, a 3β-hydroxyl group and an alkyl side chain (Figure 1). The 
difference in chemical structure between cholesterol and phytosterols is mainly 
due to the presence of a methyl or ethyl group at carbon atom 24. Small variations 
in the chemical structure (e.g. in the alkyl side chain and/or in the saturation rate) 
have led to the existence of more than 200 different phytosterols. The term 
phytosterols in fact encompasses both plant sterols and plant stanols. Plant stanols 
are the saturated forms of plant sterols, i.e., lacking a double bond in the steroid 
nucleus (Figure 1). The most abundant phytosterol is sitosterol
4
; other phytosterols 
include among others campesterol, stigmasterol, sitostanol and campestanol. 
Phytosterols esterified to fatty acids or other organic acids are called phytosterol 
esters. 
 
Phytosterols and cholesterol have several biological functions in common
5
 although 
in different hosts, i.e., phytosterols in plants and cholesterol in humans. Both 
compounds are important building blocks of cell membranes where they regulate 
membrane fluidity and permeability. Furthermore, they both play a role in cellular 
differentiation and proliferation and serve as precursors of hormones
2
. 
 
10 | Chapter 1 
 
 
Figure 1. Chemical structure of sterols. At the left, box A visualizes the steroid nucleus, box B 
the hydroxyl group at carbon 3 in the β-position, and box C the alkyl side chain. At the right, 
chemical structures of cholesterol, sitosterol and sitostanol are shown. 
 
Metabolism 
In the intestinal lumen, esterified forms of phytosterols and cholesterol are 
hydrolyzed into free sterols. These are then dissolved in mixed micelles before 
entering the intestinal cells via various mechanisms such as transportation by 
Niemann-Pick C1 like 1 (NPC1L1) proteins
6
. Once in the intestinal cells, phytosterols 
are actively excreted back into the intestinal lumen by the heterodimer ATP-
binding cassette (ABC) transporters ABCG5/8
7
, whereas this happens to a lesser 
degree with cholesterol. ABCG5/8 transporters located in the liver also excrete 
phytosterols, i.e., from the liver into the bile. Furthermore, phytosterols are a poor 
substrate for Acetyl-CoA acetyltransferase-2 (ACAT-2)
8
. ACAT-2 esterifies 
cholesterol and phytosterols in the intestinal cells before they are taken up by 
chylomicrons for distribution via the lymphatic system to the liver and into the 
blood. Particularly due to active excretion of phytosterols by the ABCG5/8 
transporters, absorption of phytosterols is much lower (<5% for plant sterols and 
<0.5% for plant stanols
9-11
) compared to absorption of cholesterol (30-80%)
10,12
. 
Moreover, in contrast to cholesterol, phytosterols cannot be synthesized in the 
human body. As such, circulating plant sterol concentrations in humans are ~250 
times lower compared to cholesterol concentrations
13
. Blood plant stanol 
concentrations are even lower, i.e., 10-50 times lower compared to plant sterol 
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concentrations
14
. Patients with homozygeous phytosterolemia, a rare genetic 
disorder, are an exception. In these patients, mutations in ABCG5/8 genes
7,15
 
hamper excretion of phytosterols from the body, resulting in severely elevated 
phytosterol concentrations in the blood
16
. 
 
Phytosterols are known to inhibit intestinal cholesterol absorption by 30-40%
17
, 
thereby reducing blood cholesterol concentrations. Cholesterol inhibition occurs 
through several hypothesized mechanisms such as competition with cholesterol for 
solubilization in dietary mixed micelles, interference with transport-mediated 
processes of cholesterol uptake, and stimulation of cholesterol excretion via the 
intestine
18-20
.  
 
Sources 
Phytosterols originate from the diet, i.e., from the lipid- and fiber-rich fractions of 
plant-based foods such as nuts, seeds, grains, fruits and vegetables
21-23
(Figure 2). 
Especially vegetable oils (e.g. corn oil) are rich sources of phytosterols
5
. Plant sterol 
intakes in the population generally range between 200 and 400 mg/d
24-27
. Only 
people with specific dietary habits such as vegetarians can reach higher plant sterol 
intakes of 500-1000 mg/d
28,29
, but such high intakes are exceptional. Intakes of 
naturally occurring plant stanols are much lower, i.e., 10-35 mg/d
24,30,31
. 
Phytosterols occur in the diet in both free and esterified forms. The composition of 
phytosterols varies among different sources
5
. 
 
Since the cholesterol-lowering properties of phytosterols were discovered in the 
1950s
32
, large doses of phytosterols in crystalline/powder form, particularly 
sitosterol, were used to treat hypercholesterolemic patients. Once it was 
discovered how phytosterols could be esterified with dietary fatty acids to enhance 
their lipid solubility, research was undertaken to investigate the cholesterol-
lowering effect of phytosterols incorporated in fat-based foods like mayonnaise
33
 
and margarine
34
. To date, a large range of phytosterol-enriched foods with 
established cholesterol-lowering properties are available on the market
35
. These 
enriched products contain considerably more phytosterols than natural food 
sources (Figure 2). 
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Figure 2. Phytosterol content of different dietary sources
21-23
. 
 
Summary 
Phytosterols encompass both plant sterols and plant stanols. They resemble 
cholesterol in molecular structure and they have similar biological functions in 
plants as cholesterol has in humans. Absorption and excretion processes of 
phytosterols are tightly regulated, resulting in very low phytosterol concentrations 
in the blood. Phytosterols lower blood cholesterol concentrations through inhibition 
of cholesterol absorption. Phytosterols originate from plant-based foods and from 
foods enriched with phytosterols. They cannot be produced by the human body. 
 
Phytosterols and blood lipids 
Cholesterol and triglycerides (TGs) are the main lipids circulating in the blood. They 
are carried by lipoproteins. Lipoproteins are biochemical structures that contain 
both proteins and lipids and that allow fats to move through water. Low-density 
lipoproteins (LDL) are lipoproteins that can deposit their fat content into artery 
walls, attract macrophages, and, consequently, promote the development of 
arterial plaques, a process leading to atherosclerosis.  
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Low-density lipoprotein cholesterol 
Elevated total cholesterol (TC), and especially LDL-cholesterol (LDL-C), is a major 
risk factor for CVD, in particular for CHD
36-38
. It has been estimated that elevated 
cholesterol resulted in 2.6 million deaths and 29.7 million disability-adjusted life 
years (DALYs), globally, in 2004
39
. According to the World Health Organization 
(WHO), around 40% of adults (>25 years) worldwide have raised TC concentrations 
(>5 mmol/L) ranging from ~20-30% in African and Asian countries up to ~50-60% in 
European and North- and South-American countries
1
. Future economic 
development, urbanization and nutritional transition will likely lead to further 
increases in cholesterol concentrations, particularly in developing countries
40
.  
 
Foods with added phytosterols lower TC and LDL-C concentrations in the blood
41-45
. 
The LDL-C-lowering effect of phytosterols appears to be dose-dependent; higher 
phytosterol doses result in larger reductions in LDL-C
46
. Initially, the dose-response 
effect for the LDL-C-lowering effect of phytosterols was investigated by calculating 
average changes in LDL-C for different categories of phytosterol doses
46
, so using a 
categorical and not a continuous approach. Because continuous analysis has the 
advantage that it allows predicting the LDL-C-lowering effect for any given dose of 
phytosterols within the range of doses investigated, we determined this continuous 
relationship by performing a meta-analysis including data from published 
intervention studies (Chapter 2). 
 
Both plant sterols and plant stanols lower LDL-C concentrations. Some data suggest 
that the maximal LDL-C-lowering effect of plant sterols (~8%) is reached already at 
doses of 1.0-1.5 g/d
47
, whereas plant stanols continue to reduce LDL-C up to 17% 
for doses as high as 9 g/d
48
. Evidence for this discrepancy is mainly based on data 
from continuous dose-response analysis
47
 that in some instances over- or 
underestimates the true effect at certain doses. In fact, a systematic review 
including studies that investigated the cholesterol-lowering efficacy of plant sterols 
and plant stanols under the same study conditions showed that plant sterols and 
plant stanols are equally efficacious in lowering LDL-C
49
. To further elucidate 
potential differences between plant sterols and plant stanols in their LDL-C-
lowering effect, we performed a meta-analysis and compared the LDL-C-lowering 
efficacy of plant sterols vs. plant stanols within different dose ranges (Chapter 3). 
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Triglycerides 
Elevated TG concentrations are also being considered to play a role in the onset of 
CVD
50,51
. According to the National Health and Nutrition Examination Survey 
(NHANES), around 30% of adults (>18 years) in the United States have above 
desirable (>1.7 mmol/L) TG concentrations
52,53
. This prevalence is expected to 
increase in the near future due to the increasing prevalence of physical inactivity 
and obesity. The relationship between elevated TG concentrations and occurrence 
of future CVD events is not as established as for LDL-C, and its independency of 
other risk factors (e.g. high-density lipoprotein (HDL)-cholesterol) remains 
controversial. Nevertheless, several health authorities such as the American Heart 
Association (AHA)
51
 and the European Atherosclerosis Society (EAS)
50
 do emphasize 
the importance of targeting elevated TGs. Especially for subjects at high risk of 
CVD, such as metabolic syndrome patients, it is recommended to lower TG 
concentrations in addition to lowering LDL-C. 
 
Reductions in fasting TG concentrations have incidentally been observed in studies 
with phytosterol-enriched foods
42,54
. These reductions are in general rather modest 
and variable, and therefore difficult to detect in studies that are primarily set up 
and statistically powered to investigate effects on LDL-C. For plant stanols, it has 
been reported that the baseline TG concentration determines the magnitude of 
their modest TG-lowering effect
55
. As there were no such data available for plant 
sterols, we conducted a pooled analysis to investigate the TG-lowering effect of 
plant sterols and the influence of baseline TG concentration on this effect (Chapter 
4). 
 
The omega-3 fish fatty acids eicosapentaenoic acid (EPA; C20:5n-3) and 
docosahexaenoic acid (DHA; C22:6n-3) can substantially lower TG concentrations
56-
58
. Most of the evidence for this effect is based on studies that used fish oil 
supplements with EPA+DHA doses >2 g/d and showed reductions in TG 
concentrations of around 25-35%
56,58
. Less is known about the TG-lowering effect 
of lower doses of EPA+DHA (<2 g/d), especially when these low doses of EPA+DHA 
are combined with plant sterols in a low-fat spread. In such spreads, the maximum 
amount of fish oil (as the source of EPA+DHA) that can be added is limited. The 
combination of EPA+DHA and plant sterols is expected to beneficially affect both 
LDL-C and TG concentrations. We performed a randomized controlled trial to 
investigate the dose-response relationship between low doses of EPA+DHA (<2 g/d) 
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and fasting TG concentrations when incorporated in a low-fat spread with added 
plant sterols while still finding a meaningful reduction in LDL-C (Chapter 5).  
 
Summary 
Foods with added phytosterols lower LDL-C, an important risk factor for CVD. So far, 
a continuous dose-response curve for this effect has not been established. Potential 
differences between plant sterols and plant stanols in their LDL-C-lowering effect 
have been suggested; this requires further research. It is not well known whether 
plant sterols can, like plant stanols, modestly lower fasting TG concentrations, 
another risk factor for CVD. High doses of the omega-3 fish fatty acids EPA and DHA 
substantially lower TG concentrations. Whether plant sterols together with 
EPA+DHA would lower both LDL-C and TG concentrations when low doses of fish oil 
(as the source of EPA+DHA) are incorporated in a low-fat, plant sterol-enriched 
spread, requires further investigation. 
 
Phytosterols and CVD risk 
Circulating phytosterol concentrations 
Phytosterols, so both plant sterols and plant stanols, are poorly absorbed after 
dietary intake
9-11
 mainly due to the activity of ABCG5/8 transporters that excrete 
phytosterols from the enterocytes into the intestinal lumen and from the liver into 
the bile. Nevertheless, when phytosterol intakes are increased (e.g. when 
consuming enriched foods), this is reflected in higher blood concentrations of these 
phytosterols. Concerns have been raised about increases in circulating 
phytosterols, particularly plant sterols. Homozygous phytosterolemic patients are 
characterized by extremely high plant sterol concentrations in their blood and 
often, but not always
59
, experience early onset of atherosclerosis
60,61
. Furthermore, 
some observational evidence suggests that modestly elevated blood plant sterol 
concentrations are associated with an increased CVD risk
62,63
, but data are 
conflicting
64
. The magnitude of the increase in circulating plant sterols after plant 
sterol-enriched food intake has so far not been systematically investigated. 
Therefore, we performed a meta-analysis to estimate the change in plant sterol 
concentrations after consumption of plant sterol-enriched foods, and to explore 
factors that influence this change (Chapter 6). 
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Cardiovascular endpoints 
To date, no randomized controlled studies have been performed on phytosterol 
intake and incidence of CVD. This type of research would provide the strongest 
evidence to substantiate a cardiovascular health benefit of phytosterols. However, 
an adequately powered endpoint study would require 36,000-76,000 
hypercholesterolemic individuals with an expected annual CVD risk level of 3% and 
long-term follow-up (6-10 years)
65
. Performing such an endpoint study is hardly 
feasible. Observational studies may help clarifying whether intake of phytosterols is 
related to incidence of CVD, and specifically CHD, at population level. Only a few 
observational studies have so far been performed and provide data on intake of 
phytosterols from natural sources, i.e., not on intake of phytosterol-enriched foods. 
Overall, these studies show that people with higher dietary phytosterol intakes 
have lower concentrations of LDL-C
30,66,67
, and tend to have a lower risk of 
myocardial infarction (MI)
68
. More prospective research is required to further 
elucidate the relation between phytosterol intakes and (cholesterol-mediated) 
reductions in cardiovascular risk. We, therefore, performed a prospective analysis 
to investigate the association between intake of naturally occurring phytosterols, 
blood lipids, and incidence of fatal and non-fatal cardiovascular events in a large 
cohort of Dutch adults (Chapter 7). 
 
Summary 
Intake of foods with added phytosterols increases blood phytosterol concentrations. 
Some observational evidence suggests that circulating plant sterols might be 
atherogenic. The magnitude of the increase in blood plant sterol concentrations 
after intake of foods with added plant sterols has so far not been systematically 
investigated. Clinical trials on phytosterol intake and incidence of CVD are lacking. 
More observational research is required to investigate relations between dietary 
phytosterols and cardiovascular risk in the population. 
 
Overall aim of the thesis 
This thesis aims to advance insights in the role of phytosterols in the management 
of blood lipid risk factors for CVD. The studies described here address the effects of 
phytosterols from enriched foods on LDL-C, TGs and blood plant sterol 
concentrations (Figure 3). In addition, the effect of different low doses of omega-3 
fish fatty acids incorporated in a plant sterol-enriched spread on blood lipids was 
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investigated (Figure 3). The association between intake of naturally occurring 
phytosterols and CVD risk was also investigated (Figure 3). This thesis includes data 
from four meta-analyses (Chapters 2, 3, 4 and 6), a randomized controlled 
intervention study (Chapter 5) and an epidemiological study (Chapter 7). 
 
 
Figure 3. Schematic overview of the relations between phytosterols, blood lipid risk factors 
and cardiovascular risk, addressed in this thesis.  
 
References 
 (1)  World Health Organization. Global status report on noncommunicable diseases 2010.  2011.  
 (2)  Moreau RA, Whitaker BD, Hicks KB. Phytosterols, phytostanols, and their conjugates in foods: 
structural diversity, quantitative analysis, and health-promoting uses. Progress in Lipid 
Research 2002;41:457-500. 
 (3)  Trautwein EA, Duchateau GSMJ. Chapter 10. Phytosterols: Sources and metabolism. In: Awad 
AB, Bradford PG, editors. Nutrition and Cancer Prevention.Buffalo: CRC Press Taylor & Francis 
Group LLC, Boca Raton, FL; 2006. 
 (4)  Weihrauch JL, Gardner JM. Sterol content of foods of plant origin. Journal of the American 
Dietetic Association 1978;73:39-47. 
 (5)  Piironen V, Lindsay DG, Miettinen TA et al. Plant sterols: biosynthesis, biological function and 
their importance to human nutrition. Journal of the Science of Food and Agriculture 
2000;80:939-966. 
 (6)  Davis HR, Zhu LJ, Hoos LM et al. Niemann-Pick C1 like 1 (NPC1L1) is the intestinal phytosterol 
and cholesterol transporter and a key modulator of whole-body cholesterol homeostasis. 
Journal of Biological Chemistry 2004;279:33586-33592. 
18 | Chapter 1 
 
 
 (7)  Berge KE, Tian H, Graf GA et al. Accumulation of dietary cholesterol in sitosterolemia caused 
by mutations in adjacent ABC transporters. Science 2000;290:1771-1775. 
 (8)  Field FJ, Mathur SN. Beta-sitosterol: esterification by intestinal acylcoenzyme A: cholesterol 
acyltransferase (ACAT) and its effect on cholesterol esterification. Journal of Lipid Research 
1983;24:409-417. 
 (9)  Ostlund RE, McGill JB, Zeng CM et al. Gastrointestinal absorption and plasma kinetics of soy 
Delta(5)-phytosterols and phytostanols in humans. Amercian Journal of Physiology - 
Endocrinology and Metabolism 2002;282:E911-E916. 
 (10)  Salen G, Ahrens EH, Jr., Grundy SM. Metabolism of beta-sitosterol in man. The Journal of 
Clinical Investigation 1970;49:952-967. 
 (11)  Gould RG, Jones RJ, LeRoy GV et al. Absorbability of beta-sitosterol in humans. Metabolism 
1969;18:652-662. 
 (12)  Bosner MS, Lange LG, Stenson WF et al. Percent cholesterol absorption in normal women and 
men quantified with dual stable isotopic tracers and negative ion mass spectrometry. Journal 
of Lipid Research 1999;40:302-308. 
 (13)  Chan YM, Varady KA, Lin Y et al. Plasma concentrations of plant sterols: Physiology and 
relationship with coronary heart disease. Nutrition Reviews 2006;64:385-402. 
 (14)  Gylling H, Miettinen TA. The effect of plant stanol ester in different subject groups. European 
Cardiology 2010;6:18-21. 
 (15)  Lee MH, Lu K, Hazard S et al. Identification of a gene, ABCG5, important in the regulation of 
dietary cholesterol absorption. Nature Genetics 2001;27:79-83. 
 (16)  Salen G, Shefer S, Nguyen L et al. Sitosterolemia. Journal of Lipid Research 1992;33:945-955. 
 (17)  Normen L, Frohlich JJ, Trautwein E. Role of plant sterols in cholesterol lowering. In: Dutta PC, 
editor. Phytosterols as functional foods components and nutraceuticals. 2003. p. 243-315. 
 (18)  Trautwein EA, Duchateau GSMJ, Lin Y et al. Proposed mechanisms of cholesterol-lowering 
action of plant sterols . European Journal of Lipid Science and Technology 2003;105:171-185. 
 (19)  Calpe-Berdiel L, Escola-Gil JC, Blanco-Vaca F. New insights into the molecular actions of plant 
sterols and stanols in cholesterol metabolism. Atherosclerosis 2009;203:18-31. 
 (20)  de Smet E, Mensink RP, Plat J. Effects of plant sterols and stanols on intestinal cholesterol 
metabolism: suggested mechanisms from past to present. Molecular Nutrition & Food 
Research 2012;56:1058-1072. 
 (21)  Normen L, Ellegard L, Brants HA et al. A phytosterol database: Fatty foods consumed in 
Sweden and the Netherlands. Journal of Food Composition and Analysis 2007;20:193-201. 
 (22)  Normen L, Johnsson M, Andersson HA et al. Plant sterols in vegetables and fruits commonly 
consumed in Sweden. European Journal of Nutrition 1999;38:84-89. 
 (23)  Normen L, Bryngelsson S, Johnsson M et al. The phytosterol content of some cereal foods 
commonly consumed in Sweden and in the Netherlands. Journal of Food Composition and 
Analysis 2002;15:693-704. 
 (24)  Klingberg S, Andersson HA, Mulligan A et al. Food sources of plant sterols in the EPIC Norfolk 
population. European Journal of Clinical Nutrition 2008;62:695-703. 
 (25)  Escurriol V, Mari-Dell'Olmo M, Rohlfs I et al. Plant sterol intake and education level in the 
Spanish EPIC cohort. Nutrition 2009;25:769-773. 
 (26)  Sioen I, Matthys C, Huybrechts I et al. Consumption of plant sterols in Belgium: estimated 
intakes and sources of naturally occurring plant sterols and beta-carotene. British Journal of 
Nutrition 2011;105:960-966. 
General introduction | 19 
 
 (27)  Jimenez-Escrig A, Santos-Hidalgo AB, Saura-Calixto F. Common sources and estimated intake 
of plant sterols in the Spanish diet. Journal of Agricultural and Food Chemistry 2006;54:3462-
3471. 
 (28)  Vuoristo M, Miettinen TA. Absorption, metabolism, and serum concentrations of cholesterol 
in vegetarians - Effects of cholesterol feeding. American Journal of Clinical Nutrition 
1994;59:1325-1331. 
 (29)  Jenkins DJ, Kendall CW, Popovich DG et al. Effect of a very-high-fiber vegetable, fruit, and nut 
diet on serum lipids and colonic function. Metabolism 2001;50:494-503. 
 (30)  Wang P, Chen YM, He LP et al. Association of natural intake of dietary plant sterols with 
carotid intima-media thickness and blood lipids in Chinese adults: a cross-section study. PLoS 
One 2012;7:e32736. 
 (31)  Normen AL, Brants HA, Voorrips LE et al. Plant sterol intakes and colorectal cancer risk in the 
Netherlands Cohort Study on Diet and Cancer. American Journal of Clinical Nutrition 
2001;74:141-148. 
 (32)  Pollak OJ. Reduction of blood cholesterol in man. Circulation 1953;7:702-706. 
 (33)  Vanhanen HT, Blomqvist S, Ehnholm C et al. Serum cholesterol, cholesterol precursors, and 
plant sterols in hypercholesterolemic subjects with different apoE phenotypes during dietary 
sitostanol ester treatment. Journal of Lipid Research 1993;34:1535-1544. 
 (34)  Miettinen TA, Puska P, Gylling H et al. Reduction of serum cholesterol with sitostanol-ester 
margarine in a mildly hypercholesterolemic population. New England Journal of Medicine 
1995;333:1308-1312. 
 (35)  Willems JI, Blommaert MA, Trautwein EA. Results from a post-launch monitoring survey on 
consumer purchases of foods with added phytosterols in five European countries. Food and 
Chemical Toxicology 2013. 
 (36)  Stone NJ, Robinson J, Lichtenstein AH et al. 2013 ACC/AHA Guideline on the treatment of 
blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: A report of the 
American College of Cardiology/American Heart Association Task Force on Practice 
Guidelines. Circulation 2013. 
 (37)  Reiner Z, Catapano AL, De BG et al. ESC/EAS Guidelines for the management of 
dyslipidaemias: the Task Force for the management of dyslipidaemias of the European 
Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). European Heart 
Journal 2011;32:1769-1818. 
 (38)  Ezzati M, Lopez AD, Rodgers A et al. Selected major risk factors and global and regional 
burden of disease. Lancet 2002;360:1347-1360. 
 (39)  World Health Organization. Global health risks - Mortality and burden of disease attributable 
to selected major risks.  2009.  
 (40)  Farzadfar F, Finucane MM, Danaei G et al. National, regional, and global trends in serum total 
cholesterol since 1980: systematic analysis of health examination surveys and 
epidemiological studies with 321 country-years and 3.0 million participants. Lancet 
2011;377:578-586. 
 (41)  Weststrate JA, Meijer GW. Plant sterol-enriched margarines and reduction of plasma total- 
and LDL-cholesterol concentrations in normocholesterolaemic and mildly 
hypercholesterolaemic subjects. European Journal of Clinical Nutrition 1998;52:334-343. 
 (42)  Clifton PM, Mano M, Duchateau GSMJ et al. Dose-response effects of different plant sterol 
sources in fat spreads on serum lipids and C-reactive protein and on the kinetic behavior of 
serum plant sterols. European Journal of Clinical Nutrition 2008;62:968-977. 
20 | Chapter 1 
 
 
 (43)  de Jong A, Plat J, Lutjohann D et al. Effects of long-term plant sterol or stanol ester 
consumption on lipid and lipoprotein metabolism in subjects on statin treatment. British 
Journal of Nutrition 2008;100:937-941. 
 (44)  Hendriks HFJ, Weststrate JA, Van Vliet T et al. Spreads enriched with three different levels of 
vegetable oil sterols and the degree of cholesterol lowering in normocholesterolaemic and 
mildly hypercholesterolaemic subjects. European Journal of Clinical Nutrition 1999;53:319-
327. 
 (45)  Plat J, Van Onselen EN, Van Heugten MMA et al. Effects on serum lipids, lipoproteins and fat 
soluble antioxidant concentrations of consumption frequency of margarines and shortenings 
enriched with plant stanol esters. European Journal of Clinical Nutrition 2000;54:671-677. 
 (46)  Katan MB, Grundy SM, Jones P et al. Efficacy and safety of plant stanols and sterols in the 
management of blood cholesterol levels. Mayo Clinic Proceedings 2003;78:965-978. 
 (47)  Musa-Veloso K, Poon TH, Elliot JA et al. A comparison of the LDL-cholesterol lowering efficacy 
of plant stanols and plant sterols over a continuous dose range: Results of a meta-analysis of 
randomized, placebo-controlled trials. Prostaglandins Leukotrienes and Essential Fatty Acids 
2011;85:9-28. 
 (48)  Mensink RP, de Jong A, Lutjohann D et al. Plant stanols dose-dependently decrease LDL-
cholesterol concentrations, but not cholesterol-standardized fat-soluble antioxidant 
concentrations, at intakes up to 9 g/d. American Journal of Clinical Nutrition 2010;92:24-33. 
 (49)  Talati R, Sobieraj DM, Makanji SS et al. The comparative efficacy of plant sterols and stanols 
on serum lipids: A systematic review and meta-analysis. Journal of the American Dietetic 
Association 2010;110:719-726. 
 (50)  Chapman MJ, Ginsberg HN, Amarenco P et al. Triglyceride-rich lipoproteins and high-density 
lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and 
guidance for management. European Heart Journal 2011;32:1345-1361. 
 (51)  Miller M, Stone NJ, Ballantyne C et al. Triglycerides and cardiovascular disease: a scientific 
statement from the American Heart Association. Circulation 2011;123:2292-2333. 
 (52)  Carroll MD, Lacher DA, Sorlie PD et al. Trends in serum lipids and lipoproteins of adults, 1960-
2002. The Journal of the American Medical Association 2005;294:1773-1781. 
 (53)  Ford ES, Li C, Zhao G et al. Hypertriglyceridemia and its pharmacologic treatment among US 
adults. Archives of Internal Medicine 2009;169:572-578. 
 (54)  Plat J, Brufau G, linga-Thie GM et al. A plant stanol yogurt drink alone or combined with a 
low-dose statin lowers serum triacylglycerol and non-HDL cholesterol in metabolic syndrome 
patients. Journal of Nutrition 2009;139:1143-1149. 
 (55)  Naumann E, Plat J, Kesler AD et al. The baseline serum lipoprotein profile is related to plant 
stanol induced changes in serum lipoprotein cholesterol and triacylglycerol concentrations. 
Journal of the American College of Nutrition 2008;27:117-126. 
 (56)  Harris WS. n-3 fatty acids and serum lipoproteins: human studies. American Journal of 
Clinical Nutrition 1997;65:1645S-1654S. 
 (57)  Eslick GD, Howe PR, Smith C et al. Benefits of fish oil supplementation in hyperlipidemia: a 
systematic review and meta-analysis. International Journal of Cardiology 2009;136:4-16. 
 (58)  Balk EM, Lichtenstein AH, Chung M et al. Effects of omega-3 fatty acids on serum markers of 
cardiovascular disease risk: a systematic review. Atherosclerosis 2006;189:19-30. 
 (59)  Hansel B, Carrie A, Brun-Druc N et al. Premature atherosclerosis is not systematic in 
phytosterolemic patients: Severe hypercholesterolemia as a confounding factor in five 
subjects. Atherosclerosis 2014;234:162-168. 
General introduction | 21 
 
 (60)  Sudhop T, Von Bergmann K. Sitosterolemia - a rare disease. Are elevated plant sterols an 
additional risk factor? Zeitschrift fur Kardiologie 2004;93:921-928. 
 (61)  Jessup W, Herman A, Chapman MJ. Phytosterols in cardiovascular disease: innocuous dietary 
components, or accelerators of atherosclerosis? Future Lipidology 2008;3:301-310. 
 (62)  Assmann G, Cullen P, Erbey JR et al. Plasma sitosterol elevations are associated with an 
increased incidence of coronary events in men: results of a nested case-control analysis of 
the Prospective Cardiovascular Munster (PROCAM) study. Nutrition Metabolism and 
Cardiovascular Diseases 2006;16:13-21. 
 (63)  Sudhop T, Gottwald BM, Von Bergmann K. Serum plant sterols as a potential risk factor for 
coronary heart disease. Metabolism 2002;51:1519-1521. 
 (64)  Genser B, Silbernagel G, De Backer G et al. Plant sterols and cardiovascular disease: a 
systematic review and meta-analysis. European Heart Journal 2012;33:444-451. 
 (65)  Gylling H, Plat J, Turley S et al. Plant sterols and plant stanols in the management of 
dyslipidaemia and prevention of cardiovascular disease. Atherosclerosis 2014;232:346-360. 
 (66)  Klingberg S, Ellegard L, Johansson I et al. Inverse relation between dietary intake of naturally 
occurring plant sterols and serum cholesterol in northern Sweden. American Journal of 
Clinical Nutrition 2008;87:993-1001. 
 (67)  Andersson SW, Skinner J, Ellegard L et al. Intake of dietary plant sterols is inversely related to 
serum cholesterol concentration in men and women in the EPIC Norfolk population: a cross-
sectional study. European Journal of Clinical Nutrition 2004;58:1378-1385. 
 (68)  Klingberg S, Ellegard L, Johansson I et al. Dietary intake of naturally occurring plant sterols is 
related to a lower risk of a first myocardial infarction in men but not in women in northern 
Sweden. Journal of Nutrition 2013;143:1630-1635. 
 
  
  
 
 
 
 
 
 
 
 
 
 
Chapter 2 
 
Continuous dose-response relationship of the LDL-
cholesterol-lowering effect of phytosterol intake 
 
Isabelle Demonty 
Rouyanne T. Ras 
Henk C. M. van der Knaap 
Guus S. M. J. E. Duchateau 
Linsie Meijer 
Peter L. Zock 
Johanna M. Geleijnse 
Elke A. Trautwein 
 
Journal of Nutrition 2009; 139: 271-284 
  
 
  
Continuous dose-response relationship between phytosterols and LDL-cholesterol | 25 
 
Abstract 
Phytosterols (plant sterols and stanols) are well known for their low-density 
lipoprotein cholesterol (LDL-C)-lowering effect. A meta-analysis of randomized 
controlled trials in adults was performed to establish a continuous dose-response 
relationship that would allow predicting the LDL-C-lowering efficacy of different 
phytosterol doses. Eighty-four trials including 141 trial arms were included. A 
nonlinear equation comprising 2 parameters (the maximal LDL-C lowering and an 
incremental dose step) was used to describe the dose-response curve. The overall 
pooled absolute (mmol/L) and relative (%) LDL-C-lowering effects of phytosterols 
were also assessed with a random effects model. The pooled LDL-C reduction was 
0.34 mmol/L (95% CI:-0.36; -0.31) or 8.8% (95% CI: -9.4; -8.3) for a mean daily dose 
of 2.15 g phytosterols. The impacts of subject baseline characteristics, food 
formats, type of phytosterols, and study quality on the continuous dose-response 
curve were determined by regression or subgroup analyses. Higher baseline LDL-C 
concentrations resulted in greater absolute LDL-C reductions. No significant 
differences were found between dose-response curves established for plant sterols 
vs. stanols, fat-based vs. non fat-based food formats and dairy vs. nondairy foods. A 
larger effect was observed with solid foods than with liquid foods only at high 
phytosterol doses (>2 g/d). There was a strong tendency (P = 0.054) towards a 
slightly lower efficacy of single vs. multiple daily intakes of phytosterols. In 
conclusion, the dose-dependent LDL-C-lowering efficacy of phytosterols 
incorporated in various food formats was confirmed and equations of the 
continuous relationship were established to predict the effect of a given 
phytosterol dose. Further investigations are warranted to investigate the impact of 
solid vs. liquid food formats and frequency of intake on phytosterol efficacy. 
 
Introduction 
Elevated plasma total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-
C) are a major risk factor for coronary heart disease (CHD). Phytosterols (plant 
sterols and stanols) are among the dietary options available to lower elevated 
plasma TC and LDL-C concentrations. The cholesterol-lowering properties of 
phytosterols were observed in humans already in the early 1950s
1
. Since then, a 
vast number of human trials have shown that phytosterols, mainly in the form of 
plant sterols or stanols esterified to vegetable oil fatty acids (mainly C18), 
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significantly lower TC and LDL-C when incorporated into various food products
2,3
. 
The most recent meta-analysis including 41 trials with mainly fat-based foods like 
spreads, margarine, mayonnaise, or salad dressings enriched with phytosterol 
esters has shown a nonlinear dose-response relationship between the daily dose of 
phytosterols consumed and their cholesterol-lowering efficacy
3
. On average, 2 g/d 
phytosterols (the equivalent dose expressed as free sterols based on 3.3 g/d 
phytosterol esters) lowered LDL-C concentrations by ~10%
3
. The effect appeared to 
taper off at intakes of ~2 g/d or more, with little additional benefit at intakes higher 
than 2.5 g/d. As a consequence, several dietary recommendations now include the 
daily consumption of 2 g of phytosterols as an additional dietary option to lower 
elevated LDL-C concentrations
4-7
. The main mechanism of action responsible for 
the cholesterol-lowering effect of phytosterols is the inhibition of intestinal 
cholesterol absorption
8
. The recommended daily intake of 2 g of phytosterols 
reduces cholesterol absorption by 30-40%
3,9
. 
 
To date, additional evidence for the cholesterol-lowering efficacy of esterified or 
free phytosterols incorporated in a wide variety of food formats, including low-fat 
or fat-free foods such as milk
10-12
, yogurt
10,11,13-16
, fruit or vegetable juices
17-19
, and 
single daily dose food formats such as yogurt drinks
13,16,20-24
, has become available. 
Although some of these trials suggested that phytosterols incorporated in these 
food formats lower LDL-C to an extent similar to that observed with fat-based food 
formats, the impact of food format on the LDL-C-lowering efficacy had not been 
systematically evaluated. In addition, the most recent meta-analysis
3
 pooled 
together trials in which different phytosterol doses were used and the cholesterol-
lowering efficacy was reported for ranges of doses (0.7-1.1, 1.5-1.9, 2.0-2.4, ≥2.5 
g/d). Using this approach, it was not possible to predict the cholesterol-lowering 
effect for a given dose of phytosterols. 
 
The main objective of the present systematic review with meta-analysis was to 
establish a continuous dose-response relationship that would allow predicting the 
LDL-C-lowering efficacy of different phytosterol doses using an equation that would 
take into account the saturable nature of the cholesterol absorption process
25
. 
Another objective was to evaluate the impact of different treatment characteristics 
such as phytosterol type (plant sterols vs. stanols) and the impact of food format 
(fat-based vs. non fat-based, dairy vs. non-dairy, and liquid vs. solid food formats) 
on the dose-response curve. As part of the investigation of heterogeneity between 
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trials, the effect of subject characteristics (age, BMI, gender, baseline LDL-C 
concentrations) and study quality was also evaluated. Finally, because the total- 
over high-density lipoprotein cholesterol (TC:HDL-C) ratio is a strong predictor of 
CHD mortality
26
 and is affected, but not solely, by changes in LDL-C concentrations, 
we attempted to determine the dose-response effect of phytosterol intake on this 
ratio. 
 
Methods 
Search strategy 
Five databases (MEDLINE, Cab Abstracts, Biological Abstracts, Web of Science, and 
the Cochrane Library) were searched in July 2007 for articles on phytosterols, with 
no specification for date of publication. The Medical Subject Headings (terms) 
phytosterols, lipids, and cholesterol were used, as well as the following search 
terms: (plant sterol* or plant stanol* or phytosterol* or phytostanol* or sitosterol* 
or sitostanol* or campesterol* or campestanol* or stigmasterol* or 
brassicasterol*) and (cholesterol* or blood lipid* or LDL cholesterol* or HDL 
cholesterol* or triglyceride*), limited to human and clinical trials whenever 
possible. There was no language restriction.  
 
Inclusion and exclusion criteria 
A first selection was made by screening the title and abstract of the publications 
based on the inclusion criteria (Table 1). Because the cholesterol-lowering effect of 
phytosterols is additive to that of statins
27,28
 or ‘‘heart healthy’’ diets (low in total, 
saturated fat, and cholesterol content)
29-32
, they were not considered as a co-
intervention as long as they were present in both the control and the treatment 
groups/phases. The use of a vegetable oil-rich diet as background diet was not 
considered as co-intervention as long as the background diet was the same in all 
treatment groups/phases. Because most phytosterol esters result from the 
esterification of phytosterols to vegetable oil fatty acids, the use of vegetable oil 
fatty acid esters of phytosterols was not considered as a co-intervention. However, 
the use of novel, non-vegetable esters of phytosterols such as fish oil fatty acid 
esters was considered as a co-intervention, because fish oil fatty acids may have a 
moderate impact on LDL-C
33-35
. This could not be distinguished from the usual 
phytosterol or phytosterol ester effect and it was not known whether this effect 
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was additive to that of phytosterols or whether some interactions could exist 
between fish oil fatty acids and phytosterols. 
 
After the full publications were read, trials were excluded based on the exclusion 
criteria (Table 1). Ferulated phytosterols were excluded, because these 
phytosterols are not commonly used for food/supplement enrichment and there is 
no consensus on whether they have a cholesterol-lowering effect
36,37
. Although 
phytosterols are thought to exert their mechanism of action in the upper 
gastrointestinal tract
8
, colectomized patients were excluded, because the 
possibility that colectomy could have consequences in the upper tract could not be 
completely discarded. 
 
Table 1. Inclusion and exclusion criteria used to select the clinical trials. 
Inclusion criteria used when screening titles and abstracts 
1) Randomized controlled trial within human adults (parallel-arm or cross-over trials) 
2) Treatment with “usual” phytosterols, where “usual phytosterols” was defined as 4-desmethylsterols 
and/or 4-desmethylstanols extracted from vegetable or plant oils such as soybean oil, rapeseed oil 
and tall oil 
3) Blood lipids as primary or secondary outcomes 
4) Absence of a co-intervention from which consumption of phytosterol-enriched foods or supplements 
could not be isolated 
Exclusion criteria used when reading the full publications 
1) Not a randomized controlled trial 
2) Relevant blood lipid data missing 
3) Phytosterols consumed for less than 2 weeks 
4) Phytosterol dose higher than 10 g/d 
5) Control group did not receive a placebo 
6) Ferulated phytosterols such as rice bran oil and shea nut oil sterols were used 
7) Colectomized patients were part of the study 
 
Data extraction 
The data were independently extracted by 2 investigators (R.R. and L.M.) using a 
custom-made database. Codings were defined for the descriptive variables to 
ensure consistency in recording. In case of discrepancy or indecisiveness, 
consensus was reached by verbal discussion among the authors. We collected the 
following data: 1) study identification (author, publication year, country); 2) study 
design (parallel-arm or cross-over); 3) subject characteristics (number of subjects, 
gender, age, BMI, body weight, health status, ethnicity); 4) background diet (free 
living conditions or diet provided by the investigators, typical or “healthy” diet); 5) 
treatment characteristics [phytosterol dose, phytosterol type (plant sterols or 
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stanols), phytosterol esterification (in free form or esterified), source of 
phytosterols, source of fatty acids used for esterification, food format, intake 
occasion (with or without a meal), frequency of intake (number of portions during 
the day), and treatment duration]; 6) blood lipid outcomes (LDL-C, HDL-C, and TC); 
7) variance measures for these outcomes; and 8) study quality. When required, the 
original authors were contacted to obtain missing information. 
 
Quality assessment 
Trial quality was assessed using a custom-designed tool (Supplemental Appendix 1) 
adapted from the Delphi Consensus
38
 and the method by Chalmers et al.
39
. 
Consensus was reached among the authors for the inclusion of the following 
criteria in the tool due to their high potential to affect the estimate of the 
treatment effect: random sequence generation, blinding of the subjects, blinding of 
the investigators, eligibility criteria specified, compliance, and carryover effects 
taken care of in case of cross-over trials. For each study or trial arm, the overall 
quality score was calculated by adding the individual criteria scores. The maximal 
quality score that could be ascribed to a parallel trial was 7. Parallel trials deserving 
less than 5.5 points were classified as low quality trials, while trials given 5.5 points 
or more were judged to be of good quality. In case of cross-over trials, the maximal 
quality score was 8; trials given 6.0 points or less were considered of low quality, 
and those provided more than 6.0 points were classified as being of good quality. 
 
The quality scores were not used to exclude lower quality trials from the meta-
analysis or to weigh the trials, because there is no consensus on which scoring 
system is the best and hence the use of such a system, which is intrinsically 
subjective, could have biased the outcome of the meta-analysis
40
. The quality 
scores were used only for performing subgroup analyses to determine whether the 
overall quality as well as 2 major quality criteria (randomization and compliance) 
considered separately could affect the dose-response curves. 
 
Statistical analysis 
The main outcome variable was the absolute net change (mmol/L) in LDL-C due to 
the phytosterol treatment. When the outcome variable was measured at various 
time points during the intervention, the value corresponding to or closest to the 4-
week time point was taken for the analysis. The absolute net change in LDL-C was 
calculated according to the formulas described in Supplemental Appendix 2. When 
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only relative outcomes were provided in the publications, they were first converted 
to absolute outcomes using, as the 100% value, the baseline lipid value of the 
corresponding group for parallel trials and the endpoint lipid value of the control 
phase for cross-over trials. Absolute changes in the TC:HDL-C ratio were also 
estimated. Because not all publications reported the ratio, it was calculated from 
the reported means of TC and HDL-C.  
 
The results of the meta-analysis were also expressed in terms of relative (%) change 
in LDL-C. When relative net changes were reported, these values were collected. 
For trials in which relative net changes were not reported, the relative changes 
were calculated as described in Supplemental Appendix 2.  
 
The within-trial variance measures for the absolute net changes in LDL-C were 
obtained as standard errors (SE) or derived from SD or 100(1-α) % CI. To derive SE 
from SD and CI, we used the equations described (Supplemental Appendix 2). If 
not provided, the within-trial variance measures of the absolute net changes were 
estimated according to the equations provided in Supplemental Appendix 2.  
 
Pooled estimates of the absolute LDL-C-lowering effect of phytosterols and of the 
LDL-C concentration at baseline were calculated using a random-effects model 
according to the method described by DerSimonian and Laird
41
 using the inverse of 
the variance (1/SE
2
) as weighing factor. A similar weighing factor was used for 
calculating the pooled estimate of the relative LDL-C-lowering effect. Heterogeneity 
between studies was assessed by calculating the DerSimonian and Laird Q 
statistic
41,42
 and by looking at the funnel plot in which weights (1/SE
2
) had been 
plotted against the absolute net changes in LDL-C
43
. The funnel plot symmetry was 
examined as an indicator for absence of potential publication bias. The absence of 
publication bias was also verified with a probability plot of the ranked changes in 
LDL-C plotted against the normal deviates.  
 
The dose-response curve was determined using the PROC NLIN function of the SAS 
System (SAS version 8.2, SAS Institute). As a model for the dose-response curve, we 
used a first-order elimination curve frequently used in pharmacokinetics
44
. The 
choice of this equation was based on the assumption that the cholesterol-lowering 
effect of phytosterols would reach a plateau with increasing doses due to the 
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saturable nature of the processes involved in cholesterol transport and 
absorption
25
: 
                        , 
where D = maximal reduction in LDL-C concentration and K = LDL-C reduction rate. 
We re-parameterized this equation into: 
                                
     
 
     
 ) 
in order to obtain the maximal LDL-C reduction that can be achieved at high 
phytosterol doses (parameter a) and the incremental dose step needed to achieve 
an additional effect, which is one-half the size of the previous dose effect 
(parameter b). Both parameters were estimated using a non-linear, unweighted 
regression analysis.  
 
When using data from studies in which different phytosterol treatments were 
administered, we conducted comparisons with a single placebo. Some correlations 
existed between strata belonging to the same study, but these correlations were 
not taken into account, because they should not have affected the overall (pooled) 
reduction in LDL-C but only the error variation of the pooled estimate. In addition, 
the potential effect of inter-trial correlations on the dose-response curve was 
expected to be minimal due to the large number of trials included in the meta-
regression. To verify whether the nonlinear regression fitted better with the 
observed relative LDL-C changes than a simple linear relationship (without a 
maximal reduction estimate), we performed a post hoc analysis to compare the 
sum of the residuals between the observed and predicted LDL-C changes obtained 
with the curve vs. a linear fit crossing the y axis at 0.  
 
To explore possible causes of heterogeneity between trials, predefined covariate 
analyses were performed with the dose-response curve. The predefined 
continuous covariates were baseline age, BMI, LDL-C concentrations and gender, 
and the categorical covariates were phytosterol type (plant sterols vs. stanols), 
food format (fat-based vs. non fat-based foods, dairy vs. non-dairy foods, solid vs. 
liquid foods), and study quality (low vs. good study quality, well vs. poorly 
randomized strata, and high vs. low compliance strata). We performed post hoc 
analyses to evaluate the impact of study design (cross-over vs. parallel) on the 
dose-response curve as well as the impact of the inclusion of trials in which 
phytosterol doses >5 g/d were used. The criteria used for classification of the strata 
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within different categories of treatment or study characteristics are provided 
(Supplemental Appendix 3). For the continuous covariates, residuals (differences 
between predicted LDL-C changes and observed LDL-C changes) were plotted 
against the covariates and PROC GLM was used to examine the correlation 
between the covariates and the residuals. For the categorical covariates, dose-
response curves were established for the different subgroups and the differences 
in the parameters describing the curves were evaluated. P ≤ 0.05 was considered 
significant. All analyses were performed with the SAS System.  
 
Results 
Overview of trials 
A total of 601 articles were identified from the search strategy. Of these, only 165 
met the inclusion criteria based on title and abstract content. After full papers were 
read for the 2
nd
 selection step, 71 articles were excluded based on the exclusion 
criteria. Ten other articles were excluded because only abstracts could be obtained 
(n = 2) or the data presented were the same as in previous publications (n = 8), 
resulting in the inclusion in the meta-analysis of 84 trials/publications comprising 
141 strata (phytosterol treatment vs. control) (Figure 1); 73 strata were from 
parallel design studies (Table 2) and 68 were from cross-over design studies (Table 
3).  
 
 
Figure 1. Flow diagram of the trial selection procedure starting with 601 trials and ending 
with 84 randomized controlled trials (RCT), including 141 strata with a phytosterol treatment.  
 
RCTs included in the 
meta-analysis
Trials n=84
Strata n=141
Trials excluded due to following reasons:
 Not a RCT (n=25)
 Inappropriate blood lipid data (n=17)
 Treatment duration < 2 weeks (n=4)
 Phytosterol intake > 10 g/day (n=4)
 Use of ferulated phytosterols (n=2)
 Non-placebo-control group (n=17)
 Colectomized patients (n=2)
 Only abstract available (n=2)
 Same data as in prior reports (n=8)
Trials excluded due to following reasons:
 Not a RCT (n=257)
 Not in humans (n=49)
 Children (n=18) 
 No phytosterol treatment (n=56)
 No blood lipids reported (n=34)
 Intentional co-intervention (n=22)
Potentially relevant trials
retrieved in 5 databases 
using search strategies
Trials n=601
Potentially relevant 
RCTs after first selection 
Trials n=165
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A total of 6805 participants were included in the trials. Most of the strata included 
European and North American participants who were apparently healthy 
regardless of baseline lipid levels. Mean age ranged from 22.7 to 66.0 y and mean 
BMI and body weight at baseline ranged from 22.0 to 31.0 kg/m
2
 and 63.0 to 88.3 
kg, respectively. Body weight did not change significantly during the intervention 
except in 9 strata, which reported small (<2 kg) but significant body weight 
changes. Baseline LDL-C concentrations were reported in 123 strata, with a pooled 
overall LDL-C concentration at baseline of 3.86 mmol/L (95% CI: 3.77; 3.98). Most 
strata included both men and women (Supplemental Appendix 4).  
 
The mean phytosterol dose given to the study participants was 2.15 g/d (range 
0.45-9.00 g/d), for a duration ranging from 21 to 182 d (Supplemental Appendix 4). 
Plant sterols were used in 74 strata and plant stanols in 53 strata; in 14 cases, a 
combination of plant sterols and stanols was used. Plant sterols and stanols were 
provided in their esterified form in most cases, except in 39 strata in which free 
plant sterols or stanols were directly dispersed or mixed in the food products. 
Phytosterols were incorporated in fat-based foods in ~65% of the strata (n = 91) 
and in foods with a lower fat content in ~35% of the strata (n = 50). In 26 strata, 
phytosterols were provided in dairy food formats. Liquid food formats were used in 
23 strata. In most strata, phytosterols were consumed in multiple daily intakes (n = 
87), at all 3 meals (n = 37), or at various combinations of 2 meals (n = 20). When 
consumed once a day (n = 14 strata), phytosterols were ingested at breakfast (n = 7 
strata), lunch (n = 5 strata), or dinner (n = 2 strata). Subjects were allowed to 
maintain their usual dietary pattern in the majority (n = 98) of strata. Overall study 
quality was good for 68 of 141 strata and low for the remaining 73 strata 
(Supplemental Appendix 4).  
 
Between-trial heterogeneity as assessed by the Q-statistic was significant (351.1, P 
<0.001 and 242583.1, P <0.001 for the absolute and relative changes in LDL-C, 
respectively). Visual inspection of the funnel plots (Figure 2) as well as the 
probability plot of the ranked changes in LDL-C (not shown) suggested the absence 
of publication bias.  
 
34 | Chapter 2  
 
Ta
b
le
 2
. O
ve
rv
ie
w
 o
f 
th
e 
p
a
ra
lle
l-
a
rm
 d
es
ig
n
 s
tr
a
ta
 in
cl
u
d
ed
 in
 t
h
e 
m
et
a
-a
n
a
ly
si
s 
O
ve
ra
ll 
q
u
al
it
y 
sc
o
re
c  
 -d
 
6.
5 
(g
o
o
d
) 
6.
5 
(g
o
o
d
) 
5.
0 
(l
o
w
) 
5.
0 
(l
o
w
) 
5.
0 
(l
o
w
) 
5.
0 
(l
o
w
) 
6.
5 
(g
o
o
d
))
 
6.
5 
(g
o
o
d
) 
5.
5 
(g
o
o
d
) 
5.
5 
(g
o
o
d
) 
5.
5 
(g
o
o
d
) 
5.
0 
(l
o
w
) 
5.
0 
(l
o
w
) 
5.
0 
(l
o
w
) 
6.
5 
(g
o
o
d
) 
6.
5 
(g
o
o
d
) 
6.
5
 (
go
o
d
) 
B
lo
o
d
 li
p
id
 o
u
tc
o
m
e
s 
LD
L-
C
 
95
%
 C
I 
m
m
o
l/
L (
-0
.6
6 
-0
.0
1)
 
(-
1.
03
  -
0.
27
) 
(-
0.
61
  0
.0
3)
 
(-
0.
77
  -
0.
39
) 
(-
0.
57
  -
0.
08
) 
(-
0.
61
  -
0.
14
) 
(-
0.
82
  -
0.
33
) 
(-
0.
52
  -
0.
21
) 
(-
0.
54
  -
0.
12
) 
(-
0.
63
  -
0.
15
) 
(-
0.
67
  -
0.
23
) 
(-
0.
55
  -
0.
11
) 
(-
0.
47
  0
.1
8)
 
(-
0.
42
  0
.1
6)
 
(-
0.
73
  -
0.
09
) 
(-
0.
81
  -
0.
41
) 
(-
0.
57
  0
.0
1)
 
(-
0.
78
  -
0.
08
) 
N
et
 
ch
an
ge
b
 
-0
.3
4
 
-0
.6
5
 
-0
.2
9
 
-0
.5
8
 
-0
.3
3
 
-0
.3
8
 
-0
.5
7
 
-0
.3
6
 
-0
.3
3
 
-0
.3
9
 
-0
.4
5
 
-0
.3
3
 
-0
.1
4
 
-0
.1
3
 
-0
.4
1
 
-0
.6
1
 
-0
.2
8
 
-0
.4
3
 
M
ea
n
 
b
as
el
in
e
 
4
.0
6
 
3
.3
1
 
4
.6
8
 
3
.1
8
 
4
.1
3
 
4
.1
6
 
4
.1
4
 
3
.8
0
 
3
.3
5
 
4
.3
5
 
4.
2
0
 
4
.3
9
 
3
.4
0
 
3
.3
6
 
3
.3
7
 
4
.7
0
 
3
.5
7
 
3
.4
4
 
                      
Tr
ea
tm
e
n
t 
ch
ar
ac
te
ri
st
ic
s 
D
o
se
 
p
h
yt
o
-
st
er
o
ls
a  
g
/d
 
1
.2
 
3.
0
 
1
.9
 
8
.6
 
0
.9
 
1
.8
 
3
.6
 
2
.9
 
3
.4
 
1
.6
 
1
.6
 
1
.6
 
3.
0
 
6.
0
 
9.
0
 
1
.8
 
2
.5
 
2
.5
 
D
u
ra
-
ti
o
n
 
d
 
21
 
28
 
56
 
24
 
26
 
26
 
26
 
28
 
42
 
21
 
21
 
21
 
28
 
28
 
28
 
28
 
11
2
 
11
2
 
Es
te
r 
o
r 
 
fr
ee
 
 
es
te
r 
es
te
r 
es
te
r 
es
te
r 
fr
e
e 
fr
e
e 
fr
e
e 
es
te
r 
es
te
r 
es
te
r 
es
te
r 
es
te
r 
es
te
r 
es
te
r 
es
te
r 
fr
e
e 
es
te
r 
es
te
r 
St
er
o
ls
  
o
r 
 s
ta
n
o
ls
 
 
st
an
o
ls
 
st
an
o
ls
 
st
an
o
ls
 
st
er
o
ls
 
m
ix
 
m
ix
 
m
ix
 
st
an
o
ls
 
st
an
o
ls
 
st
er
o
ls
 
st
er
o
ls
 
st
er
o
ls
 
st
er
o
ls
 
st
er
o
ls
 
st
er
o
ls
 
m
ix
 
st
er
o
ls
 
st
an
o
ls
 
Fo
o
d
 f
o
rm
a
t 
 
yo
gu
rt
 d
ri
n
k 
m
ar
ga
ri
n
e
 
m
ar
ga
ri
n
e
 
m
ar
ga
ri
n
e
 
lo
w
-f
at
 m
ilk
 
lo
w
-f
at
 m
ilk
 
lo
w
-f
at
 m
ilk
 
m
ar
ga
ri
n
e
 
m
ay
o
n
n
ai
se
 
m
ar
ga
ri
n
e
 
m
ar
ga
ri
n
e
 
m
ar
ga
ri
n
e
 
sp
re
ad
 /
 s
al
ad
 d
re
ss
in
g 
sp
re
ad
 /
 s
al
ad
 d
re
ss
in
g 
sp
re
ad
 /
 s
al
ad
 d
re
ss
in
g 
ch
o
co
la
te
 
m
ar
ga
ri
n
e
 
m
ar
ga
ri
n
e
 
                      
Su
b
je
ct
 c
h
ar
ac
te
ri
st
ic
s 
M
al
e
 
%
 
5
9
.4
 
5
3
.8
 
4
5
.9
 
50
.0
 
- - - 
5
9
.9
 
7
0
.1
 
5
6
.6
 
4
8
.7
 
56
.0
 
5
2
.4
 
50
.0
 
5
4
.5
 
4
8
.4
 
4
6
.2
 
4
6
.2
 
M
ea
n
 
B
M
I 
kg
/m
2  
26
.0
 
26
.6
 
25
.1
 
24
.0
 
27
.5
 
27
.3
 
27
.6
 
28
.5
 
25
.5
 
26
.8
 
26
.9
 
26
.7
 
- - - 
25
.4
 
26
.8
 
27
.0
 
M
ea
n
 
a
ge
 
y 
42
.0
 
52
.7
 
55
.1
 
36
.0
 
54
.8
 
56
.4
 
53
.3
 
56
.0
 
45
.5
 
55
.2
 
54
.5
 
54
.2
 
45
.1
 
47
.3
 
46
.1
 
57
.0
 
58
.1
 
58
.3
 
Sa
m
p
le
 s
iz
e
 
Tr
ea
t-
m
e
n
t 
 
17
 
17
 
19
 
10
 
33
 
33
 
33
 
83
 
34
 
37
 
39
 
36
 
21
 
19
 
23
 
31
 
15
 
15
 
C
o
n
-
tr
o
l 
 15
 
9 21
 
11
 
33
 
33
 
33
 
84
 
33
 
39
 
39
 
39
 
21
 
21
 
21
 
31
 
11
 
11
 
A
u
th
o
r,
 p
u
b
lic
at
io
n
 y
e
ar
, 
 
an
d
 r
ef
er
en
ce
 
 A
lg
o
rt
a 
P
in
ed
a 
et
 a
l. 
20
05
2
1
 
A
lh
as
sa
n
 e
t 
al
. 2
00
6
4
5
 
A
n
d
er
ss
o
n
 e
t 
al
. 1
9
99
4
6
 
A
ye
sh
 e
t 
al
. 1
9
99
4
7
 
B
ee
r 
et
 a
l. 
20
00
4
8
 s
tr
at
u
m
 1
e
 
B
ee
r 
et
 a
l. 
20
00
4
8
 s
tr
at
u
m
 2
 
B
ee
r 
et
 a
l. 
20
00
4
8
 s
tr
at
u
m
 3
 
B
la
ir
 e
t 
al
. 2
00
0
4
9
 
B
lo
m
q
vi
st
 e
t 
al
. 1
9
93
5
0
 
C
lif
to
n
 e
t 
al
. 2
0
08
5
1
 s
tr
at
u
m
 1
 
C
lif
to
n
 e
t 
al
. 2
0
08
5
1
 s
tr
at
u
m
 2
 
C
lif
to
n
 e
t 
al
. 2
0
08
5
1
 s
tr
at
u
m
 3
 
D
av
id
so
n
 e
t 
al
. 2
00
1
5
2
  s
tr
at
u
m
 1
 
D
av
id
so
n
 e
t 
al
. 2
00
1
5
2
  s
tr
at
u
m
 2
 
D
av
id
so
n
 e
t 
al
. 2
00
1
5
2
  s
tr
at
u
m
 3
 
d
e 
G
ra
af
 e
t 
al
. 2
00
2
5
3
 
d
e 
Jo
n
g 
et
 a
l. 
20
08
5
4
 s
tr
at
u
m
 1
 
d
e 
Jo
n
g 
et
 a
l. 
20
08
5
4
 s
tr
at
u
m
 2
 
 
Continuous dose-response relationship between phytosterols and LDL-cholesterol | 35 
 
Ta
b
le
 2
. C
o
n
ti
n
u
ed
 
O
ve
ra
ll 
q
u
al
it
y 
sc
o
re
c  
 
5.
5 
(g
o
o
d
) 
5.
5 
(g
o
o
d
) 
5.
5 
(g
o
o
d
) 
6.
5 
(g
o
o
d
) 
6.
5 
(g
o
o
d
) 
6.
5 
(g
o
o
d
) 
6.
5 
(g
o
o
d
) 
6.
5 
(g
o
o
d
) 
- d
 
- d
 
3.
0 
(l
o
w
) 
3.
0 
(l
o
w
) 
5.
0 
(l
o
w
) 
2.
0 
(l
o
w
) 
2.
0 
(l
o
w
) 
2.
0 
(l
o
w
) 
2.
0 
(l
o
w
) 
B
lo
o
d
 li
p
id
 o
u
tc
o
m
e
s 
LD
L-
C
 
95
%
 C
I 
m
m
o
l/
L (
-0
.6
2 
 -
0.
26
) 
(-
0.
19
  0
.3
5)
 
(-
0.
49
  -
0.
25
) 
(-
0.
69
  -
0.
13
) 
(-
0.
58
  -
0.
05
) 
(-
0.
96
  -
0.
26
) 
(-
0.
71
  0
.0
1)
 
(-
0.
45
  -
0.
19
) 
(-
0.
41
  -
0.
08
) 
(-
0.
46
  -
0.
18
) 
(-
0.
49
  -
0.
19
) 
(-
0.
44
  -
0.
08
) 
(-
0.
43
  -
0.
06
) 
(-
0.
54
  -
0.
20
) 
(-
0.
57
  -
0.
1
3
) 
(-
0.
69
  -
0.
16
) 
(-
0.
53
  0
.0
3)
 
N
et
 
ch
an
ge
b
 
-0
.4
4
 
0.
08
 
-0
.3
7
 
-0
.4
1
 
-0
.3
2
 
-0
.6
1
 
-0
.3
5
 
-0
.3
2
 
-0
.2
5
 
-0
.3
2
 
-0
.3
4
 
-0
.2
6
 
-0
.2
4
 
-0
.3
7
 
-0
.3
5
 
-0
.4
2
 
-0
.2
5
 
M
ea
n
 
b
as
el
in
e
 
3
.7
2
 
3
.7
2
 
3
.9
0
 
4
.2
7
 
2
.8
9
 
4
.5
4
 
4
.2
5
 
4
.0
9
 
3
.6
8
 
3
.7
0
 
3
.9
6
 
3
.9
6
 
3
.0
8
 
4
.0
1
 
4
.0
1
 
3
.8
3
 
3
.9
0
 
                     
Tr
ea
tm
e
n
t 
ch
ar
ac
te
ri
st
ic
s 
D
o
se
 
p
h
yt
o
-
st
er
o
ls
a  
g
/d
 
2.
0
 
2.
0
 
2
.8
 
1
.5
6
 
1
.8
 
2
.3
1
 
2
.1
6
 
1
.6
 
0
.8
 
1
.6
 
2.
0
 
3.
0
 
2.
0
 
2.
0
 
3.
0
 
2.
0
 
3.
0
 
D
u
ra
-
ti
o
n
 
d
 
56
 
28
 
28
 
84
 
42
 
56
 
56
 
42
 
28
 
28
 
28
 
28
 
28
 
28
 
28
 
28
 
28
 
Es
te
r 
 
o
r 
 
fr
ee
 
 
fr
e
e 
fr
e
e 
es
te
r 
es
te
r 
fr
e
e 
es
te
r 
es
te
r 
es
te
r 
fr
e
e 
fr
e
e 
es
te
r 
es
te
r 
es
te
r 
es
te
r 
es
te
r 
es
te
r 
es
te
r 
St
er
o
ls
 
o
r 
st
an
o
ls
 
 
st
er
o
ls
 
st
er
o
ls
 
st
er
o
ls
 
st
er
o
ls
 
st
an
o
ls
 
st
an
o
ls
 
st
an
o
ls
 
st
er
o
ls
 
st
er
o
ls
 
st
er
o
ls
 
st
an
o
ls
 
st
an
o
ls
 
st
an
o
ls
 
st
an
o
ls
 
st
an
o
ls
 
st
an
o
ls
 
st
an
o
ls
 
Fo
o
d
 f
o
rm
a
t 
 
o
ra
n
ge
 ju
ic
e
 
o
ra
n
ge
 ju
ic
e
 
lo
w
-f
at
 y
o
gu
rt
 d
ri
n
k 
ca
p
su
le
s 
ta
b
le
ts
 
m
ar
ga
ri
n
e
 
m
ar
ga
ri
n
e
 
lo
w
-f
at
 f
er
m
en
te
d
 m
ilk
 
ve
ge
ta
b
le
 ju
ic
e
 
ve
ge
ta
b
le
 ju
ic
e
 
m
ar
ga
ri
n
e
 
m
ar
ga
ri
n
e
 
yo
gu
rt
 
m
ar
ga
ri
n
e
 
m
ar
ga
ri
n
e
 
m
ar
ga
ri
n
e
 
m
ar
ga
ri
n
e
 
                     
Su
b
je
ct
 c
h
ar
ac
te
ri
st
ic
s 
M
al
e
 
%
 
4
0
.3
 
4
3
.1
 
44
.0
 
5
3
.7
 
3
4
.6
 
40
.0
 
3
2
.4
 
67
.0
 
5
0
.5
 
4
7
.6
 
3
3
.3
 
38
.0
 
51
.0
 
2
2
.5
 
2
9
.5
 
6
1
.9
 
5
8
.8
 
M
ea
n
 
B
M
I 
kg
/m
2  
2
5
.5
 
2
4
.5
 
2
5
.2
 
2
6
.3
 
2
7
.2
 
2
5
.6
 
2
4
.9
 
2
3
.6
 
2
3
.9
 
24
.0
 
2
3
.5
 
24
.0
 
2
2
.6
 
2
3
.5
 
24
.0
 
23
.0
 
2
3
.4
 
M
e
an
 
a
ge
 
y 
42
.5
 
46
.0
 
56
.8
 
50
.5
 
59
.5
 
44
.6
 
43
.2
 
48
.9
 
43
.7
 
43
.2
 
46
.5
 
47
.5
 
28
.7
 
48
.2
 
47
.8
 
42
.6
 
44
.6
 
Sa
m
p
le
 s
iz
e
 
Tr
e
at
-
m
e
n
t 
 
36
 
36
 
38
 
25
 
13
 
18
 
20
 
95
 
50
 
54
 
33
 
34
 
23
 
21
 
25
 
10
 
6
 
C
o
n
-
tr
o
l 
 
36
 
36
 
33
 
29
 
13
 
17
 
17
 
99
 
51
 
51
 
34
 
34
 
28
 
19
 
19
 
11
 
11
 
A
u
th
o
r,
 p
u
b
lic
at
io
n
 y
ea
r,
  
an
d
 r
ef
er
e
n
ce
 
 D
ev
ar
aj
 e
t 
al
. 2
0
04
1
7
 
D
ev
er
aj
 e
t 
al
. 2
0
06
1
8
 
D
o
o
rn
b
o
s 
et
 a
l. 
2
00
6
2
0
 
Ea
rn
es
t 
et
 a
l. 
2
00
7
5
5
 
G
o
ld
b
er
g 
et
 a
l. 
20
06
5
6
 
H
al
lik
ai
n
e
n
 &
 U
u
si
tu
p
a 
19
99
3
2
  s
tr
at
u
m
 1
 
H
al
lik
ai
n
e
n
 &
 U
u
si
tu
p
a 
19
99
3
2
  s
tr
at
u
m
 2
 
H
an
se
l e
t 
al
. 2
0
07
2
4
 
H
ir
o
n
ak
a 
et
 a
l. 
20
06
1
9
 s
tr
at
u
m
 1
 
H
ir
o
n
ak
a 
et
 a
l. 
20
06
1
9
 s
tr
at
u
m
 2
 
H
o
m
m
a 
et
 a
l. 
2
00
3
5
7
 s
tr
at
u
m
 1
 
H
o
m
m
a 
et
 a
l. 
2
00
3
5
7
 s
tr
at
u
m
 2
 
H
yu
n
 e
t 
al
. 2
0
0
5
1
3
 
Is
h
iw
at
a 
et
 a
l. 
20
02
5
8
  s
tu
d
y 
1
f  s
tr
at
u
m
 1
 
Is
h
iw
at
a 
et
 a
l. 
20
02
5
8
  s
tu
d
y 
1 
st
ra
tu
m
 2
 
Is
h
iw
at
a 
et
 a
l. 
20
02
5
8
  s
tu
d
y 
2 
st
ra
tu
m
 1
 
Is
h
iw
at
a 
et
 a
l. 
20
02
5
8
  s
tu
d
y 
2 
st
ra
tu
m
 2
 
 
36 | Chapter 2  
 
Ta
b
le
 2
. C
o
n
ti
n
u
ed
 
O
ve
ra
ll 
q
u
al
it
y 
sc
o
re
c  
 
6.
5 
(g
o
o
d
) 
7.
0 
(g
o
o
d
) 
5.
0 
(l
o
w
) 
5.
0 
(l
o
w
) 
5.
0 
(l
o
w
) 
6.
5 
(h
ig
h
) 
5.
0 
(l
o
w
) 
6.
5 
(g
o
o
d
) 
6.
5 
(g
o
o
d
) 
4.
5 
(l
o
w
) 
4.
5 
(l
o
w
) 
- d
 
7.
0 
(g
o
o
d
) 
5.
0 
(l
o
w
) 
5.
0 
(l
o
w
) 
5.
5 
(g
o
o
d
) 
6.
5 
(g
o
o
d
) 
6.
5 
(g
o
o
d
) 
6.
5 
(g
o
o
d
) 
5.
5 
(g
o
o
d
) 
5.
5 
(g
o
o
d
) 
B
lo
o
d
 li
p
id
 o
u
tc
o
m
e
s 
LD
L-
C
 
95
%
 C
I 
m
m
o
l/
L 
(-
0.
53
  -
0.
18
) 
(-
1.
22
  -
0.
06
) 
(-
0.
58
  -
0.
06
) 
(-
0.
71
  -
0.
21
) 
(-
0.
80
  -
0.
32
) 
(-
0.
46
  0
.0
6)
 
(-
0.
61
  -
0.
11
) 
(-
0.
32
  0
.0
2)
 
(-
0.
35
  0
.0
0)
 
(-
0.
45
  -
0.
17
) 
(-
0.
48
  -
0.
17
) 
(-
0.
23
  0
.2
5)
 
(-
0.
84
  -
0.
26
) 
(-
0.
55
  -
0.
08
) 
(-
0.
39
  0
.1
2)
 
(-
0.
53
  -
0.
26
) 
(-
0.
56
  0
.0
4)
 
(-
0.
43
  0
.2
1)
 
(-
0.
55
  -
0.
01
) 
(-
0.
62
  -
0.
26
) 
(-
0.
70
  -
0.
34
) 
N
et
 
ch
an
ge
b
 
-0
.3
6
 
-0
.6
4
 
-0
.3
2
 
-0
.4
6
 
-0
.5
6
 
-0
.2
 
-0
.3
6
 
-0
.1
5
 
-0
.1
7
 
-0
.3
1
 
-0
.3
3
 
0
.0
1
 
-0
.5
5
 
-0
.3
2
 
-0
.1
3
 
-0
.4
 
-0
.2
6
 
-0
.1
1
 
-0
.2
8
 
-0
.4
4
 
-0
.5
2
 
M
ea
n
 
b
as
el
in
e
 
3
.5
8
 
4
.4
5
 
4
.1
0
 
4
.1
0
 
4
.1
0
 
3
.4
0
 
4
.3
3
 
3
.2
2
 
3
.0
8
 
4
.0
8
 
4
.0
3
 
3
.7
8
 
4
.1
0
 
3
.0
3
 
3
.5
0
 
2
.9
2
 
4
.0
9
 
3
.7
3
 
3
.3
9
 
3
.9
6
 
4
.1
4
 
                         
Tr
ea
tm
e
n
t 
ch
ar
ac
te
ri
st
ic
s 
D
o
se
 
p
h
yt
o
-
st
er
o
ls
a  
g
/d
 
2.
0
 
1
.7
 
1
.6
5
 
2.
0
 
2.
0
 
2.
0
 
1
.6
 
1
.5
 
2
.3
 
1
.1
 
2
.2
 
0
.8
 
2
.7
 
1
.2
6
 
1
.0
1
 
3.
0
 
1.
0
 
1
.0
4
 
1
.2
2
 
2
.6
.0
 
2
.6
.0
 
D
u
ra
-
ti
o
n
 
d
 
35
 
30
 
42
 
42
 
42
 
21
 
28
 
35
 
35
 
30
 
30
 
28
 
28
 
42
 
42
 
28
 
63
 
63
 
63
 
18
2
 
18
2
 
Es
te
r 
 
o
r 
 
fr
ee
 
 
es
te
r 
fr
e
e 
fr
e
e 
fr
e
e 
fr
e
e 
es
te
r 
es
te
r 
es
te
r 
es
te
r 
es
te
r 
es
te
r 
fr
e
e 
es
te
r 
fr
e
e 
fr
e
e 
es
te
r 
fr
e
e 
fr
e
e 
es
te
r 
es
te
r 
es
te
r 
St
er
o
ls
  
o
r 
 
st
an
o
ls
 
 
st
an
o
ls
 
m
ix
 
m
ix
 
m
ix
 
m
ix
 
st
an
o
ls
 
st
er
o
ls
 
st
er
o
ls
 
st
er
o
ls
 
st
er
o
ls
 
st
er
o
ls
 
st
er
o
ls
 
st
er
o
ls
 
st
an
o
ls
 
st
an
o
ls
 
st
an
o
ls
 
st
er
o
ls
 
st
an
o
ls
 
st
an
o
ls
 
st
an
o
ls
 
st
an
o
ls
 
Fo
o
d
 f
o
rm
a
t 
 
h
ar
d
 c
h
ee
se
 
m
ar
ga
ri
n
e
 
yo
gu
rt
 
h
ar
d
 c
h
ee
se
 
fr
e
sh
 c
h
ee
se
 
ca
p
su
le
s 
m
ar
ga
ri
n
e
 
m
ilk
 t
ea
 
m
ilk
 t
ea
 
m
ar
ga
ri
n
e
 
m
ar
ga
ri
n
e
 
m
ay
o
n
n
ai
se
 
b
ee
f 
ta
b
le
ts
 
ca
p
su
le
s 
yo
gu
rt
 
m
ay
o
n
n
ai
se
 
m
ay
o
n
n
ai
se
 
m
ay
o
n
n
ai
se
 
m
ar
ga
ri
n
e
 
m
ar
ga
ri
n
e
 
                         
Su
b
je
ct
 c
h
ar
ac
te
ri
st
ic
s 
M
al
e
 
%
 
3
5
.8
 
10
0
.0
 
2
1
.3
 
2
1
.3
 
2
1
.3
 
- 
4
4
.4
 
3
5
.3
 
3
7
.2
 
44
.0
 
4
2
.4
 
- 
10
0
.0
 
44
.0
 
3
3
.3
 
2
6
.7
 
- - - - - 
M
ea
n
 
B
M
I 
kg
/m
2  
- - 
27
.0
 
27
.0
 
27
.0
 
25
.0
 
2
9
.1
 
26
.0
 
26
.0
 
2
7
.5
 
2
7
.3
 
2
5
.8
 
2
6
.4
 
26
.0
 
2
7
.8
 
2
3
.3
 
2
5
.2
 
2
5
.2
 
2
5
.2
 
- - 
M
e
an
 
a
ge
 
y 
43
.3
 
- 
57
.3
 
57
.3
 
57
.3
 
40
.1
 
61
.0
 
44
.5
 
44
.5
 
58
.1
 
58
.4
 
48
.0
 
22
.9
 
46
.5
 
50
.7
 
36
.0
 
45
.0
 
45
.0
 
45
.0
 
50
.0
 
51
.0
 
Sa
m
p
le
 s
iz
e
 
Tr
ea
t-
m
e
n
t 
 33
 
16
 
25
 
33
 
24
 
22
 
41
 
10
2
 
10
0
 
75
 
35
 
23
 
17
 
13
 
13
.5
 
30
 
9 7 7 51
 
51
 
C
o
n
-
tr
o
l 
 
34
 
16
 
25
 
29
 
28
 
20
 
40
 
99
 
99
 
83
 
83
 
23
 
17
 
12
 
13
.5
 
30
 
8 8 8 51
 
51
 
A
u
th
o
r,
 p
u
b
lic
at
io
n
 y
e
ar
, 
 
an
d
 r
e
fe
re
n
ce
 
 Ja
u
h
ia
in
e
n
 e
t 
al
. 2
00
6
5
9
 
Jo
n
es
 e
t 
al
. 1
9
9
9
3
0
 
K
o
rp
el
a 
et
 a
l. 
20
06
1
4
 s
tu
d
y 
1
 
K
o
rp
el
a 
et
 a
l. 
2
0
06
1
4
 s
tu
d
y 
2
 
K
o
rp
el
a 
et
 a
l. 
20
06
1
4
 s
tu
d
y 
3
 
La
gs
tr
ö
m
 e
t 
al
. 2
0
06
6
0
 
Le
e
 e
t 
al
. 2
0
03
6
1
 
Li
 e
t 
al
. 2
00
7
6
2
 s
tr
at
u
m
 1
 
Li
 e
t 
al
. 2
00
7
6
2
 s
tr
at
u
m
 2
 
M
ak
i e
t 
al
. 2
0
0
1
6
3
 s
tr
at
u
m
 1
 
M
ak
i e
t 
al
. 2
0
0
1
6
3
 s
tr
at
u
m
 2
 
M
at
su
o
ka
 e
t 
al
. 2
00
4
6
4
 
M
at
vi
e
n
ko
 e
t 
al
. 2
00
2
6
5
 
M
cP
h
e
rs
o
n
 e
t 
al
. 2
00
5
6
6
  s
tu
d
y 
1
 
M
cP
h
er
so
n
 e
t 
al
. 2
00
5
6
6
  s
tu
d
y 
2
g
 
M
en
si
n
k 
et
 a
l. 
20
02
1
5
 
M
ie
tt
in
en
 &
 V
an
h
an
en
 1
9
94
6
7
 s
tr
at
u
m
 1
 
M
ie
tt
in
en
 &
 V
an
h
an
en
 1
9
94
6
7
 s
tr
at
u
m
 2
 
M
ie
tt
in
en
 &
 V
an
h
an
en
 1
9
94
6
7
 s
tr
at
u
m
 3
 
M
ie
tt
in
en
 e
t 
al
. 1
9
95
6
8
 s
tr
at
u
m
 1
 
M
ie
tt
in
en
 e
t 
al
. 1
9
95
6
8
 s
tr
at
u
m
 2
 
 
Continuous dose-response relationship between phytosterols and LDL-cholesterol | 37 
 
Ta
b
le
 2
. C
o
n
ti
n
u
ed
 
O
ve
ra
ll 
q
u
al
it
y 
sc
o
re
c  
 
6.
5 
(g
o
o
d
) 
6.
5 
(g
o
o
d
) 
6.
5 
(g
o
o
d
) 
6.
5 
(g
o
o
d
) 
5.
0 
(l
o
w
) 
5.
0 
(l
o
w
) 
5.
0 
(l
o
w
) 
5.
0 
(l
o
w
) 
5.
0 
(l
o
w
) 
7.
0 
(g
o
o
d
) 
5.
0 
(l
o
w
) 
4.
0 
(l
o
w
) 
2.
0 
(l
o
w
) 
4.
5 
(l
o
w
) 
4.
0 
(l
o
w
) 
5.
5 
(g
o
o
d
) 
6.
5 
(g
o
o
d
) 
LD
L-
C
, l
o
w
-d
en
si
ty
 li
p
o
p
ro
te
in
 c
h
o
le
st
er
o
l.
 
a 
D
o
se
 g
iv
en
 a
s 
fr
ee
 e
q
u
iv
al
en
ts
 in
 g
/d
. 
b
 N
et
 c
h
an
ge
 w
as
 c
al
cu
la
te
d
 b
y 
su
b
tr
ac
ti
n
g 
th
e 
m
ea
n
 c
h
an
ge
 in
 t
h
e 
co
n
tr
o
l g
ro
u
p
 f
ro
m
 t
h
e 
m
ea
n
 c
h
an
ge
 in
 t
h
e 
tr
ea
tm
en
t 
gr
o
u
p
 (
w
h
er
e 
m
ea
n
 c
h
an
ge
 =
 L
D
L-
C
 a
t 
th
e 
en
d
-o
f-
in
te
rv
en
ti
o
n
 
- 
LD
L-
C
 a
t 
b
as
el
in
e)
. 
c  
Th
e 
m
ax
im
u
m
 o
ve
ra
ll 
q
u
al
it
y 
sc
o
re
 w
as
 7
 f
o
r 
p
ar
al
le
l t
ri
al
s.
 W
h
en
 a
 t
ri
al
 w
as
 g
iv
en
 <
5.
5 
p
o
in
ts
, i
t 
w
as
 ju
d
ge
d
 t
o
 b
e 
o
f 
lo
w
 q
u
al
it
y 
an
d
 a
 t
ri
al
 t
h
at
 w
as
 g
iv
en
 ≥
5
.5
 p
o
in
ts
 w
as
 ju
d
ge
d
 t
o
 b
e
 
o
f 
h
ig
h
 q
u
al
it
y.
 
d
 P
u
b
lic
at
io
n
s 
w
ri
tt
en
 in
 P
o
rt
u
gu
es
e 
o
r 
Ja
p
an
es
e,
 s
o
 n
o
t 
al
l d
es
cr
ip
ti
ve
 v
ar
ia
b
le
s 
co
u
ld
 b
e 
ex
tr
ac
te
d
. 
e  
M
u
lt
ip
le
 s
tr
at
a 
in
 1
 s
tu
d
y 
co
rr
ec
te
d
 f
o
r 
th
e 
sa
m
e 
si
n
gl
e 
co
n
tr
o
l g
ro
u
p
: 
in
d
ic
at
ed
 w
it
h
 s
tr
at
u
m
 1
, s
tr
at
u
m
 2
, s
tr
at
u
m
 3
, e
tc
. 
f  M
u
lt
ip
le
 s
tr
at
a 
in
 1
 s
tu
d
y,
 e
ac
h
 c
o
rr
ec
te
d
 f
o
r 
a 
re
sp
ec
ti
ve
 c
o
n
tr
o
l g
ro
u
p
: 
in
d
ic
at
ed
 w
it
h
 s
tu
d
y 
1,
 s
tu
d
y 
2,
 s
tu
d
y 
3,
 e
tc
. 
g  
N
u
m
b
er
 o
f 
su
b
je
ct
s 
n
o
t 
re
p
o
rt
ed
 in
 t
h
e 
p
u
b
lic
at
io
n
. T
h
er
ef
o
re
, i
t 
w
as
 a
ss
u
m
ed
 t
h
at
 t
h
e 
2
7 
su
b
je
ct
s 
w
er
e 
d
is
tr
ib
u
te
d
 e
ve
n
ly
 a
cr
o
ss
 t
h
e 
gr
o
u
p
s.
 B
lo
o
d
 li
p
id
 o
u
tc
o
m
e
s 
LD
L-
C
 
95
%
 C
I 
m
m
o
l/
L 
(-
1.
21
  -
0.
23
) 
(-
0.
88
  0
.2
9)
 
(-
0.
51
  -
0.
22
) 
(-
0.
51
  -
0.
18
) 
(-
0.
56
  -
0.
16
) 
(-
0.
21
  0
.0
7)
 
(-
0.
52
  -
0.
12
) 
(-
0.
31
  0
.1
2)
 
(-
0.
31
  0
.0
9)
 
(-
0.
84
  0
.0
3)
 
(-
0.
38
  -
0.
05
) 
(-
0.
85
  -
0.
27
) 
(-
0.
50
  -
0.
13
) 
(-
0.
56
  0
.0
0)
 
(-
0.
44
  0
.3
0)
 
(-
0.
56
  -
0.
22
) 
(-
0.
78
  0
.0
0)
 
N
et
 
ch
an
ge
b
 
-0
.7
2
 
-0
.2
8
 
-0
.3
7
 
-0
.3
4
 
-0
.3
6
 
-0
.0
7
 
-0
.3
2
 
-0
.1
0
 
-0
.1
1
 
-0
.4
0
 
-0
.2
1
 
-0
.5
6
 
-0
.3
1
 
-0
.2
8
 
-0
.0
7
 
-0
.3
9
 
-0
.3
9
 
M
e
an
 
b
as
el
in
e
 
5
.0
8
 
4
.7
3
 
2
.9
4
 
2
.9
4
 
2
.5
0
 
3
.0
1
 
2
.5
8
 
3
.4
0
 
3
.4
0
 
3
.4
0
 
3
.4
0
 
3
.8
3
 
3
.8
1
 
3
.3
9
 
3
.7
0
 
3
.5
5
 
5
.3
5
 
                     
Tr
ea
tm
e
n
t 
ch
ar
ac
te
ri
st
ic
s 
D
o
se
 
p
h
yt
o
-
st
er
o
ls
a  
g
/d
 
2
.5
 
2.
0
 
3
.7
9
 
4
.0
3
 
3
.2
 
0
.4
5
 
1
.3
4
 
2.
0
 
2.
0
 
2.
0
 
2.
0
 
1
.9
 
0
.8
8
 
0
.8
 
1
.5
 
1
.8
 
1
.6
 
D
u
ra
-
ti
o
n
 
d
 
28
 
56
 
56
 
56
 
56
 
28
 
28
 
35
 
35
 
35
 
35
 
28
 
28
 
63
 
42
 
56
 
28
 
Es
te
r 
o
r 
 
fr
ee
 
 
es
te
r 
fr
e
e 
es
te
r 
es
te
r 
es
te
r 
es
te
r 
es
te
r 
es
te
r 
es
te
r 
es
te
r 
es
te
r 
fr
e
e 
es
te
r 
es
te
r 
es
te
r 
es
te
r 
es
te
r 
St
er
o
ls
  
o
r 
 
st
an
o
ls
 
 
st
er
o
ls
 
st
er
o
ls
 
st
an
o
ls
 
st
an
o
ls
 
st
er
o
ls
 
st
er
o
ls
 
st
er
o
ls
 
st
an
o
ls
 
st
an
o
ls
 
st
an
o
ls
 
st
an
o
ls
 
st
an
o
ls
 
st
er
o
ls
 
st
an
o
ls
 
st
an
o
ls
 
st
er
o
ls
 
st
an
o
ls
 
Fo
o
d
 f
o
rm
a
t 
 
m
ar
ga
ri
n
e
 
lo
w
-f
at
 y
o
gu
rt
 d
ri
n
k 
m
ar
ga
ri
n
e
 /
 s
h
o
rt
e
n
in
g 
m
ar
ga
ri
n
e
 /
  s
h
o
rt
e
n
in
g 
m
u
ff
in
 /
 c
ro
is
sa
n
t 
b
re
ad
 
b
re
ad
 
yo
gu
rt
 
lo
w
-f
at
 y
o
gu
rt
 d
ri
n
k 
lo
w
-f
at
 y
o
gu
rt
 d
ri
n
k 
lo
w
-f
at
 m
ilk
 
le
m
o
n
ad
e
 
m
ay
o
n
n
ai
se
 
m
ay
o
n
n
ai
se
 
m
ay
o
n
n
ai
se
 
m
ar
ga
ri
n
e
 
ca
p
su
le
s 
                     
Su
b
je
ct
 c
h
ar
ac
te
ri
st
ic
s 
M
al
e
 
%
 
4
1
.9
 
5
7
.7
 
3
7
.2
 
3
6
.8
 
4
3
.9
 
10
0
.0
 
10
0
.0
 
3
6
.1
 
3
6
.1
 
3
6
.1
 
3
6
.1
 
3
3
.3
 
- 
7
3
.3
 
3
5
.7
 
3
1
.6
 
69
.0
 
M
ea
n
 
B
M
I 
kg
/m
2  
26
.0
 
2
5
.6
 
2
2
.6
 
2
3
.2
 
2
3
.3
 
2
4
.2
 
2
4
.2
 
2
5
.2
 
2
5
.2
 
2
5
.2
 
2
5
.2
 
2
6
.1
 
2
5
.3
 
2
6
.5
 
2
5
.5
 
2
6
.3
 
2
7
.5
 
M
ea
n
 
a
ge
 
y 
50
.3
 
47
.1
 
33
.0
 
33
.0
 
30
.9
 
39
.1
 
41
.2
 
46
.7
 
46
.7
 
46
.7
 
46
.7
 
50
.6
 
46
.8
 
47
.3
 
55
.0
 
56
.6
 
53
.7
 
Sa
m
p
le
 s
iz
e
 
Tr
ea
t-
m
e
n
t 
 
31
 
12
 
36
 
34
 
28
 
32
 
11
 
31
 
29
 
10
 
32
 
11
 
26
 
7 7 18
 
14
 
C
o
n
-
tr
o
l 
 
31
 
14
 
42
 
42
 
29
 
28
 
11
 
29
 
32
 
9 27
 
13
 
29
 
8 7 20
 
15
 
A
u
th
o
r,
 p
u
b
lic
at
io
n
 y
ea
r,
  
an
d
 r
ef
er
e
n
ce
 
 N
e
il 
et
 a
l. 
2
0
0
1
2
7
 
N
iit
ty
n
e
n
 e
t 
al
. 2
0
08
6
9
 s
tu
d
y 
2
 
P
la
t 
et
 a
l. 
20
0
0
b
7
0
 s
tr
at
u
m
 1
 
P
la
t 
et
 a
l. 
20
0
0
b
7
0
 s
tr
at
u
m
 2
 
Q
u
ile
z 
et
 a
l. 
2
00
3
7
1
 
Se
ki
 e
t 
al
. 2
0
0
3a
7
2
 
Se
ki
 e
t 
al
. 2
0
0
3b
7
3
 
Se
p
p
o
 e
t 
al
. 2
0
0
7
1
6
  s
tu
d
y 
1
 
Se
p
p
o
 e
t 
al
. 2
0
0
7
1
6
  s
tu
d
y 
2
 
Se
p
p
o
 e
t 
al
. 2
0
0
7
1
6
  s
tu
d
y 
3
 
Se
p
p
o
 e
t 
al
. 2
0
07
1
6
  s
tu
d
y 
4
 
Sp
ilb
u
rg
 e
t 
al
. 2
0
03
7
4
 
Ta
ic
h
i e
t 
al
. 2
0
03
7
5
 
V
an
h
an
en
 e
t 
al
. 1
9
94
a7
6
 
V
an
h
an
en
 1
99
4
b
7
7
 
V
ar
ad
y 
et
 a
l. 
20
04
7
8
 
W
o
o
d
ga
te
 e
t 
al
. 2
0
06
7
9
 
 
38 | Chapter 2  
 
 
Ta
b
le
 3
. O
ve
rv
ie
w
 o
f 
th
e 
cr
o
ss
-o
ve
r 
st
ra
ta
 in
cl
u
d
ed
 in
 t
h
e 
m
et
a
-a
n
a
ly
si
s.
 
O
ve
ra
ll 
q
u
al
it
y 
sc
o
re
c  
 
7.
0 
(g
o
o
d
) 
7.
0 
(g
o
o
d
) 
5.
0 
(l
o
w
) 
5.
0 
(l
o
w
) 
5.
0 
(l
o
w
) 
5.
0 
(l
o
w
) 
6.
0 
(l
o
w
) 
6.
0 
(l
o
w
) 
6.
0 
(l
o
w
) 
7.
5 
(g
o
o
d
) 
4.
5 
(l
o
w
) 
4.
5 
(l
o
w
) 
4.
5 
(l
o
w
) 
4.
5 
(l
o
w
) 
6.
0 
(l
o
w
) 
7.
5 
(g
o
o
d
) 
7.
5 
(g
o
o
d
) 
4.
5 
(l
o
w
) 
6.
0 
(l
o
w
) 
5.
0 
(l
o
w
) 
7.
5 
(g
o
o
d
) 
7.
5 
(g
o
o
d
) 
3.
0 
(l
o
w
) 
5.
5 
(l
o
w
) 
B
lo
o
d
 li
p
id
 o
u
tc
o
m
e
s 
LD
L-
C
 
95
%
 C
I 
m
m
o
l/
L 
(-
0.
27
  0
.1
7)
 
(-
0.
28
  0
.1
8)
 
(-
0.
79
  -
0.
25
) 
(-
0.
77
  -
0.
32
) 
(-
0.
79
  -
0.
35
) 
(-
0.
67
  -
0.
42
) 
(-
0.
62
  -
0.
26
) 
(-
0.
45
  -
0.
03
) 
(-
0.
58
  -
0.
12
) 
(-
0.
40
  -
0.
14
) 
(-
0.
57
  -
0.
27
) 
(-
0.
85
  -
0.
58
) 
(-
0.
35
  -
0.
13
) 
(-
0.
50
  -
0.
22
) 
(-
0.
29
  0
.0
7)
 
(-
0.
48
  -
0.
14
) 
(-
0.
47
  -
0.
21
) 
(-
0.
57
  -
0.
15
) 
(-
0.
66
  -
0.
24
) 
(-
0.
76
  -
0.
30
) 
(-
0.
71
  -
0.
35
) 
(-
0.
59
  -
0.
28
) 
(-
1.
10
  -
0.
14
) 
(-
0.
31
  -
0.
10
) 
N
et
 
ch
an
ge
b
 
-0
.0
5
 
-0
.0
5
 
-0
.5
2
 
-0
.5
4
 
-0
.5
7
 
-0
.5
4
 
-0
.4
4
 
-0
.2
4
 
-0
.3
5
 
-0
.2
7
 
-0
.4
2
 
-0
.7
2
 
-0
.2
4
 
-0
.3
6
 
-0
.1
1
 
-0
.3
1
 
-0
.3
4
 
-0
.3
6
 
-0
.4
5
 
-0
.5
3
 
-0
.5
3
 
-0
.4
4
 
-0
.6
2
 
-0
.2
0
 
M
ea
n
 
b
as
el
in
e
 
3
.8
0
 
3
.8
0
 
- - - - - 
3
.9
1
 
3
.9
1
 
3
.9
8
 
4
.0
3
 
4
.0
3
 
4
.0
3
 
4
.0
3
 
3
.9
4
 
- - - 
3
.9
8
 
3
.8
5
 
4
.4
3
 
4
.4
3
 
4
.1
9
 
2
.9
7
 
                            
Tr
ea
tm
e
n
t 
ch
ar
ac
te
ri
st
ic
s 
D
o
se
 
p
h
yt
o
-
st
er
o
ls
a  
g
/d
 
1
.7
2
 
1
.7
2
 
2.
0
 
3.
0
 
4.
0
 
3.
0
 
3.
0
 
1
.7
 
1
.7
 
2
.1
 
1
.6
 
1
.6
 
1
.6
 
1
.6
 
1
.3
 
3.
0
 
3.
0
 
3.
0
 
2
.4
3
 
3.
0
 
2
.0
1
 
2
.0
4
 
1
.5
 
0
.8
3
 
D
u
ra
-
ti
o
n
 
d
 
29
 
29
 
42
 
42
 
42
 
42
 
60
 
28
 
28
 
28
 
21
 
21
 
21
 
21
 
21
 
21
 
21
 
42
 
35
 
49
 
28
 
28
 
24
 
24
 
Es
te
r 
 
o
r 
 
fr
ee
 
 
fr
e
e 
es
te
r 
es
te
r 
es
te
r 
es
te
r 
es
te
r 
es
te
r 
es
te
r 
es
te
r 
es
te
r 
es
te
r 
es
te
r 
es
te
r 
es
te
r 
es
te
r 
es
te
r 
es
te
r 
es
te
r 
es
te
r 
es
te
r 
es
te
r 
es
te
r 
fr
e
e 
es
te
r 
St
er
o
ls
  
o
r 
 
st
an
o
ls
 
 
st
er
o
ls
 
st
er
o
ls
 
st
an
o
ls
 
st
an
o
ls
 
st
an
o
ls
 
st
an
o
ls
 
st
an
o
ls
 
st
er
o
ls
 
st
er
o
ls
 
st
er
o
ls
 
st
er
o
ls
 
st
er
o
ls
 
st
er
o
ls
 
st
er
o
ls
 
st
er
o
ls
 
st
er
o
ls
 
st
er
o
ls
 
st
an
o
ls
 
st
an
o
ls
 
st
an
o
ls
 
st
an
o
ls
 
st
er
o
ls
 
st
er
o
ls
 
st
er
o
ls
 
Fo
o
d
 f
o
rm
a
t 
 
m
ar
ga
ri
n
e
 
m
ar
ga
ri
n
e
 
m
ar
ga
ri
n
e
 
m
ar
ga
ri
n
e
 
m
ar
ga
ri
n
e
 
m
ar
ga
ri
n
e
 
m
ar
ga
ri
n
e
 
ve
ge
ta
b
le
 o
il 
ve
ge
ta
b
le
 o
il 
m
ar
ga
ri
n
e
 
b
re
ad
 
m
ilk
 
ce
re
al
s 
yo
gu
rt
 
m
ar
ga
ri
n
e
 
m
ar
ga
ri
n
e
 
m
ar
ga
ri
n
e
 
m
ar
ga
ri
n
e
 
b
u
tt
er
 
m
ar
ga
ri
n
e
 
m
ar
ga
ri
n
e
 
m
ar
ga
ri
n
e
 
to
rt
ill
a 
ch
ip
s 
m
ar
ga
ri
n
e
 
                            
Su
b
je
ct
 c
h
ar
ac
te
ri
st
ic
s M
al
e
 
%
 
- - 
75
.0
 
75
.0
 
75
.0
 
0
.0
 
10
0
.0
 
5
2
.4
 
5
2
.4
 
38
.0
 
3
9
.7
 
3
9
.7
 
3
9
.7
 
3
9
.7
 
5
6
.3
 
5
1
.6
 
4
0
.4
 
10
0
.0
 
0
.0
 
0
.0
 
- - 
6
6
.7
 
42
.0
 
M
ea
n
 
B
M
I 
kg
/m
2  
28
.0
 
28
.0
 
28
.0
 
28
.0
 
28
.0
 
27
.5
 
29
.5
 
25
.9
 
25
.9
 
26
.0
 
26
.2
 
26
.2
 
26
.2
 
26
.2
 
26
.1
 
23
.0
 
23
.0
 
- 
25
.7
 
26
.0
 
24
.9
 
24
.9
 
 
22
.8
 
M
e
an
 
a
ge
 
y 
59
.0
 
59
.0
 
58
.0
 
58
.0
 
58
.0
 
57
.0
 
66
.0
 
54
.2
 
54
.2
 
46
.7
 
54
.0
 
54
.0
 
54
.0
 
54
.0
 
46
.0
 
26
.0
 
25
.0
 
57
.8
 
52
.7
 
51
.0
 
48
.8
 
48
.8
 
48
.0
 
37
.0
 
Sa
m
p
le
 
si
ze
 
 30
 
30
 
8
 
8
 
8
 
13
 
10
 
21
 
21
 
50
 
58
/3
6
f  
58
/4
0
 
58
/5
8
 
58
/4
0
 
48
 
31
 
57
 
11
 
21
 
22
 
34
 
34
 
7
 
80
 
A
u
th
o
r,
 p
u
b
lic
at
io
n
 y
ea
r,
  
an
d
 r
ef
er
en
ce
 
 A
b
u
M
w
ei
s 
et
 a
l. 
2
00
6
8
0
 s
tr
at
u
m
 1
d
 
A
b
u
M
w
ei
s 
et
 a
l. 
2
00
6
8
0
  s
tr
at
u
m
 2
 
C
at
er
 e
t 
al
. 2
0
0
5
8
1
 s
tu
d
y 
1
e  
st
ra
tu
m
 1
 
C
at
er
 e
t 
al
. 2
0
0
5
8
1
 s
tu
d
y 
1 
st
ra
tu
m
 2
 
C
at
er
 e
t 
al
. 2
00
5
8
1
 s
tu
d
y 
1 
st
ra
tu
m
 3
 
C
at
er
 e
t 
al
. 2
0
0
5
8
1
 s
tu
d
y 
2
 
C
at
er
 e
t 
al
. 2
0
0
5
8
1
 s
tu
d
y 
3
 
C
h
an
 e
t 
al
. 2
00
7
8
2
 s
tr
at
u
m
 1
 
C
h
an
 e
t 
al
. 2
00
7
8
2
 s
tr
at
u
m
 2
 
C
le
gh
o
rn
 e
t 
al
. 2
00
3
3
1
 
C
lif
to
n
 e
t 
al
. 2
0
04
1
0
 s
tr
at
u
m
 1
 
C
lif
to
n
 e
t 
al
. 2
0
04
1
0
 s
tr
at
u
m
 2
 
C
lif
to
n
 e
t 
al
. 2
0
04
1
0
 s
tr
at
u
m
 3
 
C
lif
to
n
 e
t 
al
. 2
0
04
1
0
 s
tr
at
u
m
 4
 
C
o
lg
an
 e
t 
al
. 2
00
4
8
3
 
G
ee
le
n
 e
t 
al
. 2
00
2
8
4
 s
tu
d
y 
1
 
G
ee
le
n
 e
t 
al
. 2
00
2
8
4
 s
tu
d
y 
2
 
G
yl
lin
g 
&
 M
ie
tt
in
e
n
 1
99
4
8
5
 
G
yl
lin
g 
&
 M
ie
tt
in
e
n
 1
99
9
8
6
 
G
yl
lin
g 
et
 a
l. 
1
99
7
8
7
 
H
al
lik
ai
n
e
n
 e
t 
al
. 2
00
0
8
8
 s
tr
at
u
m
 1
 
H
al
lik
ai
n
e
n
 e
t 
al
. 2
00
0
8
8
 s
tr
at
u
m
 2
 
H
ay
es
 e
t 
al
. 2
0
04
8
9
 
H
en
d
ri
ks
 e
t 
al
. 1
99
9
9
0
 s
tr
at
u
m
 1
 
 
Continuous dose-response relationship between phytosterols and LDL-cholesterol | 39 
 
 
Ta
b
le
 3
. C
o
n
ti
n
u
ed
 
O
ve
ra
ll 
q
u
al
it
y 
sc
o
re
c  
 
5.
5 
(l
o
w
) 
5.
5 
(l
o
w
) 
7.
5 
(g
o
o
d
) 
8.
0 
(g
o
o
d
) 
8.
0 
(g
o
o
d
) 
8.
0 
(g
o
o
d
) 
6.
0 
(l
o
w
) 
7.
5 
(g
o
o
d
) 
7.
5 
(g
o
o
d
) 
8.
0 
(g
o
o
d
) 
8.
0 
(g
o
o
d
) 
6.
0 
(l
o
w
) 
6.
0 
(l
o
w
) 
5.
5 
(l
o
w
) 
4.
0 
(l
o
w
) 
4.
0 
(l
o
w
) 
2.
0 
(l
o
w
) 
2.
0 
(l
o
w
) 
4.
0 
(l
o
w
) 
7.
5 
(g
o
o
d
) 
7.
5 
(g
o
o
d
) 
7.
5 
(g
o
o
d
) 
7.
5 
(g
o
o
d
) 
4.
5 
(l
o
w
) 
4.
5 
(l
o
w
) 
B
lo
o
d
 li
p
id
 o
u
tc
o
m
e
s 
LD
L-
C
 
95
%
 C
I 
m
m
o
l/
L 
(-
0.
36
  -
0.
15
) 
(-
0.
41
  -
0.
20
) 
(-
0.
58
  -
0.
13
) 
(-
0.
77
  -
0.
35
) 
(-
0.
50
  -
0.
04
) 
(-
0.
41
  0
.2
5)
 
(-
0.
38
  -
0.
29
) 
(-
0.
30
  0
.1
0)
 
(-
0.
38
  -
0.
08
) 
(-
0.
61
  -
0.
23
) 
(-
0.
57
  -
0.
03
) 
(-
0.
41
  -
0.
19
) 
(-
0.
45
  -
0.
14
) 
(-
0.
37
  -
0.
15
) 
(-
0.
37
  -
0.
02
) 
(-
0.
40
  -
0.
05
) 
(-
0.
76
  -
0.
14
) 
(-
0.
60
  0
.0
0)
 
(-
0.
61
  -
0.
13
) 
(-
0.
41
  0
.0
3)
 
(-
0.
44
  -
0.
22
) 
(-
0.
51
  -
0.
31
) 
(-
0.
52
  -
0.
28
) 
(-
0.
66
  -
0.
32
) 
(-
0.
50
  -
0.
26
) 
N
et
 
ch
an
ge
b
 
-0
.2
6
 
-0
.3
0
 
-0
.3
5
 
-0
.5
6
 
-0
.2
7
 
-0
.0
8
 
-0
.3
4
 
-0
.1
0
 
-0
.2
3
 
-0
.1
9
 
-0
.3
0
 
-0
.3
0
 
-0
.2
9
 
-0
.2
6
 
-0
.1
7
 
-0
.1
9
 
-0
.4
5
 
-0
.3
0
 
-0
.3
7
 
-0
.1
9
 
-0
.3
3
 
-0
.4
1
 
-0
.4
0
 
-0
.4
9
 
-0
.3
8
 
M
ea
n
 
b
as
el
in
e
 
2
.9
7
 
2
.9
7
 
4
.5
0
 
4
.2
9
 
4
.3
5
 
4
.1
5
 
3
.6
2
 
2
.7
7
 
2
.7
7
 
3
.2
4
 
3
.9
2
 
5.
0
0
 
3
.5
0
 
3
.9
3
 
- - - - - 
3
.9
0
 
4
.3
8
 
4
.3
8
 
4
.2
0
 
4
.8
3
 
4
.8
3
 
                             
Tr
ea
tm
e
n
t 
ch
ar
ac
te
ri
st
ic
s 
D
o
se
 
p
h
yt
o
-
st
er
o
ls
a  
g
/d
 
1
.6
1
 
3
.2
4
 
2
.0
 
1
.8
4
 
1
.8
4
 
1
.8
 
2
.2
 
2
.0
3
 
1
.9
6
 
1
.8
 
1
.8
 
1
.6
8
 
2
.3
 
1
.8
2
 
1
.9
6
 
1
.9
9
 
2
.4
 
2
.4
 
2
.4
 
1
.0
 
2
.3
 
2
.5
 
2
.0
 
2
.0
 
2
.0
 
D
u
ra
-
ti
o
n
 
d
 
24
 
24
 
28
 
21
 
21
 
21
 
21
 
42
 
42
 
21
 
21
 
28
 
28
 
21
 
21
 
21
 
28
 
28
 
28
 
28
 
21
 
21
 
21
 
21
 
21
 
Es
te
r 
o
r 
 
fr
ee
 
 
es
te
r 
es
te
r 
fr
e
e 
es
te
r 
es
te
r 
fr
e
e 
es
te
r 
es
te
r 
es
te
r 
fr
e
e 
fr
e
e 
es
te
r 
es
te
r 
es
te
r 
es
te
r 
es
te
r 
es
te
r 
fr
e
e 
es
te
r 
fr
e
e 
es
te
r 
es
te
r 
es
te
r 
es
te
r 
es
te
r 
St
er
o
ls
  
o
r 
 
st
an
o
ls
 
 
st
er
o
ls
 
st
er
o
ls
 
st
er
o
ls
 
st
er
o
ls
 
st
an
o
ls
 
m
ix
 
st
er
o
ls
 
st
er
o
ls
 
st
an
o
ls
 
st
er
o
ls
 
st
er
o
ls
 
st
er
o
ls
 
st
er
o
ls
 
st
er
o
ls
 
m
ix
 
m
ix
 
st
er
o
ls
 
st
an
o
ls
 
st
er
o
ls
 
st
er
o
ls
 
st
er
o
ls
 
st
an
o
ls
 
st
er
o
ls
 
st
er
o
ls
 
st
er
o
ls
 
Fo
o
d
 f
o
rm
a
t 
 
m
ar
ga
ri
n
e
 
m
ar
ga
ri
n
e
 
m
ar
ga
ri
n
e
 
m
ar
ga
ri
n
e
 
m
ar
ga
ri
n
e
 
n
o
n
-f
at
 b
ev
er
ag
e
 
sa
la
d
 d
re
ss
in
g 
m
ar
ga
ri
n
e
 
m
ar
ga
ri
n
e
 
m
ar
ga
ri
n
e
 
m
ar
ga
ri
n
e
 
m
ar
ga
ri
n
e
 
m
ar
ga
ri
n
e
 
m
ar
ga
ri
n
e
 
m
ar
ga
ri
n
e
 
m
ar
ga
ri
n
e
 
b
re
ad
 /
 c
e
re
al
 /
 m
ar
ga
ri
n
e
 
b
re
ad
 /
 c
e
re
al
 /
 m
ar
ga
ri
n
e
 
m
ar
ga
ri
n
e
 
lo
w
-f
at
 y
o
gu
rt
 d
ri
n
k 
m
ar
ga
ri
n
e
 
m
ar
ga
ri
n
e
 
m
ar
ga
ri
n
e
 
m
ar
ga
ri
n
e
 
m
ilk
 
                             
Su
b
je
ct
 c
h
ar
ac
te
ri
st
ic
s M
al
e
 
%
 
42
.0
 
42
.0
 
8
7
.5
 
10
0
.0
 
10
0
.0
 
60
.0
 
4
9
.1
 
- - 
3
5
.7
 
40
.0
 
1
6
.7
 
25
.0
 
3
8
.7
 
3
5
.7
 
3
5
.7
 
8
1
.8
 
8
1
.8
 
- 
10
0
.0
 
4
3
.5
 
4
3
.5
 
5
7
.1
 
5
3
.8
 
5
3
.8
 
M
ea
n
 
B
M
I 
kg
/m
2  
22
.8
 
22
.8
 
25
.9
 
- - - 
26
.3
 
22
.0
 
22
.0
 
30
.2
 
26
.9
 
26
.4
 
25
.0
 
24
.0
 
23
.4
 
23
.4
 
24
.0
 
24
.0
 
- 
25
.6
 
26
.2
 
26
.2
 
26
.0
 
25
.9
 
25
.9
 
M
e
an
 
a
ge
 
y 
37
.0
 
37
.0
 
55
.5
 
- - - 
47
.1
 
32
.0
 
32
.0
 
54
.5
 
55
.1
 
55
.8
 
50
.6
 
42
.0
 
33
.8
 
33
.8
 
60
.0
 
60
.0
 
43
.7
 
41
.0
 
56
.7
 
56
.7
 
57
.3
 
51
.5
 
51
.5
 
Sa
m
p
le
 
si
ze
 
 
80
 
80
 
39
 
15
 
25
 
25
 
53
 
17
 
17
 
14
 
15
 
60
 
46
 
62
 
42
 
42
 
22
 
22
 
15
 
15
 
46
 
46
 
35
 
39
 
39
 
A
u
th
o
r,
 p
u
b
lic
at
io
n
 y
e
ar
, 
 
an
d
 r
e
fe
re
n
ce
 
 H
en
d
ri
ks
 e
t 
al
. 1
99
9
9
0
 s
tr
at
u
m
 2
 
H
en
d
ri
ks
 e
t 
al
. 1
99
9
9
0
 s
tr
at
u
m
 3
 
Ja
ku
lj 
et
 a
l. 
2
00
5
9
1
 
Jo
n
es
 e
t 
al
. 2
0
00
2
9
 s
tr
at
u
m
 1
 
Jo
n
es
 e
t 
al
. 2
0
00
2
9
 s
tr
at
u
m
 2
 
Jo
n
es
 e
t 
al
. 2
0
03
9
2
 
Ju
d
d
 e
t 
al
. 2
0
02
9
3
 
K
ra
tz
 e
t 
al
. 2
0
07
9
4
 s
tr
at
u
m
 1
 
K
ra
tz
 e
t 
al
. 2
0
07
9
4
 s
tr
at
u
m
 2
 
La
u
 e
t 
al
. 2
00
5
9
5
 s
tu
d
y 
1
 
La
u
 e
t 
al
. 2
00
5
9
5
 s
tu
d
y 
2
 
Lo
tt
en
b
er
g 
et
 a
l. 
2
00
3
9
6
 
M
ad
se
n
 e
t 
al
. 2
0
07
9
7
 
M
u
ss
n
er
 e
t 
al
. 2
0
02
9
8
 
N
au
m
an
n
 e
t 
al
. 2
0
03
9
9
 s
tr
at
u
m
 1
 
N
au
m
an
n
 e
t 
al
. 2
0
03
9
9
 s
tr
at
u
m
 2
 
N
e
st
el
 e
t 
al
. 2
0
01
1
0
0
  s
tu
d
y 
1 
st
ra
tu
m
 1
 
N
e
st
el
 e
t 
al
. 2
0
01
1
0
0
 s
tu
d
y 
1 
st
ra
tu
m
 2
 
N
e
st
el
 e
t 
al
. 2
0
01
1
0
0
 s
tu
d
y 
2
 
N
iit
ty
n
e
n
 e
t 
al
. 2
0
08
6
9
 s
tu
d
y 
1
 
N
o
ak
es
 e
t 
al
. 2
0
02
1
0
1
 s
tu
d
y 
1
 s
tr
at
u
m
 1
 
N
o
ak
es
 e
t 
al
. 2
0
02
1
0
1
 s
tu
d
y 
1
 s
tr
at
u
m
 2
 
N
o
ak
es
 e
t 
al
. 2
0
02
1
0
1
 s
tu
d
y 
2
 
N
o
ak
es
 e
t 
al
. 2
0
05
1
1
 s
tu
d
y 
1
 s
tr
at
u
m
 1
 
N
o
ak
es
 e
t 
al
. 2
0
05
1
1
 s
tu
d
y 
1
 s
tr
at
u
m
 2
 
 
40 | Chapter 2  
 
 
Ta
b
le
 3
. C
o
n
ti
n
u
ed
 
O
ve
ra
ll 
q
u
al
it
y 
sc
o
re
c  
 
4.
5 
(l
o
w
) 
7.
5 
(g
o
o
d
) 
7.
5 
(g
o
o
d
) 
5.
5 
(l
o
w
) 
5.
0 
(l
o
w
) 
7.
5 
(g
o
o
d
) 
7.
5 
(g
o
o
d
) 
6.
5 
(g
o
o
d
) 
7.
5 
(g
o
o
d
) 
4.
0 
(l
o
w
) 
4.
0 
(l
o
w
) 
8.
0 
(g
o
o
d
) 
8.
0 
(g
o
o
d
) 
8.
0 
(g
o
o
d
) 
6.
5 
(g
o
o
d
) 
5.
5 
(l
o
w
) 
5.
5 
(l
o
w
) 
7.
5 
(g
o
o
d
) 
7.
5 
(g
o
o
d
) 
LD
L-
C
, l
o
w
-d
en
si
ty
 li
p
o
p
ro
te
in
 c
h
o
le
st
er
o
l.
 
a 
D
o
se
 g
iv
en
 a
s 
fr
ee
 e
q
u
iv
al
en
ts
 in
 g
/d
. 
b
 T
h
e 
n
et
 c
h
an
ge
 in
 L
D
L-
C
 w
as
 c
al
cu
la
te
d
 a
s 
th
e 
m
ea
n
 L
D
L-
C
 c
o
n
ce
n
tr
at
io
n
 a
t 
th
e 
en
d
 o
f 
th
e 
p
h
yt
o
st
e
ro
l t
re
a
tm
en
t 
p
er
io
d
 m
in
u
s 
th
e 
m
ea
n
 L
D
L-
C
 c
o
n
ce
n
tr
at
io
n
s 
at
 t
h
e 
en
d
 o
f 
th
e 
co
n
tr
o
l p
er
io
d
. 
c  
Th
e 
m
ax
im
u
m
 o
ve
ra
ll 
q
u
al
it
y 
sc
o
re
 w
as
 8
 f
o
r 
cr
o
ss
-o
ve
r 
tr
ia
ls
. 
W
h
en
 a
 t
ri
al
 w
as
 g
iv
en
 ≤
6
.0
 p
o
in
ts
, 
it
 w
as
 j
u
d
ge
d
 t
o
 b
e 
o
f 
lo
w
 q
u
al
it
y 
an
d
 a
 t
ri
al
 t
h
at
 w
as
 g
iv
en
 >
6
.0
 p
o
in
ts
 w
a
s 
ju
d
ge
d
 t
o
 b
e 
o
f 
h
ig
h
 q
u
al
it
y.
 
d
 M
u
lt
ip
le
 s
tr
at
a 
in
 1
 s
tu
d
y 
co
rr
ec
te
d
 f
o
r 
th
e 
sa
m
e 
si
n
gl
e 
co
n
tr
o
l g
ro
u
p
: 
in
d
ic
at
ed
 w
it
h
 s
tr
at
u
m
 1
, s
tr
at
u
m
 2
, s
tr
at
u
m
 3
, e
tc
. 
e  
M
u
lt
ip
le
 s
tr
at
a 
in
 1
 s
tu
d
y,
 e
ac
h
 c
o
rr
ec
te
d
 f
o
r 
a 
re
sp
ec
ti
ve
 c
o
n
tr
o
l g
ro
u
p
: 
in
d
ic
at
ed
 w
it
h
 s
tu
d
y 
1,
 s
tu
d
y 
2,
 s
tu
d
y 
3,
 e
tc
. 
f  C
lif
to
n
 e
t 
al
. (
20
04
)1
0  
u
se
d
 a
n
 in
co
m
p
le
te
 c
ro
ss
-o
ve
r 
d
es
ig
n
 w
it
h
 4
 p
h
yt
o
st
er
o
l t
re
a
tm
en
ts
 a
n
d
 1
 c
o
n
tr
o
l t
re
at
m
en
t;
 a
ll 
su
b
je
ct
s 
fo
llo
w
ed
 a
 p
er
io
d
 w
it
h
 c
o
n
tr
o
l t
re
at
m
en
t 
an
d
 o
n
ly
 
3 
p
er
io
d
s 
w
it
h
 p
h
yt
o
st
er
o
l t
re
at
m
en
t.
 T
h
u
s,
 t
h
e 
to
ta
l n
u
m
b
er
 o
f 
su
b
je
ct
s 
p
er
 t
re
at
m
en
t 
w
as
 n
o
t 
th
e 
sa
m
e:
 5
8 
fo
r 
th
e 
co
n
tr
o
l t
re
at
m
en
t 
an
d
 3
6
, 
4
0
, 
5
8
, a
n
d
 4
0
 f
o
r 
th
e 
p
h
yt
o
st
er
o
l 
tr
ea
tm
en
ts
, r
es
p
ec
ti
ve
ly
. 
g  
W
es
ts
tr
at
e 
an
d
 M
ei
je
r 
(1
9
9
8)
10
8  
u
se
d
 a
n
 in
co
m
p
le
te
 c
ro
ss
-o
ve
r 
d
es
ig
n
 w
it
h
 5
 p
h
yt
o
st
er
o
l t
re
at
m
en
ts
 (
2 
o
f 
w
h
ic
h
 a
re
 in
cl
u
d
ed
 in
 t
h
is
 m
et
a
-a
n
al
ys
is
) 
an
d
 1
 c
o
n
tr
o
l t
re
a
tm
en
t;
 d
u
e 
to
 4
 d
ro
p
-o
u
ts
 i
n
 t
h
e 
fi
rs
t 
p
er
io
d
 a
n
d
 1
 d
ro
p
-o
u
t 
in
 t
h
e 
3
rd
 p
er
io
d
, 
th
e 
to
ta
l 
n
u
m
b
er
 o
f 
su
b
je
ct
s 
p
er
 p
h
yt
o
st
er
o
l 
tr
ea
tm
en
t 
va
ri
ed
: 
7
6
 a
n
d
 7
7
 d
u
ri
n
g 
th
e 
p
h
yt
o
st
er
o
l 
tr
ea
tm
en
ts
, 
re
sp
e
ct
iv
el
y.
 
B
lo
o
d
 li
p
id
 o
u
tc
o
m
e
s 
LD
L-
C
 
95
%
 C
I 
m
m
o
l/
L 
(-
0.
69
  -
0.
41
) 
(-
0.
33
  -
0.
13
) 
(-
0.
37
  -
0.
17
) 
(-
0.
39
  -
0.
17
) 
(-
0.
58
  -
0.
24
) 
(-
0.
39
  -
0.
19
) 
(-
0.
41
  -
0.
20
) 
(-
0.
23
  -
0.
15
) 
(-
0.
62
  -
0.
31
) 
(-
0.
42
  -
0.
18
) 
(-
0.
53
  -
0.
28
) 
(-
0.
65
  -
0.
17
) 
(-
0.
66
  -
0.
18
) 
(-
0.
70
  -
0.
22
) 
(-
0.
51
  -
0.
17
) 
(-
0.
48
  -
0.
40
) 
(-
0.
44
  -
0.
36
) 
(-
0.
48
  0
.0
0)
 
(-
0.
33
  0
.1
5)
 
N
et
 
ch
an
ge
b
 
-0
.5
5
 
-0
.2
3
 
-0
.2
7
 
-0
.2
8
 
-0
.4
1
 
-0
.2
9
 
-0
.3
1
 
-0
.1
9
 
-0
.4
7
 
-0
.3
0
 
-0
.4
0
 
-0
.4
1
 
-0
.4
2
 
-0
.4
6
 
-0
.3
4
 
-0
.4
4
 
-0
.4
0
 
-0
.2
4
 
-0
.0
9
 
M
ea
n
 
b
as
el
in
e
 
4
.8
3
 
4
.4
8
 
4.
4
8
 
- - - - - 
4
.2
9
 
4
.3
7
 
4
.3
7
 
4.
0
0
 
4
.1
1
 
4
.1
8
 
4
.6
7
 
3
.5
4
 
3
.5
4
 
4
.1
8
 
3
.6
0
 
                       
Tr
ea
tm
e
n
t 
ch
ar
ac
te
ri
st
ic
s 
D
o
se
 
p
h
yt
o
-
st
er
o
ls
a  
g
/d
 
4.
0
 
1
.8
 
1
.7
 
1
.8
 
0
.7
4
 
2
.4
7
 
2
.4
6
 
0
.8
 
2
.1
 
1
.1
7
 
1
.6
 
1
.8
 
1
.8
 
1
.8
 
1
.0
8
 
3
.2
 
2
.7
 
1
.8
 
1
.8
 
D
u
ra
-
ti
o
n
 
d
 
21
 
21
 
21
 
21
 
28
 
28
 
28
 
21
 
28
 
28
 
28
 
21
 
21
 
21
 
28
 
21
 
21
 
21
 
21
 
Es
te
r 
o
r 
 
fr
ee
 
 
es
te
r 
es
te
r 
es
te
r 
fr
e
e 
fr
e
e 
es
te
r 
es
te
r 
fr
e
e 
es
te
r 
fr
e
e 
fr
e
e 
fr
e
e 
fr
e
e 
fr
e
e 
fr
e
e 
es
te
r 
es
te
r 
fr
e
e 
fr
e
e 
St
er
o
ls
  
o
r 
 
st
an
o
ls
 
 
st
er
o
ls
 
st
an
o
ls
 
st
er
o
ls
 
st
er
o
ls
 
st
er
o
ls
 
st
an
o
ls
 
st
an
o
ls
 
st
er
o
ls
 
st
er
o
ls
 
st
er
o
ls
 
st
er
o
ls
 
st
er
o
ls
 
st
an
o
ls
 
m
ix
 
st
er
o
ls
 
st
er
o
ls
 
st
an
o
ls
 
m
ix
 
m
ix
 
Fo
o
d
 f
o
rm
a
t 
 
m
ar
ga
ri
n
e
 /
 m
ilk
 
yo
gu
rt
 
yo
gu
rt
 
m
ar
ga
ri
n
e
 
b
u
tt
er
 
m
ar
ga
ri
n
e
 
m
ar
ga
ri
n
e
 /
 s
h
o
rt
e
n
in
g 
m
ar
ga
ri
n
e
 
m
ar
ga
ri
n
e
 
m
ilk
 
m
ilk
 
b
u
tt
er
 
b
u
tt
er
 
b
u
tt
er
 
lo
w
-f
at
 y
o
gu
rt
 d
ri
n
k 
m
ar
ga
ri
n
e
 
m
ar
ga
ri
n
e
 
ce
re
al
 b
ar
 
ce
re
al
 b
ar
 
                       
Su
b
je
ct
 c
h
ar
ac
te
ri
st
ic
s 
M
al
e
 
%
 
5
3
.8
 
4
2
.5
 
4
2
.5
 
4
9
.1
 
10
0
.0
 
2
8
.2
 
2
8
.2
 
5
1
.3
 
5
2
.4
 
2
6
.1
 
2
6
.1
 
60
.0
 
60
.0
 
60
.0
 
70
.0
 
50
.0
 
50
.0
 
4
3
.8
 
3
0
.8
 
M
e
an
 
B
M
I 
kg
/m
2  
25
.9
 
26
.5
 
26
.5
 
23
.7
 
22
.3
 
22
.7
 
22
.7
 
24
.4
 
25
.0
 
25
.9
 
25
.9
 
30
.8
 
30
.8
 
30
.8
 
- 
24
.2
 
24
.2
 
27
.7
 
31
.0
 
M
e
an
 
a
ge
 
y 
51
.5
 
60
.4
 
60
.4
 
45
.1
 
22
.7
 
31
.0
 
31
.0
 
44
.0
 
55
.0
 
60
.0
 
60
.0
 
47
.8
 
47
.8
 
47
.8
 
- 
45
.0
 
45
.0
 
55
.2
 
56
.8
 
Sa
m
p
le
 
si
ze
 
 39
 
40
 
40
 
53
 
12
 
39
 
39
 
75
 
42
 
69
 
69
 
15
 
15
 
15
 
30
 
76
/7
6
g  
76
/7
7
 
16
 
13
 
A
u
th
o
r,
 p
u
b
lic
at
io
n
 y
ea
r,
  
an
d
 r
ef
er
en
ce
 
 N
o
ak
es
 e
t 
al
. 2
0
05
1
1
 s
tu
d
y 
1
 s
tr
at
u
m
 3
 
N
o
ak
es
 e
t 
al
. 2
0
05
1
1
 s
tu
d
y 
2
 s
tr
at
u
m
 1
 
N
o
ak
es
 e
t 
al
. 2
0
05
1
1
 s
tu
d
y 
2
 s
tr
at
u
m
 2
 
N
ta
n
io
s 
et
 a
l. 
2
00
2
1
0
2
 
P
e
lle
ti
er
 e
t 
al
. 1
99
5
1
0
3
 
P
la
t 
et
 a
l. 
20
00
a1
0
4
 s
tr
at
u
m
 1
 
P
la
t 
et
 a
l. 
20
00
a1
0
4
 s
tr
at
u
m
 2
 
Si
er
ks
m
a 
et
 a
l. 
1
99
9
3
6
 
Te
m
m
e 
et
 a
l. 
2
00
2
1
0
5
 
Th
o
m
se
n
 e
t 
al
. 2
0
04
1
2
 s
tr
at
u
m
 1
 
Th
o
m
se
n
 e
t 
al
. 2
0
04
1
2
 s
tr
at
u
m
 2
 
V
an
st
o
n
e 
et
 a
l. 
20
02
1
0
6
 s
tr
at
u
m
 1
 
V
an
st
o
n
e 
et
 a
l. 
20
02
1
0
6
 s
tr
at
u
m
 2
 
V
an
st
o
n
e 
et
 a
l. 
20
02
1
0
6
 s
tr
at
u
m
 3
 
V
o
lp
e 
et
 a
l. 
2
00
1
1
0
7
 
W
es
ts
tr
at
e 
&
 M
ei
je
r 
1
99
8
1
0
8
 s
tr
at
u
m
 1
 
W
es
ts
tr
at
e 
&
 M
ei
je
r 
1
99
8
1
0
8
 s
tr
at
u
m
 2
 
Yo
sh
id
a 
et
 a
l. 
20
06
1
0
9
 s
tu
d
y 
1
 
Yo
sh
id
a 
et
 a
l. 
20
06
1
0
9
 s
tu
d
y 
2
 
 
Continuous dose-response relationship between phytosterols and LDL-cholesterol | 41 
 
 
Figure 2. Funnel plots of the weights (1/SE
2
) against the absolute changes in LDL-C (A) and 
the relative changes in LDL-C (B) in 141 strata from 81 randomized controlled trials 
investigating the cholesterol-lowering effect of phytosterols. The LDL-C changes are scattered 
around the pooled overall estimate of -0.34 mmol/l (A) and -8.83% (B). 
 
Effect of phytosterol intake on LDL-C and TC:HDL-C  
On average, phytosterols lowered LDL-C by 0.34 mmol/L (95% CI: -0.36; -0.31), 
which corresponds to a relative decrease of 8.8% (95% CI: -9.4; -8.3). There was an 
absolute reduction in LDL-C concentrations in 139 of 141 strata (Tables 2 and 3) 
and the reduction was significant in 109 strata. In only 2 strata
18,64
, LDL-C 
concentrations were not decreased at 4 week (time point used for the meta-
analysis). Data reported for these strata after 8 or 12 week showed a significant 
reduction in LDL-C.  
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The dose-response curve for the relationship between phytosterol dose and LDL-C-
lowering was described by the equation, where the best parameters to fit the 
observed data were: a = -0.43 mmol/L (95% CI: -0.51; -0.35) and b = 0.83 g/d (95% 
CI: 0.42; 1.23) for the predicted absolute LDL-C change (mmol/L) (P <0.001) and a = 
-12.68% (95% CI: -15.38; -9.99) and b = 1.12 g/d (95% CI: 0.62; 1.63) for the relative 
(%) LDL-C change (P <0.001), respectively (Figure 3). According to the dose-
response relationship, the predicted LDL-C-lowering effect of the recommended 
daily dose of phytosterols (2 g) would be -0.35 mmol/L or -9%.  
 
 
Figure 3. Dose-response relationship for the absolute (A) and relative (B) LDL-C-lowering 
effect of phytosterols.  
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The equation was also used to describe the relationship between phytosterol dose 
and absolute changes in TC:HDL-C ratios. The values of parameters a and b 
obtained for the equation describing the absolute changes in TC:HDL-C were -0.42 
(95% CI: -0.57; -0.27) and 1.06 g/d (95% CI: 0.23; 1.90), respectively (P <0.001). For 
the recommended dose of 2 g/d phytosterols, the equation predicts a 0.31 
decrease in the TC:HDL-C ratio. To verify whether this estimate was reliable, the 
deviations between the mean ratio calculated from individual ratios available from 
8 of our previous studies and the ratios calculated from the mean TC and HDL-C 
concentrations (as was done in the present meta-analysis) were determined. The 
mean deviation, weighted by the number of subjects, was -6.45% (range: -3.99% to  
-8.78%), suggesting that TC:HDL-C ratios calculated from the reported means were 
underestimated. 
 
Impact of subject baseline characteristics on the LDL-C-lowering effect of 
phytosterols  
Residuals (differences between the absolute LDL-C changes predicted with the 
dose-response curve and the observed LDL-C changes) were most strongly 
correlated with baseline LDL-C concentrations (r = -0.4; P <0.0001), with 16% of the 
variation in residuals explained by this variable. Age was also correlated with the 
residuals (r = -0.17; P = 0.045) but explained only 3% of the variation. BMI was not 
significantly correlated with gender (r = -0.17; P = 0.051) or residuals (r = -0.18; P = 
0.052). When all 4 covariates were simultaneously included in the model, the effect 
of age on the residuals was no longer significant (P = 0.45), whereas the impact of 
baseline LDL-C concentrations remained significant (P = 0.001), suggesting co 
linearity between age and baseline LDL-C concentrations. Given the substantial 
impact of baseline LDL-C concentrations on the absolute LDL-C reductions due to 
phytosterol intake, with the larger reductions in populations with higher baseline 
LDL-C concentrations, comparisons between subgroups of categorical covariates 
were made by comparing not only the absolute but also the relative curves. Indeed, 
the use of the relative (%) changes resulted in less variation in residuals (only 0.05% 
of the variation was due to baseline LDL-C) than the use of the absolute values and 
the relative curve was more precise (F = 477.1) than the absolute curve (F = 425.9).  
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Impact of food format and other treatment characteristics on the LDL-C-lowering 
effect of phytosterols  
The impact of the categorical covariates was evaluated by comparing the dose-
response curves obtained for the respective subgroups (Table 4). The fat content of 
the food format (fat-based vs. non fat-based) and the type of phytosterols (plant 
sterols vs. stanols) did not significantly affect the absolute and relative dose-
response curves (Table 4; Figure 4). The dairy or non-dairy nature of the foods also 
did not significantly affect the absolute dose-response curve (not shown). A relative 
curve for the dairy food formats could not be calculated due to the small number 
of strata and the narrow distribution of the net changes in LDL-C. Therefore, the 
mean relative LDL-C changes were calculated separately for strata in which dairy 
and non-dairy foods were used and for a narrow range (1.6-2.0 g/d) of doses. The 
mean LDL-C-lowering effect of dairy and non-dairy food formats was -8.53% (95% 
CI: -9.71; -7.34) for a mean phytosterol intake of 1.85 g/d and -7.97% (95% CI: -
8.79; -7.15) for a mean dose of 1.81 g/d, respectively, indicating no significant 
difference between dairy and non-dairy food formats. The only significant effect 
was the effect of solid compared to liquid food format on the relative curve. At high 
doses, the maximal estimated LDL-C-lowering effect of solid foods was 5.2% larger 
than that of liquid foods (parameter a), and at low doses, the curve was steeper for 
liquid than for solid foods (parameter b) (Table 4). However, the curves obtained 
for solid vs. liquid foods crossed at phytosterol intakes of ~1.5 g/d, and at ~2 g/d, 
the difference between the 2 curves was small (data not shown).  
 
 
Figure 4. Relative dose-response curves of the LDL-C-lowering effect of phytosterols 
incorporated in fat-based compared to non fat-based food formats. 
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Post hoc analyses were performed to evaluate the impact of phytosterol 
esterification and frequency of intake on the dose-response curve. Free 
phytosterols and phytosterol esters did not differ in the maximal LDL-C reduction 
or in the incremental dose-step (Table 4). Due to the small number of strata (n = 
14) in the single daily intake subgroup and the narrow distribution of net LDL-C 
changes in this subgroup, a dose-response curve could not be established for the 
once-a-day intakes. Therefore, to evaluate the effect of frequency of intake, the 
mean relative LDL-C change for a narrow range of doses (1.6-2.0 g/d) was 
calculated for strata in which phytosterols were consumed once per day compared 
to ≥2 times/d. The relative LDL-C-lowering effect was more pronounced when 
phytosterols were consumed in multiple daily intakes (-8.91%; 95% CI: -9.75; -8.07, 
for a mean phytosterol dose of 1.81 g/d) than in single daily intakes (-6.14%; 95%CI: 
-8.19; -4.10, for a mean dose of 1.76 g/d). Because the mean dose was slightly 
higher for the multiple daily intakes, regression analyses were performed to 
determine the respective impact of dose and frequency of consumption. When 
included separately in the model, the dose contributed to 14% of the variation in 
LDL-C changes (P < 0.0001) and the frequency of intake contributed to 5% of the 
variation (P = 0.0054). An increase in the number of daily intakes was associated 
with a larger decrease in LDL-C concentrations. However, when dose and frequency 
of intake were simultaneously included in the model (r
2
 = 0.26), the effect of dose 
on LDL-C changes remained significant (P <0.0001), whereas frequency of intake 
only tended (P = 0.054) to affect the relative decreases in LDL-C concentrations. 
These data suggest that the effect of frequency of intake was partly confounded by 
the influence of dose.  
 
Impact of study quality and study design on the LDL-C–lowering effect of 
phytosterols  
The overall quality of the trials, the compliance, and the randomization method did 
not significantly affect either the absolute or the relative dose-response curve. We 
performed a post hoc analysis to evaluate the effect of study design (cross-over vs. 
parallel) on the dose-response curves. Study design did not have an impact on the 
curves (Table 4). 
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Table 4. Impact of categorical covariates related to the type of phytosterols, food format, 
study quality and study design on the absolute and relative dose-response curve. 
Treatment  
or study 
characteristic 
Categories compared 
(number of strata) 
Difference in 
parameter aa,b 
(mmol/L or %) 
95% CI Difference in 
parameter 
ba,b (g/d) 
95% CI 
Absolute curvec 
Type of 
phytosterols 
Plant stanols (n = 53) vs. plant 
sterols (n = 74) 
-0.13 (-0.38, 0.12) 0.65 (-0.63, 1.93) 
Food format Non fat-based (n = 50) vs. fat-
based (n = 88) 
0.05 (-0.12, 0.21) -0.24 (-1.08, 0.60) 
 Non-dairy (n = 114) vs. dairy 
(n = 26) 
-0.02 (-0.18, 0.14) 0.36 (-0.45, 1.16) 
 Solid (n = 116) vs. liquid (n = 24) -0.11 (-0.24, 0.02) 0.51 (-0.27, 1.29) 
Quality High (n = 85) vs. low (n = 52) 
compliance 
-0.01 (-0.17, 0.16) -0.09 (-0.95, 0.76) 
 Well (n =  110) vs. poorly (n = 27) 
randomized 
-0.04 (-0.20, 0.11) 0.15 (-0.46, 1.14) 
 High (n = 68) vs. low (n = 69) 
quality 
-0.04 (-0.25, 0.17) 0.29 (-0.76, 1.33) 
Design Cross-over (n = 68) vs. parallel 
(n = 73) 
1.96 (-5.90, 9.81) -0.38 (-1.79, 1.03) 
Relative curvec 
Type of 
phytosterols 
Plant stanols (n = 53) vs. plant 
sterols (n = 74) 
-6.66 (-18.33, 5.02) 1.13 (-0.98, 3.23) 
Food format Non fat-based (n = 50) vs. fat-
based (n = 88) 
1.45 (-4.83, 7.72) -0.17 (-1.31, 0.97) 
 Non-dairy (n = 114) vs. dairy 
(n = 26) 
- - - - 
 Solid (n = 116) vs. liquid (n = 24) -5.23 (-8.63, -1.83)* 0.86 (0.02, 1.71)* 
Quality High (n = 85) vs. low (n = 52) 
compliance 
-0.93 (-7.07, 5.20) 0.09 (-1.05, 1.23) 
 Well (n =  110) vs. poorly (n = 27) 
randomized 
-3.36 (-7.73, 1.02) 0.75 (-0.11, 1.61) 
 High (n = 68) vs. low (n = 69) 
quality 
-8.66 (-27.49, 10.17) 1.66 (-1.59, 4.90) 
Design Cross-over (n = 68) vs. parallel 
(n = 73) 
0.12 (-0.16, 0.39) -0.60 (-1.89, 0.69) 
a The differences in parameters a and b of the curves obtained for subcategories of a covariable were calculated by re-
parameterizing the equation with terms for differences between categories. 
b Parameter a is the maximal LDL-C-lowering effect and parameter b is the dose step needed to achieve an additional 
effect, which is one half the size of the previous dose effect. 
c
 For the absolute curve, the change in parameter a is expressed in mmol/L, and for the relative curve, it is expressed in 
% from baseline/control. 
* P < 0.05. 
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Discussion 
The key outcome of this review and meta-analysis is the generation of a 
physiologically relevant, continuous dose-response relationship for the LDL-C-
lowering effect of phytosterols. By including not only fat-based foods consumed 
multiple times per day but also low-fat or fat-free foods and food formats intended 
for once-a-day use, this approach provides an updated estimation of the LDL-C-
lowering efficacy of phytosterols in the variety of available food formats. The dose-
response equation predicts an LDL-C-lowering effect of 29% for the recommended 
2 g/d dose of phytosterols, which is consistent with our pooled estimate showing 
an 8.8% decrease in LDL-C for a mean dose of 2.15 g/d and with the mean 8.9% 
reduction reported by Katan et al.
3
 for phytosterol doses of 2.0-2.4 g/d provided 
mainly in fat-based food formats.  
 
We attempted to estimate as well the dose-response relationship for the effect of 
phytosterols on the TC:HDL-C ratio, but firm conclusions could not be drawn 
because the ratio calculated from the reported means of TC and HDL-C was 
underestimated. Results from a recent meta-analysis of individual subject data
110
 
provide more insights into this question. Phytosterols (in this case, plant stanols) 
were shown to significantly lower TC:HDL-C ratios and decreases were more 
pronounced in subjects with higher baseline values. In subjects with low baseline 
HDL-C concentrations, HDL-C was slightly increased, while in subjects with high 
baseline concentrations, it was marginally lowered
110
. According to the authors, 
this slight reduction in HDL-C in subjects with high baseline values would not 
increase cardiovascular risk, because at the same time, LDL-C would be decreased 
substantially. 
 
The LDL-C-lowering dose-response curve obtained from the present meta-analysis 
had a plateau at phytosterol intakes of ~3 g/d, corresponding to an LDL-C-lowering 
effect of -10.7%, which is consistent with the estimation by Katan et al.
3
, according 
to which doses >2.5 g/d provided only little additional benefit. The present meta-
analysis indicated that most phytosterol treatment characteristics (fat-based vs. 
non fat-based formats, dairy vs. non-dairy formats, free phytosterols vs. 
phytosterol esters, and plant sterols vs. stanols) had no noticeable impact on the 
LDL-C-lowering efficacy. The LDL-C-lowering effect of free phytosterols and 
phytosterol esters has so far not been directly compared in single trials, but 
cholesterol absorption inhibition was shown to be similar
111
 or even larger
112
 with 
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free plant sterols than with the esters. In short (3-4-week)
29,88,101,108
 and longer 
term (up to 85-week)
113
 trials where stanols and sterols were compared side by 
side, no difference was observed between sterols and stanols, which is consistent 
with the present results.  
 
Results from the present meta-analysis suggest that solid food formats may result 
in a larger LDL-C-lowering effect than liquid foods when the phytosterol dose is 
high (>2 g/d). In a previous study, a yogurt drink enriched with ~3 g/d plant sterols 
had a greater efficacy when consumed with a lunch meal than after an overnight 
fast
20
. These data could provide support to the hypothesis of a beneficial impact of 
the simultaneous presence of a solid meal on the cholesterol-lowering efficacy of 
liquid food formats, perhaps by a longer transit time in the gastrointestinal tract. 
However, in most studies included in this meta-analysis, the phytosterol-enriched 
liquid foods were consumed at meal time. Proper side-by-side comparisons in the 
same trial and using the same daily dose would be needed to confirm a difference 
in efficacy between solid and liquid food formats. One previous study comparing 
the efficacy of plant sterol-enriched (1.6 g/d) milk, yogurt, cereal, and bread 
consumed at meal time showed the greatest efficacy with the milk format
10
. In 
addition, the greater efficacy of solid food formats was observed in this meta-
analysis only at high intakes, for which few strata were available, suggesting that 
this finding may have little practical relevance for phytosterol doses close to the 
recommended intake of 2 g/d.  
 
Another factor that may affect the LDL-C–lowering efficacy of phytosterols is the 
number of portions consumed over the day. So far, only one trial has directly 
compared the effects of once per day compared to a 3 times/d intake of 
phytosterols provided in a fat-based spread consumed at meal time and showed no 
significant difference between the two frequencies of intakes
104
. Other studies in 
which once-per-day intake of phytosterols was assessed had significant reductions 
in LDL-C
13,16,21-24
. Nevertheless, the tendency towards a larger effect of multiple 
daily intakes than single intakes in the present meta-analysis may suggest that a 
modest effect of frequency of intake may exist but was not detected previously due 
to a lack of statistical power. Based on the main mechanism of action of 
phytosterols, which is considered to be the competition with cholesterol for 
micellar incorporation
8
, it could be hypothesized that multiple daily intakes, by 
favoring the simultaneous presence in the gut of phytosterols, cholesterol, and bile 
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acids in repeated occasions during the day, would lead to a greater efficacy than a 
single intake. In fact, the mechanisms by which once-a-day intake of phytosterols 
would substantially lower LDL-C are not fully understood and warrant further 
investigations.  
 
The present meta-analysis shows a clear impact of baseline LDL-C concentrations 
on the magnitude of the absolute decreases in LDL-C concentrations resulting from 
phytosterol consumption. The previous meta-analyses by Law et al.
2
 and Katan et 
al.
3
 had shown larger reductions in older subjects and it was hypothesized that this 
effect was due mainly to the higher baseline LDL-C concentrations with increasing 
age. The regression analysis performed in the present work, with no significant 
effect of age when baseline LDL-C concentrations were included in the model, 
confirmed this hypothesis. A recent meta-analysis of individual subject data
110
 also 
showed larger absolute LDL-C reductions with plant stanol consumption when 
baseline concentrations were higher. The relative dose-response curves obtained 
from the present meta-analysis therefore present an advantage over the absolute 
curves by taking into account the baseline LDL-C levels.  
 
The equations describing the continuous dose-response relationship offer a novel 
approach to predict the LDL-C-lowering effect of a given dose of phytosterols in 
populations, which could not be derived from previous data
3
. However, due to the 
large variability between studies in which the same dose of phytosterols was 
tested, the predicted effect should be used as an indication only. It could be argued 
that with such variability around the dose-response curve, a linear fit would have 
performed as well as the nonlinear relationship. To verify this hypothesis, the sum 
of the residuals between the observed LDL-C changes and the predicted changes 
obtained with the curve or with a linear fit crossing the y axis at zero (without a 
maximal reduction estimate) were compared. The sum of the residuals was 
considerably lower with the curve (370%) than with the linear relationship (475%), 
indicating that the nonlinear, physiologically relevant model is more appropriate.  
 
The dose-response curves reported here were established by deliberately including 
studies in which phytosterol intakes could be as high as 10 g/d, because data 
obtained with such intakes could provide useful information regarding the 
expected plateau while still being realistically achievable through the consumption 
of phytosterol-enriched foods or supplements. A post hoc analysis showed that the 
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dose-response curve was not significantly influenced by the inclusion of studies 
with doses of 5-10 g/d. Indeed, the maximal LDL-C reduction (parameter a) and the 
incremental dose step (parameter b) were -13.26 (95% CI: -17.04; -9.48) and 1.22 
(95% CI: 0.54; 1.90) for the curve including doses of < 5 g/d compared to -12.68 
(95% CI: -15.38; -9.99) and 1.12 (95% CI: 0.62; 1.63) for the curve including doses of 
up to 10 g/d. 
 
Although various background diets were used in the studies included in the present 
meta-analysis, comprising usual diets as well as low-fat, low-cholesterol diets 
consumed both in free-living or more controlled conditions, we did not investigate 
the potential impact of the background diet on the cholesterol-lowering efficacy of 
phytosterols. Results from one recent trial suggest that the cholesterol content of 
the background diet may have no significant effect on plant sterol efficacy
114
. 
Subject ethnicity is another factor that could potentially affect phytosterol efficacy 
beyond baseline LDL-C concentrations. Additional investigations to further study 
this factor, together with the effect of genetic polymorphisms, are warranted. 
 
In summary, the present meta-analysis confirmed the significant LDL-C-lowering 
effect of phytosterols. Equations based on the underlying mechanism of action of 
plant sterols and stanols were determined to describe the dose-response 
relationship and could potentially be used to predict the LDL-C-lowering effect of a 
given phytosterol dose. However, the use of the curve as a prediction tool should 
be done cautiously due to the large intertribal variability at fixed doses. For the 
recommended intake of 2 g/d, the expected LDL-C-lowering effect of phytosterols 
is 29%. A reduction in LDL-C of ~10% would reduce the incidence of CHD by ~10-
20%
2,4
. Although no direct evidence is available yet for the ability of phytosterols to 
lower CHD incidence, the well-documented cholesterol-lowering effect of 
phytosterols is the basis for recommendations to include phytosterols into 
strategies to lower LDL-C concentrations. The present meta-analysis did not show 
significant differences in efficacy of various food formats providing phytosterol 
doses around the recommended intake. However, at high phytosterol doses, solid 
food formats may have a more pronounced LDL-C-lowering effect than liquid food 
formats. Although not significant (P = 0.054), the possibility of an impact of 
frequency of intake over the day could not be excluded. Further investigations are 
warranted to gain more insights into the effect of these factors on the efficacy of 
phytosterols to lower LDL-C concentrations. 
Continuous dose-response relationship between phytosterols and LDL-cholesterol | 51 
 
Acknowledgements 
I. Demonty, H. C. M. van der Knaap, G. S. M. J. E. Duchateau, P. L. Zock, and E. A. Trautwein are 
employed by the Unilever Research and Development, Vlaardingen, The Netherlands. R. Ras and L. 
Meijer worked on this study during their internship at the Unilever Research and Development, 
Vlaardingen, The Netherlands, as part of their education program at Wageningen University, 
Wageningen, The Netherlands. J. M. Geleijnse, no conflict of interest. 
 
References 
 (1)  Pollak OJ. Reduction of blood cholesterol in man. Circulation 1953;7:702-706. 
 (2)  Law M. Plant sterol and stanol margarines and health. British Medical Journal 2000;320:861-
864. 
 (3)  Katan MB, Grundy SM, Jones P et al. Efficacy and safety of plant stanols and sterols in the 
management of blood cholesterol levels. Mayo Clinic Proceedings 2003;78:965-978. 
 (4)  NCEP ATP III. Third report of the National Cholesterol Education Program (NCEP) expert panel 
on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment 
panel III).  U.S. Department of Health and Human Services - National Heart, Lung, and Blood 
Institute; 2002. Report No.: NIH Publication No. 02-5215. 
 (5)  Lichtenstein AH, Appel LJ, Brands M et al. Diet and lifestyle recommendations revision 2006: 
a scientific statement from the American Heart Association Nutrition Committee. Circulation 
2006;114:82-96. 
 (6)  Poli A, Marangoni F, Paoletti R et al. Non-pharmacological control of plasma cholesterol 
levels. Nutrition Metabolism and Cardiovascular Disease 2008;18:S1-16. 
 (7)  International Atherosclerosis Society. International Atherosclerosis Society harmonised 
clinical guidelines on prevention of atherosclerotic vascular disease. Full report.  2003.  
 (8)  Trautwein EA, Duchateau GSMJ, Lin Y et al. Proposed mechanisms of cholesterol-lowering 
action of plant sterols . European Journal of Lipid Science and Technology 2003;105:171-185. 
 (9)  Normen L, Frohlich JJ, Trautwein E. Role of plant sterols in cholesterol lowering. In: Dutta PC, 
editor. Phytosterols as functional foods components and nutraceuticals. 2003. p. 243-315. 
 (10)  Clifton PM, Noakes M, Sullivan D et al. Cholesterol-lowering effects of plant sterol esters 
differ in milk, yoghurt, bread and cereal. European Journal of Clinical Nutrition 2004;58:503-
509. 
 (11)  Noakes M, Clifton PM, Doornbos AM et al. Plant sterol ester-enriched milk and yoghurt 
effectively reduce serum cholesterol in modestly hypercholesterolemic subjects. European 
Journal of Nutrition 2005;44:214-222. 
 (12)  Thomsen AB, Hansen HB, Christiansen C et al. Effect of free plant sterols in low-fat milk on 
serum lipid profile in hypercholesterolemic subjects. European Journal of Clinical Nutrition 
2004;58:860-870. 
 (13)  Hyun YJ, Kim OY, Kang JB et al. Plant stanol esters in low-fat yogurt reduces total and low-
density lipoprotein cholesterol and low-density lipoprotein oxidation in 
normocholesterolemic and mildly hypercholesterolemic subjects. Nutrition Research 
2005;25:743-753. 
 (14)  Korpela R, Tuomilehto J, Hogstrom P et al. Safety aspects and cholesterol-lowering efficacy of 
low fat dairy products containing plant sterols. European Journal of Clinical Nutrition 2006. 
52 | Chapter 2  
 
 (15)  Mensink RP, Ebbing S, Lindhout M et al. Effects of plant stanol esters supplied in low-fat 
yoghurt on serum lipids and lipoproteins, non-cholesterol sterols and fat soluble antioxidant 
concentrations. Atherosclerosis 2002;160:205-213. 
 (16)  Seppo L, Jauhiainen T, Nevala R et al. Plant stanol esters in low-fat milk products lower serum 
total and LDL cholesterol. European Journal of Nutrition 2007;46:111-117. 
 (17)  Devaraj S, Jialal I, Vega-Lopez S. Plant sterol-fortified orange juice effectively lowers 
cholesterol levels in mildly hypercholesterolemic healthy individuals. Arteriosclerosis 
Thrombosis and Vascular Biology 2004;24:e25-e28. 
 (18)  Devaraj S, Autret BC, Jialal I. Reduced-calorie orange juice beverage with plant sterols lowers 
C-reactive protein concentrations and improves the lipid profile in human volunteers. 
American Journal of Clinical Nutrition 2006;84:756-761. 
 (19)  Hironaka T, Shioya N, Matsubara H et al. Double-blind, placebo-controlled study of effects of 
plant sterol enriched vegetable juice on serum cholesterol concentrations in mildly 
hypercholesterolemic subjects and safety evaluation . Journal of Oleo Science 2006;55 :593-
606. 
 (20)  Doornbos AM, Meynen EM, Duchateau GSMJ et al. Intake occasion affects the serum 
cholesterol lowering of a plant sterol-enriched single-dose yoghurt drink in mildly 
hypercholesterolaemic subjects. European Journal of Clinical Nutrition 2006;60:325-333. 
 (21)  Algorta Pineda J, Chinchetru Ranedo MJ, Aguirre AJ et al. Hypocholesteremic effectiveness of 
a yogurt containing plant stanol esters. Revista Clinica Espanola 2005;205:63-66. 
 (22)  Salo P, Wester I. Low-fat formulations of plant stanols and sterols. American Journal of 
Cardiology 2005;96:51D-54D. 
 (23)  Plana N, Nicolle C, Ferre R et al. Plant sterol-enriched fermented milk enhances the 
attainment of LDL-cholesterol goal in hypercholesterolemic subjects. European Journal of 
Nutrition 2008;47:32-39. 
 (24)  Hansel B, Nicolle C, Lalanne F et al. Effect of low-fat, fermented milk enriched with plant 
sterols on serum lipid profile and oxidative stress in moderate hypercholesterolemia. 
American Journal of Clinical Nutrition 2007;86:790-796. 
 (25)  Thurnhofer H, Hauser H. Uptake of cholesterol by small intestinal brush border membrane is 
protein-mediated. Biochemistry 1990;29:2142-2148. 
 (26)  Lewington S, Whitlock G, Clarke R et al. Blood cholesterol and vascular mortality by age, sex, 
and blood pressure: a meta-analysis of individual data from 61 prospective studies with 
55,000 vascular deaths. Lancet 2007;370:1829-1839. 
 (27)  Neil HA, Meijer GW, Roe LS. Randomised controlled trial of use by hypercholesterolaemic 
patients of a vegetable oil sterol-enriched fat spread. Atherosclerosis 2001;156:329-337. 
 (28)  Simons LA. Additive effect of plant sterol-ester margarine and cerivastatin in lowering low-
density lipoprotein cholesterol in primary hypercholesterolemia. American Journal of 
Cardiology 2002;90:737-740. 
 (29)  Jones PJH, Raeini-Sarjaz M, Ntanios FY et al. Modulation of plasma lipid levels and cholesterol 
kinetics by phytosterol versus phytostanol esters. Journal of Lipid Research 2000;41:697-705. 
 (30)  Jones PJH, Ntanios FY, Raeini-Sarjaz M et al. Cholesterol-lowering efficacy of a sitostanol-
containing phytosterol mixture with a prudent diet in hyperlipidemic men. American Journal 
of Clinical Nutrition 1999;69:1144-1150. 
 (31)  Cleghorn CL, Skeaff CM, Mann J et al. Plant sterol-enriched spread enhances the cholesterol-
lowering potential of a fat-reduced diet. European Journal of Clinical Nutrition 2003;57:170-
176. 
Continuous dose-response relationship between phytosterols and LDL-cholesterol | 53 
 
 (32)  Hallikainen MA, Uusitupa MI. Effects of 2 low-fat stanol ester-containing margarines on 
serum cholesterol concentrations as part of a low-fat diet in hypercholesterolemic subjects. 
American Journal of Clinical Nutrition 1999;69:403-410. 
 (33)  Harris WS. n-3 fatty acids and serum lipoproteins: human studies. American Journal of 
Clinical Nutrition 1997;65:1645S-1654S. 
 (34)  Balk EM, Lichtenstein AH, Chung M et al. Effects of omega-3 fatty acids on serum markers of 
cardiovascular disease risk: a systematic review. Atherosclerosis 2006;189:19-30. 
 (35)  Robinson JG, Stone NJ. Antiatherosclerotic and antithrombotic effects of omega-3 fatty acids. 
American Journal of Cardiology 2006;98:39i-49i. 
 (36)  Sierksma A, Weststrate JA, Meijer GW. Spreads enriched with plant sterols, either esterified 
4,4-dimethylsterols or free 4-desmethylsterols, and plasma total- and LDL-cholesterol 
concentrations. British Journal of Nutrition 1999;82:273-282. 
 (37)  Vissers MN, Zock PL, Meijer GW et al. Effect of plant sterols from rice bran oil and triterpene 
alcohols from sheanut oil on serum lipoprotein concentrations in humans. American Journal 
of Clinical Nutrition 2000;72:1510-1515. 
 (38)  Verhagen AP, de Vet HC, de Bie RA et al. The Delphi list: a criteria list for quality assessment 
of randomized clinical trials for conducting systematic reviews developed by Delphi 
consensus. Journal of Clinical Epidemiology 1998;51:1235-1241. 
 (39)  Chalmers TC, Smith H, Jr., Blackburn B et al. A method for assessing the quality of a 
randomized control trial. Controlled Clinical Trials 1981;2:31-49. 
 (40)  Khan KS, ter Riet G, Popay J, Nixon J, Kleijnen J. Study quality assessment. In: Khan KS, ter Riet 
G, Glanville J, Sowden AJ, Kleijnen J, editors. Undertaking systematic reviews of research on 
effectiveness: CRD's guidance for carrying out or commissioning reviews.York: University of 
York; 2001. p. 1-20. 
 (41)  Dersimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clinical Trials 1986;7:177-
188. 
 (42)  Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Statistics in Medicine 
2002;21:1539-1558. 
 (43)  Egger M, Davey SG, Smith G et al. Bias in meta-analysis detected by a simple, graphical test. 
British Medical Journal 1997;315:629-634. 
 (44)  Vandeginste BGM, Massart DL, Buydens LMC, De Jong S, Lewi PJ, Smeyers-Verbeke J. 
Handbook of Chemometircs and Qualimetrics Part B. Amsterdam: Elsevier; 1998. 
 (45)  Alhassan S, Reese KA, Mahurin J et al. Blood lipid responses to plant stanol ester 
supplementation and aerobic exercise training. Metabolism 2006;55:541-549. 
 (46)  Andersson A, Karlstrom B, Mohsen R et al. Cholesterol-lowering effects of a stanol ester-
containing low-fat margarine used in conjunction with a strict lipid-lowering diet. European 
Heart Journal 1999;1:S80-S90. 
 (47)  Ayesh R, Weststrate JA, Drewitt PN et al. Safety evaluation of phytosterol esters. Part 5. 
Faecal short-chain fatty acid and microflora content, faecal bacterial enzyme activity and 
serum female sex hormones in healthy normolipidaemic volunteers consuming a controlled 
diet either with or without a phytosterol ester-enriched margarine. Food and Chemical 
Toxicology 1999;37:1127-1138. 
 (48)  Beer MU, Pritchard H, Belsey EM et al. Effect of a milk drink enriched with increasing doses of 
free tall oil phytosterols on plasma lipid levels of mildly hypercholesteroleamic subjects. 
Document submitted to FDA 2000;Docket No OOP1275 and OOP1276. 
54 | Chapter 2  
 
 (49)  Blair SN, Capuzzi DM, Gottlieb SO et al. Incremental reduction of serum total cholesterol and 
low-density lipoprotein cholesterol with the addition of plant stanol ester-containing spread 
to statin therapy. American Journal of Cardiology 2000;86:46-52. 
 (50)  Blomqvist SM, Jauhiainen M, Vantol A et al. Effect of sitostanol ester on composition and size 
distribution of low-density and high-density-lipoprotein. Nutrition Metabolism and 
Cardiovascular Diseases 1993;3:158-164. 
 (51)  Clifton PM, Mano M, Duchateau GSMJ et al. Dose-response effects of different plant sterol 
sources in fat spreads on serum lipids and C-reactive protein and on the kinetic behavior of 
serum plant sterols. European Journal of Clinical Nutrition 2008;62:968-977. 
 (52)  Davidson MH, Maki KC, Umporowicz DM et al. Safety and tolerability of esterified 
phytosterols administered in reduced-fat spread and salad dressing to healthy adult men and 
women. Journal of the American College of Nutrition 2001;20:307-319. 
 (53)  de Graaf J, Sauvage Nolting PR, Van Dam M et al. Consumption of tall oil-derived phytosterols 
in a chocolate matrix significantly decreases plasma total and low-density lipoprotein-
cholesterol levels. British Journal of Nutrition 2002;88:479-488. 
 (54)  de Jong A, Plat J, Bast A et al. Effects of plant sterol and stanol ester consumption on lipid 
metabolism, antioxidant status and markers of oxidative stress, endothelial function and low-
grade inflammation in patients on current statin treatment. European Journal of Clinical 
Nutrition 2008;62:263-273. 
 (55)  Earnest CP, Mikus CR, Lemieux I et al. Examination of encapsulated phytosterol ester 
supplementation on lipid indices associated with cardiovascular disease. Nutrition 
2007;23:625-633. 
 (56)  Goldberg AC, Ostlund RE, Bateman JH et al. Effect of plant stanol tablets on low-density 
lipoprotein cholesterol lowering in patients on statin drugs. American Journal of Cardiology 
2006;97:376-379. 
 (57)  Homma Y, Ikeda I, Ishikawa TT et al. Decrease in plasma low-density lipoprotein cholesterol, 
apolipoprotein B, cholesteryl ester transfer protein, and oxidized low-density lipoprotein by 
plant stanol ester-containing spread: a randomized, placebo-controlled trial. Nutrition 
2003;19:369-374. 
 (58)  Ishiwata K, Homma Y, Ishikawa TT et al. Influence of apolipoprotein E phenotype on 
metabolism of lipids and apolipoproteins after plant stanol ester ingestion in Japanese 
subjects. Nutrition 2002;18:561-565. 
 (59)  Jauhiainen T, Salo P, Niittynen L et al. Effects of low-fat hard cheese enriched with plant 
stanol esters on serum lipids and apolipoprotein B in mildly hypercholesterolaemic subjects. 
European Journal of Clinical Nutrition 2006. 
 (60)  Lagstrom H, Helenius H, Salo P. Serum cholesterol-lowering efficacy of stanol ester 
incorporated in gelatin capsules. Scandinavian Journal of Food and Nutrition 2006;-1300. 
 (61)  Lee YM, Haastert B, Scherbaum W et al. A phytosterol-enriched spread improves the lipid 
profile of subjects with type 2 diabetes mellitus - A randomized controlled trial under free-
living conditions. European Journal of Nutrition 2003;42:111-117. 
 (62)  Li NY, Li K, Qi Z et al. Plant sterol-enriched milk tea decreases blood cholesterol 
concentrations in Chinese adults: a randomised controlled trial. British Journal of Nutrition 
2007;1-6. 
 (63)  Maki KC, Davidson MH, Umporowicz DM et al. Lipid responses to plant-sterol-enriched 
reduced-fat spreads incorporated into a National Cholesterol Education Program Step I diet. 
American Journal of Clinical Nutrition 2001;74:33-43. 
Continuous dose-response relationship between phytosterols and LDL-cholesterol | 55 
 
 (64)  Matsuoka R, Masuda Y, Takeuchi A et al. A double-blind, placebo controlled study on the 
effects of mayonnaise containing free plant sterol on serum cholesterol concentration; safety 
evaluation for normocholesterolemic and mildy hyerpcholesterolemic Japanese subjects. 
Journal of Oleo Science 2004;53:79-88. 
 (65)  Matvienko OA, Lewis DS, Swanson M et al. A single daily dose of soybean phytosterols in 
ground beef decreases serum total cholesterol and LDL cholesterol in young, mildly 
hypercholesterolemic men. American Journal of Clinical Nutrition 2002;76:57-64. 
 (66)  McPherson TB, Ostlund RE, Goldberg AC et al. Phytostanol tablets reduce human LDL-
cholesterol. Journal of Pharmacy and Pharmacology 2005;57:889-896. 
 (67)  Miettinen TA, Vanhanen H. Dietary sitostanol related to absorption, synthesis and serum 
level of cholesterol in different apolipoprotein E phenotypes. Atherosclerosis 1994;105:217-
226. 
 (68)  Miettinen TA, Puska P, Gylling H et al. Reduction of serum cholesterol with sitostanol-ester 
margarine in a mildly hypercholesterolemic population. New England Journal of Medicine 
1995;333:1308-1312. 
 (69)  Niittynen LH, Jauhiainen TA, Poussa TA et al. Effects of yoghurt enriched with free plant 
sterols on the levels of serum lipids and plant sterols in moderately hypercholesterolaemic 
subjects on a high-fat diet. International Journal of Food Sciences and Nutrition 2008;59:357-
367. 
 (70)  Plat J, Mensink RP. Vegetable oil based versus wood based stanol ester mixtures: effects on 
serum lipids and hemostatic factors in non-hypercholesterolemic subjects. Atherosclerosis 
2000;148:101-112. 
 (71)  Quilez J, Rafecas M, Brufau G et al. Bakery products enriched with phytosterol esters, alpha-
tocopherol and beta-carotene decrease plasma LDL-cholesterol and maintain plasma beta-
carotene concentrations in normocholesterolemic men and women. Journal of Nutrition 
2003;133:3103-3109. 
 (72)  Seki S, Hidaka I, Kojima K et al. Effects of phytosterol ester-enriched vegetable oil on plasma 
lipoproteins in healthy men. Asia Pacific Journal of Clinical Nutrition 2003;12:282-291. 
 (73)  Seki S, Abe T, Hidaka I et al. Effects of phytosterol ester-enriched vegetable oil on serum 
cholesterol and assessment of safety in healthy men. Journal of Oleo Science 2003;52:205-
213. 
 (74)  Spilburg CA, Goldberg AC, McGill JB et al. Fat-free foods supplemented with soy stanol-
lecithin powder reduce cholesterol absorption and LDL cholesterol. Journal of the American 
Dietetic Association 2003;103:577-581. 
 (75)  Taichi I. Effects of long-term intake of mayonnaise containing phytosterolester on blood 
cholesterol concentration in Japanese with borderline or mild cholesterolemia. Journal of 
Clinical Biochemistry and Nutrition 2003;33:75-82. 
 (76)  Vanhanen HT, Kajander J, Lehtovirta H et al. Serum levels, absorption efficiency, faecal 
elimination and synthesis of cholesterol during increasing doses of dietary sitostanol esters in 
hypercholesterolaemic subjects. Clinical Science 1994;87:61-67. 
 (77)  Vanhanen HT. Cholesterol malabsorption caused by sitostanol ester feeding and neomycin in 
pravastatin-treated hypercholesterolaemic patients. European Journal of Clinical 
Pharmacology 1994;47:169-176. 
 (78)  Varady KA, Ebine N, Vanstone CA et al. Plant sterols and endurance training combine to 
favorably alter plasma lipid profiles in previously sedentary hypercholesterolemic adults after 
8 wk. American Journal of Clinical Nutrition 2004;80:1159-1166. 
56 | Chapter 2  
 
 (79)  Woodgate D, Chan CHM, Conquer JA. Cholesterol-lowering ability of a phytostanol softgel 
supplement in adults with mild to moderate hypercholesterolemia. Lipids 2006;41 :127-132. 
 (80)  AbuMweis SS, Vanstone CA, Ebine N et al. Intake of a single morning dose of standard and 
novel plant sterol preparations for 4 weeks does not dramatically affect plasma lipid 
concentrations in humans. Journal of Nutrition 2006. 
 (81)  Cater NB, Garcia-Garcia AB, Vega GL et al. Responsiveness of plasma lipids and lipoproteins 
to plant stanol esters. American Journal of Cardiology 2005;96:23-28. 
 (82)  Chan YM, Demonty I, Pelled D et al. Olive oil containing olive oil fatty acid esters of plant 
sterols and dietary diacylglycerol reduces low-density lipoprotein cholesterol and decreases 
the tendency for peroxidation in hypercholesterolaemic subjects. British Journal of Nutrition 
2007;98:563-570. 
 (83)  Colgan HA, Floyd S, Noone EJ et al. Increased intake of fruit and vegetables and a low-fat diet, 
with and without low-fat plant sterol-enriched spread consumption: effects on plasma 
lipoprotein and carotenoid metabolism. Journal of Human Nutrition and Dietetics 
2004;17:561-569. 
 (84)  Geelen A, Zock PL, de Vries JHM et al. Apolipoprotein E polymorphism and serum lipid 
response to plant sterols in humans. European Journal of Clinical Investigation 2002;32:738-
742. 
 (85)  Gylling H, Miettinen TA. Serum cholesterol and cholesterol and lipoprotein metabolism in 
hypercholesterolaemic NIDDM patients before and during sitostanol ester-margarine 
treatment. Diabetologia 1994;37:773-780. 
 (86)  Gylling H, Miettinen TA. Cholesterol reduction by different plant stanol mixtures and with 
variable fat intake. Metabolism 1999;48:575-580. 
 (87)  Gylling H, Radhakrishnan R, Miettinen TA. Reduction of serum cholesterol in postmenopausal 
women with previous myocardial infarction and cholesterol malabsorption induced by 
dietary sitostanol ester margarine: women and dietary sitostanol. Circulation 1997;96:4226-
4231. 
 (88)  Hallikainen M, Sarkkinen ES, Gylling H et al. Comparison of the effects of plant sterol ester 
and plant stanol ester-enriched margarines in lowering serum cholesterol concentrations in 
hypercholesterolaemic subjects on a low-fat diet. European Journal of Clinical Nutrition 
2000;54:715-725. 
 (89)  Hayes KC, Pronczuk A, Perlman D. Nonesterified phytosterols dissolved and recrystallized in 
oil reduce plasma cholesterol in gerbils and humans. Journal of Nutrition 2004;134:1395-
1399. 
 (90)  Hendriks HFJ, Weststrate JA, Van Vliet T et al. Spreads enriched with three different levels of 
vegetable oil sterols and the degree of cholesterol lowering in normocholesterolaemic and 
mildly hypercholesterolaemic subjects. European Journal of Clinical Nutrition 1999;53:319-
327. 
 (91)  Jakulj L, Trip MD, Sudhop T et al. Inhibition of cholesterol absorption by the combination of 
dietary plant sterols and ezetimibe: effects on plasma lipid levels. Journal of Lipid Research 
2005;46:2692-2698. 
 (92)  Jones PJH, Vanstone CA, Raeini-Sarjaz M et al. Phytosterols in low- and nonfat beverages as 
part of a controlled diet fail to lower plasma lipid levels. Journal of Lipid Research 
2003;44:1713-1719. 
 (93)  Judd JT, Baer DJ, Chen SC et al. Plant sterol esters lower plasma lipids and most carotenoids 
in mildly hypercholesterolemic adults. Lipids 2002;37:33-42. 
Continuous dose-response relationship between phytosterols and LDL-cholesterol | 57 
 
 (94)  Kratz M, Kannenberg F, Gramenz E et al. Similar serum plant sterol responses of human 
subjects heterozygous for a mutation causing sitosterolemia and controls to diets enriched in 
plant sterols or stanols. European Journal of Clinical Nutrition 2007;61:896-905. 
 (95)  Lau VW, Journoud M, Jones PJH. Plant sterols are efficacious in lowering plasma LDL and non-
HDL cholesterol in hypercholesterolemic type 2 diabetic and nondiabetic persons. American 
Journal of Clinical Nutrition 2005;81:1351-1358. 
 (96)  Lottenberg AMP, Nunes VS, Nakandakare ER et al. The human cholesteryl ester transfer 
protein I405V polymorphism is associated with plasma cholesterol concentration and its 
reduction by dietary phytosterol esters. Journal of Nutrition 2003;133:1800-1805. 
 (97)  Madsen MB, Jensen AM, Schmidt EB. The effect of a combination of plant sterol-enriched 
foods in mildly hypercholesterolemic subjects. Clinical Nutrition 2007;26:792-798. 
 (98)  Mussner MJ, Parhofer KG, Von Bergmann K et al. Effects of phytosterol ester-enriched 
margarine on plasma lipoproteins in mild to moderate hypercholesterolemia are related to 
basal cholesterol and fat intake. Metabolism 2002;51:189-194. 
 (99)  Naumann E, Plat J, Mensink RP. Changes in serum concentrations of noncholesterol sterols 
and lipoproteins in healthy subjects do not depend on the ratio of plant sterols to stanols in 
the diet. Journal of Nutrition 2003;133:2741-2747. 
 (100)  Nestel P, Cehun M, Pomeroy S et al. Cholesterol-lowering effects of plant sterol esters and 
non-esterified stanols in margarine, butter and low-fat foods. European Journal of Clinical 
Nutrition 2001;55:1084-1090. 
 (101)  Noakes M, Clifton PM, Ntanios FY et al. An increase in dietary carotenoids when consuming 
plant sterols or stanols is effective in maintaining plasma carotenoid concentrations. 
American Journal of Clinical Nutrition 2002;75:79-86. 
 (102)  Ntanios FY, Homma Y, Ushiro S. A spread enriched with plant sterol-esters lowers blood 
cholesterol and lipoproteins without affecting vitamins A and E in normal and 
hypercholesterolemic Japanese men and women. Journal of Nutrition 2002;132:3650-3655. 
 (103)  Pelletier X, Belbraouet S, Mirabel D et al. A diet moderately enriched in phytosterols lowers 
plasma cholesterol concentrations in normocholesterolemic humans. Annals of Nutrition and 
Metabolism 1995;39:291-295. 
 (104)  Plat J, Van Onselen EN, Van Heugten MMA et al. Effects on serum lipids, lipoproteins and fat 
soluble antioxidant concentrations of consumption frequency of margarines and shortenings 
enriched with plant stanol esters. European Journal of Clinical Nutrition 2000;54:671-677. 
 (105)  Temme EHM, Van Hoydonck PGA, Schouten EG et al. Effects of a plant sterol-enriched spread 
on serum lipids and lipoproteins in mildly hypercholesterolaemic subjects. Acta Cardiologica 
2002;57:111-115. 
 (106)  Vanstone CA, Raeini-Sarjaz M, Parsons WE et al. Unesterified plant sterols and stanols lower 
LDL-cholesterol concentrations equivalently in hypercholesterolemic persons. American 
Journal of Clinical Nutrition 2002;76:1272-1278. 
 (107)  Volpe R, Niittynen L, Korpela R et al. Effects of yoghurt enriched with plant sterols on serum 
lipids in patients with moderate hypercholesterolaemia. British Journal of Nutrition 
2001;86:233-239. 
 (108)  Weststrate JA, Meijer GW. Plant sterol-enriched margarines and reduction of plasma total- 
and LDL-cholesterol concentrations in normocholesterolaemic and mildly 
hypercholesterolaemic subjects. European Journal of Clinical Nutrition 1998;52:334-343. 
 (109)  Yoshida M, Vanstone CA, Parsons WD et al. Effect of plant sterols and glucomannan on lipids 
in individuals with and without type II diabetes. European Journal of Clinical Nutrition 2006. 
58 | Chapter 2  
 
 (110)  Naumann E, Plat J, Kesler AD et al. The baseline serum lipoprotein profile is related to plant 
stanol induced changes in serum lipoprotein cholesterol and triacylglycerol concentrations. 
Journal of the American College of Nutrition 2008;27:117-126. 
 (111)  Richelle M, Enslen M, Hager C et al. Both free and esterified plant sterols reduce cholesterol 
absorption and the bioavailability of beta-carotene and alpha-tocopherol in 
normocholesterolemic humans. American Journal of Clinical Nutrition 2004;80:171-177. 
 (112)  Mattson FH, Grundy SM, Crouse JR. Optimizing the effect of plant sterols on cholesterol 
absorption in man. American Journal of Clinical Nutrition 1982;35:697-700. 
 (113)  de Jong A, Plat J, Lutjohann D et al. Effects of long-term plant sterol or stanol ester 
consumption on lipid and lipoprotein metabolism in subjects on statin treatment. British 
Journal of Nutrition 2008;100:937-941. 
 (114)  Kassis A, Vanstone CA, AbuMweis SS et al. Efficacy of plant sterols is not influenced by dietary 
cholesterol intake in hypercholesterolemic individuals. Metabolism-Clinical and Experimental 
2008;57:339-346. 
 
Supplemental material 
Supplemental Appendix 1 - Study quality assessment tool used to evaluate the 
quality of the studies included in the systematic review with meta-analysis of the 
LDL-C-lowering effect of phytosterols 
 
Quality item Coding Explanation 
Quality 
score 
Random 
sequence 
generation 
Adequate Sequences obtained are unpredictable: computer generated 
random-numbers, table of random numbers, coin tossing, 
throwing dice, drawing lots or opaque, sealed envelopes 
2 
Inadequate Incomplete randomization but treatment sequences obtained 
seems unpredictablea 
0 
Not specified Term randomized or randomly allocated used, but no more 
explanation, without indication of inadequacy 
2 
Not reported Randomization seems adequate but no term “randomization” in 
text 
0 
Blinding of 
subjects 
Adequate Placebo described as indistinguishable from treatment (“single-
blind or double-blind”)b 
1 
Inadequate Placebo can be distinguished from treatment 0 
Not reported No details or no term single- or double-blind used in text 0 
Blinding of 
investigators 
Adequate Independent person or panel assessing the outcome or 
assessment by the investigator but in clear blind conditions 
(“double-blind”)b 
1 
Inadequate Clearly reported that the investigator was not blinded 0 
Not specified No statement on blinding procedures and not deducible 0 
Eligibility 
criteria 
specified 
Adequate Clear explanation and good follow-up of in- and exclusion criteria 1 
Inadequate In- and exclusion criteria incomplete or not in accordance to study 
objectives or not followed-up correctlyc 
0 
Not specified No statement on procedures and not deducible 
 
0 
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Quality item Coding Explanation 
Quality 
score 
Compliance Adequate with 
supervision 
Phytosterol intake under supervision 2 
Adequate without 
supervision 
Phytosterol intake without supervision: Quantitative description 
of compliance (>85%) and no difference in compliance between 
placebo and treatment groups 
1.5 
Inadequate Difference in compliance between placebo and treatment group 
or very low compliance (<85%) for both groups d 
0 
Not specified Only qualitative description of compliance (“good compliance”) 0.5 
Not reported No statement on procedures and not deducible 0 
Carry-over 
effect taken 
care of for 
cross-over 
trials 
Adequate  If treatment phase <3 weeks: wash-out period 2 weeks 
included to prevent carry-over effects 
 If treatment duration ≥3 weeks: no wash-out necessarye 
1 
Inadequate Wash-out period insufficient (<2 weeks) or no wash-out period 
between treatment phases when treatment phases are less than 3 
weeks long 
0 
Not specified No statement on procedures and not deducible 0 
a Inadequate random sequence generation: for example, when the sequence of treatments was not the same for every 
subject (which is good), but the subjects did not receive all the treatments that were under investigation (e.g. 5 test 
foods, but the subjects had to consume only 4 out of 5 test foods in 4 different test phases). Another example of 
inadequate random sequence generation is when the numbers of subjects in the control group and in the test group 
were noticeably different (e.g. control group with 90 participants and treatment group with 50 participants). 
b Blinding was scored as follows: double-blind was given 2 points, single-blind was given 1 point and open label was 
given 0 points. 
c An example of eligibility criteria not followed-up correctly: the eligibility criteria specified that only subjects with BMI 
<30 would be selected, but from the reported data it was obvious that subjects with BMI >30 were included. 
d The threshold of adequate compliance (≥85%) is quite high, but it was considered that high compliance was 
important, otherwise it could not be assumed that the dose of phytosterols truly consumed by the subjects was as 
reported in the method section of the article. 
e Carry-over taken care of: Cross-over trials have more potential to be given the highest quality score on this criterion 
(“adequate” = 1 point) than to be given the lowest score (“inadequate” or “not specified” = 0 points) for the following 
reasons: 
 Duration of the treatment phase was included in the exclusion criteria (exclude when duration is <2 weeks). 
 When there was an active treatment period of 3 weeks before crossing over, it was justified to have no wash 
out period at all, and therefore such a study would still be judged as “adequate” for this quality criterion. 
 When carry-over effects were explicitly reported in the articles, only data of the first phase were extracted 
for the meta-analysis, and therefore the carry-over effect was automatically taken care of and would have no 
practical influence on the outcome of the meta-analysis. Nevertheless, this criterion was kept in the quality 
assessment tool, because it was necessary to evaluate whether carry-over was taken care of for studies with 
treatment durations between 2-3 weeks. Indeed, the absence of an appropriate wash-out period could have 
biased the outcome of such studies. 
 
Classification of the studies according the quality assessment 
For each study or strata, the overall quality score was calculated by adding the 
individual criteria scores. Adequate random sequence generation, overall blinding 
and compliance were given 2 points because they were judged to potentially have 
the greatest impact on the outcome of the meta-analysis. The maximal quality 
score that could be ascribed to a study was 7 in case of a parallel trial and 8 in case 
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of a cross-over trial. The cut-off point used to distinguish low and good quality trials 
was the mean quality score calculated from all trials with the corresponding design. 
For parallel trials, the mean quality score was 5.4, and a rounded cut-off point of 
5.5 was used. Therefore, trials deserving less than 5.5 points were classified as low 
quality trials, while trials given 5.5 points or more were judged to be of good 
quality. For cross-over trials, the mean quality score was 6.1 and a cut-off point of 
6.0 was used. Trials were of low quality when given 6.0 points or less, or of good 
quality when given more than 6.0 points.  
 
 
Supplemental Appendix 2 - Equations used to calculate the absolute and relative 
net changes in LDL-C as well as the variance measures for the meta-analysis of the 
LDL-C-lowering effect of phytosterols  
 
A. Calculation of the absolute net changes 
 
Parallel trials: 
                                                          
                                   (1) 
where  LDLTendpoint = mean LDL-C at end-of-intervention in the treatment group 
 LDLTbaseline = mean LDL-C at baseline in the treatment group 
LDLCendpoint = mean LDL-C at end-of-intervention in the control group 
 LDLCbaseline = mean LDL-C at baseline in the control group 
 
 
Cross-over trials:  
                                                           (2) 
where  LDLTendpoint = mean LDL-C at the end of the intervention period 
 LDLCendpoint = mean LDL-C at the end of the control period 
 
B. Calculation of the relative net changes 
 
Parallel trials:  
                                                (3) 
where 
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LDL
LDL - LDL
100  LDL%       (4) 
Cbaseline
CbaselineCendpoint
C
LDL
LDL - LDL
100  LDL%       (5) 
 
Cross-over trials:  
                                 
                         
            
     (6) 
 
C. Calculation of the variance measures 
 
To derive SEs from SDs and CIs the following formulas were used: 
n
SD
SE             (7) 
α/2Z
limitlower2limit)upperlimit(lower
SE

       (8) 
where n = number of subjects per group/period  
 Z/2 = normal deviate for 2-sided 100(1-)%  
 
If not provided, the within-trial variance measures of the absolute net changes 
were estimated according to the equations detailed below. For these calculations, 
the method of Follmann et al. (J Clin Epidemiol 1992; 45:769-773) was used, 
assuming a correlation between baseline and endpoint lipid levels for parallel trials, 
and between lipid levels at the end of the phytosterol treatment and the control 
treatment for cross-over trials. The 0.80 within-individual correlation coefficient 
was estimated based on phytosterol trials for which both the within-trial variance 
measure for the net change and the SEs at (baseline and) endpoint were available 
for the control and the treatment groups/periods separately. 
 
Parallel trials:  
Variance measures of the relative or absolute changes from baseline for the 
treatment and control groups were used. Otherwise, the variance measures of 
baseline and endpoint lipid levels were used to estimate the variance measure of 
the net change: 
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2
Tbaseline
2
Tendpoint
2
TbaselineT         (10) 
)SE)((SEr2)SE(SESE 2Cendpoint
2
Cbaseline
2
Cendpoint
2
CbaselineC         (11) 
where  SET is the SE of the change within the treatment group 
 SEC is the SE of the change within the control group 
 SETbaseline is the SE at baseline in the treatment group 
 SETendpoint is the SE at the end-of-intervention in the treatment group 
 SECbaseline is the SE at baseline in the control group 
 SECendpoint is the SE at the end-of-intervention in the control group 
r = 0.80 and is the within-subject correlation between LDL-C 
measurements made before and after the intervention 
 
Cross-over trials:  
The variance measure of the net change was estimated using only the variances of 
endpoint lipid levels:  
)SE)((SEr2)SE(SESE 2C
2
T
2
C
2
Tchangenet                   (12) 
where SET is the SE at the end of the intervention period 
 SEC is the SE at the end of the control period 
r = 0.80 and is the within-subject correlation between LDL-C 
measurements made after the control and the phytosterol treatment 
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Supplemental Appendix 3 - Definition of the subgroups of treatment or study 
characteristics used in the meta-analysis of the LDL-C-lowering effect of 
phytosterols 
 
Treatment or study 
characteristic 
Categories compared Categories Definition categories 
Saturation  
of phyosterols 
Plant stanols vs. plant 
sterols 
Plant stanols Strata using plant stanols 
Plant sterols Strata using plant sterols 
Food format Solid vs. liquid food 
formats 
Solid foods Strata using margarine, butter, 
mayonnaise, yoghurt, hard cheese, fresh 
cheese, beef, cereals, cereal bar, bread, 
tortilla chips, chocolate, bakery products, 
salad dressing, shortening, vegetable oil, 
tablets and capsules 
Liquid foods Strata using yoghurt-drink, milk, orange 
juice, lemonade, vegetable juice and milk 
tea 
Low-fat vs. high-fat  
food formats 
Low-fat foods Strata using yoghurt, yoghurt-drink, hard 
cheese, fresh cheese, beef, milk, orange 
juice, vegetable juice, milk tea, cereals, 
cereal bar, tortilla chips, chocolate, 
bakery products, tablets and capsules 
High-fat foods Strata using margarine, butter, 
mayonnaise, shortening, salad dressing 
and vegetable oil 
Non-dairy vs. dairy food 
formats 
Non-dairy foods Strata using margarine, butter, 
mayonnaise, beef, orange juice, 
lemonade, vegetable juice, milk tea, 
cereals, cereal bar, bread, tortilla chips, 
chocolate, bakery products, salad 
dressing, shortening, vegetable oil, 
tablets, capsules 
Dairy foods Strata using milk, yoghurt and yoghurt 
drink, hard cheese, fresh cheese 
Quality aspects Low vs. high compliance 
strata 
Low compliance 
strata 
Strata with compliance score <1 
High compliance 
strata 
Strata with compliance score ≥1 
Bad vs. good 
randomized strata 
Bad randomized 
strata 
Strata with randomization score <1 
Good randomized 
strata 
Strata with randomization score ≥1 
Low quality vs. high 
quality strata 
Low quality strata Parallel strata with quality score <5.5 and 
cross-over strata with quality score ≤6 
High quality strata Parallel strata with quality score ≥5.5 and 
cross-over strata with quality score >6 
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Supplemental Appendix 4 - General characteristics of the trials included in the 
meta-analysis of the LDL-C-lowering effect of phytosterols 
 
 Number of strata 
Overall study characteristics  
Total number of trials 84 
Total number of strata 141 
Parallel design 73 
Cross-over design 68 
Overall study quality  
Good 68 
Low 69 
Study participants  
Nationality  
European 63 
North-American 42 
Australian 19 
Asian 16 
South-American 1 
Health status  
Apparently healthy (regardless of baseline lipid levels) 116 
Subjects with specific apoE phenotypes 6 
Subjects with health problems 16 
Type II diabetics 4 
Statin users 9 
Previous myocardial infarction 1 
Family members of subjects with familial hypercholesterolemia 2 
Information could not be recorded (publication could not be translated) 3 
Baseline anthropometry  
Mean age: Range 22.7 to 66.0 years 135 
Mean baseline BMI: Range: 22.0 to 31.0 kg/m2 127 
Mean baseline body weight Range: 63.0 to 88.3 kg 56 
Body weight change mentioned 110 
No change 76 
Non-significant change 25 
Small (<2 kg) body weight change 22 
Body weight change >2kg 0 
Baseline plasma LDL-C concentrations reported 23 
Pooled overall LDL-C concentration at baseline: 3.86 mmol/L (95% CI: 3.77; 3.98) 23 
Phytosterol treatment  
Mean phytosterol dose: 2.15 g/d (range: 0.45-9.00 g/d) 141 
Duration: 21-182 d 141 
Type of phytosterols  
Plant sterols 74 
Plant stanols 53 
Combination of plant sterols and stanols 
 
14 
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 Number of strata 
Phytosterol source  
Soybean oil 39 
Tall oil 31 
Undefined vegetable oil or combination of various phytosterol sources 29 
Not specified 42 
Phytosterol form  
Fatty acid esters 102 
Fatty acids from rapeseed oil 42 
Fatty acids from sunflower oil 25 
Others or information not available 35 
Free form, directly dissolved or mixed in the food products 39 
Food formats  
Fat-based foods 88 
Mix of fat-based and non fat-based foods 3 
Non fat-based foods 50 
Dairy food formats 26 
Mix of dairy and non-dairy food formats 1 
Non-dairy food formats 114 
Liquid food formats 24 
Mix of liquid and solid food formats 1 
Solid food formats 116 
Frequency and time of intake  
   Multiple daily intakes 87 
   Single daily intakes 14 
   Frequency of intake not specified 40 
Consumption with or without a meal was reported 106 
   Consumption without a meal 4 
   Meal(s) with which phytosterols were consumed was reported 73 
Single daily intake 14 
Breakfast 7 
Lunch 5 
Dinner 2 
Multiple daily intakes 59 
All three meals 35 
Various combinations of two meals 22 
Before two meals 2 
Background diet  
Typical (usual) dietary pattern in a free-living setting 87 
Typical diet provided 11 
Free-living “heart healthy” diet (low in fat and cholesterol) and/or dietary advice 33 
At least 2 meals provided every day to the participants 17 
  
  
  
 
 
 
 
 
 
 
 
 
 
Chapter 3 
 
LDL-cholesterol-lowering effect of plant sterols and 
stanols across different dose ranges: a meta-
analysis of randomised controlled studies 
 
Rouyanne T. Ras 
Johanna M. Geleijnse 
Elke A. Trautwein 
 
British Journal of Nutrition 2014; 112: 214-219 
 
  
  
LDL-cholesterol-lowering effect of phytosterols across different dose ranges | 69 
 
Abstract 
Phytosterols (comprising plant sterols and plant stanols) have been proven to lower 
low-density lipoprotein cholesterol (LDL-C) concentrations. The dose-response 
relationship for this effect has been evaluated in several meta-analyses by 
calculating averages for different dose ranges or by applying continuous dose-
response functions. Both approaches have advantages and disadvantages. So far, 
the calculation of averages for different dose ranges has not been done for plant 
sterols and stanols separately. The objective of the present meta-analysis was to 
investigate the combined and separate effects of plant sterols and stanols when 
classified into different dose ranges. Studies were searched and selected based on 
predefined criteria. Relevant data were extracted. Average LDL-C effects were 
calculated when studies were categorized by dose, according to random-effects 
models while using the variance as weighing factor. This was done for plant sterols 
and stanols combined and separately. In total, 124 studies (201 strata) were 
included. Plant sterols and stanols were administered in 129 and 59 strata, 
respectively; the remaining used a mix of both. The average phytosterol dose was 
2.1 (range 0.2-9.0) g/d. Phytosterol intakes of 0.6-3.3 g/d were found to gradually 
reduce LDL-C concentrations by, on average, 6-12%. When plant sterols and stanols 
were analyzed separately, clear and comparable dose-response relationships were 
observed. Studies carried out with phytosterol doses exceeding 4 g/d were not 
pooled, as these were scarce and scattered across a wide range of doses. In 
conclusion, the LDL-C-lowering effect of both plant sterols and stanols continues to 
increase up to intakes of approximately 3 g/d to an average effect of 12 %. 
 
Introduction 
Phytosterols, comprising both plant sterols and plant stanols, are compounds that 
naturally occur in all foods of plant origin such as vegetable oils, nuts, seeds, grain 
products, fruits and vegetables. The intake of naturally occurring phytosterols from 
the general diet is about 200-400 mg/d
1-3
. Higher phytosterol intakes can be 
achieved by consuming vegetable-based diets such as vegetarian diets for which 
phytosterol intakes are almost doubled
4,5
 or by consuming food products enriched 
with phytosterols. Phytosterol-enriched foods are well known for their total 
cholesterol and especially low-density lipoprotein cholesterol (LDL-C)-lowering 
properties
6
. Having elevated LDL-C concentrations is one of the most important risk 
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factors for CVD. Phytosterol-enriched foods are considered a valuable option as 
part of healthy diet and lifestyle changes in the management of 
hypercholesterolaemia
7,8
.  
 
Since the 1950’s, abundant research into the LDL-C-lowering effect of phytosterols 
has been carried out and this wealth of evidence has been summarized in several 
meta-analyses
6,9-12
. In these meta-analyses, the dose-response relationship for the 
LDL-C-lowering efficacy of phytosterols has been investigated. The meta-analyses 
carried out by Law
9
, Katan et al.
6
 and Abumweis et al.
10
 described a dose-response 
relationship based on the calculation of average LDL-C-lowering effects for 
different categories of phytosterol doses. More recently, Demonty et al.
11
 have 
investigated a continuous dose-response relationship, as determined by a first-
order elimination function based on the assumption that processes involved in 
cholesterol transport and absorption are saturable. Musa-Veloso et al.
12
 
subsequently established similar continuous dose-response curves, but this time 
for plant sterols and stanols separately. Overall, these analyses concluded that with 
an increasing dose of phytosterols, the LDL-C-lowering effect increases, but that 
this effect tapers off at doses of 2-3 g/d.  
 
The applied approaches used to study the dose-response relationship differ 
between showing average effects for ranges of doses and establishing continuous 
dose-response functions. Both approaches have advantages and disadvantages. 
Establishing a continuous dose-response relationship has the advantage that it 
allows predicting effects for a given dose of phytosterols. However, the shape of 
the curve largely depends on the distribution of studies across the entire range of 
doses; if this distribution is not balanced, this type of analysis may become 
vulnerable for over- or underestimation of the estimated effects at certain doses. 
For example, in the meta-analysis carried out by Musa-Veloso et al.
12
, the depicted 
plant sterol curve clearly underestimated the effects of plant sterols at doses of 
2.7-3.3 g/d. As a result, it was suggested that a larger maximal lowering effect 
exists for plant stanols than for plant sterols. The calculation of average effects for 
predefined ranges of phytosterol doses is less sensitive to potential over- or 
underestimation, but this approach does not allow predicting effects over a 
continuous range of doses. 
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So far, the calculation of weighted averages for different dose ranges has not been 
done for plant sterols and stanols separately. Such an analysis would provide useful 
insights into the comparison of the LDL-C-lowering efficacy of these two types of 
phytosterols for which some debate exists
12-15
. Therefore, the main objective of the 
present analysis was to investigate the combined and separate LDL-C-lowering 
effects of plant sterols and stanols when classified into different dose ranges. It was 
hypothesized that plant sterols and stanols would exert a similar LDL-C-lowering 
effect at least up to intakes of, on average, 3 g/d
16
. 
 
Experimental methods 
Search strategy and selection of eligible studies  
To retrieve potentially relevant human studies eligible for the present analysis, we 
relied on the systematic searches carried out by the authors of the two most recent 
meta-analyses
11,12
 that used almost identical search strategies. In the meta-analysis 
carried out by Demonty et al.
11
, eighty-one studies with 141 study arms were 
included, whereas in the more recent meta-analysis carried out by Musa-Veloso et 
al.
12
, 114 studies with 182 study arms were included. To retrieve eligible studies 
that had been published after these two meta-analyses, an additional search was 
carried out using nine databases (MEDLINE, Embase, BIOSIS, CAB Abstracts, FROSTI, 
Food Science and Technology Abstracts, Chemical Abstracts, PASCAL and 
AGRICOLA) from September 2010 to September 2011. Again, identical search terms 
were used, limited to human studies with no restriction on language. 
 
Based on the criteria described in the two most recent meta-analyses
11,12
, we 
formulated the following criteria for selecting more recently published studies: (1) 
randomized controlled studies in human adults; (2) treatment with 4-
desmethylsterols and/or 4-desmethylstanols extracted from vegetable oils such as 
soyabean oil, rapeseed oil and tall oil (so no ferulated phytosterols such as those 
from rice bran oil or shea nut oil); (3) investigation of blood lipids as primary or 
secondary outcomes; (4) absence of a co-intervention from which the intake of 
phytosterol-enriched foods or supplements could not be isolated; (5) availability of 
relevant LDL-C data; (6) use of proper placebo in the control group/period; (7) 
consumption of phytosterols for at least 2 weeks; (8) dose of phytosterols not 
exceeding 10 g/d; (9) no studies including colectomized patients because it cannot 
be excluded that colectomy does not have an impact on efficacy. 
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Data extraction and statistical analysis 
For the present analysis, the following data were extracted: reference information 
(first author and year of publication); study design (parallel or cross-over); number 
of subjects (sample size); test product characteristics (dose, type of phytosterols 
(plant sterols or plant stanols or mix) and food format); the placebo-adjusted 
relative (%) change in LDL-C concentration plus accompanying variance measure. In 
case relative changes were not reported, these were calculated as follows: 
 
For parallel studies, 
                                      
where 
                   
                                      
                     
 
                 
                                  
                   
 
 
For cross-over studies, 
                
                               
              
 
 
When LDL-C concentrations were measured at various time points during the 
intervention, the concentration corresponding to or closest to the 4-week time 
point was taken for the analysis. When variance measures of the relative changes 
were not provided and could not be retrieved based on P values or 95% CI, these 
were calculated using variance measures at baseline and end of the intervention in 
active and placebo groups/periods assuming, based on an earlier investigation
17
, a 
within-subject correlation coefficient of 0.8.  
 
Human intervention studies were divided into six categories based on their 
phytosterol dose: dose <1.0 g/d; 1.0≤ dose <1.5 g/d; 1.5≤ dose <2.0 g/d; 2.0≤ dose 
<2.5 g/d; 2.5≤ dose <3.0 g/d; 3.0≤ dose ≤4.0 g/d. This approach was chosen so that 
the incremental dose step was 0.5 g/d except for the lowest and highest categories 
as the number of studies using doses <0.5 and between 3.5 and 4.0 g/d was rather 
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limited (n = 6 each). Study arms with doses exceeding 4 g/d were scarce (n = 5) and 
scattered across a wide range of phytosterol doses (5.8-9.0 g/d); therefore, pooling 
these studies into a single category was judged to be inappropriate; these studies 
were solely used for descriptive purposes. For each study, the PS dose was 
determined by the actual dose administered; when not reported, the intended 
dose was used. Throughout this article, the doses of plant sterols/stanols are 
expressed as free (unesterified) plant sterol/stanol equivalents, rounded off at one 
decimal. 
 
Pooled LDL-C effects were calculated while studies were categorised based on their 
PS dose (i.e., subgroup analysis with subgroups defined by the PS dose), using 
random-effects models according to the methods described by DerSimonian & 
Laird
18
. Random-effects models were used as they take into account the variation 
in LDL-C-lowering effects observed within and between studies. Studies were 
weighted by the inverse of their variance (1/SE
2
). Analyses were carried out for 
plant sterols and stanols combined and separately. When required, a more in-
depth analysis was carried out to investigate the impact of food format on the LDL-
C-lowering efficacy of PS. The pooled estimates and accompanying 95% CI were 
determined using the PROC MIXED function of the SAS System (version 9.2; SAS 
Institute). 
 
Results 
Overview of the included studies 
In total, 124 human studies with a total of 201 study arms were included in the 
present analysis. In 116 study arms, a parallel design was used whereas in 85 study 
arms, a cross-over design was used. Plant sterols and stanols were administered in 
129 and 59 study arms, respectively; in the remaining 13 study arms, a mix of plant 
sterols and stanols was administered. The number of subjects per study arm was, 
on average, 48 (range: 7-201). The average phytosterol dose was 2.1 (range: 0.2-
9.0) g/d. In most of the studies, (low-fat) margarines/spreads or dairy-type 
products were used for enrichment with phytosterols; other food formats included, 
among others, cereals, mayonnaise, salad dressing, soya products, bakery 
products, orange juice and vegetable oils. An overview of the included studies is 
given in Supplemental Appendix 1.  
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LDL-cholesterol-lowering effect of plant sterols and stanols combined and 
separately 
The average phytosterol doses and relative effects on LDL-C concentrations for 
each of the defined dose ranges are summarized in Table 1. When plant sterols and 
stanols were analyzed together, phytosterol intakes were found to reduce LDL-C 
concentrations in a dose-dependent manner (P <0.001; Figure 1). When plant 
sterols and stanols were analyzed separately, clear and comparable dose-response 
relationships were observed (Figure 2). The impact of dose was significant in both 
analyses (P <0.001 for plant sterols and P = 0.001 for plant stanols).  
 
Table 1. Average LDL-cholesterol-lowering effect for different dose ranges of phytosterols 
combined and separately for plant sterols and stanols (mean values and 95% CI). 
Phytosterol 
dose category 
(g/d)a 
Study arms    
(n) 
Average 
phytosterol 
dose (g/d) 
  Average LDL-C effect (%) 
Combined  Plant sterols  Plant stanols 
Mean 95% CI  Mean 95% CI  Mean 95% CI 
Dose <1.0 24 (1 mix, 22 
sterol, 1 stanol) 
0.6 -5.7 -7.1; -4.4  -5.6 -7.1; -4.2  -7.4 -15.2; 0.4 
≥1.0 dose <1.5 13 (2 mix, 9 
sterol, 2 stanol) 
1.1 -6.4 -8.2; -4.6  -6.5 -8.6; -4.4  -6.3 -12.0; -0.6 
≥1.5 dose <2.0 55 (7 mix, 39 
sterol, 9 stanol) 
1.7 -7.6 -8.4; -6.8  -7.6 -8.6; -6.7  -6.7 -8.8; -4.7 
≥2.0 dose <2.5 60 (2 mix, 40 
sterol, 18 stanol) 
2.1 -8.4 -9.2; -7.6  -8.0 -9.0; -7.0  -10.0 -11.3; -8.6 
≥2.5 dose <3.0 17 (0 mix, 6 
sterol, 11 stanol) 
2.6 -10.3 -11.8; -8.9  -10.5 -13.7; -7.3  -10.4 -11.7; -9.1 
≥3.0 dose ≤4.0 27 (1 mix, 11 
sterol, 15 stanol) 
3.3 -12.4 -13.6; -11.2  -12.3 -14.0; -10.6  -12.5 -14.1; -10.8 
P (dose effect)  <0.001  <0.001  0.001 
LDL-C, low-density lipoprotein cholesterol 
a Studies carried out using doses exceeding 4 g/d were not included in the present analysis, as these were scarce and 
scattered across a wide range of doses; clustering them was judged to be inappropriate. 
 
In the present analysis, in the dose category 2·0≤ dose <2·5 g/d, an apparent 
difference of 2% in LDL-C-lowering efficacy was observed between plant sterols and 
stanols. In post hoc analysis that was set up to investigate factors that might 
explain this finding, it was observed that the consistency of the food format (either 
solid/edible or liquid/drinkable) may play a role. In fact, within this particular dose 
category, fifteen of forty plant sterol studies used liquid food formats, whereas 
only four of eighteen stanol studies used this type of food format. Irrespective of 
the type of phytosterols used, liquid foods lowered LDL-C concentrations by, on 
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average, 6.5%, whereas solid foods lowered LDL-C concentrations by, on average, 
9.2% (P = 0.003). 
 
 
Figure 1. Average effects on LDL-cholesterol concentration for different dose ranges of 
phytosterols (PS) up to 4 g/d. The dots represent outcomes of single high-dose studies that 
were not pooled as these were scarce and scattered across a wide range of doses. Values are 
means, with 95% CI represented by vertical bars. 
 
 
Figure 2. Average effects on LDL-cholesterol concentration for different dose ranges of 
phytosterols (PS), separately for plant sterols (black squares) and plant stanols (grey 
triangles). The dots represent outcomes of single high-dose studies that were not pooled as 
these were scarce and scattered across a wide range of doses. Values are means, with 95% CI 
represented by vertical bars. 
76 | Chapter 3 
 
Discussion 
The present meta-analysis based on dose ranges showed that plant sterols and 
stanols lower LDL-C concentrations to a similar extent and in a dose-dependent 
manner, at least up to approximately 3 g/d. The observed comparability between 
plant sterols and stanols with regard to their cholesterol-lowering potential is in 
line with the findings of a recent meta-analysis
16
. In this meta-analysis
16
, fourteen 
studies that side by side compared the LDL-C-lowering efficacy of plant sterols with 
that of plant stanols at doses ranging from 0.6 to 3.3 g/d were included. Of the 
fifteen study arms reporting usable LDL-C data, seven study arms showed a non-
significantly larger LDL-C-lowering effect for plant sterols than for plant stanols, 
whereas eight study arms showed a relatively larger effect for plant stanols than 
for plant sterols. Overall, it was concluded that plant sterols and stanols do not 
have statistically or clinically relevant differing effects on blood lipids. At higher 
intakes (>4 g/d), some individual studies suggest a larger LDL-C-lowering effect for 
plant stanols
19,20
 than for plant sterols
21
. However, high-dose studies are scarce and 
scattered across a wide range of phytosterol doses (5.8-9.0 g/d). For proper high-
dose equivalence testing, a direct comparison study would be needed with subjects 
on either high-dose plant sterol or high-dose plant stanol treatment being studied 
under the same conditions. As such a study has so far not been carried out, 
drawing conclusions on potential differences in efficacy between plant sterols and 
stanols at higher doses is not justified, as has been recently discussed by Plat et 
al.
13
.  
 
The dose dependency of the LDL-C-lowering effect of phytosterols has previously 
been demonstrated in several meta-analyses
6,9-12
 and in individual dose-response 
studies
19,22-24
. So far, meta-analyses have suggested that the LDL-C-lowering effect 
of phytosterols tapers off at intakes of 2-3 g/d with little additional benefit at 
higher intakes
6,11
. Consequently, several health authorities have included 2 g/d of 
phytosterols from enriched foods as part of their diet and lifestyle guidelines in the 
management of hypercholesterolaemia 
7,8,25
. From the present analysis, it appears 
that at least up to approximately 3 g/d of phytosterols, there is a proportional 
dose-response effect. As the inhibition of cholesterol absorption by phytosterols is 
probably a saturable process, some tapering-off effect would, however, be 
expected, but probably at doses slightly higher than 3 g/d. If indeed phytosterol 
intakes >3 g/d lead to a greater LDL-C benefit, this would be meaningful from a 
clinical viewpoint as additional LDL-C-lowering could lead to a greater CVD risk 
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reduction. However, the practical implications of higher phytosterol intakes, such 
as the technical feasibility of incorporating higher amounts of phytosterols into 
foods, cost-benefit aspects and, especially, the compliance of consumers, need to 
be considered. Based on research in populations that actually use foods with added 
phytosterols, it appears that the intake of phytosterols in real life is far below the 
recommendation
26,27
; on average, users consume 14 g/d of phytosterol-enriched 
margarine, which corresponds to a phytosterol intake of approximately 1 g/d. 
Therefore, encouraging people to consume phytosterols at amounts exceeding 
approximately 3 g/d seems unrealistic. In addition, because of the observations of 
premature atherosclerosis in rare homozygous sitosterolaemic patients
28
 and due 
to epidemiological evidence suggesting a positive association between plasma 
plant sterol concentrations and CVD risk
29
, some concerns have been raised related 
to the increase in plasma plant sterol concentrations following high intakes of plant 
sterols from enriched foods. However, a recent meta-analysis summarized the 
totality of observational studies that investigated the association between 
modestly elevated plasma plant sterol concentrations and CVD risk and concluded 
that such an association does not exist
30
. Furthermore, plasma plant sterol 
concentrations after the intake of foods with added plant sterols remain below 1% 
of total sterol concentrations circulating in the blood
17
. All in all, taking these 
aspects into account, the current recommendations to consume 2-3 g/d of 
phytosterols for achieving a significant cholesterol-lowering effect seem to be still 
valid. 
 
The use of different approaches to investigate dose-response relationships in meta-
analyses may sometimes lead to different conclusions being drawn. For instance, 
Musa-Veloso et al.
12
 previously concluded that the maximal LDL-C-lowering efficacy 
was greater for plant stanols (16.4 %) than for plant sterols (8.3 %) when analysing 
continuous dose-response curves. Also in the meta-analysis carried out by 
Demonty et al.
11
, a non-significant 6.7% difference in maximal cholesterol-lowering 
efficacy was observed between plant stanols and sterols based on continuous 
analysis. Such an approach offers the opportunity to predict the LDL-C-lowering 
effect of a given phytosterol dose. However, the applied model seems to 
underestimate the LDL-C-lowering effect of plant sterols at doses of about 3 g/d. It 
is likely that this has affected the shape of the overall dose-response curve for plant 
sterols. This underestimation may have been caused by an unequal distribution of 
studies across the entire dose range. In fact, the availability of a large number of 
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low-dose sterol studies with relatively high efficacy probably pulled the plant sterol 
curve towards a more curvy shape, whereas the stanol curve was mostly influenced 
by high-dose studies; indeed the number of stanol studies carried out using low 
doses (<1.5 g/d) was limited. The calculation of average effects for different dose 
ranges, as has been done in the present analysis, is less influenced by an imbalance 
of data points across the entire dose range. Moreover, this approach offers the 
opportunity to better take into account the large between-study variation by 
means of using random-effects models. On the other hand, one of the limitations 
of the dose-response approach is that the definition of the dose ranges is rather 
subjective. Especially between 1·5 and 2·5 g/d, small differences in cut-off values 
(e.g. <2 or ≤2 g/d) could have a significant impact on the distribution of studies in 
the adjacent dose ranges and subsequently on the pooled averages for these 
particular dose ranges. In the present analysis, dose steps of 0·5 g/d were used 
between adjacent dose ranges, except for the outmost dose ranges, as these 
ranges would otherwise become too small. Although this approach led to a 
symmetrical distribution of the number of studies in the different dose ranges (n 
24, n 13, n 55, n 60, n 17 and n 27 in ascending ranges), the ratio of plant sterol 
studies:plant stanol studies was disproportional by this definition (22:1, 9:2, 39:9, 
40:18, 6:11 and 11:15, respectively). In any case, one should acknowledge that 
none of the dose-response approaches is ideal and should consider the pros and 
cons of the dose range vs. the continuous approach before deciding which 
approach to choose for the research questions being addressed. 
 
Besides the limitations of the applied dose-response method as discussed above, 
some other limitations should be mentioned. The present analysis was not set up 
as a typical meta-analysis, but in fact builds on previous published meta-
analyses
11,12
 by highlighting the importance of using different analysis techniques. 
Therefore, heterogeneity tests and publication bias tests were not carried out. 
However, as between-study variation can never be ruled out, we decided 
beforehand to use random-effects models that take into account some of this 
variation. In addition, the baseline cholesterol concentration and the dose of 
phytosterols have been shown to be important factors affecting the size of the LDL-
C-lowering effect of phytosterols
6,10,11
; by looking at relative changes and dose-
response relationships, we believe that we have addressed these two important 
factors. Nevertheless, we cannot exclude that confounding by other factors, such 
as differences in food formats across the range of phytosterol doses, might have 
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affected the study outcomes. For example, in the present analysis, we found 
slightly lower efficacy for plant sterols than for plant stanols in the dose category 
2.0≤ dose <2.5 g/d; this was probably due to a larger number of liquid food formats 
among the plant sterol studies than among the plant stanol studies. Phytosterols in 
liquid foods vs. solid foods might be less effective at lowering cholesterol 
concentrations due to a shorter transit time in the gastrointestinal tract. Also, 
liquid foods (drinks) are not per definition consumed together with a meal; 
sufficient ingestion of food (i.e., fat) is required to trigger bile release for 
phytosterols to optimally compete with cholesterol for micellar incorporation and 
subsequently to optimally inhibit cholesterol absorption
31
. Given the substantial 
number of studies included, we assume that publication bias had not affected the 
findings severely. Lastly, the quality of studies was not assessed as we believe that 
rating study quality is a rather subjective exercise and it has not been shown that 
excluding low-quality studies leads to different conclusions
10
. 
 
In summary, the present analysis showed that the LDL-C-lowering effect of 
phytosterols continues to increase up to intakes of approximately 3 g/d to an 
average effect of 12%. This was shown for both plant sterols and stanols. The 
importance of considering the advantages and disadvantages of different meta-
analytical dose-response methods was discussed; future studies should decide on 
the most suitable dose-response approach depending on the research questions 
being addressed and the data available.  
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Supplemental Appendix 1 - Overview of the studies  
 
Reference Design 
Sample 
size 
Type of 
phyto-
sterols 
Food format 
Dose of 
phytosterols
a 
Relative change 
in LDL-C 
Effect (%) SE 
AbuMweis et al. 2006 #1
b 
X 30 sterol margarine 1.7 -1.4 3.1 
AbuMweis et al. 2006 #2 X 30 sterol margarine 1.7 -1.4 3.2 
Algorta-Pineda et al. 2005 P 32 stanol yoghurt drink 2.0 -8.4 3.9 
Alhassan et al. 2006 P 26 stanol low-fat margarine 3.0 -20.4 6.6 
Andersson et al. 1999 P 40 stanol low-fat margarine 1.9 -7.2 2.9 
Athyros et al. 2011 P 100 stanol margarine 2.0 -13.8 1.3 
Banuls et al. 2010 P 40 sterol low-fat milk 2.0 -8.1 2.8 
Banuls et al. 2011 P 75 sterol low-fat milk 2.0 -9.9 2.8 
Beer et al 2000 #1 P 47 mix low-fat milk 0.9 -7.4 3.5 
Beer et al 2000 #2 P 52 mix low-fat milk 1.8 -8.6 3.3 
Beer et al 2000 #3 P 47 mix low-fat milk 3.6 -13.2 3.4 
Blair et al. 2000 P 141 stanol margarine 2.9 -9.0 1.8 
Blomqvist et al. 1993 P 66 stanol mayonnaise 3.4 -9.9 3.3 
Cater et al. 2005 study 1c #1 X 8 stanol margarine 2.0 -12.3 3.3 
Cater et al. 2005 study 1 #2 X 8 stanol margarine 3.0 -13.0 2.6 
Cater et al. 2005 study 1 #3 X 8 stanol margarine 4.0 -13.6 2.3 
Cater et al. 2005 study 2 X 13 stanol margarine 3.0 -13.0 2.3 
Cater et al. 2005 study 3 x 10 stanol margarine 3.0 -14.9 3.3 
Chen et al. 2009 x 22 sterol dressing and margarine 3.3 -12.4 1.9 
Christiansen et al. 2001 #1 p 92 sterol margarine 1.5 -6.4 1.9 
Christiansen et al. 2001 #2 p 88 sterol margarine 3.0 -9.1 2.4 
Cleghorn et al. 2003 x 50 sterol margarine 2.1 -7.2 1.7 
Clifton et al. 2004 #1 x 36 sterol bread 1.6 -9.8 1.4 
Clifton et al. 2004 #2 x 40 sterol milk 1.6 -12.4 1.3 
Clifton et al. 2004 #3 x 58 sterol cereals 1.6 -5.6 1.3 
Clifton et al. 2004 #4 x 40 sterol yoghurt 1.6 -9.8 1.2 
Clifton et al. 2008 #1 p 76 sterol low-fat spread 1.6 -9.1 3.4 
Clifton et al. 2008 #2 p 78 sterol low-fat spread 1.6 -11.4 3.3 
Clifton et al. 2008 #3 p 75 sterol low-fat spread 1.6 -7.3 3.4 
Colgan et al. 2004 x 48 sterol low-fat margarine 1.3 -2.9 2.4 
Davidson et al. 2001 #1 p 38 sterol low-fat spread 3.0 -4.3 5.0 
Davidson et al. 2001 #2 p 37 sterol dressing 6.0 -3.9 4.5 
Davidson et al. 2001 #3 p 40 sterol low-fat spread and 
dressing 
9.0 -12.2 4.9 
de Graaf et al. 2002 p 62 mix chocolate 1.8 -11.1 3.1 
de Jong et al. 2008a #1 p 26 sterol low-fat margarine 2.5 -8.2 5.6 
de Jong et al. 2008a #2 p 26 stanol low-fat margarine 2.5 -12.8 5.1 
de Jong et al. 2008b #1 p 35 sterol low-fat margarine 2.5 -12.4 4.3 
de Jong et al. 2008b #2 p 36 stanol low-fat margarine 2.5 -9.5 4.3 
Devaraj et al. 2004 p 72 sterol orange juice 2.0 -11.8 2.5 
Devaraj et al. 2006 p 72 sterol orange juice 2.0 2.1 3.7 
Doornbos et al. 2006 #1 p 71 sterol low-fat yoghurt drink 3.2 -9.5 2.2 
Doornbos et al. 2006 #2 p 71 sterol low-fat yoghurt drink 2.8 -9.3 2.2 
Eady et al. 2011 x 39 sterol spread 1.6 -5.6 1.7 
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Reference Design 
Sample 
size 
Type of 
phyto-
sterols 
Food format 
Dose of 
phytosterolsa 
Relative change 
in LDL-C 
Effect (%) SE 
Earnest et al. 2007 p 54 sterol capsules 1.6 -9.9 3.4 
Escuriol et al. 2010 x 44 sterol milk 2.0 -4.1 2.0 
Fuentes et al. 2008 #1 x 30 sterol low-fat margarine 2.0 -7.7 2.7 
Fuentes et al. 2008 #2 x 30 sterol low-fat margarine 2.0 -3.3 3.0 
Geelen et al. 2002  study 1 x 31 sterol low-fat margarine 3.2 -9.9 2.6 
Geelen et al. 2002  study 2 x 57 sterol low-fat margarine 3.2 -12.4 2.2 
Goldberg et al. 2006 p 26 stanol tablets 1.8 -9.1 4.5 
Goncalves et al. 2007 p 34 sterol milk 2.0 4.0 4.8 
Gylling & Miettinen 1994 x 11 stanol margarine 3.0 -9.3 2.8 
Gylling & Miettinen 1996 #1 x 8 stanol margarine 3.0 -14.4 2.1 
Gylling & Miettinen 1996 #2 x 8 stanol margarine 3.0 -9.7 3.9 
Gylling & Miettinen 1999 x 21 stanol butter 2.4 -12.0 2.0 
Gylling et al. 1997 x 22 stanol margarine 3.0 -14.5 2.9 
Gylling et al. 2010 p 49 stanol margarine and oat-
based drink 
8.9 -17.4 2.6 
Hallikainen & Uusitupa 1999 #1 p 35 stanol low-fat margarine 2.3 -14.0 3.0 
Hallikainen & Uusitupa 1999 #2 p 37 stanol low-fat margarine 2.2 -7.8 3.2 
Hallikainen et al. 2000 #1 x 34 stanol margarine 2.0 -12.7 2.2 
Hallikainen et al. 2000 #2 x 34 sterol margarine 2.0 -10.4 1.9 
Hallikainen et al. 2008 p 19 stanol margarine 2.2 -18.6 8.8 
Hallikainen et al. 2011 p 24 stanol margarine 3.2 -13.7 5.2 
Hansel et al. 2007 p 194 sterol low-fat fermented milk 1.6 -9.2 1.0 
Hayes et al.  2004 x 7 sterol tortilla chips 1.5 -15.3 5.9 
Heggen et al. 2010 #1 x 59 sterol low-fat margarine 2.0 -9.0 1.8 
Heggen et al. 2010 #2 x 59 sterol low-fat margarine 2.0 -8.2 1.6 
Hendriks et al. 1999 #1 x 80 sterol margarine 0.8 -6.2 1.8 
Hendriks et al. 1999 #2 x 80 sterol margarine 1.6 -9.2 1.8 
Hendriks et al. 1999 #3 x 80 sterol margarine 3.2 -9.8 1.8 
Hendriks et al. 2003 p 185 sterol low-fat spread 1.6 -4.3 2.4 
Hernandez-Mijares et al. 2010 p 55 sterol low-fat milk 2.0 -10.2 2.3 
Hernandez-Mijares et al. 2011 
study 1 
p 24 sterol low-fat milk 2.0 -0.5 3.8 
Hernandez-Mijares et al. 2011 
study 2 
p 24 sterol low-fat milk 2.0 -10.5 3.7 
Hironaka et al. 2006 #1 p 101 sterol vegetable/fruit juice 0.8 -6.7 2.1 
Hironaka et al. 2006 #2 p 105 sterol vegetable/fruit juice 1.6 -8.8 2.0 
Homma et al. 2003 #1 p 67 stanol low-fat spread 2.0 -8.9 1.9 
Homma et al. 2003 #2 p 68 stanol low-fat spread 3.0 -6.6 2.3 
Houweling et al. 2009 x 82 sterol low-fat margarine 2.0 -7.8 2.0 
Hyun et al. 2005 p 51 stanol low-fat yoghurt 2.0 -7.8 3.0 
Ishizaki et al. 2003 p 55 sterol mayonnaise 0.9 -8.2 2.4 
Jakulj et al. 2005 #1 x 39 sterol low-fat spread 2.0 -4.7 1.7 
Jakulj et al. 2005 #2 x 39 sterol low-fat spread 2.0 -3.5 2.3 
Jauhiainen et al. 2006 p 67 stanol low-fat cheese 2.0 -10.3 2.3 
Jones et al. 1999 p 32 mix margarine 1.7 -15.5 5.4 
Jones et al. 2000 #1 x 15 sterol low-fat margarine 1.8 -13.3 2.3 
Jones et al. 2000 #2 x 15 stanol low-fat margarine 1.8 -6.4 2.7 
Jones et al. 2003 x 15 mix non-fat beverage 1.8 -2.1 4.4 
Judd et al. 2002 x 53 sterol salad dressing 2.2 -10.1 0.7 
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Reference Design 
Sample 
size 
Type of 
phyto-
sterols 
Food format 
Dose of 
phytosterolsa 
Relative change 
in LDL-C 
Effect (%) SE 
Kassis et al. 2008 x 22 sterol margarine 1.7 -4.5 1.3 
Khandelwal et al. 2009 study 1 p 93 sterol yoghurt drink 2.0 -3.3 2.9 
Khandelwal et al. 2009 study 2 p 85 sterol yoghurt drink 2.0 -5.0 2.8 
Korpela et al. 2006 study 1 p 50 sterol low-fat yoghurt 1.7 -7.7 3.6 
Korpela et al. 2006 study 2 p 62 sterol low-fat hard cheese 2.0 -11.2 3.4 
Korpela et al. 2006 study 3 p 52 sterol low-fat fresh cheese 2.0 -13.8 3.5 
Kratz et al. 2007 #1 x 17 sterol low-fat margarine 2.0 -4.0 4.2 
Kratz et al. 2007#2 x 17 stanol low-fat margarine 2.0 -9.1 2.7 
Kurokawa et al. 2008a #1 p 35 sterol dressing 0.5 -2.2 5.2 
Kurokawa et al. 2008a #2 p 35 sterol dressing 0.9 -6.7 5.2 
Kurokawa et al. 2008a #3 p 34 sterol dressing 1.3 -7.3 4.8 
Kurokawa et al. 2008b p 59 sterol dressing 0.8 -5.2 1.7 
Lagstrom et al. 2006 p 42 stanol capsules 2.0 -7.0 3.2 
Lau et al. 2005  study 1 x 14 sterol margarine 1.8 -7.1 7.8 
Lau et al. 2005  study 2 x 15 sterol margarine 1.8 -8.4 3.8 
Lee et al. 2003 p 81 sterol low-fat spread 1.6 -8.1 2.4 
Li et al. 2007 #1 p 201 sterol milk tea powder 1.5 -2.5 1.6 
Li et al. 2007 #2 p 199 sterol milk tea powder 2.3 -3.4 1.6 
Lin et al. 2011 x 21 sterol beverage 2.5 -6.5 3.2 
Lottenberg et al. 2003 x 60 sterol margarine 1.7 -6.4 1.1 
Madsen et al. 2007 x 46 sterol low-fat margarine and 
low-fat milk 
2.3 -7.7 2.2 
Maki et al. 2001 #1 p 158 sterol low-fat spread 1.1 -7.6 1.7 
Maki et al. 2001 #2 p 118 sterol low-fat spread 2.2 -8.1 1.9 
Mannarino et al. 2009 p 116 sterol low-fat fermented milk 1.6 -8.3 1.6 
Matsuoka et al. 2004a p 46 sterol mayonnaise 0.8 0.2 3.1 
Matsuoka et al. 2004b  
study 1 #1 
p 16 sterol mayonnaise 0.2 -5.3 4.9 
Matsuoka et al. 2004b  
study 1 #2 
p 19 sterol mayonnaise 0.4 3.1 5.0 
Matsuoka et al. 2004b  
study 1 #3 
p 16 sterol mayonnaise 0.6 -0.8 4.9 
Matsuoka et al. 2004b  
study 1 #4 
p 16 sterol mayonnaise 0.8 -7.1 3.9 
Matsuoka et al. 2004b  
study 2 #1 
p 15 sterol mayonnaise 0.8 -12.3 6.3 
Matsuoka et al. 2004b  
study 2 #2 
p 17 sterol mayonnaise 1.6 -8.6 4.0 
Matsuoka et al. 2004b  
study 2 #3 
p 15 sterol mayonnaise 2.4 -11.0 4.8 
Matvienko et al. 2002 p 34 sterol beef 2.7 -13.4 3.6 
McPherson et al. 2005 study 1 p 25 stanol tablets 1.3 -10.4 4.0 
McPherson et al. 2005 study 2 p 27 stanol capsules 1.0 -2.5 3.9 
Mensink et al. 2002 p 60 stanol yoghurt 3.0 -10.3 4.7 
Mensink et al. 2010 #1 p 46 stanol margarine 2.8 -7.4 2.9 
Mensink et al. 2010 #2 p 44 stanol soy-based yoghurt 5.8 -11.9 3.2 
Mensink et al. 2010 #3 p 47 stanol margarine and soy-
based yoghurt 
 
8.7 -17.1 3.1 
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Reference Design 
Sample 
size 
Type of 
phyto-
sterols 
Food format 
Dose of 
phytosterolsa 
Relative change 
in LDL-C 
Effect (%) SE 
Miettinen and Vanhanen  
1994 #1 
p 17 sterol mayonnaise 1.0 -6.2 3.8 
Miettinen and Vanhanen  
1994 #2 
p 15 mix mayonnaise 1.0 -2.6 4.1 
Miettinen and Vanhanen  
1994 #3 
p 15 mix mayonnaise 1.2 -7.7 3.7 
Miettinen et al. 1995 #1 p 102 stanol margarine 2.6 -11.1 2.1 
Miettinen et al. 1995 #2 p 102 stanol margarine 2.6 -12.5 2.2 
Mussner et al. 2002 x 62 sterol margarine 1.8 -6.5 1.4 
Naumann et al. 2003 #1 x 42 mix low-fat margarine 2.0 -6.0 3.1 
Naumann et al. 2003 #2 x 42 mix low-fat margarine 2.0 -6.7 3.0 
Neil et al. 2001 p 62 sterol spread 2.5 -14.2 3.3 
Nestel et al. 2001 x 15 sterol dairy spread 2.4 -7.9 2.5 
Nigon et al. 2001 x 53 sterol low-fat spread 1.6 -5.3 1.6 
Niittynen et al. 2007 study 1 x 15 sterol low-fat yoghurt drink 1.0 -4.2 3.3 
Niittynen et al. 2007 study 2 p 26 sterol low-fat yoghurt drink 2.0 -6.0 4.3 
Noakes et al. 2002 study 1 #1 x 46 sterol low-fat spread 2.3 -7.7 1.2 
Noakes et al. 2002 study 1 #2 x 46 stanol low-fat spread 2.5 -9.5 1.2 
Noakes et al. 2002 study 2 x 35 sterol spread 2.0 -9.6 1.5 
Noakes et al. 2005 study 1 #1 x 39 sterol margarine 2.0 -10.1 1.6 
Noakes et al. 2005 study 1 #2 x 39 sterol low-fat milk 2.0 -7.9 1.6 
Noakes et al. 2005 study 1 #3 x 39 sterol low-fat milk and 
margarine 
4.0 -11.4 1.5 
Noakes et al. 2005 study 2 #1 x 40 sterol low-fat yoghurt 1.8 -6.1 1.6 
Noakes et al. 2005 study 2 #2 x 40 stanol low-fat yoghurt 1.7 -5.2 1.7 
Ntanios et al. 2002 x 53 sterol margarine 1.8 -9.1 1.6 
Ooi et al. 2007 x 9 sterol cereal and margarine 2.0 -6.4 7.8 
Pelletier et al. 1995 x 12 sterol butter 0.7 -15.2 3.1 
Plana et al. 2008 p 83 sterol low-fat fermented milk 1.6 -12.2 3.1 
Plat and Mensink 2000 #1 p 78 stanol margarine and 
shortening 
3.8 -12.6 3.3 
Plat and Mensink 2000 #2 p 76 stanol margarine and 
shortening 
4.0 -11.6 3.7 
Plat et al. 2000 #1 x 39 stanol margarine 2.5 -9.4 1.5 
Plat et al. 2000 #2 x 39 stanol margarine and 
cake/cookie 
2.5 -10.4 1.9 
Quilez et al. 2003 p 57 sterol muffin and croissant 3.2 -14.7 4.5 
Racette et al. 2010 #1 x 18 sterol beverage 0.4 -5.0 2.1 
Racette et al. 2010 #2 x 18 sterol beverage 2.0 -8.9 2.3 
Raitakari et al. 2008 p 190 stanol low-fat margarine 2.0 -9.3 3.1 
Rudkowska et al. 2008 #1 x 26 sterol low-fat yoghurt 1.6 -2.3 1.8 
Rudkowska et al. 2008 #2 x 26 sterol low-fat yoghurt 1.6 -5.1 1.8 
Ruiu et al. 2009 x 15 sterol yoghurt drink 1.0 -4.6 2.2 
Saito et al. 2006 #1 p 33 sterol DAG-containing 
mayonnaise 
0.3 -7.1 2.7 
Saito et al. 2006 #2 p 33 sterol DAG-containing 
mayonnaise 
0.4 -5.9 3.2 
Saito et al. 2006 #3 p 34 sterol DAG-containing 
mayonnaise 
0.5 -9.3 2.7 
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Reference Design 
Sample 
size 
Type of 
phyto-
sterols 
Food format 
Dose of 
phytosterolsa 
Relative change 
in LDL-C 
Effect (%) SE 
Seki et al. 2003a p 60 sterol vegetable oil in bread 0.5 -2.3 2.4 
Seki et al. 2003b p 22 sterol vegetable oil in bread 1.3 -12.6 3.9 
Seki et al. 2003c #1 p 45 sterol vegetable oil in bread 0.3 0.8 1.8 
Seki et al. 2003c #2 p 44 sterol vegetable oil in bread 0.5 -7.7 1.9 
Seppo et al. 2007 study 1 p 60 stanol low-fat yoghurt 2.0 -2.9 3.2 
Seppo et al. 2007 study 2 p 61 stanol low-fat yoghurt drink 2.0 -3.2 3.0 
Seppo et al. 2007 study 3 p 19 stanol low-fat yoghurt drink 2.0 -11.8 7.0 
Seppo et al. 2007 study 4 p 59 stanol low-fat milk 2.0 -6.2 2.4 
Sialvera et al. 2011 p 108 sterol yoghurt drink 4.0 -19.7 1.7 
Sierksma et al. 1999 x 75 sterol margarine 0.8 -6.1 0.6 
Simons 2002 study 1 p 77 sterol margarine 2.0 -10.2 2.8 
Simons 2002 study 2 p 75 sterol margarine 2.0 -6.1 3.6 
Soderholm et al. 2011 p 63 sterol rye bread 2.0 -8.1 3.5 
Spilburg et al. 2003 p 24 stanol lemonade 1.9 -14.3 4.5 
Takeshita et al. 2008 p 29 sterol DAG-containing cooking 
oil 
0.5 -6.0 4.4 
Temme et al. 2002 x 42 sterol low-fat margarine 2.1 -9.6 1.4 
Theuwissen & Mensink 2007 x 40 stanol cereal 1.5 -4.4 2.1 
Theuwissen et al. 2009 p 28 stanol margarine 2.5 -9.5 4.6 
Thomsen et al. 2004 #1 x 69 sterol low-fat milk 1.2 -7.1 1.5 
Thomsen et al. 2004 #2 x 69 sterol low-fat milk 1.6 -9.6 1.5 
Vanhanen 1994 p 14 stanol mayonnaise 1.5 -2.0 7.6 
Vanhanen et al. 1994 p 15 stanol mayonnaise 0.8 -7.7 3.8 
Vanstone et al. 2002 #1 x 15 sterol butter 1.8 -10.2 2.8 
Vanstone et al. 2002 #2 x 15 stanol butter 1.8 -10.5 2.8 
Vanstone et al. 2002 #3 x 15 mix butter 1.8 -11.5 2.7 
Varady et al. 2004 study 1 p 38 sterol low-fat margarine 1.8 -11.3 2.4 
Varady et al. 2004 study 2 p 36 sterol low-fat margarine 1.8 -12.8 3.8 
Volpe et al. 2001 x 30 sterol low-fat yoghurt drink 1.1 -7.6 1.9 
Weidner et al. 2008 p 50 sterol soy drink 1.6 -5.2 2.8 
Weststrate & Meijer 1998 #1 x 76 sterol margarine 3.2 -13.1 0.6 
Weststrate & Meijer 1998 #2 x 77 stanol margarine 2.7 -11.9 0.6 
Woodgate et al. 2006 p 29 stanol softgel capsules 1.6 -7.2 3.7 
Yoshida et al. 2006 study 1 x 16 mix cereal bar 1.8 -6.1 2.5 
Yoshida et al. 2006 study 2 x 13 mix cereal bar 1.8 -2.8 3.7 
DAG, diacylglycerol; LDL-C, low-density lipoprotein cholesterol. 
a Dose given as free equivalents in g/d, rounded off at 1 decimal. 
b Multiple study arms in 1 study corrected for the same single control group/period: indicated with # 1, # 2, # 3, etc. For 
some cross-over studies, different active treatments were compared with a separate corresponding placebo treatment; 
however, as the same subjects were included in those periods, these are indicated with #1, #2, #3 etc. 
c Multiple study arms in 1 study, each corrected for a respective control group (i.e., different set of subjects): indicated 
with study 1, study 2, study 3, etc. 
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Abstract 
Purpose - Plant sterols (PS) are well-known for their low-density lipoprotein 
cholesterol-lowering effect. Until recently, they were believed to have little or no 
impact on blood triglycerides (TG). However, studies taken individually were 
possibly lacking statistical power to detect modest TG decreases. This study was 
performed to quantify the TG-lowering effect of PS by pooling individual subject 
data from 12 randomized controlled trials that investigated the effects of PS on 
blood lipids. 
Methods - The main outcome variable was the control-adjusted PS effect on 
relative (%) and absolute (mmol/L) changes in TG. The relative and absolute 
changes in high-density lipoprotein cholesterol (HDL-C) were also assessed. 
Differences in changes of serum lipid concentrations between PS and control 
treatments were estimated by an ANCOVA using a random effect model which 
included PS intake (active or control), study, and pre-defined subject 
characteristics.  
Results - The twelve randomized controlled trials included in total 935 
hypercholesterolemic subjects not preselected based on their baseline TG 
concentrations. In most studies, the PS dose ranged between 1.6 and 2.5 g/d. PS 
intake significantly lowered serum TG by 6.0% (95% CI: -10.7; -1.2) or 0.12 mmol/L 
(95% CI: -0.20; -0.04). No significant interaction was observed between PS intake 
and baseline TG concentrations on relative changes, but, on absolute changes, 
interaction was significant with larger TG decreases observed with higher TG 
concentrations at baseline. No effects were observed on HDL-C concentrations.  
Conclusions - These results show that PS exert a modest TG-lowering effect which is 
dependent on baseline concentrations. 
 
Introduction 
Plant sterols (PS) and stanols, their saturated counterparts, are well known for their 
total and low-density lipoprotein cholesterol (LDL-C)-lowering effect. To date, 
several meta-analyses have summarized and quantified the LDL-C-lowering effect 
of PS/stanol-enriched foods and their dose-response relationship
1-4
. Possibly due to 
the fact that the large number of human intervention studies with PS/stanols were 
designed and powered to detect a significant effect on LDL-C, in most studies taken 
individually the effect of PS/stanols on serum triglycerides (TG) was not estimated 
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or not detected. However, significant reductions in TG concentrations after PS 
intervention have incidentally been observed
5-8
. Furthermore, a recent meta-
analysis of individual subject data from five studies, which aimed at studying the 
relationship between subjects’ baseline characteristics and the effects of plant 
stanol-enriched spreads on serum lipid concentrations, indicated that plant stanols 
not only lower serum concentrations of LDL-C, but also TG concentrations
9
. More 
recently, large TG reductions were observed in metabolic syndrome patients 
consuming PS/stanol-enriched foods
10,11
. 
 
Elevated TG concentrations are increasingly being recognized as a possible 
independent risk factor for coronary heart disease (CHD), and TG-lowering therapy 
next to lowering LDL-C may be considered relevant especially in high risk 
populations such as e.g. subjects with dyslipidemia as characterized in the 
metabolic syndrome
12-14
.  
 
In the recent meta-analysis that indicated a TG-lowering effect of plant stanols
9
, 
significant interaction was observed between baseline TG concentrations and plant 
stanol intake, resulting in larger TG reductions (expressed in mmol/L) with higher 
baseline TG concentrations. Even when expressed in terms of relative (expressed in 
%) changes from baseline, TG reductions were more pronounced when baseline TG 
concentrations were higher. For investigating the TG-lowering effect of PS, having 
individual subject data would thus allow making better adjustments for baseline TG 
concentrations resulting in more precise estimations. As such, the aim of the 
present study was to quantitatively evaluate the TG-lowering effect of PS by 
pooling individual subject data from randomized controlled trials that were made 
available by investigators from independent research groups.  
 
In order to specifically take into account the baseline TG concentrations in the 
estimation of the TG-lowering effect, the main outcome was expressed as the 
relative change in TG from baseline values. In addition, and for better 
understanding the impact of baseline concentrations on the observed reductions in 
TG, the absolute changes were calculated. As high-density lipoprotein cholesterol 
(HDL-C) metabolism is closely related to that of TG via the action of the cholesterol-
ester transfer protein (CETP)
15
, the effect of PS-enriched food consumption on HDL-
C concentrations was also evaluated.  
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Methods 
Selection of the studies 
Data sets of 14 Unilever-sponsored PS intervention studies published in 12 
publications were made available by different independent research groups
5,16-26
 
that published their findings in peer-reviewed journals. Studies were eligible for the 
current pooled analysis if they were randomized placebo-controlled trials with 
human adults not preselected based on their baseline TG concentrations, had used 
the ‘usual’ plant sterols (4-desmethylsterols), had disposal of TG data at baseline 
and at end-of-intervention as well as relevant co-variable data, and had no co-
intervention from which the effect of PS could not be isolated.  
 
Ferulated PS as found e.g. in rice bran oil were excluded because these are not 
commonly used for food/supplement enrichment. In addition, there is no 
consensus on their cholesterol-lowering effect
17,27
, thus their potential impact on 
serum TG and/or HDL-C may also be different from that of other PS. Because the 
cholesterol-lowering effect of PS is additive to that of statins
18,28
 and dietary fat 
modifications (diets low in total, saturated fat, and cholesterol content or high in 
vegetable oil)
29-31
, we assumed that a similar additive effect could be expected in 
case of an impact on serum TG and HDL-C. Therefore, studies that prescribed 
statins or dietary fat modifications in both the control and the treatment 
group/phase within each study were included in the present analysis.  
 
Eligibility for inclusion in the pooled analysis was judged by evaluating the full 
publication, the study protocol and the data set. Out of the 14 studies, one study 
was excluded because it did not measure TG concentrations
19
 and another because 
initial lipid values were not readily available
20
. One study
24
 consisted of two parallel 
arms with a randomized controlled cross-over design within each arm; these 
parallel arms were considered as two separate cross-over studies. In another 
study
25
, 2 separate cross-over trials were described. Thus, individual subject data 
from a total of 12 studies from 10 publications that met the selection criteria were 
available for inclusion in the current pooled analysis
5,16-18,21-26
.  
 
Data extraction and quality assessment 
For each subject, the following data was extracted from the different data sets: 
study identification, gender, BMI, age, treatment (active or control), and TG and 
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HDL-C data at baseline and at end-of-intervention. When the lipids were measured 
at various time points during the intervention, the values corresponding to or 
closest to the 4-week time point were taken for the analysis. If measurements were 
done on two different days at the end of the intervention, the mean value of those 
two measurements was taken.  
 
Study quality was assessed as previously reported
3
 using a custom-designed tool 
adapted from the Delphi Consensus
32
 and the method by Chalmers et al.
33
. 
However, due to a lack of consensus on which scoring system is the best and hence 
scoring is intrinsically subjective
34
, quality scores were not used to exclude lower 
quality trials or to weigh the data accordingly.  
 
Statistical analysis  
The primary outcome variables were the control-adjusted relative (%) and absolute 
(mmol/L) changes from baseline in TG due to the PS treatment. The secondary 
outcome variables were defined as the control-adjusted relative and absolute 
changes from baseline in HDL-C. The relative changes in serum TG and HDL-C were 
calculated as follows for each subject: 
 
                    
                      
             
 
 
Baseline lipid concentrations were defined as the lipid concentrations at the start 
of the intervention phase (end of run-in when a run-in phase was present). For 
cross-over trials in which start-of-intervention measurements were not available (n 
= 1), the lipid concentrations at screening were used as baseline concentrations.   
 
In order to standardize the variability structure of all data in the overall pooled 
analysis, we only used the data from the first study phase of cross-over studies, so 
that all studies were treated as parallel studies.  
 
For the absolute changes, analysis was done on end-of-intervention serum lipid 
concentrations while adjusting for baseline concentrations. Differences in mean 
relative changes and absolute serum TG and HDL-C concentrations between the PS 
group and the control group were determined by an ANCOVA using a model which 
initially included plant sterol intake (active or control), study and the predefined 
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subject characteristics age, gender, BMI and baseline lipid concentrations and their 
interactions with PS intake. Because age and gender did not significantly (P 0.1) 
contribute to the model, the subject characteristics kept in the final model were 
the respective baseline lipid concentrations and BMI (and the interaction between 
baseline TG concentrations and PS intake in the case of absolute changes). The 
statistical analysis was performed for the quasi intention-to-treat population
35
, i.e., 
using all subjects for whom end-of-intervention TG or HDL-C values were available, 
and according to a random effect model. 
 
Sensitivity analysis was performed to determine whether the presence of one study 
with patients on statins
18
 influenced the outcome. The effect of PS on TG and HDL-
C (expressed as relative change) were thus also determined when using only the 
eleven studies with healthy subjects.  In order to verify that the use of only the first 
phase of cross-over trials in the overall analysis did not affect the outcome, a 
separate analysis was performed by using all phases of the cross-over trials.  
 
Heterogeneity between studies was assessed by calculating the Q statistic as 
described by DerSimonian and Laird
36
.  
 
All analyses were performed with the statistical software program The SAS System 
(SAS Version 9.2, SAS Institute, Inc.,Cary, NC, USA). ProcMixed was used to perform 
the analyses.  
 
Results 
Overview of included studies and subjects 
In total, 12 studies from 10 publications were available for the current pooled 
analysis
5,16-18,21-26
. The study by Noakes et al.
25
 included PS and plant stanol 
treatments; only the data from the PS arm were used. When parallel design studies 
included different PS treatments (e.g. PS from different sources) provided in the 
same food format, these strata were combined
5,23
. In all studies, blood lipid 
concentrations were measured after an overnight fast. TG concentrations were 
included in the eligibility criteria of 9 out of 12 studies and were defined as less 
than 3.4-4.5 mmol/L in most (n = 8) studies. Table 1 shows the characteristics of 
the studies included. The majority of studies was judged as of good quality (data 
not shown). 
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PS were esterified to vegetable oil fatty acids in all studies except one
17
 which used 
free PS. The food format was margarine or spread in the majority of studies (n = 9). 
In one study, a combination of spread and milk (n = 1) was used
26
, and in two 
studies, the vehicle for PS was a salad dressing
24
. The PS dose varied between 0.8 
and 4 g/d, with the majority of studies (n = 9) testing doses ranging between 1.6 
and 2.5 g/d. Doses of 0.8, 1.3 and 4 g/d were used in the other studies
16,17,26
. In 
most cases, PS-enriched foods were consumed for a period of 3 weeks; in three 
studies, the treatment duration was longer than 4 weeks, namely 5, 8 or 52 
weeks
18,21,23
. In these cases, data obtained at 3 or 4 weeks were used in order to 
standardize the data from all studies to a similar point in time after the start of the 
intervention. Frequency of test product intake was not reported in three 
studies
16,17,26
, whereas PS were consumed 2-3 times/d with meals in the other 
studies. Subjects were allowed to keep their usual, self-selected diet during the 
intervention in half of the studies
5,17,18,21,22,26
. In the other studies, the subjects 
were either provided a typical North-American diet
24
, or were advised to follow the 
NCEP Step 1 diet
16,23
 or to consume a diet rich in carotenoid-rich fruits and 
vegetables
25
.  
 
A total of 935 participants were included in the current pooled analysis. In 11 of the 
12 studies, the subjects were overall healthy and were not taking any lipid-lowering 
medication. The only exception was the study by Neil et al.
18
 in which subjects 
received statins and half of them had familial hypercholesterolemia. In all studies, 
subjects were Caucasian. The mean age of the study populations varied between 
44  12 and 58  11 years. On average, the subjects were slightly overweight (mean 
BMI ranging between 24.0  2.9 and 27.3  3.7 kg/m
2
). Mean baseline TG 
concentrations were on average normal to borderline high (ranging from 1.37  
0.52 to 1.93  1.08 mmol/L) according to the NCEP classification
14
, whereas LDL-C 
concentrations were on average above optimal to very high (ranging from 3.15  
0.86 to 5.11  1.07 mmol/L). The baseline characteristics of the subjects in each of 
the studies are presented in Table 1.  
 
Heterogeneity analysis 
For the relative changes in TG, there was no significant heterogeneity between the 
studies as assessed by the Q statistic (Q = 0.22, 11 degrees of freedom, P 0.95). 
For HDL-C, no significant heterogeneity was observed either (Q = 2.18, 11 degrees 
of freedom, P 0.95). 
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TG outcomes 
When combining the individual subject data from all studies, PS significantly 
lowered serum TG by 6.0% (95% CI: -10.7; -1.2, P = 0.02) (Figure 1). No significant 
interaction was observed between TG effects of PS intake and baseline TG 
concentrations (P = 0.38).  
 
When the study with statin users
18
 was removed from the analysis, the pooled 
estimate was a 6.3% reduction in TG (95% CI: -11.3; -1.3, P = 0.02). An analysis of 
only cross-over studies including all treatment phases showed a similar effect, 
namely a 5.6% reduction in TG (95% CI: -9.3; -2.0). The ANCOVA performed for 
each study separately showed non-significant TG reductions in 8 out of 12 studies 
(Figure 1).  
 
 
Figure 1. Forest plots. Forest plots showing the effect of PS on TG and HDL-C estimated for 
each of the studies included in the overall analysis using individual subject data. The squares 
represent the averages for each of the individual studies. Error bars represent 95% CI. The 
diamonds represent the pooled results. The solid vertical line extending upward from zero is 
the null value. In both the overall and individual study analyses, only the first phase of cross-
over trials was used. Both types of analyses were performed using individual subject data. 
The overall estimate was obtained by pooling together the individual subject data from all 
studies. The same statistical model was used for the individual studies and the overall 
analysis; the model included PS intake, study, age, gender, BMI, and the respective baseline 
concentrations and their interactions with PS intake.  
 
When the effects were expressed in absolute values, PS intake modestly but 
significantly lowered TG by 0.12 mmol/L (95% CI: -0.20; -0.04, P = 0.01). In contrast 
Plant sterols modestly lower fasting triglyceride concentrations | 99 
 
with the results obtained when the effects were expressed relatively, a significant 
(P 0.01) interaction between PS intake and baseline TG concentrations was 
observed on absolute end-of-intervention concentrations. In line with this finding, 
larger reductions vs. control were observed in subjects with higher baseline TG 
concentrations (Figure 2). 
 
 
Figure 2. Impact of baseline TG concentrations. Impact of baseline TG concentrations on the 
absolute (expressed in mmol/L) TG reductions achieved with PS consumption in twelve 
randomized controlled trials. In the majority of studies (n = 9), doses of 1.6-2.5 g/d were 
tested (range: 0.8-4.0 g/d). 
 
HDL-C outcomes 
No significant effect of PS was observed on HDL-C; the relative change from 
baseline was +0.3% (95% CI: -1.8; +2.5, P = 0.73) (Figure 1). There was no 
interaction between PS intake and baseline HDL-C concentrations (P = 0.75). The 
removal of the study with statin users
18
 did also not have an impact (HDL-C change: 
+0.5%, 95% CI: -1.8; +2.8, P = 0.66).  
 
When the analysis was performed on the absolute HDL-C concentrations, also no 
significant effect of PS intake was observed (+0.01 mmol/L; 95% CI: -0.02, +0.04, P = 
0.54) and there was no PS intake  baseline HDL-C interaction (P = 0.44). 
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Discussion 
The present pooled analysis including individual subject data from 12 randomized 
controlled trials shows that PS intakes of around 2 g/d exert a modest TG-lowering 
effect of about 6% or 0.12 mmol/L in hypercholesterolemic subjects not 
preselected based on their baseline TG concentrations. Given the high inter-
individual variation in TG concentrations, and the fact that the individual PS studies 
were primarily powered to assess the effect of PS on LDL-C concentrations, it is 
likely that the absence of statistically significant TG-lowering effects in these 
studies was due to insufficient statistical power. For example, a recent study by 
Mensink et al.
37
 studied the serum lipid effects of doses of plant stanols up to 9 g/d 
but failed to show a significant TG reduction (e.g. ~8% for 9 g/d; P = 0.187) with 
only a limited number of subjects in each of the treatment groups (~22 to 25 
subjects).  
 
The 6% TG-lowering effect observed here with PS use is consistent with the 
outcome of a previous meta-analysis of individual subject data from five studies
9
 
which showed a 4% reduction in TG after 2 g/d plant stanol intake in subjects with 
baseline concentrations of ~2 mmol/L. These data thus show that both PS and 
stanols exert a comparable TG-lowering effect. Other recently published studies 
using similar doses of PS (~2 g/d) also support the findings of our pooled analysis; 
TG concentrations were significantly lowered by 9-19% after 4-6 weeks of 
intervention with PS-enriched (soy)milk or spread in subjects with baseline TG 
concentrations >1.5 mmol/L
5-8
. For plant stanols as well, significant decreases in TG 
concentrations were shown in subjects with overt hypertriglyceridemia
38
. 
 
The TG-lowering effect observed in our pooled analysis seems robust. 
Heterogeneity analysis did not reveal significant variability between studies. In 
addition, the sensitivity analysis showed that removing the study with statin users 
did not affect the outcome. Also, the use of only the first phase of cross-over trials 
in the overall analysis did not change the results. At last, the majority of studies 
included in the pooled analysis were of good quality, and most individual studies 
showed a tendency towards the same direction in the form of non-significant TG 
reductions. 
 
Our results indicate that the absolute (mmol/L) reductions in TG achieved with PS 
intake are dependent of baseline TG concentrations. A significant interaction on 
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relative (%) TG changes was not present. However, it cannot be fully excluded that 
the current analysis may have been underpowered to detect such an effect. 
Nevertheless, the present results suggest that the impact of baseline TG is more 
pronounced on absolute changes in TG concentrations than on relative changes 
from baseline. By expressing TG changes as % change from baseline, at least part of 
the variability in PS effects due to inter-individual variations in baseline TG is taken 
into account. Therefore, it appears preferable to express the TG changes in relative 
terms when referring to the mean effect in a population.  
 
Our data fit well with the findings of two studies reporting large control-adjusted 
TG reductions of 19-28% (corresponding to 0.23 to ~0.4 mmol/L) following the 
consumption of 2-4 g/d PS/stanols in metabolic syndrome subjects with baseline 
TG concentrations of 2.2-2.4 mmol/L
10,11
. We estimated, for our study population, a 
reduction of 0.18 mmol/L in subjects with baseline TG concentrations at the 75
th
 
percentile (1.9 mmol/L). If our pooled analysis had comprised a larger proportion of 
subjects with higher baseline TG concentrations and/or subjects with the metabolic 
syndrome, it is likely that even larger TG reductions would have been observed. 
Taken together, these data suggest that PS/stanols would be particularly useful for 
a dual benefit on both LDL-C and TG in subjects with both lipid abnormalities. 
 
Based on the significant reductions in large and medium size VLDL particles 
observed in subjects with the metabolic syndrome, Plat et al.
39
 suggested that a 
reduced hepatic VLDL1 secretion could be a mechanism involved in the TG-
lowering effect of plant stanols. The unaltered CETP mass observed in their 
subjects coupled with unchanged HDL-C concentrations
39
 are consistent with the 
absence of effect of PS on HDL-C observed in the present study. Overall, these data 
suggest that the reduced TG concentrations attributable to either PS or stanol 
consumption may not be ascribed to a remodeling of TG-rich lipoproteins via CETP 
activity.    
 
The findings of the current pooled analysis are limited by the fact that the 
randomized controlled trials included in the analysis present only a selection of 
studies available in the literature. Also because the included studies were all 
industry-sponsored, selection bias might possibly be present. However, all studies 
were planned and executed by independent research groups and published in 
peer-reviewed journals. Because we re-analyzed individual subject data of a large 
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number of subjects (935 in total), we believe that there was sufficient power to 
substantiate the conclusions drawn, and that adding more subject data from other 
studies would not have changed the outcomes. In addition, because most studies 
used PS doses within a narrow range (between 1.6 and 2.5 g/d), this does not allow 
drawing any conclusion on a possible dose-response relationship for the TG-
lowering effect of PS. 
 
In the absence of intervention studies that directly quantified the CHD risk 
reduction resulting from lowering TG only, it is difficult to determine whether the 
additional effect that a modest 6% TG reduction may have on CHD risk is clinically 
relevant next to the average 10% LDL-C reduction achievable with an intake of 2 
g/d of PS. Nevertheless, although not as strong as LDL-C, elevated TG is increasingly 
being recognized as a possible risk factor for CHD
12-14
. Additional research into the 
relevance of TG-lowering for CHD risk reduction, and into interventions (e.g. diet 
and lifestyle interventions) that beneficially impact TG, is therefore warranted.  
 
In conclusion, foods enriched with PS modestly lower TG concentrations, especially 
in those with high TG concentrations at baseline. This effect may add to the overall 
benefit of using PS-enriched foods as part of therapeutic lifestyle and diet changes 
for improving blood lipid profiles. 
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Abstract 
Plant sterols (PS) lower low-density lipoprotein cholesterol (LDL-C) concentrations, 
whereas the n–3 (ω-3) fish fatty acids eicosapentaenoic acid (EPA) and 
docosahexaenoic acid (DHA) lower triglyceride (TG) concentrations. Incorporating 
both PS and EPA+DHA from fish oil (FO) in a single food format was expected to 
beneficially affect two blood lipid risk factors. The aim of this study was to 
investigate the dose-response relation between low doses (<2 g/d) of EPA+DHA 
from FO, incorporated in a low-fat PS-enriched spread, and TG concentrations. In 
addition, effects on LDL-C were investigated. The study was designed as a 
randomized, double-blind, placebo-controlled parallel study. After a 4-week run-in 
period, subjects were randomly assigned to consume either a control (C) spread 
(no PS, no FO) or 1 of 4 intervention spreads containing a fixed amount of PS (2.5 
g/d) and varying amounts of FO (0.0, 0.9, 1.3, and 1.8 g/d of EPA+DHA) for 4 weeks. 
Before and after the intervention, fasting blood samples were drawn for measuring 
serum lipids and EPA and DHA in erythrocyte membranes. In total, 85 
hypercholesterolemic men and 247 women with a mean age of 57.9 y (range: 25-
74 y) were included. Eighteen subjects dropped out during the study. At baseline, 
mean TG and LDL-C concentrations were 1.09 and 4.00 mmol/L, respectively. After 
the intervention, a significant dose-response relation for the TG-lowering effect of 
EPA+DHA (βLn(TG) = -0.07mmol/L per gram of EPA+DHA; P <0.01) was found. 
Compared with the C group, TG concentrations were 9.3-16.2% lower in the 
different FO groups (P <0.05 for all groups). LDL-C concentrations were 11.5-14.7% 
lower in the different PS groups than in the C group (P <0.01 for all groups). EPA 
and DHA in erythrocyte membranes were dose-dependently higher after FO intake 
than after the C spread, indicating good compliance. Consumption of a low-fat 
spread enriched with PS and different low doses of n-3 fatty acids from FO 
decreased TG concentrations in a dose-dependent manner and decreased LDL-C 
concentrations. This trial was registered at clinicaltrials.gov as NCT01313988.  
 
Introduction 
Elevated low-density lipoprotein cholesterol (LDL-C) is an established risk factor for 
coronary heart disease (CHD)
1
. Phytosterols, including both plant sterols (PS) and 
their saturated counterparts, plant stanols, are proven to lower LDL-C. To date, 
several meta-analyses have been published that quantified the LDL-C-lowering 
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effect of phytosterols when incorporated into various foods; a mean phytosterol 
intake of 2 g/d decreases LDL-C by 0.31-0.34 mmol/L or 8-10%
2-5
. Although not as 
strong and established as LDL-C, elevated triglyceride (TG) concentrations also 
represent an emerging blood lipid risk factor for CHD. A recent Mendelian 
randomization study even suggested a causal role of TG-rich lipoproteins in the 
development of CHD
6
. Especially in individuals at high risk of CHD, such as 
individuals with diabetes, attempts to decrease elevated TG concentrations are 
recommended in addition to treating elevated LDL-C
7,8
. The very long-chain n-3 
fatty acids (FAs) eicosapentaenoic acid (EPA, 20:5n-3) and docosahexaenoic acid 
(DHA, 22:6n-3) were shown to decrease fasting TG concentrations
9-13
. Evidence for 
this is mainly based on studies that used EPA+DHA in the form of fish oil (FO) 
capsules at doses >2 g/d and showed reductions in TG concentrations of 25-35%
9,11
. 
 
The consumption of a combination of PS and EPA+DHA from FO would address two 
blood lipid risk factors simultaneously. Some studies have investigated the lipid-
modifying effects of this combination, with both ingredients being provided in 
separate formats or being esterified with each other. Overall, these studies showed 
decreasing effects on both LDL-C and TGs
14-19
. Whether the combination of 
EPA+DHA from FO and PS is also efficacious when both are incorporated into a 
single food format, i.e., a spread with a reduced-fat content, is unknown. Spreads 
are rich sources of unsaturated FAs and would therefore fit well within dietary 
approaches for improving blood lipid profiles. However, in low-fat spreads (~35% 
fat), the maximum amount of FO that can be added is limited. Furthermore, FO 
contains relatively large amounts of saturated FAs (SFAs), which are known to 
increase LDL-C concentrations
20
. Adding large amounts of FO into PS-enriched 
spreads could thus potentially lessen the LDL-C-lowering effect of PS. Recent dose-
response investigation revealed that intakes of EPA+DHA as low as 0.2-0.5 g/d 
decrease TG concentrations by ~3-7%
10
. 
 
The aim of the present study was to investigate the dose-response relation 
between low doses of EPA+DHA from FO, incorporated in a low-fat spread enriched 
with PS, and TG concentrations. Also, we investigated the effect of PS and FO on 
LDL-C concentrations. Furthermore, the effects of PS and FO on total cholesterol 
(TC), high-density lipoprotein cholesterol (HDL-C), and, as a compliance marker, on 
EPA and DHA in erythrocyte membranes were investigated. 
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Materials and Methods 
This study was conducted according to the ethical principles laid down in the 
Declaration of Helsinki, as adopted in 1964 with later revisions. The protocol, 
informed consent and other subject information were approved by the ethical 
committee of Uppsala, Sweden (Regionala etikprövningsnämnden i Uppsala). The 
study took place from March 2011 to November 2011 at the clinical research 
organization Food Files, formerly known as Good Food Practice, in Uppsala, 
Sweden. Written informed consent was obtained from all subjects. The study was 
registered at clinicaltrials.gov (NCT01313988). 
 
Study population 
Subjects were recruited among inhabitants of Uppsala and surroundings. 
Interested subjects (n = 704) were referred to the study web site where they were 
requested to fill out a short questionnaire. Subjects whose eligibility was indicated 
by the results of the questionnaire (n = 562) were invited to join the screening 
procedure. Subjects were eligible if they met the following main selection criteria: 
apparently healthy; aged 25-75 y; fasting TC concentration between 5 and 8 
mmol/L [i.e., borderline-high or high TC concentrations
8
 as usually used in studies 
investigating the effects of PS on blood lipids]; BMI between 18 and 30 kg/m
2
; 
systolic blood pressure ≤160 mm Hg, diastolic blood pressure ≤90 mm Hg and heart 
rate between 50 and 100 beats/min; no use of medication that could influence the 
study outcomes (e.g., lipid-lowering drugs or antibiotics); no use of nicotine-
containing products; 10-y cardiovascular disease risk ≤10 according to the 
Systematic Coronary Risk Evaluation (SCORE); willing to comply with the study 
protocol (e.g., consume test products and follow several dietary and lifestyle 
restrictions); and having signed the informed and biobank consents. In total, 332 
men and women fulfilled all inclusion and exclusion criteria and were enrolled into 
the study (Figure 1). 
 
Study design 
This study was designed as a randomized, double-blind, placebo-controlled, parallel 
efficacy study. Subjects followed a 4-week run-in period during which they 
consumed the control (C) spread to stabilize blood lipids and to get familiarized 
with the study regimen. After the run-in phase, subjects were randomly allocated, 
without further stratification, to consume either the C spread or 1 of 4 intervention 
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spreads containing a fixed amount of PS (2.5 g/d) and varying amounts of EPA+DHA 
(0-1.8 g/d) for 4 weeks. At the end of the run-in and intervention phases, fasted 
blood samples were drawn on two consecutive days for measuring serum lipids (on 
the basis of double blood sampling) and percentage of EPA and DHA of total 
erythrocyte membrane FAs (on the basis of single blood sampling). Body weight 
was also measured. Breakfast was served on all four test days. Health and well-
being, compliance with test product intake and dietary restrictions, use of 
concomitant medication, and adverse events (AEs) were monitored online 
throughout the study. 
 
Test products and dietary and lifestyle instructions 
During the intervention phase, subjects were provided with 1 of the following test 
spreads: 30 g/d low-fat spread (C), 30 g/d low-fat spread with 12.5% PS esters (PS), 
30 g/d low-fat spread with 12.5% PS esters and 11% (i.e., low-dose) FO (PS+FOL), 
30 g/d low-fat spread with 12.5% PS esters and 16.5% (i.e., medium-dose) FO 
(PS+FOM), or 30 g/d low-fat spread with 12.5% PS esters and 22% (i.e., high-dose) 
FO (PS+FOH). The PS esters consisted of 60% PS and 40% FA esters (BASF 
Corporation). The FO consisted of 27% EPA+DHA as TG molecules (Ocean 
Nutrition). The ratio of EPA to DHA was 2:1. The FA composition of the FO is 
provided in Supplemental Appendix 1. The formulations of the 5 test spreads were 
similar (same base composition) except for FO, which replaced sunflower oil, and 
PS esters, which replaced water (PS) and sunflower oil (FA esters). In the PS+FOH 
spread, as much sunflower oil as possible was replaced by FO (i.e., 1.8 g EPA+DHA 
per daily serving); the PS+FOL spread consisted of half this maximal FO dose (i.e., 
0.9 g EPA+DHA per daily serving). The nutritional compositions of the test spreads 
are shown in Table 1. All test spreads were produced in 3 production batches at the 
pilot plant of Unilever Research and Development Vlaardingen. Content analysis 
was performed after the production of the test spreads; the mean amounts of 
EPA+DHA were 0.9, 1.3, and 1.8 g per daily serving of the different FO spreads, 
whereas the mean amount of PS was 2.5 g (as free equivalents) per daily serving of 
the spreads containing PS. This amount is at the upper end of the recommended PS 
intake of 1.5-2.4 g/d
21,22
. All test products used in this study underwent standard 
microbiologic clearance and safety testing. The test spreads were provided in 10-g 
tubs packed in carton boxes and were stored under cooled (4-8°C) conditions. 
Subjects were instructed to consume 3 tubs daily (i.e., 1 tub with each main meal). 
Subjects were requested to consume the spread on bread or on other foods at 
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room temperature; the use of the spread on top of hot meals could have released a 
fishy smell and was therefore not allowed to avoid making them aware of their 
treatment group. The subjects and all staff involved in the conduct of the study 
were unaware of the treatment groups; the different test products were as similar 
as possible with respect to taste and appearance. 
 
Table 1. Nutritional composition of the control spread, the spread with plant sterols alone 
and the spreads with plant sterols and various amounts of fish oil. 
 
Test spread 
 
C PS PS+FOL PS+FOM PS+FOH 
 
unit/30 g spread 
Energy, kJ 388.9 388.9 388.2 388.2 388.2 
Energy, kcal 94.6 94.6 94.4 94.4 94.4 
Total protein, g 0.0 0.0 0.0 0.0 0.0 
Total carbohydrates, g 0.0 0.0 0.0 0.0 0.0 
Sugar, g 0.0 0.0 0.0 0.0 0.0 
Total fat, g 10.5 10.5 10.5 10.5 10.5 
SFAs, g 2.4 2.4 3.0 3.3 3.7 
MUFAs, g 2.5 2.5 2.5 2.4 2.4 
PUFAs, g 5.5 5.5 4.8 4.5 4.1 
Total n-3 PUFAs, g 0.0 0.0 0.9 1.4 1.8 
ALA, g 0.0 0.0 0.0 0.0 0.1 
EPA, mg 0.0 0.0 594 891 1188 
DHA, mg 0.0 0.0 297 446 594 
Total n-6 PUFAs, g 5.5 5.5 3.4 2.4 1.4 
TFA, g 0.1 0.1 0.2 0.2 0.2 
Cholesterol, mg 0.2 0.2 33.1 49.6 66.1 
PS estera, g 0.00 3.75 3.75 3.75 3.75 
Sodium, mg 3.5 3.2 3.2 3.2 3.2 
Potassium, mg 7.8 7.8 7.8 7.8 7.8 
Vitamin A, µg 30.0 30.0 30.0 30.0 30.0 
Vitamin E, mg 4.8 4.2 2.4 1.5 0.6 
Water, g 19.4 17.2 17.2 17.2 17.2 
ALA, a-linolenic acid; C, control; MUFA, monounsaturated fatty acids; PS, plant sterols; PS+FOH, plant sterols + high-
dose fish oil; PS+FOL, plant sterols + low-dose fish oil; PS+FOM, plant sterols + medium-dose fish oil; PUFA, 
polyunsaturated fatty acids; SFA, saturated fatty acids; TFA, trans fatty acids.
 
a 3.75 g of PS esters contains 2.5 g free PS. 
 
Subjects were asked to maintain their normal diet and lifestyle during the entire 
study period but to refrain from consuming foods or supplements enriched with 
FO, EPA+DHA, or PS/stanols and to restrict the intake of fish to a maximum of 3 
portions/week. Furthermore, the intake of aspirin or other anticoagulants on a 
daily basis was discouraged. Strenuous exercise was not allowed during the 24 h 
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preceding each blood sampling. Test product intake and deviations from the 
protocol were recorded daily by the subjects in an online diary. If subjects did not 
enter any data in their diary for 3 days or if they showed noncompliance on a 
regular basis, they were contacted. Compliance with test product intake was 
determined by counting test product intake as reported in the online diaries and by 
measuring EPA and DHA in erythrocyte membranes. 
 
Blood sampling and assays 
Venous blood was collected from all subjects after an overnight fast (of at least 12 
h) on 2 consecutive days pre- and post intervention. Blood samples for the serum 
lipid analysis were prepared at the test facility by centrifuging at 850 x g for 5 min; 
serum was then separated into aliquots and stored at -80°C until analysis after the 
study was completed. The EDTA samples for the FA analysis in erythrocytes were 
prepared at the test facility by centrifuging at 1400 x g for 10 min at 4°C. Two 
aliquots of erythrocytes were washed twice with HEPES buffered saline and stored 
at -80°C until further preparation. Erythrocyte membranes were isolated through 
several centrifuge and wash steps with decreasing concentrations of phosphate 
buffered saline (PBS). The final membrane pellets were suspended in isotonic stock 
PBS, and the tubes were dipped in dry ice/ethanol before being placed in an -80°C 
freezer until analysis after completion of the study. Serum concentrations of TC, 
LDL-C, HDL-C, and TGs were analyzed directly by photometry on an Abbot Architect 
ci8200 auto-analyzer. FAs were analyzed with the FAME-N3 method as previously 
reported
23,24
. All samples obtained from 1 subject were analyzed within the same 
assay. 
 
Statistical analyses 
The study was powered to find a significant slope of the dose-response relation 
between low doses of EPA+DHA and serum TG concentrations. Assuming a mean 
baseline TG concentration of 1.3 mmol/L and an SD of 0.5 mmol/L, a total of at 
least 222 subjects divided across the 4 PS groups were required for reaching a 
power of 0.8 (α = 0.05, 2-sided) when aiming for a 10% reduction in TG 
concentration. The study was also powered to find a significant LDL-C-lowering 
effect of 8% in each of the PS groups vs. the C group. Assuming a mean baseline 
LDL-C concentration of 4.0 mmol/L and an SD of 0.5 mmol/L, 60 subjects per 
treatment group were required (i.e., 300 in total) to arrive at a power of 0.8 (α = 
0.05, 2-sided). This number covered the 222 subjects required to power the study 
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to find a significant TG slope. To account for possible dropouts (10%), a total of 330 
subjects were included, 66 per treatment group. Two additional subjects acted as 
reserves and replaced dropouts during the run-in period. 
 
Data were analyzed according to the intention-to-treat principle and the per-
protocol principle, i.e., excluding data from subjects who had been noncompliant 
with the protocol (i.e., low test product compliance, not being weight stable, or use 
of prohibited drugs). Here, we only report the results based on the intention-to-
treat analysis; the per-protocol analysis yielded similar results. For each subject, 
serum lipid concentrations as determined on the 2 consecutive days pre- and post 
intervention were averaged. In case of not normally distributed variables (i.e., for 
TGs), natural log transformation was applied and statistical analysis was performed 
on the basis of the log transformed data [ln(TG)]. Statistical analysis was performed 
on end-of intervention concentrations with corrections for baseline. 
 
To investigate the dose-response effect of EPA+DHA on TG concentrations, 
regression analysis was performed including only the 4 groups who consumed PS. 
To investigate between-group differences vs. the C group, a mixed-model ANCOVA 
was carried out followed by post hoc multiple comparisons of the least square 
means (LSMeans) by using a Dunnett-Hsu adjustment. Between-group differences 
vs. the PS group were also investigated but were only reported for TGs. Full models 
included treatment, baseline, treatment x baseline, gender, age, BMI, change in 
body weight, period (before or after summer), and cohort (time of study start per 
subject). Reduced models included treatment and baseline and a selection of the 
other covariates in case these contributed significantly to the model (if P <0.10). 
Results obtained with the reduced models are reported here. Relative differences 
in LSMeans were calculated with the LSMean of the C group (or the PS group) as 
the reference. A P value <0.05 was considered significant. All analyses were 
performed with the statistical software package SAS version 9.2 (SAS Institute). 
 
Results 
Subject characteristics and compliance 
A total of 247 women (74.4%) and 85 men (25.6%) were included in the study. 
Eighteen subjects (5.4%) dropped out during the study (Figure 1); 8 subjects chose 
to discontinue for personal reasons, 6 experienced an AE (e.g., fever, diarrhea, 
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upset stomach), 3 were lost to follow-up, and 1 subject was excluded by the study 
physician for medical reasons (low hemoglobin). An overview of subjects’ 
characteristics at baseline is provided in Table 2. Compliance with test product 
intake on the basis of the diaries was excellent (98.2%), with no difference between 
the run-in period (98.2%) and the intervention period (98.2%). Compliance with 
dietary and lifestyle restrictions was also high. Body weights after intervention did 
not differ between the groups (P = 0.75). 
 
 
Figure 1. Subject flow throughout the study. Hypercholesterolemic men and women were 
randomly assigned across 5 different treatment groups consuming a control spread (C), a 
spread with plant sterols (PS) or one of the spreads with PS and a low dose of fish oil 
(PS+FOL), a medium dose of fish oil (PS+FOM) or a high dose of fish oil (PS+FOH). ITT, 
intention-to-treat. 
 
Serum lipids 
The analysis of the ln(TG) data revealed a clear dose-response relation (β = -0.07, P 
<0.01) for the TG-lowering effect of EPA+DHA (Figure 2). After 4 weeks, serum TGs 
were significantly lower in all FO groups than in the C group (ranging from -9.3% to 
-16.2%; P <0.05 for all; Table 3). The effect was not present after treatment with PS 
only (-5.3%; P = 0.36). Compared with the PS group, TGs were significantly lower in 
the PS+FOM and PS+FOH groups [-9.4% (P = 0.02) and -11.5% (P <0.01), 
respectively], whereas no effect was observed in the PS+FOL group (-4.3%; P = 
0.47). 
 
PS
66 subjects
Control
66 subjects
PS+FOH
67 subjects
562 subjects screened at visit 1
142 subjects found ineligible
230 subjects found ineligible 
or withdrew during screening
332 subjects randomised
704 potentially eligible subjects screened online
62 subjects were 
included in the ITT
analysis population
64 subjects were 
included in the ITT
analysis population
4 subjects
withdrew
2 subjects
withdrew
PS+FOL
66 subjects
64 subjects were 
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analysis population
62 subjects were 
included in the ITT 
analysis population
62 subjects were 
included in the ITT 
analysis population
PS+FOM
67 subjects
2 subjects
withdrew
5 subjects
withdrew
5 subjects
withdrew
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Table 2. Overview of the subject characteristics at baseline. 
  Treatment group 
 All C PS PS+FOL PS+FOM PS+FOH 
Gender (F/M), n/n 230/84 42/20 45/19 45/19 48/14 50/12 
Age, y 57.9 ± 0.6 56.2 ± 1.5 58.3 ± 1.5 55.8 ± 1.4 59.9 ± 1.2 59.4 ± 1.3 
Weight, kg 72.3 ± 0.6 73.5 ± 1.2 71.1 ± 1.4 73.3 ± 1.4 73.8 ± 1.5 69.7 ± 1.4 
BMI, kg/m2 25.0 ± 0.1 25.0 ± 0.3 24.6 ± 0.3 25.1 ± 0.3 25.7 ± 0.3 24.3 ± 0.4 
SBP, mmHg 128.2 ± 0.8 127.1 ± 1.5 127.7 ± 1.9 130.0 ± 1.9 129.6 ± 1.8 126.7 ± 1.8 
DBP, mmHg 77.7 ± 0.4 77.6 ± 0.9 77.5 ± 1.0 77.6 ± 0.9 79.0 ± 0.8 76.8 ± 1.0 
Heart rate, beats/min 65.7 ± 0.5 64.4 ± 1.2 65.5 ± 1.4 65.5 ± 1.1 66.0 ± 1.1 67.1 ± 1.3 
SCOREa 2.5 ± 0.1 2.5 ± 0.3 2.7 ± 0.3 2.6 ± 0.3 2.6 ± 0.3 2.3 ± 0.3 
Serum TC, mmol/L 6.45 ± 0.05 6.39 ± 0.11 6.39 ± 0.10 6.49 ± 0.10 6.60 ± 0.12 6.36 ± 0.10 
Serum LDL-C, mmol/L 4.00 ± 0.04 4.01 ± 0.09 3.91 ± 0.09 4.10 ± 0.09 4.06 ± 0.10 3.89 ± 0.10 
Serum HDL-C, mmol/L 1.63 ± 0.02 1.59 ± 0.04 1.67 ± 0.06 1.57 ± 0.05 1.68 ± 0.05 1.64 ± 0.04 
Serum TG, mmol/L 1.09 ± 0.03 1.09 ± 0.06 1.13 ± 0.07 1.11 ± 0.08 1.09 ± 0.06 1.02 ± 0.05 
C, control; DBP, diastolic blood pressure; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein 
cholesterol; PS, plant sterols; PS+FOH, plant sterols + high-dose fish oil; PS+FOL, plant sterols + low-dose fish oil; 
PS+FOM, plant sterols + medium-dose fish oil; SBP, systolic blood pressure; SCORE, Systematic Coronary Risk 
Evaluation; TC, total cholesterol; TG, triglycerides. Values are means ± SEs. 
a Ten-year cardiovascular disease risk according to the SCORE. 
 
 
Figure 2. Dose-response effect of eicosapentaenoic acid (EPA) and docosahexaenoic acid 
(DHA) from fish oil incorporated in a plant sterol-enriched spread on serum triglyceride (TG) 
concentrations in hypercholesterolemic men and women. Least square means and 95% CIs of 
log-transformed TG [ln(TG)] concentrations are shown, n = 252. The relation was linear. 
 
LDL-C concentrations were significantly lower after the intervention with all 
spreads containing PS vs. the C spread; the average effects ranged from -11.5% to -
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14.7% (P <0.01 for all) (Table 3). TC concentrations were also significantly lower vs. 
the C group (-5.6% to -9.0%; P <0.01 for all). HDL-C concentrations did not differ 
except for a 4.7% higher concentration in the PS+FOH group vs. the C group (P = 
0.03).  
 
Table 3. Serum lipid concentrations in hypercholesterolemic men and women supplemented 
with plant sterols or with plant sterols and various amounts of fish oil for 4 weeks.  
Outcome and 
treatment group 
Baseline End-of-
intervention 
Absolute difference  
(95% CI) in LSMeansa vs. C 
P Relative difference 
in LSMeans vs. C 
 mmol/L mmol/L mmol/L  % 
Ln(TG)b      
C 0.02 0.04 - - - 
PS 0.06 0.00 -0.05 (-0.13; 0.02) 0.36 -5.3 
PS+FOL 0.05 -0.04 -0.10 (-0.17; -0.03) 0.03 -9.3 
PS+FOM 0.03 -0.09 -0.15 (-0.22; -0.08) <0.01 -13.9 
PS+FOH 0.06 -0.13 -0.18 (-0.25; -0.11) <0.01 -16.2 
LDL-C      
C 3.80 3.85 - - - 
PS 3.77 3.34 -0.45 (-0.59; -0.32) <0.01 -11.7 
PS+FOL 3.98 3.50 -0.45 (-0.58; -0.31) <0.01 -11.5 
PS+FOM 3.93 3.46 -0.49 (-0.63; -0.36) <0.01 -12.7 
PS+FOH 3.77 3.26 -0.57 (-0.70; -0.43) <0.01 -14.7 
TC      
C 6.16 6.23 - - - 
PS 6.25 5.72 -0.57 (-0.74; -0.40) <0.01 -9.0 
PS+FOL 6.34 5.91 -0.44 (-0.61; -0.27) <0.01 -6.9 
PS+FOM 6.40 6.09 -0.36 (-0.53; -0.19) <0.01 -5.6 
PS+FOH 6.26 5.93 -0.39 (-0.56; -0.22) <0.01 -6.2 
HDL-C      
C 1.58 1.59 - - - 
PS 1.68 1.66 -0.03 (-0.09; 0.02) 0.64 -1.9 
PS+FOL 1.58 1.58 -0.01 (-0.06; 0.05) 1.00 -0.4 
PS+FOM 1.65 1.72 0.06 (0.00; 0.11) 0.16 3.4 
PS+FOH 1.64 1.72 0.08 (0.02; 0.13) 0.03 4.7 
C, control; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; LSMean, least square 
mean; PS, plant sterols; PS+FOH, plant sterols + high-dose fish oil; PS+FOL, plant sterols + low-dose fish oil; PS+FOM, 
plant sterols + medium-dose fish oil; TC, total cholesterol; TG, triglycerides. 
a LSMeans were corrected for baseline and, if significantly contributing to the model (P <0.10), for treatment x baseline, 
gender, age, BMI, change in body weight, period (before or after summer), and cohort (time of study start per subject). 
b 
Statistical analysis was conducted by using log-transformed TG concentrations [ln(TG)] because these were not 
normally distributed. Negative end-of-intervention values indicate that the values are <1 mmol/L on the normal scale. 
Relative differences in LSMeans vs. C are based on back-transformed LSMeans. 
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EPA and DHA in erythrocyte membranes 
After intervention, the percentages of EPA and DHA in total erythrocyte membrane 
FAs were not different in the PS group compared with the C group. In the different 
FO groups, the erythrocyte contents of EPA were 61.1%, 87.5%, and 120.8% higher, 
respectively, vs. the C group (P <0.01 for all). The erythrocyte contents of DHA were 
also significantly higher in the different FO groups vs. the C group (ranging from 
7.1% to 9.4%; P <0.01 for all), although the relative effect sizes were smaller 
compared with EPA (Table 4). 
 
Table 4. EPA and DHA of total erythrocyte membrane fatty acids in hypercholesterolemic 
men and women supplemented with plant sterols or with plant sterols and various amounts 
of fish oil for 4 weeks. 
Outcome and 
treatment group 
Baseline 
End-of-
intervention 
Absolute difference 
(95% CI) in LSMeansa vs. C 
P 
Relative difference 
in LSMeans vs. C 
 % total FAs % total FAs % total FAs  % 
EPA      
C 1.15 1.09 -  - 
PS 1.14 1.10 0.02 (-0.13; 0.17) 1.00 1.7 
PS+FOL 1.17 1.76 0.68 (0.53; 0.83) <0.01 61.1 
PS+FOM 1.15 2.16 0.97 (0.82; 1.12) <0.01 87.5 
PS+FOH 1.26 2.56 1.34 (1.19; 1.49) <0.01 120.8 
DHA      
C 4.93 4.86 - - - 
PS 4.98 4.91 -0.01 (-0.19; 0.16) 1.00 -0.3 
PS+FOL 4.96 5.23 0.37 (0.19; 0.54) <0.01 7.4 
PS+FOM 4.95 5.24 0.35 (0.17; 0.52) <0.01 7.1 
PS+FOH 5.13 5.53 0.46 (0.29; 0.63) <0.01 9.4 
C, control; EPA, eicosapentaenoic acid; DHA, docosahexaenoic acid; FA, fatty acid; LSMean, least square mean; PS, 
plant sterols; PS+FOH, plant sterols + high-dose fish oil; PS+FOL, plant sterols + low-dose fish oil; PS+FOM, plant sterols 
+ medium-dose fish oil. 
a LSMeans were corrected for baseline and, if significantly contributing to the model (P <0.10), for treatment x baseline, 
gender, age, BMI, change in body weight, period (before or after summer), and cohort (time of study start per subject).  
 
Adverse events  
A total of 126 subjects experienced 214 AEs during the intervention period. Overall, 
AEs were mild, with major complaints being headache (n = 43), acute 
nasopharyngitis (n = 35), abdominal pain (n = 11), and nausea (n = 10) and were 
unlikely to be or not related to the study procedures. In total, 3 subjects 
experienced a serious AE (concussion, hospitalized due to chest pain, or diagnosed 
with an ileal diverticulum); none were related to the study procedures and all were 
resolved. There was no remarkable difference in the number of subjects 
120 | Chapter 5 
 
experiencing AEs or in the nature and frequency of AEs between the 5 treatment 
groups. 
 
Discussion 
This randomized controlled intervention study showed that the combination of 
EPA+DHA from FO (with doses ranging from 0.9 to 1.8 g/d) and PS (at a dose of 2.5 
g/d) decreases TG concentrations in a dose-dependent manner (9-16%) while also 
decreasing LDL-C concentrations (~13%) in a population with elevated cholesterol 
but normal TG concentrations. On the basis of data from statin trials, a 0.45-0.57 
mmol/L (~13%) reduction in LDL-C could potentially reduce the risk of CHD by ~12-
14%
25
. On the basis of currently available Mendelian randomization data
6
, it can be 
estimated that a 10% decrease in TG could lower CHD risk by 4-5% independently 
of changes in LDL-C. Whether these estimated CHD risk reductions, if present at all, 
would be additive when consuming a combination of PS and FO incorporated in a 
single food format remains unclear and requires further investigation. 
 
The dose-response relation for the TG-lowering effect of EPA+DHA was previously 
shown in 2 meta-analyses
10,12
. In the meta-analysis by Eslick et al.
12
, 47 studies 
were selected, all including adults at risk of cardiovascular disease. Mean EPA+DHA 
intakes ranged between 0.9 and 6.8 g/d. On the basis of linear meta-regression 
analysis, it was shown that the decrease in TGs was significantly related to the dose 
of EPA+DHA (P <0.01). The meta-analysis by Musa-Veloso et al.
10
 included 15 
studies and established a continuous dose-response curve from which the TG-
lowering effect for a given dose of EPA+DHA could be calculated. Mean intakes of 
EPA+DHA ranged between 0.2 and 5.6 g/d. On the basis of this dose-response 
curve, EPA+DHA doses of 0.9, 1.3, and 1.8 g/d were predicted to decrease TGs by 
11.7%, 15.4%, and 18.9%, respectively. These outcomes are in accordance with the 
findings of our study that investigated different doses of FO side-by-side; compared 
with the C group, mean changes in TG concentrations were -9.3%, -13.9%, and         
-16.2%, respectively. On the basis of the established dose-response curve (i.e., 
correcting for the PS group), TG-lowering effects of 6.3%, 8.9%, and 12.2%, 
respectively, were found. Hence, this suggests that part of the TG-lowering effect 
of the combination of PS and EPA+DHA from FO might be explained by the 
presence of PS that seem to exert a modest ~6% TG-lowering effect
26
. 
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So far, 6 studies have investigated the effects on blood lipids of PS in combination 
with EPA+DHA
14-19
. In these studies, PS were either esterified to fish FAs and 
provided in supplements
16,18
 or oil or margarine
15,19
, or were provided separately 
from the FO, i.e., applying FO capsules next to PS-enriched yogurt drinks
17 
or 
spreads
14
. The current study is the first to our knowledge that used a single food 
format (i.e., low-fat spread) that was enriched with both PS, in their ester form, and 
FO. Overall and in accordance with our study findings, the previous studies showed 
that the combination of PS and EPA+DHA from FO decreased both TG and LDL-C 
concentrations, although the decrease in LDL-C seemed somewhat diminished with 
high intakes of EPA+DHA (≥5 g/d), possibly due to the relatively high SFA content of 
FO.  
 
Strengths of this randomized study include the large number of subjects (n = 332) 
who were followed up under well-controlled, double-blind conditions. 
Furthermore, this study was designed as a parallel study, minimizing the risk of 
carryover effects. Last, self-reported compliance with test product intake was 
excellent; this was further reflected in a dose-dependent higher content of EPA and 
DHA in erythrocyte membranes. DHA in erythrocyte membranes is known to be 
higher and tends to increase less upon intervention than does EPA
27,28
. In the study 
by Katan et al.
27
, for example, 1 g/d of EPA resulted in an increase in erythrocyte 
EPA of 2% of total FAs, whereas a similar intake of DHA resulted in an increase in 
erythrocyte DHA of 1% of total FAs after 12 months of intervention. The average 
increases observed in the current 4-week study are somewhat lower (~1.3% for 
EPA and ~0.5% for DHA); reaching a new steady state probably requires more time 
than 1 month of intervention. Nevertheless, it is clear from these analyses that, 
overall, subjects used different, i.e., increasing, doses of EPA+DHA in the different 
treatment groups. 
 
Some limitations of this study should be mentioned as well. First, in the current 
study, FO was used as a rich source of EPA+DHA. Although the TG-lowering effect 
of FO is known to be attributable to its EPA+DHA content, we cannot exclude that 
other ingredients in FO (e.g., trans fat and SFAs) may have affected the blood lipid 
concentrations to some extent (e.g., smaller PS-induced reductions in LDL-C with 
increasing doses of SFA-containing FO). In the current study, however, we did not 
observe such effects. It is likely that the amount of SFAs in the FO used was too 
small to partly counteract the LDL-C-lowering effect of PS. Second, it is known that 
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the magnitude of the TG-lowering effect is influenced by the initial TG 
concentration
10,12
. In the current study, subjects were selected on the basis of 
elevated cholesterol concentrations, whereas elevated TG concentrations were not 
a requirement for inclusion. Indeed, the mean TG concentration at baseline was 
within normal ranges (~1.12 mmol/L). We cannot rule out that larger effects would 
have been found if subjects with higher initial TG concentrations had been 
included. Nevertheless, it is remarkable that significant reductions in TGs of 9-16% 
were observed in our study population with normal TG concentrations.  
 
According to the World Health Organization, ~40% of adults (>25 y) worldwide 
have elevated TC (>5 mmol/L) concentrations
29
. Future economic development, 
urbanization, and nutritional transition might lead to further increases in 
cholesterol concentrations, particularly in developing countries
30
. Furthermore, 
~30% of adults (>18 y) in the United States have above desirable (>1.7 mmol/L) TG 
concentrations
31,32
, and this proportion is expected to increase in the near future 
due to the increasing prevalence of obesity and type 2 diabetes. Interestingly, 
lifelong lower exposures to risk factors (e.g., LDL-C) seem to be associated with a 
greater reduction in CHD risk per unit of cholesterol-lowering than that observed 
with a statin treatment later in life
25,33
. Thus, from a preventative point of view, 
there is an increasing need to manage blood lipid risk factors to prevent future CHD 
events.  
 
In summary, the consumption of a low-fat spread enriched with PS and different 
low (<2 g/d) doses of EPA+DHA from FO lowers TG concentrations in a dose-
dependent manner in addition to significantly decreasing LDL-C concentrations. 
The use of low-fat spreads enriched with both PS and FO may thus offer an 
interesting opportunity for a combined blood lipid benefit that would fit in diet and 
lifestyle changes for improving blood lipid profiles. 
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Supplemental material 
Supplemental Appendix 1 – Fatty acid composition of the fish oil 
 
 Composition, g/100g 
SFAs  
14:0 7.4 
15:0 0.5 
16:0 16.9 
17:0 0.4 
18:0 3.4 
MUFAs  
16:1 9.0 
17:1 0.3 
18:1n-9 9.3 
18:1n-7 3.1 
20:1n-9 1.0 
22:1n-11 1.0 
24:1n-9 0.4 
PUFAs  
16:2n-6 1.4 
18:2n-6 1.2 
18:3n-3 0.7 
18:4n-3 2.3 
20:4n-6 1.1 
20:4n-3 0.8 
20:5n-3 (EPA) 19.8 
21:5n-3 0.9 
22:5n-6 0.4 
22:5n-3 2.5 
22:6n-3 (DHA) 10.4 
TFAs <5 
Cholesterol <1.5 
EPA, eicosapentaenoic fatty acid; DHA; docosahexaenoic fatty acid; 
MUFA, monounsaturated fatty acid; PUFA, polyunsaturated fatty acid;  
SFA, saturated fatty acid; TFA, trans fatty acid 
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Abstract 
Objective - Intake of plant sterol (PS)-enriched foods effectively lowers plasma total 
cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C) concentrations 
while increasing plasma PS concentrations. The magnitude of this increase has not 
been systematically assessed. This study aimed to investigate the effect of PS-
enriched foods on plasma PS concentrations by performing a meta-analysis of 
randomized controlled studies.  
Methods - Published PS intervention studies reporting plasma PS concentrations 
were searched through June 2012. Studies were selected that fulfilled predefined 
in- and exclusion criteria. Data were extracted, particularly on campesterol, 
sitosterol, TC and LDL-C. Random-effects models were used to calculate net effects 
while weighing each study by the inverse of its variance. Potential sources of 
heterogeneity were investigated.  
Results - The meta-analysis included data from 41 studies (55 strata) with in total 
2084 subjects. The average dose of PS from enriched foods was 1.6 g/d (range: 0.3-
3.2 g/d). Plasma sitosterol and campesterol concentrations were increased by on 
average 2.24 µmol/L (31%) and 5.00 µmol/L (37%), respectively, compared to 
control. TC and LDL-C were reduced by on average 0.36 mmol/L (5.9%) and 0.33 
mmol/L (8.5%), respectively. The increase in sitosterol and campesterol was 
impacted by the dose of PS, the baseline PS concentration and the PS composition 
of the test products. In the highest PS dose category (2.0-3.2 g/d), increases in 
sitosterol and campesterol were on average 3.56 and 7.64 µmol/L, respectively.  
Conclusion - Intake of PS-enriched foods increases plasma sitosterol and 
campesterol concentrations. However, total PS remain below 1% of total sterols 
circulating in the blood. 
 
Introduction 
Plant sterols (PS) are found in all foods of plant origin and are structurally similar to 
cholesterol except for a slight difference in their side chain, i.e., an additional ethyl 
or methyl group at C24. The two major PS are sitosterol (24α-ethylcholesterol) and 
campesterol (24α-methylcholesterol). Intake of PS-enriched foods or supplements 
has been shown to effectively lower total cholesterol (TC) and low-density 
lipoprotein cholesterol (LDL-C) concentrations
1,2
. Based on recent meta-analyses, a 
PS intake of 2 g/d lowers LDL-C by on average 0.31-0.34 mmol/L or 8-10%
3-5
. 
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Elevated TC, and especially LDL-C, is an established risk factor for cardiovascular 
disease (CVD) and reducing cholesterol by dietary or drug interventions is known to 
reduce the risk of CVD
6,7
. Hence, the cholesterol-lowering properties of PS have 
been acknowledged by health associations such as the National Cholesterol 
Education Program Adult Treatment Panel III
8
, the American Heart Association
9
, the 
European Society of Cardiology and the European Atherosclerosis Society
10
. 
 
PS lower plasma cholesterol by partly inhibiting cholesterol absorption in the gut, 
mainly through competition with cholesterol for micellar incorporation
11
. In 
contrast to cholesterol, PS themselves are not bioavailable in significant quantities 
as they are excreted back from the intestinal mucosa into the intestinal lumen by 
the heterodimer ATP-binding cassette (ABC) transporters ABCG5/8
12
. Only a small 
amount of dietary PS can be absorbed and reaches the systemic circulation
13
. 
Furthermore, PS are not synthesized in the human body. As such, circulating PS 
concentrations are ~200 times lower compared to cholesterol concentrations in 
subjects consuming habitual diets
14
.  
 
When people consume the recommended dose of 2 g/d PS for cholesterol-lowering 
purposes, they ingest 7-10 times more PS than what is normally reached when 
consuming typical Western diets which contain natural sources of PS such as 
vegetable oils, cereals, vegetables, fruits, nuts and seeds. In these Western-type 
diets, PS intakes range between 200 and 300 mg/d
15-18
 whilst vegetarians can 
consume up to 500-1000 mg/d of PS
19,20
. Despite the low bioavailability of PS, 
higher intakes of PS, especially with enriched foods, do eventually result in 
increased plasma/serum PS concentrations.  
 
Recently, potential health concerns have been voiced related to elevated PS 
concentrations following the intake of PS-enriched foods mainly because of two 
reasons. First, patients with homozygous sitosterolemia, a rare genetic disorder 
with mutations in ABCG5/8 genes, have extremely elevated PS concentrations 
(~500-1200 µmol/L) and often experience early onset of atherosclerosis 
independent of circulating cholesterol
21,22
. Second, some, but not all, observational 
studies suggest a positive association between modestly elevated PS 
concentrations and CVD risk although the overall evidence, as summarized in a 
recent meta-analysis, does not support such an association
23
. 
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Until now, the effect of PS-enriched food intake on plasma PS concentrations has 
not yet been systematically investigated and the size of the increase in circulating 
PS seems often overestimated by referring to single studies. Therefore, the 
objective of this study was to perform a meta-analysis of randomized controlled 
studies to estimate the absolute and relative change in plasma concentrations of 
the main PS (i.e., sitosterol and campesterol) with and without correction for TC 
concentrations after consumption of PS-enriched food. Additionally, we estimated 
the change in plasma LDL-cholesterol and TC concentrations in the selected PS 
intervention studies. Furthermore, sources that could possibly explain some of the 
between-study heterogeneity in changes in plasma PS and cholesterol 
concentrations were investigated. 
 
Methods 
Search strategy 
To retrieve as many potentially relevant studies as possible, six databases (Medline, 
Embase, Cab Abstracts, Food Science & Technology Abstracts, HCA Plus and Biosis) 
were systematically searched through June 2012. For this, a search strategy was 
developed including the Medical Subject Heading ‘phytosterols’ and the search 
terms ‘plant sterol* or phytosterol* or sitosterol* or campesterol* or stigmasterol* 
or brassicasterol*’ and ‘blood* or plasma or serum’, limited to humans and 
intervention studies were possible. There was no restriction on language. For 
simplicity, throughout this paper, the term “plasma” is used when referring to 
plasma or serum depending on what has been used in the different studies.  
 
Selection of studies 
The following criteria for selecting eligible studies were pre-defined: (a) 
randomized placebo-controlled study in humans (studies with (familial 
hypercholesterolemic) children were allowed); (b) oral intake of PS-enriched foods 
or supplements as active treatment (throughout this paper, the term “enriched 
foods” encompasses also supplements which were used in only a few studies); (c) 
absence of co-intervention from which consumption of PS-enriched foods could 
not be isolated; (d) no studies with colectomized patients or patients with hetero- 
or homozygous sitosterolemia; (e) duration of treatment of at least two weeks; (f) 
reporting of treatment effects on plasma sitosterol and campesterol 
concentrations; (g) treatment with “common” plant sterols defined as 4-
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desmethylsterols extracted from common vegetable oils and no ferulated PS such 
as from rice bran oil and/or sheanut oil; (h) dose of PS <10 g/d; (i) composition of 
the phytosterol mixture containing at least 80% PS (max 20% plant stanols); (j) no 
treatment with ezetimibe; and (k) no conference proceedings or duplicates.  
 
Selection of studies was done in two rounds. In the first selection round, titles and 
abstracts were screened and those studies that were obviously not fulfilling the 
predefined selection criteria were excluded, e.g. reviews, studies testing other 
ingredients than PS or acute-effect studies. Because investigating effects on plasma 
PS is usually not the primary objective in PS intervention studies, we did not limit 
our search by only selecting studies that reported results on plasma PS 
concentrations in their abstracts. In the second selection round, full publications 
were read to judge eligibility of the studies. A co-intervention was defined as any 
additional test ingredient next to PS which was not added to the placebo 
intervention (e.g. the portfolio diet containing soluble fiber, nuts, PS and soy 
protein vs. a placebo diet). The source of fatty acid esters used to esterify PS into 
PS esters was not considered as a co-intervention. The PS mixtures used in the 
studies were not allowed to contain more than 20% plant stanols
24
 as stanols are 
known to reduce plasma PS concentrations
25
. Studies including ezetimibe 
treatment were not selected because ezetimibe is known to directly impact plasma 
PS concentrations via mechanisms in the gut. In case of indecisiveness, eligibility 
was discussed amongst authors until consensus was reached. 
 
Data extraction and transformation 
Data were collected on (a) publication characteristics (reference details and year of 
publication); (b) study characteristics (parallel or cross-over, sample size and study 
duration); (c) subject characteristics (health status of subjects, mean age, mean 
BMI and gender distribution); (d) treatment characteristics (PS dose, form of PS 
(free or esterified PS), food format, PS source, etc); (e) measurement 
characteristics (methodology used and serum or plasma); and (f) outcome variables 
(plasma concentrations of sitosterol, campesterol (including those standardized for 
TC, e.g. expressed in µmol/mmol TC), LDL-C, TC and high-density lipoprotein 
cholesterol (HDL-C)). We have not assessed the quality of the individual studies 
because scoring of quality is rather subjective and excluding studies based on this 
subjective scoring was judged not appropriate. 
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For each of the outcome variables, data (mean absolute concentration and 
accompanying variance measure) were extracted at baseline and at end-of-
intervention. When outcome variables were measured at different time points, the 
data closest to 4 weeks of intervention were selected in order to standardize the 
intervention duration amongst the studies. Original authors were contacted in case 
the sitosterol and campesterol data were solely expressed as concentrations 
corrected for TC
26-28
. 
 
In case concentrations of cholesterol were expressed in mg/dL, data were 
transformed to derive concentrations in mmol/L by using the molecular weight of 
cholesterol (386.65 g/mol). In case concentrations of sitosterol and campesterol 
were expressed in mg/L, mg/dL, µg/dL, ng/dL, µg/mL or ng/mL, data were 
transformed based on the molecular weights of sitosterol (414.71 g/mol) or 
campesterol (400.68 g/mol) to derive concentrations in µmol/L. These 
transformations were done both for means and SEs or SDs. 
 
Control-adjusted absolute (µmol/L or mmol/L) and relative (%) changes plus 
accompanying within-study SEs for sitosterol, campesterol, LDL-C, TC and HDL-C 
were calculated for each study. For parallel studies, the absolute and relative 
changes plus accompanying SEs were calculated based on the average 
concentrations and variance measures at baseline and at end-of-intervention of 
treatment and control groups. For cross-over studies that reported baseline data, 
the absolute and relative changes were calculated similarly as for the parallel 
studies. Otherwise, these were calculated based on the data at the end of the 
treatment and control periods. In Supplemental Appendix 1, a complete overview 
is provided of the formulas that were used to transform the data. 
 
Statistical analysis 
For each of the main outcome variables, a net effect was calculated according to a 
random-effects model while weighing the studies by the inverse of their within-
study variance (1/SE
2
)
29
. This was done for baseline concentrations, end-of-
intervention concentrations, absolute changes and relative changes. In contrast to 
fixed-effects models, random-effects models take into account both the within-
study variation as well as the large variation between studies and assume that the 
treatment effects of the individual studies vary around some overall average 
treatment effect.  
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Funnel plots were developed with the effect sizes of all individual studies expressed 
against their precisions (1/SE). These plots visualize the likeliness of heterogeneity 
(when effect sizes fall outside the confidence limits) as well as the likeliness of 
publication bias (when clear holes in the funnel (i.e., asymmetry) are detected). 
Heterogeneity was furthermore assessed by calculating Q-statistics and I
2
-
statistics
29
 whereas publication bias was analyzed according to Egger tests
30
. Forest 
plots were developed for the absolute (µmol/L) and relative changes (%) in 
sitosterol and campesterol.  
 
Covariate analysis was performed to investigate the impact of pre-specified 
covariates on the absolute and relative changes in plasma PS and cholesterol 
concentrations after consumption of PS-enriched foods. These covariates were 
dose of PS tested, baseline PS or cholesterol concentration and PS composition 
(i.e., amount of sitosterol or campesterol in the PS mixture of the test products). 
Subgroup analysis was performed for determining differences between subgroups 
after stratification based on the above mentioned covariates. Also meta-regression 
analysis was used for assessing their correlations with the effect sizes found.  
 
P values below 0.05 were considered statistically significant based on two-sided 
hypothesis testing. All analyses were performed with the statistical software 
package SAS version 9.2 (SAS Institute, Inc., Cary, NC, USA). The PRISMA statement 
guidelines for reporting in systematic reviews and meta-analyses were followed. 
 
Results 
Overview of included studies 
With the systematic search, 1034 papers were identified. After two selection 
rounds, 41 human intervention studies including 55 strata were judged eligible for 
inclusion in the current meta-analysis (Figure 1). Most of the studies were excluded 
because they were no randomized controlled studies with human subjects, 
investigated a different active ingredient or did not report plasma or serum PS 
concentrations.  
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Figure 1. Flow-chart of the study selection process. 
 
Of the 41 studies, 21 studies were parallel studies
26-28,31-48
, 19 were cross-over 
studies
49-67
 and 1 paper described a parallel and a cross-over study
68
. Non-
standardized concentrations of sitosterol and campesterol were available for all 
studies (55 strata). For 12 studies (14 strata), PS concentrations corrected for TC 
concentrations (e.g. expressed in µmol/mmol TC) were available.  
 
In total, 2084 subjects were included in the studies. The average age of the subjects 
was 49.3 years (range: 10.5-60.1 years) and the average BMI was 26.0 kg/m
2
 
(range: 19.0-35.2 kg/m
2
). Six strata included healthy or normocholesterolemic 
subjects, 39 strata included hypercholesterolemic but otherwise healthy subjects 
and 10 strata included (hypercholesterolemic) subjects characterized as metabolic 
syndrome patients, diabetics or statin users.  
 
The median duration of studies was 28 days (range: 21-315 days). The PS dose 
tested was an average 1.6 g/d (median: 1.7 g/d; range: 0.3-3.2 g/d). The majority of 
studies used (low-fat) spreads (n = 28) whilst others used dairy products like 
yoghurt, milk etc (n = 12) or other formats like dressing, mayonnaise, bread or 
supplements (n = 15). PS were in most cases esterified to different fatty acids (n = 
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43); only 12 strata used free PS as active ingredient. Depending on the source of PS, 
PS mixtures typically contained 20-30% campesterol, 45-50% sitosterol and some 
other minor sterols/stanols for soybean PS or 5-10% campesterol, 75-80% 
sitosterol and some other minor sterols/stanols for tall oil PS
33
. Tables 1 and 2 
show overviews of the parallel and cross-over studies, respectively, including 
sitosterol and campesterol data. In Supplemental Appendix 2, an overview is 
provided summarizing the blood cholesterol data. 
 
Plasma PS outcomes 
At baseline, plasma sitosterol and campesterol concentrations were on average 
6.92 and 13.07 µmol/L, respectively. After intake of on average 1.6 g/d PS from 
enriched foods, plasma PS concentrations were significantly increased by on 
average 2.24 µmol/L for sitosterol and 5.00 µmol/L for campesterol, compared to 
control. Corresponding relative increases were 31.3% and 37.3%, respectively. 
Total PS remained below 1% of total sterols circulating in the blood. When 
corrected for TC, sitosterol concentrations significantly increased by on average 
0.59 µmol/mmolTC (41.7%) and campesterol by on average 1.34 µmol/mmolTC 
(60.8%). Table 3 gives an overview of the weighted net effects. Forest plots of the 
absolute changes in sitosterol and campesterol are shown in Figure 2. Forest plots 
of the relative changes are provided in Supplemental Appendix 3. 
 
For both absolute and relative changes in sitosterol and campesterol 
concentrations, there was significant heterogeneity between the studies as 
assessed by inspecting funnel plots (a considerable number of studies reported 
effects outside the confidence limits) and calculating I
2
-statistics (P <0.05) 
(Supplemental Appendix 4). Furthermore, regression analysis of the standard 
normal deviate as a function of the precision and the asymmetrical shape of the 
funnel plots indicated that publication bias was likely present in all sitosterol and 
campesterol analyses (Egger test: P (intercept) <0.05; studies reporting relatively 
small increases in plasma PS concentrations at the bottom of the funnel seemed 
lacking).  
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Figure 2. Forest plots of the absolute (µmol/L) changes in plasma sitosterol and campesterol 
concentrations. 
 
Plasma cholesterol outcomes 
LDL-C and TC concentrations at baseline were on average 3.90 and 6.04 mmol/L, 
respectively. LDL-C was reduced by on average 0.33 mmol/L (8.5%) and TC by 0.36 
mmol/L (5.9%) with an average PS intake of 1.6 g/d, compared to control (Table 3). 
Heterogeneity was statistically significant for absolute changes in TC (P = 0.029) 
whereas it was not significant for absolute and relative changes in LDL-C and for 
relative changes in TC (P >0.05). The heterogeneity in cholesterol changes was 
clearly less obvious as compared to the heterogeneity in plasma PS changes. Visual 
inspection of symmetrical funnel plots as well as the outcomes of the Egger tests (P 
of intercept ranging between 0.397 and 0.613) suggested absence of publication 
bias for LDL-C and TC (Supplemental Appendix 5). HDL-C did not change upon PS 
intervention (-0.00 mmol/L or -0.1%; Table 3). 
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Table 3. Weighted net effects (baseline, end-of-intervention, absolute change and relative 
change) of plasma sitosterol, campesterol, LDL-cholesterol, total cholesterol and HDL-
cholesterol, based on random effects models. 
Parameter Unit Baseline 
concentrationa 
Concentration after 
PS interventionb 
Absolute change vs. 
placebo 
Relative change 
vs. placebo (%) 
Sitosterol µmol/L 6.92 (6.23; 7.61) 9.29 (8.20; 10.38) 2.24 (1.71; 2.77) 31.3 (26.0; 36.7) 
 µmol/mmolTCc 1.22 (0.88; 1.56) 1.77 (1.14; 2.41) 0.59 (0.25; 0.92) 41.7 (31.0; 52.5) 
Campesterol µmol/L 13.07 (11.65; 14.48) 18.18 (15.99; 20.38) 5.00 (3.86; 6.14) 37.3 (29.3; 45.3) 
 µmol/mmolTCc 2.10 (1.63; 2.56) 3.39 (2.43; 4.34) 1.34 (0.83; 1.85) 60.8 (44.7; 76.9) 
LDL-C mmol/L 3.90 (3.76; 4.03) 3.59 (3.47; 3.72) -0.33 (-0.37; -0.30) -8.5 (-9.2; -7.7) 
TC mmol/L 6.04 (5.90; 6.18) 5.69 (5.56; 5.82) -0.36 (-0.40; -0.32) -5.9 (-6.5; -5.3) 
HDL-C mmol/L 1.42 (1.37; 1.47) 1.41 (1.36; 1.47) -0.00 (-0.02; 0.01) -0.1 (-1.1; 0.9) 
HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; PS, plant sterols; TC, total 
cholesterol; TG, triglycerides. 
a
 The weighted average baseline concentration was calculated based on the baseline concentrations in the active and 
placebo groups for parallel studies. For cross-over studies, the baseline concentrations were used when reported; 
otherwise the end-of-intervention concentrations of the placebo periods were used. 
b The weighted average concentration after PS intervention was calculated based on the concentrations after PS 
intervention in the active treatment groups for parallel studies, and based on the end-of-intervention concentrations of 
the active periods in case of cross-over studies. 
c The weighted net effects of the PS to cholesterol ratios were based on only 12 studies (14 strata) that reported plasma 
PS concentrations corrected for total cholesterol concentrations. The non-standardized weighted net effects are based 
on 41 studies (55 strata). 
Expressed as means (95% CI) 
 
Covariate analyses 
Meta-regression analyses revealed that dose of PS, baseline PS concentration and 
PS composition significantly impacted the absolute changes in plasma PS 
concentrations. Absolute increases in sitosterol and campesterol were larger in 
studies with higher doses of PS (β = 1.02, P = 0.014 and β = 2.37, P = 0.009, 
respectively), with higher average baseline concentrations (β = 0.39, P <0.001 and β 
= 0.35, P <0.001, respectively), and with higher amount of either sitosterol or 
campesterol in the PS mixture (β = 0.06, P = 0.004 and β = 0.27, P <0.001, 
respectively). When looking at the relative changes, the impact of baseline 
concentrations was, as expected, not present anymore. Subgroup analyses showed 
comparable results except for a weaker (non-significant) impact of PS composition 
on absolute and relative changes in plasma sitosterol and a weaker impact of PS 
dose on relative changes in plasma campesterol. In the subgroup with the highest 
dose studies (2.0-3.2 g/d PS), increases in sitosterol and campesterol were on 
average 3.56 µmol/L (42.2%) and 7.64 µmol/L (47.9%), respectively. The results of 
the covariate analyses are shown in Table 4. 
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Post hoc analyses 
To investigate the shape of the dose-response relationship between PS doses and 
changes in plasma PS, we established continuous dose-response curves based on 
first-order elimination functions. A slight tapering-off effect seemed present for 
changes in both plasma sitosterol (Figure 3, Panel A) and campesterol 
concentrations (Figure 3, Panel B). It should however be noted that these curves 
are severely limited by the heterogeneous distribution of the observed changes 
across the range of doses included. 
 
In addition, we investigated the impact of food format (dairy-type foods vs. (low-
fat) margarine), blood matrix (serum vs. plasma), subjects’ health status 
(diabetics/metabolic syndrome patients vs. hypercholesteromic subjects vs. 
normocholesterolemic/healthy subjects) and study duration (≤4 weeks vs. >4 
weeks) on the changes in plasma PS concentrations. No significant impact of these 
potential covariates on the absolute and relative changes in plasma PS 
concentrations could be detected (P >0.05). Regarding duration, we additionally 
analyzed whether there was a statistically significant difference between halfway 
and end-of-intervention plasma PS changes in studies that reported plasma PS 
concentrations at several time points
27,32,44,47
; again, no significant impact of 
duration was detected (P >0.05).  
 
Covariate analyses furthermore revealed that absolute and relative reductions in 
LDL-C and TC were larger with higher doses of PS and that absolute reductions in 
LDL-C and TC were larger with higher respective baseline concentrations. The 
impact of baseline cholesterol concentrations on the relative changes was weaker, 
especially for LDL-C (see Table 4). 
 
At last, we analyzed whether the relative changes in LDL-C were related to the 
relative changes in plasma PS (Supplemental Appendix 6). In fact, no such 
correlation was found. Perhaps differences in metabolic fates between cholesterol 
and PS, e.g. circulating cholesterol is derived from synthesis and absorption 
whereas circulating PS can only be obtained through absorption, provide an 
explanation for this finding. Also, the considerable heterogeneity in plasma PS 
changes might have blurred the association with LDL-C. 
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Figure 3. Dose-response relationship between doses of plant sterols (PS) and relative (%) 
changes in plasma sitosterol (Panel A) and campesterol (Panel B) concentrations. A first-
order elimination curve was plotted through the observed changes. 
 
Discussion 
For the first time, the effect of PS-enriched food intake on plasma PS 
concentrations was systematically investigated by reviewing available data from 
published PS intervention studies. We observed significant increases in plasma 
sitosterol and campesterol concentrations after intake of PS-enriched foods, as was 
expected. The average increases in plasma sitosterol and campesterol 
concentrations were 2.24 µmol/L (31%) and 5.00 µmol/L (37%), respectively, with 
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an average intake of 1.6 g/d PS. In the highest PS dose category (2.0-3.2 g/d), the 
average absolute increases were 3.56 µmol/L (42%) and 7.64 µmol/L (48%), 
respectively. The baseline plasma sitosterol and campesterol concentrations that 
we observed in the current meta-analysis (6.9 and 13.1 µmol/L, respectively) were 
comparable to what has previously been reported by Chan et al.
14
. In this review 
including data of 45 studies, average baseline concentrations for sitosterol and 
campesterol in the general population were 7.9 and 14.2 µmol/L, respectively. We 
furthermore observed an average reduction in LDL-C of 0.33 mmol/L (8.5%) which 
is similar to the pooled LDL-C-lowering effect expected for 1.6 g/d of PS based on 
several recent meta-analyses
3-5
. So, despite the smaller number of studies 
(reporting plasma PS concentrations) included in the current meta-analysis 
compared to the more extensive cholesterol-lowering efficacy meta-analyses, our 
selection of studies seems representative for a broader range of studies. Also, with 
no less than 41 studies, a robust overview of the available literature has been 
developed.  
 
In the current meta-analysis, the change in plasma PS concentrations was related 
to the dose of PS consumed per day, i.e., the higher the dose, the larger the 
increase in both sitosterol and campesterol concentrations. For PS-induced 
cholesterol-lowering, it is known that the decrease in plasma cholesterol 
concentrations would reach a plateau with increasing dose of PS due to saturable 
processes in cholesterol uptake and transport and subsequent feedback on 
cholesterol synthesis. Whether such tapering-off effect exists for plasma PS 
concentrations is yet unclear. In an attempt to investigate this, we established 
continuous dose-response curves for the relationship between PS doses and 
changes in plasma PS concentrations. These curves suggest that some tapering-off 
might exist although the maximal increase in plasma PS will likely be reached at 
doses higher than 3.2 g/d which was the highest dose tested in our meta-analysis. 
Studies investigating higher PS doses are scarce. Only two studies tested PS doses 
exceeding 3 g/d and reported serum PS concentrations. The study by Davidson et 
al.
69
 tested PS intakes of 3, 6 and 9 g/d from enriched foods, but only reported 
medians and ranges of plasma PS concentrations. Based on their analysis, the 
increase in serum PS did not significantly differ between the three PS doses, except 
for the TC-standardized increase in campesterol. Noteworthy, even with the 
highest dose of PS (9 g/d), overall absolute PS concentrations remained below 2 
mg/dL (~50 µmol/L). Another study by Tuomilehto et al.
70
 investigated increasing 
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intakes of PS (1.25, 2.5 and 5 g/d) together with a mix of minerals during three 
consecutive 5-week periods. Serum sitosterol concentrations increased in a dose-
dependent manner whereas no dose-dependent increase was observed in serum 
campesterol concentrations. From these data, together with the findings of the 
current meta-analysis which included studies investigating PS doses in the range of 
0.3 to 3.2 g/d, no firm conclusions can be drawn on the dose-response behaviour 
for plasma PS concentrations at higher PS doses (>3 g/d). The composition of the PS 
mixture, and related to this the PS source, also influenced the magnitude of the 
increase in plasma sitosterol and campesterol concentrations. For instance, studies 
that used PS derived from tall oil which contains less campesterol (~5-10%) and 
more sitosterol (75-80%) compared to e.g. soybean oil (20-30% campesterol and 
45-50% sitosterol), showed smaller increases in plasma campesterol concentrations 
whereas increases in sitosterol concentrations were larger. 
 
The concentrations of PS at baseline also seemed to explain part of the 
heterogeneity observed between different study results; in studies with higher 
average baseline PS concentrations, the absolute increase in plasma sitosterol and 
campesterol concentrations was larger compared to studies with lower average 
baseline concentrations. It could be that subjects with higher cholesterol/PS 
absorption efficiency (as indicated by higher baseline PS concentrations) are likely 
to absorb more PS when on PS intervention. Alternatively, the use of different 
analytical techniques to measure plasma PS concentrations could potentially have 
caused differences (systematic errors) in baseline concentrations and thus in 
changes upon intervention. This latter hypothesis is supported by the observation 
that baseline concentrations had no impact on relative changes in plasma PS 
concentrations which are less affected by systematic errors. Interestingly, Hendriks 
et al.
35
 found that in subjects with the highest baseline PS concentrations, the 
average relative increase after one year consumption of PS-enriched margarine 
was even smaller as compared to subjects with lower baseline PS concentrations. 
This might suggest that some kind of feedback mechanism arises (e.g. upregulation 
of ABCG5/8) when PS are consumed for a longer period of time. Indeed, based on 
studies that reported plasma PS concentrations at different time points
27,32,44,47
, the 
increase in plasma sitosterol and campesterol seemed to stabilize over time, which 
we confirmed in post hoc analyses. For example, in the study by de Jong et al.
27
, 
plasma sitosterol and campesterol concentrations were similar after 45 weeks and 
85 weeks of PS intervention.  
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The plasma PS concentrations that we observed in our meta-analysis are much 
lower than those reported in patients with homozygous sitosterolemia. Patients 
with this disease display plasma PS concentrations in the range of ~500-1200 
µmol/L (~20 to 50 mg/dL)
22
. This is 20-45 times higher than the average total 
plasma PS concentration after intake of PS-enriched foods observed in the current 
meta-analysis. In this respect, the PS-induced increase in plasma PS can be 
considered modest and is not reaching the levels seen in homozygous 
sitosterolemics. Subjects with heterozygous sitosterolemia do not have such 
elevated plasma PS concentrations although their plasma PS concentrations are 
somewhat elevated (35-37%) compared to healthy controls
71
. These elevated 
concentrations are of the same order of magnitude as the increases in plasma 
sitosterol and campesterol concentrations after PS-enriched food intake seen in 
our study. Several studies
60,63,72,73
 investigated what would happen if subjects with 
heterozygeous sitosterolemia would regularly consume PS-enriched foods and 
found that these subjects showed similar plasma PS responses as compared to 
control subjects.  
 
Recent evidence suggests that moderate, lifelong elevations in plasma PS 
concentrations in heterozygeous sitosterolemics being carriers of the ABCG8-
G574R variant are not associated with increased intima-media thickness (IMT). 
These subjects even showed lower IMT compared to controls
71
. IMT is a commonly 
used predictor for CVD, although evidence does so far not convincingly support 
that progression of IMT is associated with CVD risk
74
. In contrast to the findings by 
Horenstein et al.
71
, in a genome wide association study, gene variants in ABCG8 
were found to be significantly associated with increased serum PS concentrations 
and increased CVD risk
75
. However, as stated by Plat et al.
76
, it cannot be ruled out 
that this association may be an epiphenomenon because plasma PS concentrations 
also reflect cholesterol absorption and, therefore, the association with CVD risk 
may be explained by increased absorption of cholesterol. Genser et al.
23
 recently 
published a meta-analysis of observational studies that aimed to investigate the 
association between serum sitosterol and campesterol concentrations and CVD 
risk. The individual studies included in this meta-analysis showed conflicting 
evidence. However, based on seventeen studies reporting either plasma PS 
concentrations in CVD cases vs. controls or relative risks for CVD, it was concluded 
that, overall, no association between circulating PS (sitosterol and campesterol) 
and risk of CVD exists. In our meta-analysis, the observed control-adjusted average 
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changes in plasma sitosterol and campesterol concentrations (2 and 5 µmol/L, 
respectively) were at least smaller than the difference between the upper and the 
lower tertiles of the sitosterol and campesterol distributions (6 and 10 µmol/L, 
respectively) reported in the Genser meta-analysis. Evidence from endpoint studies 
demonstrating a reduced risk of CVD has so far not been generated with intake of 
PS.  
 
This meta-analysis has some limitations that need to be addressed. A considerable 
amount of heterogeneity was observed among the studies, more for circulating 
sitosterol and campesterol than for LDL-C and TC concentrations. Some of this 
heterogeneity could be explained by differences in PS dose, baseline PS 
concentrations and in PS composition. However, many other factors could have 
induced variability between studies such as differences in study designs, test 
products and study populations. In particular, between-study differences in plasma 
PS concentrations may have been induced by differences in analytical methods 
used to measure plasma PS (i.e., differences in PS separation and detections 
methods). For better comparison between studies, there is a clear need for 
standardization of methods to measure plasma PS concentrations. Furthermore, 
the quality of the meta-analysis depends on the quality of the studies that have 
been included. As such, we had pre-defined rigorous selection criteria in order to 
exclusively retrieve studies that were suitable to answer our study objectives. We 
have not considered the quality of each individual study due to the rather 
subjective nature of such quality scoring. Finally, there is considerable indication 
that publication bias was present; the funnel plots suggested that studies reporting 
relatively small increases in plasma PS concentrations with low precision were 
lacking. In PS studies, determining changes in plasma PS concentrations is usually 
not the primary aim, and thus, it may well be that in some studies, blood samples 
were drawn to measure circulating PS but were eventually not analyzed or 
reported due to unknown reasons. In any case, given the observation that studies 
reporting relatively small increases in plasma PS seemed lacking, our findings are 
likely not underestimated. Despite these limitations, the current meta-analysis 
provides a good overview of all evidence available on this topic.  
 
In summary, our meta-analysis including data from 41 randomized controlled 
studies showed that intake of PS-enriched foods (average PS dose was ~1.6 g/d) 
increases circulating sitosterol and campesterol concentrations (2.24 and 5.00 
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µmol/L, respectively) whilst reducing TC and LDL-C concentrations (0.36 and 0.33 
mmol/L, respectively). Overall, total PS remained below 1% of total sterols 
circulating in the blood which is far below levels seen in homozygous 
sitosterolemics. Since a considerable amount of heterogeneity was observed in 
plasma PS concentrations amongst the included studies, attempts to harmonize 
methods for measuring plasma PS concentrations should be undertaken.  
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Supplemental material 
Supplemental Appendix 1 - Overview of data transformation steps 
 
1. General remarks 
In parallel studies, the mean age and BMI of the study population was usually 
reported per study group (treatment or control). To derive one mean for the whole 
group, the following formulas were used: 
o            
o       
                
     
 
where   
 Ntot is the number of subjects of the whole group 
 Xtot is the mean X of the whole group 
 NC is the number of subjects in the control group 
 NT is the number of subjects in the treatment group 
 XC is the mean X in the control group 
 XT is the mean X in the treatment group  
 
For the current meta-analysis, the main outcome variables were the following: 
sitosterol, campesterol, LDL-cholesterol, total cholesterol and HDL-cholesterol. For 
each of these variables, the following information was extracted from the papers: 
 N (number of subjects per group/period) 
 At baseline: mean and SE (standard error) or SD (standard deviation) 
 At end of intervention: mean and SE or SD 
 
To derive SEs from SDs or vice versa, the following formulas were used: 
o            
o    
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2. Baseline data 
To calculate the baseline means plus accompanying variance measures for each of 
the main variables in each of the studies, the following formulas were used. 
 
2.1. Calculation of the baseline mean 
 
Parallel studies: 
o            
o           
                       
     
 
where   
 Ntot is the number of subjects of the whole group 
 NC is the number of subjects in the control group 
 NT is the number of subjects in the treatment group 
 Xtotbase is the mean X at baseline of the whole group 
 XCbase is the mean X at baseline in the control group 
 XTbase is the mean X at baseline in the treatment group  
 
Cross-over studies:  
o            
o           
                       
     
 
where   
 Ntot is the number of subjects of the whole group 
 NC is the number of subjects at the start of the control period 
 NT is the number of subjects at the start of the treatment period 
 Xtotbase is the mean X at baseline of the whole group 
 XCbase is the mean X at the start of the control period 
 XTbase is the mean X at the start of the treatment period  
 
2.2. Variance measure of baseline mean 
To estimate the within-trial variance measures of the baseline means, 
approximately the same formula was used for parallel and cross-over studies. 
 
Parallel studies: 
o            
      
        
       
  
      
        
       
  
156 | Chapter 6 
 
Cross-over studies:  
o            
 
 
       
  
 
 
       
  
where  
 SEtotbase is the SE at baseline of the whole group 
 NTbase is the number of subjects at baseline in the treatment group 
 NCbase is the number of subjects at baseline in the control group 
 Ntotbase is the number of subjects of the whole group at the start of the 
intervention  
 SETbase is the SE at baseline in the treatment group/period 
 SECbase is the SE at baseline in the control group/period 
 
 
3. Absolute changes  
To calculate the absolute changes plus accompanying variance measures for each 
of the main variables in each of the studies, the following formulas were used. 
 
3.1. Calculation of the absolute change 
 
Parallel studies: 
o                                          
where   
 Xabschange is the absolute change in X of the whole group 
 XTend is the mean X at the end-of-intervention in the treatment group 
 XTbase is the mean X at baseline in the treatment group 
 XCend is the mean X at the end-of-intervention in the control group 
 XCbase is the mean X at baseline in the control group 
 
Cross-over studies:  
In case baseline data of both intervention periods were reported, absolute changes 
were calculated based on the formula mentioned above (same as for parallel 
studies). Otherwise, absolute changes were calculated using the following formula. 
 
o                        
where   
 Xabschange is the absolute change in X of the whole group 
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 XTend is the mean X at the end of the treatment period 
 XCend is the mean X at the end of the control period 
 
3.2. Variance measure of absolute change 
To estimate the within-trial variance measures of the absolute changes, a 
correlation was assumed between baseline and endpoint values of X for parallel 
studies, and between values of X at the end of the phytosterol period and the 
control period for cross-over studies. This within-subject correlation coefficient was 
estimated based on studies for which both the SE of the net change and the SEs at 
baseline and end-of-intervention for parallel studies, and SEs at both endpoints for 
cross-over studies, were available. It was estimated that for all main outcome 
variables, a correlation coefficient of 0.8 should be used. 
 
Parallel studies:  
o                 
     
  
o              
        
                     
o              
        
                       
where   
 SEabschange is the SE of the absolute change of the whole group 
 SET is the SE of the absolute change in the treatment group 
 SEC is the SE of the absolute change in the control group 
 SETbase is the SE at baseline in the treatment group 
 SETend is the SE at the end-of-intervention in the treatment group 
 SECbase is the SE at baseline in the control group 
 SECend is the SE at the end-of-intervention in the control group 
 r is the within-subject correlation between repeated measurements of X 
(i.e., 0.8 for cholesterol and plasma/serum PS) 
 
Cross-over studies:  
In case baseline data of both intervention periods were reported, variance 
measures of the absolute changes were calculated based on the formulas 
mentioned above (same as for parallel studies). Otherwise, variance measures of 
the absolute changes were calculated using the following formula. 
 
o                    
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where  
 SEabschange is the SE of the absolute change of the whole group 
 SETend is the SE at the end of the treatment period 
 SECend is the SE at the end of the control period 
 r is the within-subject correlation between repeated measurements of X 
(i.e., 0.8 for cholesterol and plasma/serum PS) 
 
 
4. Relative changes 
To calculate the relative changes plus accompanying variance measures for each of 
the main variables in each of the studies, the following formulas were used. 
 
4.1. Calculation of the relative change 
 
Parallel studies:  
o                       
where 
o          
            
      
 
o          
            
      
 
where   
 Xrelchange is the relative change in X of the whole group 
 % XT is the relative change in X of the treatment group 
 % XC is the relative change in X of the control group 
 XTend is the mean X at the end-of-intervention in the treatment group 
 XTbase is the mean X at baseline in the treatment group 
 XCend is the mean X at the end-of-intervention in the control group 
 XCbase is the mean X at baseline in the control group 
 
Cross-over studies:  
In case baseline data of both intervention periods were reported, relative changes 
were calculated based on the formulas mentioned above (same as for parallel 
studies). Otherwise, relative changes were calculated using the following formulas. 
 
o                
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where   
 Xrelchange is the relative change in X of the whole group 
 XTend is the mean X at the end of the treatment period 
 XCend is the mean X at the end of the control period 
 
4.2. Variance measure of relative change 
It was estimated that for all main outcome variables, a within-subject correlation 
coefficient of 0.8 should be used. 
 
Parallel studies:  
o                      
          
  
where 
o           
         
  
 
o           
         
  
 
where 
o            
     
      
     
 
  
      
 
     
  
       
 
      
  
                 
            
  
o            
     
      
     
 
  
      
 
     
  
       
 
      
  
                 
            
  
where 
 SErelchange is the SE of the relative change of the whole group 
 SETratio is the SE of the relative change in the treatment group 
 SECratio is the SE at of the relative change in the control group 
 VarTratio is the variance of the relative change in the treatment group 
 VarCratio is the variance of the relative change in the control group 
 NT is the number of subjects in the treatment group 
 NC is the number of subjects in the control group 
 XTend is the mean X at the end-of-intervention in the treatment group 
 XTbase is the mean X at baseline in the treatment group 
 XCend is the mean X at the end-of-intervention in the control group 
 XCbase is the mean X at baseline in the control group 
 SDTend is the SD at the end-of-intervention in the treatment group 
 SDTbase is the SD at baseline in the treatment group 
 SDCbase is the SD at baseline in the control group 
 SDCend is the SD at the end-of-intervention in the control group 
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 r is the within-subject correlation between repeated measurements of X 
(i.e., 0.8 for cholesterol and plasma/serum PS) 
 
Cross-over studies:  
In case baseline data of both intervention periods were reported, variance 
measures of the relative changes were calculated based on the formulas 
mentioned above (same as for parallel studies). Otherwise, variance measures of 
the relative changes were calculated using the following formulas. 
o              
        
    
 
o           
     
     
     
 
  
      
 
     
  
      
 
     
  
                
           
  
o            
where 
 SErelchange is the SE of the relative change of the whole group 
 Varratio is the variance of the relative change of the whole group 
 XTend is the mean X at the end of the treatment period 
 XCend is the mean X at the end of the control period 
 SDTend is the SD at the end of the treatment period 
 SDCend is the SD at the end of the control period 
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Supplemental Appendix 2 - Study overview with blood cholesterol data 
 
Reference information 
LDL-C 
 
TC 
 
HDL-C 
Absolute 
change 
(mmol/L) 
Relative 
change 
(%) 
Absolute 
change 
(mmol/L) 
Relative 
change 
(%) 
Absolute 
change 
(mmol/L) 
Relative 
change 
(%) 
Parallel studiesa 
        
Carr et al. 2009 -0.29 -6.7 
    
0.11 6.8 
Christiansen et al. 2001 stratum 1 -0.27 -6.4 
 
-0.34 -5.1 
 
0.00 0.0 
Christiansen et al. 2001 stratum 2 -0.39 -9.1 
 
-0.40 -5.9 
 
-0.01 -0.6 
Clifton et al. 2008 stratum 1 -0.38 -8.7 
 
-0.43 -6.6 
 
-0.02 -1.5 
Clifton et al. 2008 stratum 2 -0.45 -10.5 
 
-0.58 -9.0 
 
-0.03 -2.2 
Clifton et al. 2008 stratum 3 -0.33 -7.5 
 
-0.46 -7.1 
 
-0.02 -1.5 
De Jong et al. 2006 -0.29 -8.2 
 
-0.34 -6.0 
 
0.05 3.8 
De Jong et al. 2008 -0.40 -12.4 
 
-0.48 -9.1 
 
0.00 0.0 
Hansel et al. 2007 -0.32 -7.8 
 
-0.30 -4.8 
 
0.02 1.1 
Hendriks et al. 2003 -0.24 -6.6 
 
-0.31 -5.3 
 
-0.02 -1.3 
Hernandez-Mijares et al. 2010 -0.43 -10.2 
 
-0.44 -7.2 
 
0.07 5.3 
Korpela et al. 2006 -0.45 -11.0 
 
-0.42 -6.5 
   
Kurokawa et al. 2008 -0.23 -5.9 
 
-0.23 -3.9 
 
0.08 5.4 
Maki et al. 2001 stratum 1 -0.37 -9.0 
 
-0.45 -7.3 
 
-0.03 -2.3 
Maki et al. 2001 stratum 2 -0.55 -13.0 
 
-0.57 -9.0 
 
0.03 2.2 
Mannarino et al. 2008 -0.40 -9.4 
 
-0.40 -5.8 
 
-0.04 -3.4 
Masuda et al. 2007 -0.21 -5.7 
 
-0.14 -2.4 
 
0.02 1.2 
Neil et al. 2001 -0.51 -10.0 
 
-0.57 -7.8 
 
0.04 2.7 
Nittynen et al. 2007 study 2 -0.30 -6.0 
 
-0.41 -6.0 
 
-0.14 -9.5 
Plana et al. 2008 -0.36 -9.5 
 
-0.36 -6.1 
 
-0.01 -0.9 
Saito et al. 2006 stratum 1 -0.27 -7.1 
 
-0.24 -4.0 
 
-0.05 -3.4 
Saito et al. 2006 stratum 2 -0.24 -5.9 
 
-0.35 -5.6 
 
-0.05 -3.0 
Saito et al. 2006 stratum 3 -0.31 -9.3 
 
-0.38 -6.6 
 
-0.04 -2.6 
Seki et al. 2003a -0.07 -2.3 
 
-0.13 -2.5 
 
0.02 1.6 
Seki et al. 2003b -0.32 -12.6 
 
-0.43 -9.5 
 
-0.01 -0.5 
Takeshita et al. 2007a -0.10 -3.0 
 
-0.29 -5.5 
 
-0.10 -7.4 
Takeshita et al. 2008 -0.24 -6.0 
 
-0.26 -4.2 
 
0.02 0.8 
Varady et al. 2004 study 1 -0.40 -11.6 
 
-0.42 -6.9 
 
0.01 0.8 
Varady et al. 2004 study 2 -0.46 -12.8 
 
-0.41 -7.5 
 
-0.03 -1.8 
Cross-over studiesb 
        
AbumWeis et al. 2006 stratum 1 -0.05 -1.4 
 
-0.07 -1.2 
 
0.10 7.9 
AbumWeis et al. 2006 stratum 2 -0.05 -1.4 
 
-0.04 -0.7 
 
0.08 6.3 
Amundsen et al. 2004 -0.59 -10.2 
 
-0.53 -7.2 
 
0.03 2.4 
Casas-Agustench et al. 2012 -0.36 -8.0 
 
-0.52 -7.8 
 
-0.03 -1.9 
Clifton et al. 2004 stratum 1 -0.42 -9.8 
 
-0.35 -5.4 
 
0.04 2.7 
Clifton et al. 2004 stratum 2 -0.53 -12.4 
 
-0.53 -8.2 
 
-0.03 -2.1 
Demonty et al. 2006 -0.22 -5.6 
 
-0.21 -3.7 
 
0.05 4.0 
Hallikainen et al. 2000 -0.45 -10.7 
 
-0.46 -7.5 
 
0.05 3.3 
Heggen et al. 2010 stratum 1 -0.39 -9.8 
 
-0.40 -6.6 
 
-0.03 -1.9 
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Reference information 
LDL-C 
 
TC 
 
HDL-C 
Absolute 
change 
(mmol/L) 
Relative 
change 
(%) 
Absolute 
change 
(mmol/L) 
Relative 
change 
(%) 
Absolute 
change 
(mmol/L) 
Relative 
change 
(%) 
Heggen et al. 2010 stratum 2 -0.35 -8.8 
 
-0.40 -6.6 
 
-0.05 -3.1 
Houweling et al. 2009 study 1 -0.30 -8.2 
 
-0.34 -6.1 
 
-0.01 -0.9 
Houweling et al. 2009 study 2 -0.25 -7.8 
 
-0.26 -5.3 
 
-0.02 -2.0 
Jakulj et al. 2005 -0.23 -5.7 
 
-0.35 -5.4 
 
-0.07 -4.0 
Jones et al. 2000 -0.39 -9.3 
 
-0.47 -7.4 
 
-0.01 -1.0 
Kratz et al. 2007 -0.13 -5.3 
 
-0.15 -3.0 
 
0.02 1.1 
Lau et al. 2005 study 1 -0.84 -26.5 
 
-0.34 -5.3 
 
0.10 8.5 
Lau et al. 2005 study 2 -0.38 -9.6 
 
0.05 0.5 
 
0.03 2.1 
Mussner et al. 2002 -0.26 -6.5 
 
-0.23 -3.8 
 
0.05 3.5 
Myrie et al. 2012 -0.62 -18.7 
 
-0.43 -7.5 
 
-0.13 -10.9 
Nittynen et al. 2007 study 1 -0.17 -4.2 
 
-0.13 -2.1 
 
0.02 1.4 
Ooi et al. 2007 -0.22 -6.4 
 
-0.15 -2.8 
 
0.03 2.6 
Rudkowska et al. 2008 stratum 1 -0.14 -3.8 
 
-0.24 -4.1 
 
-0.08 -5.5 
Rudkowska et al. 2008 stratum 2 -0.29 -7.7 
 
-0.42 -7.0 
 
-0.11 -7.5 
Takeshita et al. 2007b -0.41 -11.6 
 
-0.60 -10.0 
 
-0.09 -5.3 
Vanstone et al. 2002 -0.35 -8.8 
 
-0.44 -7.4 
 
-0.01 -1.0 
Weststrate et al. 1998 -0.40 -12.2 
 
-0.41 -8.0 
 
0.00 0.3 
HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; TC, total cholesterol. 
a For parallel studies, the absolute and relative changes were calculated based on the average concentrations at 
baseline and at end-of-intervention of treatment and control groups.  
b For cross-over studies that reported baseline data, the absolute and relative changes were calculated similarly as for 
the parallel studies. Otherwise, these were calculated based on the data at the end of the treatment and control 
periods. 
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Supplemental Appendix 3 - Forest plots of the relative (%) changes in plasma 
sitosterol and campesterol concentrations 
 
 
  
Weststrate et al. 1998
Hallikainen et al. 2000
Jones et al. 2000
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Maki et al. 2001 stratum 1
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Neil et al. 2001
Mussner et al. 2002
Vanstone et al. 2002
Hendriks et al. 2003
Seki et al. 2003a
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Clifton et al. 2004 stratum 1
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Lau et al. 2005 study 1
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AbumWeis et al. 2006 stratum 1
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Saito et al. 2006 stratum 1
Saito et al. 2006 stratum 2
Saito et al. 2006 stratum 3
Hansel et al. 2007
Kratz et al. 2007
Masuda et al. 2007
Nittynen et al. 2007 study 1
Nittynen et al. 2007 study 2
Ooi et al. 2007
Takeshita et al. 2007a
Takeshita et al. 2007b
Clifton et al. 2008 stratum 1
Clifton et al. 2008 stratum 2
Clifton et al. 2008 stratum 3
De Jong et al. 2008
Kurokawa et al. 2008
Mannarino et al. 2008
Plana et al. 2008
Rudkowska et al. 2008 stratum 1
Rudkowska et al. 2008 stratum 2
Takeshita et al. 2008
Carr et al. 2009
Houweling et al. 2009 study 1
Houweling et al. 2009 study 2
Heggen et al. 2010 stratum 1
Heggen et al. 2010 stratum 2
Hernandez-Mijares et al. 2010
Casas-Agustench et al. 2012
Myrie et al. 2012
Overall
Relative change (%) in sitosterol Relative change (%) in campesterol
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Supplemental Appendix 4 - Funnel plots of the absolute (µmol/L) and relative (%) 
changes in plasma sitosterol and campesterol 
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I2 = 90.9; P-value <0.001
Egger test: P-value (intercept) = 0.016
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Egger test: P-value (intercept) = 0.007
I2 = 95.7; P-value <0.001
Egger test: P-value (intercept) <0.001
P
re
c
is
io
n
 (
1
/S
E
)
P
re
c
is
io
n
 (
1
/S
E
)
Plant sterols increase plasma plant sterol concentrations | 165 
 
Supplemental Appendix 5 - Funnel plots of the absolute (mmol/L) and relative (%) 
changes in plasma LDL-cholesterol and total cholesterol 
 
 
  
Absolute change in LDL-cholesterol (mmol/L) Relative change in LDL-cholesterol (%) 
I2 = 23.3; P-value = 0.071
Egger test: P-value (intercept) = 0.613
I2 = 15.2; P-value = 0.178
Egger test: P-value (intercept) = 0.533
Absolute change in total cholesterol (µmol/L) Relative change in total cholesterol (%) 
I2 = 22.3; P-value = 0.083
Egger test: P-value (intercept) = 0.397
I2 = 29.1; P-value = 0.029
Egger test: P-value (intercept) 0.585
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Supplemental Appendix 6 - The changes in LDL-cholesterol concentrations (%) 
expressed against the changes in plasma sitosterol (%, see Panel A) and plasma 
campesterol (%, see Panel B) 
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Abstract 
Background - Phytosterols are known to lower low-density lipoprotein cholesterol 
(LDL-C), an established risk factor for cardiovascular disease (CVD). Whether a high 
intake of phytosterols reduces CVD risk is unknown. This observational study aimed 
to investigate the associations between intake of naturally occurring phytosterols, 
blood lipids and CVD risk.  
Methods - The study included 35,597 Dutch men and women, participating in the 
EPIC-NL study. At baseline, intakes of naturally occurring phytosterols were 
estimated with a validated food frequency questionnaire and non-fasting blood 
lipids were measured. Occurrence of CVD, coronary heart disease (CHD) and 
myocardial infarction (MI) was determined through linkage with registries.  
Results - The average energy-adjusted phytosterol intake at baseline was 296 mg/d 
(range: 83-966 mg/d). During 12.2 years of follow-up, 3,047 CVD cases (8.6%) were 
documented. After adjustment for confounders, phytosterol intake was not 
associated with risk of CVD, CHD or MI (P trend >0.05); hazard ratios ranged from 
0.90 to 0.99 for CVD, from 0.83 to 0.90 for CHD and from 0.80 to 0.95 for MI risk 
across quintiles of phytosterol intake and were almost all non-significant. Higher 
phytosterol intake was associated with lower total cholesterol (-0.06 mmol/L per 
50 mg/d; P = 0.038) and lower LDL-C (-0.07 mmol/L; P = 0.007), particularly among 
men. In mediation analysis, LDL-C did not materially affect the association between 
phytosterol intake and CVD risk. 
Conclusions - In this population with relatively narrow range of low naturally 
occurring phytosterol intakes, intake of phytosterols was not associated with 
reduced CVD risk despite lower LDL-C concentrations in men. 
 
Introduction 
Plant sterols and plant stanols (together they are referred to as phytosterols) are 
bioactive compounds found in all foods of plant origin. Phytosterols are well-known 
for their total cholesterol (TC)-lowering, and especially low-density lipoprotein 
cholesterol (LDL-C)-lowering properties; an average phytosterol intake of 2 g/d 
lowers LDL-C by on average 8-10%
1,2
. Intakes of around 2 g/d of phytosterols 
cannot be reached with habitual diets; phytosterol intakes in the general 
population usually range between 200-400 mg/d
3,4
. With specific dietary habits 
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such as vegetarians diets, higher phytosterol intakes of 500-1000 mg/d can be 
reached
5,6
. 
 
Elevated LDL-C is an established risk factor for cardiovascular disease (CVD)
 7
. As 
phytosterols lower LDL-C, one could assume that high intakes of phytosterols 
would reduce CVD risk. Direct evidence supporting such a reduced risk of CVD is 
however lacking. Given the difficulties in performing fully controlled CVD endpoint 
trials with phytosterol intervention, observational studies could help to clarify 
whether intake of naturally occurring phytosterols is associated with blood lipid risk 
markers and incidence of CVD.  
 
A few observational studies with dietary phytosterol intakes have been performed 
and showed that people with higher intakes of naturally occurring phytosterols 
have lower concentrations of LDL-C
8-10
 and tend to have a lower carotid intima-
media thickness.
9
 A recent study showed that a high intake of naturally occurring 
phytosterols was related to a lower risk of a first myocardial infarction (MI)
 11
. 
However, this association was not apparent when phytosterol intake was corrected 
for energy intake and no significant associations were observed in women.  
 
We aimed to prospectively investigate the association between intake of 
phytosterols from natural sources and occurrence of cardiovascular events (total 
CVD, total coronary heart disease (CHD) and MI. As secondary objectives, we cross-
sectionally investigated the association between naturally occurring phytosterol 
intake and blood lipid concentrations at baseline and whether associations 
between phytosterol intake and CVD were mediated through effects on LDL-C. 
 
Subjects and Methods 
Study population 
The EPIC-NL cohort
12
 consists of two contributions to the EPIC collaboration; the 
Monitoring Project on Risk Factors for Chronic Diseases (MORGEN) cohort and the 
Prospect cohort. The MORGEN cohort consists of 22,654 men and women, aged 
20-64 years, recruited through random sampling from the general population 
between 1993 and 1997. Prospect is a cohort study among 17,357 women, aged 
49-70 years, recruited during the same time period (1993-1997) through a breast 
cancer screening programme. The procedures in both cohorts were set up 
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simultaneously and using similar methods with the exception of the blood pressure 
(BP) assessment. The data have been harmonized and merged in one database in 
2006. The study complies with the Declaration of Helsinki and was approved by 
local medical ethical committees. All participants provided informed consent 
before study inclusion. 
 
For the prospective analysis, the following exclusion criteria were applied: 
prevalent CVD based on self-report or identified through linkage with the National 
Medical Registry (1990-1997) (n = 1,264), missing dietary intake data (n = 203), 
having extremely low or high reported energy intakes (i.e. ratio of energy intake 
over basal metabolic rate in the lowest or highest 0.5%) (n = 385), and missing 
follow-up data (n = 2,562). Thus, in total 35,597 participants were included. For the 
cross-sectional analysis, we only included participants of a random 6.5% sample (n 
= 2,604) for which we had data on complete blood lipid profile. Similar exclusion 
criteria were applied as mentioned above, except that participants were excluded 
when blood lipid data instead of follow-up data on CVD endpoints were missing. 
The numbers of participants included in the blood lipid analyses were 2,417 for TC, 
2,383 for LDL-C, 2,383 for high-density lipoprotein cholesterol (HDL-C) and 2,410 
for triglycerides (TGs). 
 
Baseline assessments 
At baseline, participants filled out a general questionnaire on demographics, 
disease history and lifestyle characteristics, a physical activity questionnaire and a 
validated food-frequency questionnaire (FFQ)
13
. A physical examination was 
performed as earlier described
12
 and non-fasting venous blood samples were 
drawn at baseline. Physical activity was assessed by calculating the Cambridge 
Physical Activity Score. Smoking was classified in current, past or non-smoker and 
education level was categorized based on nine categories ranging from primary 
education to university completed. Menopausal status was classified as pre-, peri, 
or (surgical) postmenopausal; men were considered postmenopausal. Diagnosis of 
hyperlipidemia was determined based on self-report (‘ever diagnosed?’ yes/no), 
whereas hypertension was determined based on measured BP (>140 mmHg 
systolic or >90 mmHg diastolic BP), use of BP-lowering medication or self-report. 
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Assessment of nutrient and phytosterol intake 
The self-administered FFQ contained questions on consumption frequency of 79 
main food items during the past year
13
. Additional questions were asked about sub-
items, preparation methods or additions. Consumption of in total 178 foods when 
considering the sub-items could be calculated. Portion sizes were estimated using 
specified units or photographed portions. Energy and nutrient intakes were 
calculated based on the Dutch food composition table. Because this table does not 
contain information on phytosterol content of foods, we estimated total 
phytosterol intake by using a phytosterol database that was developed by Ghent 
University, Belgium
4
, based on the Finnish, United Kingdom and United States food 
composition tables
14-16
, scientific literature
17
, Dutch recipes
18
, ingredient lists on 
packaging, and known phytosterol composition of equivalent foods. Intake data of 
individual phytosterols, such as sitosterol or campesterol, were not available. 
phytosterol-enriched foods were not available on the market at the time of the 
dietary intake assessment and, information on consumption of such products 
during later years was not available. 
  
We used data from a previous validation study
13
 among 63 men and 58 women to 
estimate the relative validity of the phytosterol intake as measured with the FFQ 
against twelve standardized 24-hour recalls. Reproducibility was tested against two 
other FFQs taken at 6-month intervals. We observed a reasonable to good relative 
validity of the estimated phytosterol intake with Pearson correlation coefficients of 
0.72 for the crude phytosterol intake and 0.59 for the energy-adjusted phytosterol 
intake. Reproducibility was good with Pearson correlation coefficients ranging 
between 0.84-0.87 for the crude phytosterol intake and 0.68-0.69 for the energy-
adjusted phytosterol intake.  
 
Assessment of blood lipids 
Data on baseline blood lipids were available for a random 6.5% sample of the total 
study population (n = 2,604) representative of the full cohort
12
, and for all CVD 
cases that occurred until January 2006 (n = 2,068). Non-fasting TC and TG were 
measured using enzymatic methods. Non-fasting HDL-C and LDL-C were measured 
using a homogeneous assay with enzymatic endpoint, on an autoanalyser 
(Beckman Coulter, Mijdrecht, the Netherlands). 
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Follow-up assessments 
Participants were followed for occurrence of chronic diseases and death through 
linkage with several national registries. Vital status was obtained through linkage 
with municipal population registries. Causes of death were obtained via ‘Statistics 
Netherlands’. Data on morbidity were obtained from the Dutch Hospital 
Association and Order of Medical Specialists. Registries were linked to the cohort 
based on a validated probabilistic method
19
. Follow-up was complete until January 
2008. Incidences of fatal and non-fatal events were combined, taking only the first-
occuring events into account. The CVD events were coded according to ICD-9. CVD 
was based on codes 410-414 (ischemic heart disease), 427.5 (cardiac arrest), 428 
(heart failure), 415.1 (pulmonary disease), 443.9 (unspecified peripheral vascular 
disease), 430-438 (cerebrovascular disease), 440-442 (atherosclerosis and 
aneurysms), 444 (arterial embolism and thrombosis) and 798.1, 798.2 and 798.9 
(sudden death), CHD based on codes 410-414, 427.5, 798.1, 798.2 and 798.9 and 
acute MI based on code 410.  
 
Data analysis 
Person-years were calculated from the date of return of the questionnaire until the 
date of CVD occurrence, date of death or 1 January 2008, whichever came first. 
Data on physical activity were missing in 14% of all participants. Missing values for 
physical activity were therefore imputed using the single imputation method (SPSS 
Missing Value Analysis). For all other variables, the few missing values (<0.5%) were 
imputed using the mean for continuous variables and a missing indicator for 
categorical variables. Nutrients were adjusted for energy intake using the 
regression residual method
20
. Blood lipid variables were log transformed in case of 
non-normally distributed data. 
 
Cox proportional hazard models were used to prospectively analyze associations 
between intake of naturally occurring phytosterols and risk of total CVD, total CHD 
and MI. Associations were analyzed categorically based on quintiles of energy-
adjusted phytosterol intake with the lowest quintile as the reference. All analyses 
were stratified for cohort (i.e. MORGEN or Prospect). Associations were adjusted 
for confounders. The first model adjusted for age and gender. The second model 
additionally adjusted for CVD risk factors, i.e. BMI, education, smoking status, 
physical activity, menopause and total energy intake. The third, fully-adjusted, 
model additionally adjusted for dietary factors known to affect blood lipids and/or 
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CVD risk, i.e. energy-adjusted intakes of saturated, polyunsaturated and 
monounsaturated fat, fiber, dietary cholesterol and alcohol. Two additional models 
were investigated to explore possible confounding by intake of sodium, retinol, β-
carotene, vitamin D and vitamin E (model 4) or by hypertension (model 5). Effect 
modification by gender, waist circumference and hyperlipidemia was investigated 
by including interaction terms with phytosterol intake in the third model. 
Exploratory analyses were performed with stroke as outcome variable. The 
proportionality assumption was checked in the final models. Sensitivity analyses 
were performed to ensure robustness of the findings. We checked the impact of 
censoring at 2000 (i.e. the year that phytosterol-enriched foods were introduced 
onto the market), exclusion of participants with cancer or diabetes at baseline, 
exclusion of energy under- and over-reporters as determined by the Goldberg 
criteria
21
, exclusion of participants with a survival time <2 years (i.e. any 
undiagnosed illness preceding the early censoring may have changed a partipants’ 
diet) and additional adjustment for diabetic status/drug use.  
 
Associations between energy-adjusted phytosterol intake and blood lipids at 
baseline were analyzed using linear regression analysis based on the same models 
as defined for the prospective analysis. Effect modification by gender, waist 
circumference and hyperlipidemia was tested. To investigate whether associations 
between phytosterol intake and CVD risk were mediated through effects on LDL-C, 
we applied a case-cohort design including all cases until January 2006 and the 
random 6.5% sample for which we had LDL-C data. Modified Cox proportional 
hazard models were used accounting for case-cohort design by Prentice-
weighting
22
; LDL-C was included in the third model to assess its mediation effect. 
Even if associations would be non-significant, mediation analysis could reveal 
relevant information as long as the HR is not 1.00.  
 
A P-value below 0.05 was considered statistically significant. All statistical analyses 
were performed using the statistical package SAS (SAS version 9.2, SAS Institute). 
 
Results 
Overview of study population 
Of the 35,597 participants, 25% were men and 75% were women (Table 1). The 
average age was 49.3 years. After a median of 12.2 years of follow-up, 3,047 cases 
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of CVD were documented, including 1,807 cases of CHD and 606 cases of MI. The 
average baseline energy-adjusted phytosterol intake in the whole population was 
295.8±49.2 mg/d (mean±SD). Average phytosterol intakes ranged from 231.3±22.0 
to 366.0±34.9 mg/d between the lowest and the highest quintiles. The most 
important dietary sources of phytosterols were fruits and vegetables (25.5%), 
bread and cereal products (25.1%), and fats, oils and sauces (19.3%). With higher 
naturally occurring phytosterol intakes, participants were younger, more often 
female, had higher BMI, were more physically active, were lower educated and 
smoked less (Table 1). Furthermore, intakes of carbohydrates, mono- and 
polyunsaturated fat, and fiber were higher, whereas intakes of protein, saturated 
fat, cholesterol and alcohol were lower with higher phytosterol intakes. 
 
Cardiovascular disease risk 
In the fully-adjusted model (Table 2), no association was observed between 
energy-adjusted intake of naturally occurring phytosterols and total CVD risk (Ptrend 
= 0.94) with non-significant hazard ratios (HRs) ranging between 0.90 and 0.99 
across quintiles of phytosterol intake. Phytosterol intake was also not associated 
with total CHD risk (Ptrend = 0.17); however, phytosterol intake was significantly 
associated with a lower risk of CHD in the second (HR=0.83, 95% CI: 0.72; 0.97) and 
in the third (0.84; 0.72; 0.98) quintiles of phytosterol intake vs. the quintile with the 
lowest phytosterol intake. In the fourth and fifth quintiles, HRs for CHD were 0.90 
(95% CI: 0.76; 1.06) and 0.84 (95% CI: 0.70; 1.01). Phytosterol intake was not 
associated with MI risk (Ptrend = 0.19) after adjustment for confounders; non-
significant HRs ranged from 0.80 to 0.95 across quintiles of phytosterol intake.  
 
Models 4 and 5 showed essentially similar results indicating that a possible relation 
was not obscured by confounding of other dietary factors or hypertension. 
Interactions of phytosterol intake with gender, waist circumference or 
hyperlipidemia were not statistically significant. No associations were observed 
between phytosterol intake and occurrence of stroke (Supplemental Appendix 1). 
In sensitivity analyses, censoring the analysis at year 2000, excluding participants 
with cancer or diabetes at baseline, excluding energy under- and over-reporters, 
excluding participants with a survival time <2 years and adjusting additionally for 
diabetic status/drug use did not change our results (data not shown). 
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Table 1. Overview of the study population when classified into categories of energy-adjusted 
phytosterol intake. 
Characteristics 
Quintiles based on energy-adjusted phytosterol intakea 
All 
participants 
Q1 
(<257 mg/d) 
Q2 
(257-282 
mg/d) 
Q3 
(283-305 
mg/d) 
Q4 
(306-333 
mg/d) 
Q5 
(>333 mg/d) 
Demographics       
Total n 7120 7118 7121 7118 7120 35597 
CVD cases 713 (10.0) 588 (8.3) 553 (7.8) 567 (8.0) 626 (8.8) 3047 (8.6) 
CHD cases 436 (6.1) 327 (4.6) 333 (4.7) 359 (5.0) 352 (4.9) 1807 (5.1) 
MI cases 154 (2.2) 121 (1.7) 115 (1.6) 103 (1.5) 113 (1.6) 606 (1.7) 
Stroke cases 124 (1.7) 118 (1.7) 113 (1.6) 93 (1.3) 132 (1.9) 580 (1.6) 
Cohort (MORGENb) 3830 (53.8) 3962 (55.7) 4046 (56.8) 4076 (57.3) 3839 (53.9) 19753 (55.5) 
Age (y) 50.4 ± 11.7 49.2 ± 12.0 48.9 ± 12.0 48.6 ± 11.9 49.3 ± 11.5 49.3 ± 11.9 
Gender (male) 1943 (27.3) 1755 (24.7) 1847 (25.9) 1789 (25.1) 1592 (22.4) 8926 (25.1) 
BMI (kg/m
2
) 25.6 ± 4.0 25.5 ± 13.8 25.6 ± 4.0 25.6 ± 3.8 26.0 ± 4.2 25.6 ± 4.0 
Waist circumference (cm) 86.0 ± 11.8 84.9 ± 11.2 85.1 ± 11.2 84.7 ± 11.1 84.9 ± 11.5 85.1 ± 11.4 
Smoking status (non-smoker) 2367 (33.2) 2699 (37.9) 2878 (40.4) 2868 (40.3) 2884 (40.5) 13696 (38.5) 
Physically active 2710 (38.1) 2960 (41.6) 3089 (43.4) 3105 (43.6) 3100 (43.5) 14964 (42.0) 
Education (higher level) 1502 (21.1) 1571 (22.1) 1501 (21.1) 1407 (19.8) 1279 (18.0) 7260 (20.4) 
Pre-menopausal status 1336 (18.8) 1687 (23.7) 1735 (24.4) 1788 (25.1) 1781 (25.0) 8327 (23.4) 
Hypertension 2641 (37.1) 2567 (36.1) 2613 (36.7) 2585 (36.3) 2719 (38.2) 13125 (36.9) 
SBP (mmHg) 127.2 ± 19.2 126.3 ± 19.0 126.3 ± 18.9 125.8 ± 18.3 126.2 ± 19.0 126.4 ± 18.9 
DBP (mmHg) 78.1 ±10.7 77.7 ± 10.5 77.9 ± 10.7 77.8 ± 10.5 78.1 ± 10.6 77.9 ± 10.6 
Hyperlipidemia 522 (7.3) 502 (7.1) 532 (7.5) 611 (8.6) 607 (8.5) 2774 (7.8) 
Dietc       
Total energy intake (kcal/d) 2026 ± 595 2046 ± 584 2077 ± 593 2082 ± 609 2024 ± 640 2051 ± 605 
Total carbohydrate intake (g/d) 214.2 ± 34.5 221.7 ± 30.3 223.5 ± 28.6 224.5 ± 28.6 224.9 ± 29.6 221.8 ± 30.7 
Total protein intake (g/d) 78.0 ± 12.3 77.0 ± 10.9 76.1 ± 10.4 75.0 ± 10.0 73.1 ± 10.4 75.9 ± 11.0 
Total fat intake (g/d) 76.1 ± 11.9 76.6 ± 10.9 77.4 ± 10.7 78.3 ± 11.0 80.1 ± 11.6 77.7 ± 11.3 
SFA intake (g/d) 34.3 ± 6.6 32.9 ± 5.7 32.4 ± 5.4 32.0 ± 5.4 31.6 ± 5.8 32.6 ± 5.8 
MUFA intake (g/d) 28.9 ± 5.2 29.1 ± 4.9 29.4 ± 4.9 29.6 ± 5.1 30.3 ± 5.3 29.5 ± 5.1 
PUFA intake (g/d) 12.2 ± 2.9 14.0 ± 3.0 15.0 ± 3.2 16.0 ± 3.6 17.5 ± 4.2 14.9 ± 3.9 
Phytosterol intake (mg/d) 231.3 ± 22.0 270.1 ± 7.3 293.4 ± 6.7 318.2 ± 8.1 366.0 ± 34.9 295.8 ± 49.2 
Fiber intake (g/d) 19.9 ± 4.1 22.3 ± 3.9 23.7 ± 4.1 24.7 ± 4.2 26.4 ± 4.9 23.4 ± 4.8 
Cholesterol intake (mg/d) 237.8 ± 63.8 221.1 ± 55.3 214.0 ± 54.3 210.4 ± 54.9 204.7 ± 59.6 217.6 ± 58.8 
Alcohol intake (g/d) 17.0 ± 23.4 11.8 ± 16.7 9.9 ± 15.1 8.8 ± 13.2 7.7 ± 13.2 11.0 ± 17.1 
CHD, coronary heart disease; CVD, cardiovascular disease; DBP diastolic blood pressure; MI, myocardial infarction; 
MUFA, monounsaturated fatty acids; PUFA, polyunsaturated fatty acids; SFA, saturated fatty acids; SBP, systolic blood 
pressure.  
a 
P for trend was <0.001, except for prevalence of stroke cases, DBP, prevalence of hypertension and total energy 
intake.  
b MORGEN is the name of one of the two cohorts that were part of this study  
c All nutrients, except for total energy intake, were energy-adjusted. 
Values are mean ± SD or n (%).  
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Table 2. Energy-adjusted phytosterol intake and risk of cardiovascular disease, coronary 
heart disease and myocardial infarction in the EPIC-NL cohort.  
 
Quintiles based on energy-adjusted phytosterol intake 
P for trend 
 
Q1 Q2 Q3 Q4 Q5 
(<257 mg/d) 
(257-282 
mg/d) 
(283-305 
mg/d) 
(306-333 
mg/d) 
(>333 mg/d) 
n 7120 7118 7121 7118 7120  
HR (Total CVD)       
Model 1a 1.0 0.90 0.85 0.88 0.98 0.6033 
(0.80; 1.00) (0.76; 0.95) (0.79; 0.98) (0.88; 1.09) 
Model 2b 1.0 0.96 0.92 0.95 1.03 0.7334 
(0.86; 1.07) (0.82; 1.03) (0.85; 1.06) (0.92; 1.15) 
Model 3c 1.0 0.95 0.90 0.92 0.99 0.9401 
(0.84; 1.06) (0.79; 1.02) (0.81; 1.05) (0.86; 1.14) 
HR (Total CHD)       
Model 1 1.0 0.82 0.84 0.92 0.91 0.4232 
(0.71; 0.95) (0.73; 0.97) (0.80; 1.06) (0.79; 1.04) 
Model 2 1.0 0.88 0.90 0.98 0.94 0.7476 
(0.76; 1.01) (0.78; 1.04) (0.85; 1.13) (0.82; 1.08) 
Model 3 1.0 0.83 0.84 0.90 0.84 0.1722 
(0.72; 0.97) (0.72; 0.98) (0.76; 1.06) (0.70; 1.01) 
HR (MI)       
Model 1 1.0 0.88 0.83 0.76 0.84 0.0763 
(0.69; 1.11) (0.65; 1.06) (0.59; 0.97) (0.66; 1.07) 
Model 2 1.0 0.99 0.95 0.86 0.93 0.3267 
(0.78; 1.26) (0.74; 1.21) (0.66; 1.10) (0.72; 1.18) 
Model 3 1.0 0.95 0.90 0.80 0.84 0.1878 
(0.74; 1.22) (0.68; 1.17) (0.59; 1.06) (0.62; 1.15) 
CHD, coronary heart disease; CVD, cardiovascular disease; HR, hazard ratio; MI, myocardial infarction.  
a Model 1: corrected for age, gender and cohort (only for women). 
b Model 2: corrected for variables in model 1 + BMI, smoking status, education, physical activity level, menopausal 
status (only for women) and total energy intake. 
c 
Model 3: corrected for variables in model 2 + intake of saturated, polyunsaturated and monounsaturated fat, dietary 
cholesterol, fiber and alcohol. 
Values are HR (95% CI).  
 
Blood lipids 
In the fully-adjusted model, energy-adjusted intake of naturally occurring 
phytosterols was significantly, inversely associated with TC, LDL-C and HDL-C (P 
<0.05); each 50 mg/d incremental phytosterol intake was significantly associated 
with a 0.06 mmol/L (95% CI: -0.11; -0.00) lower TC, a 0.07 mmol/L (95% CI: -0.11; -
0.02) lower LDL-C, and a 0.02 mmol/L (95% CI: -0.04; -0.00) lower HDL-C. 
Furthermore, a significant association was observed between phytosterol intake 
and TG concentrations (0.04 mmol/L, 95% CI: 0.01; 0.06). Effect modification by 
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gender was significant for LDL-C. When stratifying according to gender, phytosterol 
intake was more strongly inversely associated with LDL-C in men (-0.18 mmol/L, 
95% CI: -0.29; -0.08) than in women (-0.03 mmol/L, 95% CI: -0.08; 0.03). 
Interactions of phytosterol intake with waist circumference or hyperlipidemia were 
not significant for the lipid parameters. An overview of the associations with blood 
lipids is provided in Supplemental Appendix 2. 
 
In mediation analysis, LDL-C hardly changed the association between phytosterol 
intake and cardiovascular risk; the mediation effect was low for each quintile and at 
maximum 5% for total CVD, 3% for total CHD and 6% for MI risk. When analyzing 
the mediation effect of LDL-C separately for men and women, we observed similar 
results. 
 
Discussion 
In this large cohort of 35,597 Dutch men and women, we observed no association 
between energy-adjusted intake of phytosterols from natural sources and CVD risk 
during 12 years of follow-up. However, higher naturally occurring phytosterol 
intake was significantly associated with lower TC and LDL-C concentrations at 
baseline, particularly among men.  
 
Intake of two grams per day of phytosterols has been shown to lower LDL-C by on 
average 10%.
1
 Based on data from statin trials
23
, such a reduction in LDL-C could 
potentially reduce the absolute risk of CHD by ~9%. Considering that the intakes of 
naturally occurring phytosterols are much lower than 2 g/d (i.e. on average 296 
mg/d in the current study), only small risk reductions were expected: ~2% lower 
CHD risk given the predicted LDL-C lowering effect for a difference in phytosterol 
intake of 150 mg/d between the highest and lowest quintiles of phytosterol intake 
or ~4% lower CHD risk given the observed ~5% lower LDL-C concentration between 
the highest and lowest quintiles of phytosterol intake. In the current study, we 
observed surprisingly strong CHD hazard ratios ranging between 0.83 and 0.90 
across quintiles of phytosterol intake, but these were not all statistically significant. 
Klingberg et al. recently showed in a nested case-referent study
11
 that a high 
absolute phytosterol intake was related to a reduced risk of a first MI in men with 
an odds ratio in the highest vs. the lowest quartile of 0.71. However, when 
corrected for total energy intake, this association of phytosterol intake with MI was 
not significant anymore. In women, neither the absolute nor the energy-adjusted 
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phytosterol intakes were associated with risk of MI
11
. In our opinion, adjustment 
for total energy intake is required, since associations of phytosterol intake with 
CVD risk may easily be confounded by energy intake. All in all, the findings of the 
current study are in line with previous investigation
11
.
 
 
The significant associations between intake of naturally occurring phytosterols and 
lower TC and LDL-C concentrations were also found in previous observational 
studies with similar ranges of naturally occurring phytosterol intakes
8-10,24,25
. It 
should be noted that in our study, the association with TC and LDL-C was only 
present in men whereas evidence from randomized controlled trials have shown 
that TC and LDL-C are lowered in both men and women
1,2
. It is not clear why this 
discrepancy exists. The association observed between phytosterol intake and lower 
HDL-C concentrations was also found in other population studies, with some 
studies showing more pronounced effects in women
10
 (similar to our observation) 
whereas other studies showed more pronounced effects in men.
8,9
 As randomized 
controlled trials clearly show that HDL-C concentrations are not changed upon 
phytosterol intervention
26
, it might be that residual confounding has played a role 
in this association. 
 
The mechanism by which phytosterols are expected to reduce CVD risk is their LDL-
C-lowering effect. However, in our population with relatively narrow range of low 
naturally occurring phytosterol intakes, mediation analysis did not support that low 
dietary phytosterol intakes are associated with reduced CVD risk through 
reductions in LDL-C. Whether higher intakes of phytosterols would eventually be 
significantly associated with reduced CVD risk through effects on LDL-C has yet to 
be investigated. This should preferably be done in populations with higher and 
broader ranges of phytosterol intakes, for example by including people with diets 
containing predominantly rich sources of phytosterols (e.g. cereal products and 
vegetable oils) and users of foods enriched with phytosterols. Users of phytosterol-
enriched foods consume much higher amounts of phytosterols (~1.0-1.3 g/d) and 
seem to have lower TC concentrations vs. non-users after 5 years of follow-up
27,28
.  
 
Strengths of this study include the large sample size and its continuous, prospective 
and almost complete follow-up for disease occurrence, but there are also some 
limitations. First, the intakes of phytosterols from natural sources were low within 
a relatively narrow range, thereby limiting the capacity to detect an association 
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between dietary phytosterol intake and CVD risk. Second, dietary intake was 
assessed only at baseline. It cannot be ruled out that participants changed their 
dietary behaviours during follow-up thereby influencing the occurrence of disease, 
and, thus, the findings of this study. However, excluding participants that most 
likely changed their dietary habits (those with chronic diseases at baseline and 
cases occurring during the first 2 years) did not alter our findings. Furthermore, 
assessment of the long-term reproducibility of the FFQ in the EPIC-Heidelberg 
cohort showed fairly high correlation between dietary assessments at baseline and 
at follow-up
29
. Related to this, we cannot exclude that our findings may be 
confounded by a small part of the study population that started using phytosterol-
enriched foods or cholesterol-lowering medication during follow-up. Although the 
proportion of people consuming phytosterol-enriched foods was only ~6% in a 
subset of our study population
28
, these foods contain high concentrations of 
phytosterols and can therefore contribute considerably to the daily intake of 
phytosterols. A sensitivity analysis with follow-up until 2000 (i.e. the year that 
phytosterol-enriched foods were introduced onto the European market) however 
did not reveal different results. The influence of cholesterol-lowering medication 
use during follow-up could not be tested in sensitivity analysis and remains a 
limitation of our study. Third, because a national database with phytosterol 
composition data did not exist for the Netherlands, a specific database was 
developed for the analysis
4
. Although this database was developed with utmost 
care, some misclassification of the level of phytosterol exposure may have occurred 
due to incomplete information on phytosterol content in foods. At last, food intake 
was estimated with FFQs that are vulnerable for misreporting. Exclusion of 
misreporters in sensitivity analysis did however not affect the results. Moreover, 
the main dietary phytosterol sources (fruits and vegetables, cereal products and 
vegetable oils) and the average phytosterol intakes in the current study were 
comparable to those observed in other populations
3,4,30
. Additionally, we could 
demonstrate good relative validity and reproducibility of the phytosterol intake 
estimated with our FFQ.  
 
In summary, intake of phytosterols from natural sources was not associated with a 
reduced CVD risk despite a lower LDL-C concentration particularly in men. Future 
studies should preferably investigate the association between phytosterol intake 
and CVD risk in populations with higher and broader ranges of phytosterol intake. 
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Supplemental material 
Supplementary Appendix 1 - Energy-adjusted phytosterol intake and risk of stroke 
in the EPIC-NL cohort 
 
 
Quintiles based on energy-adjusted intake of phytosterols 
P for 
trend 
 
Q1 Q2 Q3 Q4 Q5 
(<257 mg/d) 
(257-282 
mg/d) 
(283-305 
mg/d) 
(306-333 
mg/d) 
(>333 mg/d) 
n 7120 7118 7121 7118 7120  
HR (Stroke)       
Model 1a 1.00 1.04 1.02 0.85 1.20 0.3771 
(0.81; 1.34) (0.79; 1.32) (0.65; 1.11) (0.94; 1.54) 
Model 2b 1.00 1.10 1.10 0.91 1.27 0.1917 
(0.86; 1.42) (0.85; 1.42) (0.69; 1.19) (0.99; 1.63) 
Model 3c 1.00 1.12 1.12 0.93 1.30 0.2411 
(0.86; 1.46) (0.84; 1.48) (0.68; 1.26) (0.94; 1.79) 
HR (Ischemic stroke)       
Model 1 1.00 0.90 0.99 0.73 1.25 0.3191 
 (0.64; 1.27) (0.71; 1.38) (0.51; 1.05) (0.91; 1.72) 
Model 2 1.00 0.97 1.08 0.80 1.33 0.1765 
 (0.69; 1.36) (0.77; 1.51) (0.55; 1.15) (0.97; 1.84) 
Model 3 1.00 0.97 1.08 0.80 1.34 0.2475 
 (0.68; 1.39) (0.74; 1.57) (0.52; 1.22) (0.88; 2,04) 
HR (Hemorrhagic stroke)       
Model 1 1.00 1.15 0.84 0.99 0.95 0.6683 
 (0.73; 1.83) (0.51; 1.38) (0.62; 1.61) (0.59; 1.54) 
Model 2 1.00 1.22 0.89 1.07 1.01 0.8793 
 (0.77; 1.93) (0.54; 1.48) (0.66; 1.73) (0.62; 1.65) 
Model 3 1.00 1.36 1.05 1.31 1.33 0.4639 
 (0.83; 2.21) (0.60; 1.84) (0.75; 2.31) (0.71; 2.47) 
HR, hazard ratio.  
a Model 1: corrected for age, gender and cohort (only for women). 
b
 Model 2: corrected for variables in model 1 + BMI, smoking status, education, physical activity level, menopausal 
status (only for women) and total energy intake. 
c Model 3: corrected for variables in model 2 + intake of saturated, polyunsaturated and monounsaturated fatty acids, 
dietary cholesterol, fiber and alcohol.  
Values are HR (95% CI). 
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Supplementary Appendix 2 - Energy-adjusted phytosterol intake and blood lipid 
concentrations in the EPIC-NL cohort 
 
 
Overall Men Women 
 
β per 50 
mg/d 
phytosterols 
95% CI P 
β per 50 
mg/d 
phytosterols 
95% CI P 
β per 50 
mg/d 
phytosterols 
95% CI P 
TC (mmol/L)        
n 2417 605 1812 
Average 5.32 ± 1.05 5.59 ± 1.11 5.23 ± 1.02 
Model 1
a 
-0.05 (-0.09; -0.01) 0.0070 -0.07 (-0.16; 0.01) 0.1024 -0.05 (-0.09; -0.00) 0.0324 
Model 2
b 
-0.05 (-0.09; -0.01) 0.0093 -0.08 (-0.17; 0.01) 0.0679 -0.04 (-0.09; 0.00) 0.0529 
Model 3
c 
-0.06 (-0.11; -0.00) 0.0384 -0.13 (-0.24; -0.01) 0.0307 -0.03 (-0.09; 0.03) 0.2891 
LDL-C (mmol/L)        
n 2383 593 1790 
Average 3.09 ± 0.87 3.19 ± 0.98 3.06 ± 0.83 
Model 1 -0.05 (-0.09; -0.02) 0.0029 -0.12 (-0.20; -0.04) 0.0039 -0.03 (-0.07; 0.01) 0.0926 
Model 2 -0.05 (-0.09; -0.02) 0.0038 -0.12 (-0.20; -0.04) 0.0023 -0.03 (-0.07; 0.01) 0.1367 
Model 3 -0.07 (-0.11; -0.02) 0.0074 -0.18 (-0.29; -0.08) 0.0007 -0.03 (-0.08; 0.03) 0.3294 
HDL-C (mmol/L)        
n 2383 593 1790 
Average 1.27 ± 0.35 1.14 ± 0.28 1.32 ± 0.35 
Model 1 -0.02 (-0.03; -0.01) 0.0025 -0.01 (-0.03; 0.01) 0.4088 -0.02 (-0.04; -0.01) 0.0035 
Model 2 -0.02 (-0.03; -0.01) 0.0026 -0.01 (-0.03; 0.02) 0.5478 -0.02 (-0.04; -0.01) 0.0027 
Model 3 -0.02 (-0.04; -0.00) 0.0211 0.00 (-0.03; 0.03) 0.9442 -0.03 (-0.05; -0.01) 0.0123 
ln(TG) (mmol/L)         
n 2410 605 1805 
Average 0.30 ± 0.54 0.54 ± 0.55 0.22 ± 0.51 
Model 1 0.01 (-0.01; 0.03) 0.3450 0.03 (-0.01; 0.08) 0.1350 0.00 (-0.02; 0.03) 0.8493 
Model 2 0.01 (-0.01; 0.03) 0.4075 0.02 (-0.02; 0.07) 0.2684 0.00 (-0.02; 0.03) 0.8548 
Model 3
 
0.04 (0.01; 0.06) 0.0142 0.04 (-0.01; 0.10) 0.1494 0.03 (-0.00; 0.07) 0.0516 
β, regression coefficient; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; TC, 
total cholesterol; TG, triglycerides.  
a Model 1: corrected for age, gender and cohort (only for women). 
b Model 2: corrected for variables in model 1 + BMI, smoking status, education, physical activity level, menopausal 
status (only for women) and total energy intake. 
c Model 3: corrected for variables in model 2 + intake of saturated, polyunsaturated and monounsaturated fat, dietary 
cholesterol, fiber and alcohol.  
Averages are mean ± SD. Effects are β (95% CI). 
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The aim of this thesis was to advance insights in the role of phytosterols in the 
management of blood lipid risk factors for cardiovascular disease (CVD). 
Phytosterols are lipid-like compounds that occur naturally in small amounts in 
plant-based foods and in high amounts in specific enriched foods. An overview of 
the main results of this thesis is presented in Table 1.  
 
Table 1. Overview of the main results of the studies presented in this thesis. 
Chapter Type of research Exposure Main results 
2 Meta-analysis of 
84 randomized 
controlled trials 
Plant sterol- or 
stanol-enriched 
food intake 
A non-linear, continuous dose-response relationship 
was established for the LDL-C-lowering effect of plant 
sterol/stanol intakes. The pooled LDL-C reduction was 
0.34 mmol/L (95% CI: -0.36; -0.31) or 8.8% (95% CI:        
-9.4; -8.3) for a mean daily dose of 2.15 g plant 
sterols/stanols. 
3 Meta-analysis of 
124 randomized 
controlled trials 
Plant sterol- or 
stanol-enriched 
food intake 
Plant sterol/stanol intakes of 0.6-3.3 g/d gradually 
reduced LDL-C concentrations by, on average, 6-12%. 
When plant sterols and stanols were analyzed 
separately, clear and comparable dose-response 
relationships were observed. 
4 Meta-analysis of 
12 randomized 
controlled trials, 
using individual 
subject data 
Plant sterol-
enriched food 
intake 
Plant sterol intake (~2 g/d) significantly lowered fasting 
TG concentrations by 6.0% (95% CI: -10.7; -1.2) or 0.12 
mmol/L (95% CI: -0.20; -0.04). Larger absolute 
decreases were observed with higher TG concen-
trations at baseline. 
5 Randomized 
controlled trial 
with 332 subjects 
Plant sterol- 
and fish oil-
enriched 
spread intake 
Intake of a low-fat spread with added plant sterols (2.5 
g/d) and different low doses (<2 g/d) of omega-3 fatty 
acids from fish oil decreased fasting TG concentrations 
in a dose-dependent manner (5.3% to 16.2%) while 
also decreasing LDL-C concentrations (on average 13%). 
6 Meta-analysis of 
41 randomized 
controlled trials 
Plant sterol-
enriched food 
intake 
Intake of foods with added plant sterols (~1.6 g/d) 
increased blood sitosterol and campesterol 
concentrations by on average 2.24 µmol/L (31%) and 
5.00 µmol/L (37%), respectively, while reducing TC and 
LDL-C by 0.36 mmol/L (6%) and 0.33 mmol/L (9%), 
respectively. Overall, total plant sterol concentrations 
remained below 1% of total sterols circulating in the 
blood. 
7 Epidemiological 
study with 35,597 
Dutch participants 
followed-up for 
~12 years 
Intake of 
naturally 
occurring 
phytosterols 
In a population with a relatively narrow range of low 
naturally occurring phytosterol intakes (231-366 mg/d), 
intake of phytosterols was not associated with reduced 
CVD, CHD or MI risk. Phytosterol intake was associated 
with lower LDL-C concentrations at baseline in men      
(-0.18 mmol/L per 50 mg/d; 95% CI: 0.29; -0.08). 
CHD, coronary heart disease; CVD, cardiovascular disease; LDL-C, low-density lipoprotein cholesterol; MI, myocardial 
infarction; TC, total cholesterol; TG, triglyceride 
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In this chapter, the methodological aspects of the studies presented in this thesis 
are considered and the relevance of our findings in relation to CVD risk is discussed. 
Implications for public health are indicated and recommendations for future 
research are given. 
 
Methodological considerations 
This thesis includes data from four meta-analyses of randomized trials (Chapters 2, 
3, 4 and 6), one intervention study (Chapter 5) and one epidemiological study 
(Chapter 7). In this section, the main strengths and limitations of these studies are 
highlighted. 
 
Meta-analyses 
In meta-analyses, the results from multiple studies are combined to increase the 
precision of the overall effect estimate and to identify and quantify sources of 
variation in results across studies. Some limitations of meta-analyses should 
however be considered. 
 
In meta-analyses, bias in the selection of studies can occur. Especially meta-
analyses based on individual subject data (like in Chapter 4) are prone to selection 
bias when only the original data of part of the studies performed can be accessed. 
To estimate the effect of plant sterol intake on triglyceride (TG) concentrations, 
data of twelve industry-sponsored studies were available. These studies also 
formed part of the meta-analysis on low-density lipoprotein cholesterol (LDL-C) 
(Chapter 3), which included a total of 124 studies. We assessed whether the twelve 
selected studies were representative of the total body of evidence by comparing 
the LDL-C response in that subset with the overall response reported in Chapter 3. 
The change in LDL-C in the twelve industry-sponsored studies was around 8% for an 
average plant sterol dose of 1.9 g/d. In Chapter 3, an average phytosterol dose of 
1.7 g/d (based on 55 study arms) lowered LDL-C by ~7.6% whereas an average dose 
of 2.1 g/d (60 study arms) lowered LDL-C by ~8.4%. Based on this observation, it 
can be assumed that also the effects on TGs in the twelve studies included in 
Chapter 4 are representative of the total body of evidence. 
 
A concern related to the validity of meta-analyses is publication bias. This type of 
bias occurs when published studies are systematically unrepresentative of all the 
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studies that have been done. For example, small studies with unexpected or 
neutral results are less likely to be published than studies with statistically 
significant, positive results. In our meta-analyses on phytosterols and LDL-C 
(Chapters 2 and 6), funnel plots suggested absence of publication bias. On the 
contrary, for the plasma plant sterol concentrations (Chapter 6), publication bias 
may have been present; studies reporting no or relatively small increases in plasma 
plant sterols with low precision were lacking. The estimated increase in plasma 
plant sterols, for which some concern exists
1
, may thus have been slightly 
overestimated. However, this bias is probably not substantial as studies with low 
precision would not contribute much in estimating the variance-weighted net 
effect.  
 
Heterogeneity in meta-analyses refers to the degree of variation in results of 
individual studies, which may be caused by differences in study design 
(methodological variation) and/or study populations (biological variation). If the 
results of individual studies are too heterogeneous, the conclusions of a meta-
analysis cannot be generalized but only apply to the average population under the 
average conditions of the included studies. Conversely, if the presence of 
heterogeneity can be explained by variables such as the health status of the 
subjects or the dose of the active ingredient, this provides relevant information 
that may not have been picked up in single studies. In our meta-analyses, 
heterogeneity was clearly present and we identified two factors that were 
repeatedly shown to influence the relationships under investigation. Both the dose 
of phytosterols (Chapters 2, 3 and 6) and the pre-intervention lipid values 
(Chapters 2, 4 and 6) clearly explained part of the variation in observed effects on 
LDL-C, TGs and/or plasma plant sterols. Regarding the plasma plant sterol 
concentrations (Chapter 6), another source of variation was likely present. 
Measurements of plasma non-cholesterol sterols, like plant sterols, are not well 
standardized resulting in considerable variability when measured by different 
research groups
2
. Differences in internal standards, extraction, derivatization, 
separation and detection techniques explain about 25% of the variability in 
reported plasma plant sterol concentrations
2,3
. As relative changes are overall less 
affected by systematic errors, these are probably more reliable than the absolute 
changes in plasma plant sterol concentrations observed in our meta-analysis.  
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Intervention studies 
Randomized controlled trials, if correctly designed and executed, provide the 
strongest evidence for a causal relationship. High quality trials have a randomized, 
placebo-controlled, double-blind design, a sufficient number of subjects to detect 
the expected effects and a high degree of compliance with the study protocol. The 
intervention study described in this thesis (Chapter 5) fulfills these criteria. With 
332 subjects, it had ample power to detect effects on LDL-C and TGs. Plant sterols 
were provided via enriched spreads and compliance with these foods was high 
(>95%). The number of subjects that dropped out during the study was low (5.4%). 
The effects on blood lipids in the intervention group were compared to the effects 
in a placebo control group. The observed effects on LDL-C and TGs can therefore be 
fully ascribed to the plant sterol and/or fish oil interventions. 
 
Intervention studies, however, also have their limitations. They are often 
performed in selected populations with relatively high doses of the food or active 
ingredient and it may be difficult to ensure sufficient compliance. The findings of 
such studies cannot easily be translated to the general population in free-living 
settings. In our study, we selected hypercholesterolemic but otherwise healthy 
subjects and instructed them to consume 30 g/d of the test spread with main 
meals. In free-living settings, people usually consume less, typically half of this 
amount of spread
4,5
. The effects on blood lipids in the general population are thus 
likely lower than in well-controlled studies. Furthermore, it is challenging to 
conduct large intervention studies under controlled conditions for long periods of 
time. Nutritional intervention studies in primary prevention settings therefore 
focus more frequently on metabolic risk factors (e.g. blood lipids or blood pressure) 
rather than on actual disease outcome (e.g. CVD events)
6
. Also, the intervention is 
often dietary advice or counseling rather than supply of actual foods/diets. Hence, 
dietary recommendations rely not only on intervention studies, but also take into 
account evidence from epidemiological studies on associations of dietary exposure 
with disease outcome. 
 
Epidemiological studies 
Epidemiological studies examine associations between exposures and outcomes at 
the population level or in a selected subset of the population. While 
epidemiological studies in general cannot prove causality, they may provide 
insights that cannot be obtained from short-term intervention studies, like for 
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example insights in relation to disease outcome. The EPIC-NL cohort that we used 
for our epidemiological investigations (Chapter 7) included 35,597 participants with 
extensive information on diet and lifestyle at baseline and almost complete follow-
up for disease incidence
7
.  
 
Our epidemiological study was however limited by the relatively low and narrow 
intake of phytosterols from natural sources (231-366 mg/d between the lowest and 
highest quintiles). The interquintile difference in phytosterol intake of ~150 mg/d is 
estimated to lower LDL-C by ~0.05 mmol/L
8
 as was confirmed in our cross-sectional 
analysis. Based on this estimate, the expected reduction in CVD risk would be ~2%
9
. 
We observed hazard ratios between 0.90 and 0.99 across quintiles of phytosterol 
intake, but these were all not statistically significant (Chapter 7). Apart from no 
relationship being present, there are alternative explanations why we found no 
significant association. Phytosterol intake was estimated only once at baseline, 
using a self-administered food frequency questionnaire. Next to measurement 
imprecision, people could have over-reported the intake of healthy plant-based 
foods and (consequently) of phytosterols. Furthermore, the database of 
phytosterol concentrations in foods that was used for our study (see Chapter 7) 
may have been incomplete. These measurement errors have likely caused 
misclassification of individuals for their true phytosterol intake, which could have 
diluted the association with CVD outcomes.  
 
A general limitation of observational studies is confounding. Confounding occurs 
when a certain variable correlates with both the exposure and the outcome and is 
not an intermediate in the causal pathway from exposure to outcome. People who 
have a high phytosterol intake have also a high intake of plant-based foods and are 
often more health conscious. In our analyses, we adjusted for many potential 
confounders that are related to diet and lifestyle, including smoking, education, 
physical activity, saturated and unsaturated fats and fiber. Nevertheless, some 
residual confounding from unknown or imprecisely measured variables may have 
remained. If this is the case, the inverse, though non-significant, associations that 
we observed may have been overestimated. On the other hand, it is also possible 
that we have overcorrected for confounders. In that case, significant inverse 
associations with CVD risk may have been missed. Considering its limitations, our 
epidemiological study does not provide a definitive answer on the relation between 
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intake of phytosterols from habitual, non-fortified foods and CVD risk. It at least 
shows the need for population studies with broader ranges of phytosterol intakes. 
 
Interpretation of findings 
The data presented in this thesis showed that foods enriched with phytosterols 
dose-dependently lower LDL-C concentrations (Chapters 2 and 3), and that plant 
sterols alone and in combination with omega-3 fatty acids from fish oil lower 
fasting TG concentrations (Chapters 4 and 5). Blood levels of plant sterols increased 
significantly during intake of enriched foods, indicating that some of the dietary 
plant sterols were absorbed (Chapter 6). Whether phytosterols through their 
effects on blood lipids could lower the risk of CVD has not been established 
(Chapter 7). To date, CVD endpoint trials with phytosterols have not been 
performed.  
 
The section below discusses the relevance of changes in LDL-C, TGs and plasma 
phytosterols with phytosterol intake for future CVD risk (Figure 1).  
 
 
Figure 1. Overview of the relationships between habitual and supplemental intakes of 
phytosterols, various blood markers and cardiovascular risk as observed in epidemiological 
and/or intervention studies. Bold lines indicate relations that were investigated in the current 
thesis. Dotted lines indicate relations that were investigated in other published studies. 
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Relevance of blood low-density lipoprotein cholesterol  
LDL-C is an established risk factor for CVD, particularly for CHD. Substantiation for 
this relationship is based on several types of evidence. Epidemiological studies have 
shown that people with elevated LDL-C are more likely to suffer from a 
cardiovascular event
10,11
. In randomized trials, LDL-C lowering by means of drugs 
(statins)
9,12
 or diets
13
 has convincingly been shown to reduce the risk of CHD. This 
effect is irrespective of the type of intervention
14
. Furthermore, the reduction in 
CHD incidence appears to be related to the magnitude of the decrease in LDL-C 
with no indication for a threshold level at lower LDL-C concentrations
15
. These 
reductions in CHD risk were overall caused by relatively short interventions (2-5 
years) beginning later in life in adult populations at various degrees of risk. If LDL-C 
concentrations remain at lower levels for longer periods of time, reductions in CHD 
risk are expected to be more pronounced
16,17
. Indeed, life-long exposure to lower 
LDL-C (0.07-0.43 mmol/L) due to the presence or absence of specific variations in 
DNA sequences (single-nucleotide polymorphisms, SNPs) was associated with a 6-
28% lower risk of CHD
16
. When standardized per unit lower LDL-C, these alleles 
were associated with a 9%, 18%, 33% or 54% lower risk of CHD for each 0.125, 
0.25, 0.5 or 1 mmol/L lower LDL-C, respectively
16
. This risk reduction due to 
prolonged exposure to lower LDL-C early in life is 2- to 3-fold larger compared to 
the risk reduction from statin treatment started later in life (i.e., 21% per 1 mmol/L 
LDL-C for CHD or 24% per 1 mmol/L for CVD)
9
. In the current thesis, an average 
phytosterol intake of 2 g/d was shown to lower LDL-C by on average 0.35 mmol/L 
or 9%. Such a decrease in LDL-C is predicted to reduce the risk of CHD by ~9% in 5 
years at population level
9
. For this estimation, data from statin trials are used; it 
should be realized that these LDL-C-lowering drugs may impact CHD risk also via 
other mechanisms, e.g. via decreases in low-grade inflammation. In the case of life-
long decreases in LDL-C, the reduction in CHD risk may augment to ~25% 
16
.  
 
Relevance of blood triglycerides 
While the clinical relevance of decreases in LDL-C is well established, this is less so 
for decreases in TGs. Observational evidence suggests that people with higher TG 
concentrations have a higher risk of CVD
18
 or CHD
19
. However, whether this 
association is independent of changes in other blood lipids, particularly high-
density lipoprotein cholesterol (HDL-C), remains uncertain. For example, in a large 
meta-analysis with >300,000 people, the hazard ratio for CHD per SD increase in 
plasma TGs dropped from 1.37 (95% CI: 1.31; 1.42) after adjustment for non-lipid 
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risk factors to 0.99 (95% CI: 0.94; 1.05) after further adjustment for HDL- and non-
HDL-C
20
. Randomized controlled trials with fibrates, an effective group of TG-
lowering drugs, have shown that reducing TGs lowers the risk of CVD, particularly in 
populations with initially high levels of TGs and low levels of HDL-C
21,22
. Fibrates 
though also reduce, to some extent, LDL-C and increase HDL-C. Based on evidence 
from genetic studies, SNPs that have strong associations with TGs but minimal 
associations with other lipids are significantly related to CHD risk
23,24
. Thus, 
although assessment of TGs appears to have little predictive value for CHD risk on 
top of HDL-C, data from these genetic studies do suggest some role of TGs in the 
development of CHD. It might be that blood TGs are a marker of TG-rich lipoprotein 
remnants, particularly intestinal-derived chylomicron remnants and liver-derived 
very-low-density lipoprotein (VLDL) remnants. Increasing evidence suggests that 
these remnants are atherogenic
25,26
. To establish the relevance of TG-lowering 
effects of phytosterols and/or omega-3 fish fatty acids for CVD or CHD risk, their 
effects on these atherogenic lipoprotein remnants should be further explored. 
 
Relevance of blood phytosterols 
Concerns have been raised about a potential atherogenic effect of increased 
plasma plant sterol concentrations (Chapter 6) based on several lines of evidence.  
 
First, patients with homozygous phytosterolemia cannot sufficiently excrete 
phytosterols from the body due to mutations in ABCG5/8 genes. These patients 
therefore have extremely high levels of plant sterols (~500-1200 µmol/L) and plant 
stanols (up to 200 µmol/L) in their blood
27,28
. In the very few patients who suffer 
from this genetic disorder (approximately 50-80 reported worldwide
29
), sterol-rich 
fat depositions in tendons and other body parts, so called xanthomas, are formed. 
In these patients, symptoms of premature atherosclerosis are observed
28,29
. 
However, in five recently published case studies, no signs of atherosclerosis were 
reported
30
. Our meta-analysis on plasma plant sterol concentrations (Chapter 6) 
showed concentrations in plasma plant sterols after intake of plant sterol-enriched 
foods that were 20-45 times lower than plasma plant sterol concentrations 
observed in patients with homozygous phytosterolemia. Heterozygous 
phytosterolemic subjects have moderately higher (35-37%) plasma plant sterol 
concentrations compared to healthy controls
31
. The relative plasma plant sterol 
responses in heterozygous phytosterolemic subjects after consumption of plant 
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sterol-enriched foods are similar to the responses in subjects without 
phytosterolemia 
32,33
. 
 
Second, elevated plasma plant sterol concentrations have been associated with 
increased CVD risk in some
34,35
, but not all
36,37
, observational studies. In a meta-
analysis of 17 observational studies, no overall association between circulating 
sitosterol and campesterol and CVD risk could be identified
38
. The sizes of the 
average increases in plasma sitosterol and campesterol (about 2 and 5 µmol/L, 
respectively) observed in Chapter 6 were covered by the ranges of plasma 
sitosterol and campesterol investigated in this meta-analysis (about 3-9 µmol/L for 
sitosterol and about 4-14 µmol/L for campesterol)
38
. In a genome-wide association 
study with data from 3 studies (4,412 subjects)
39
, genetic variants related to plasma 
plant sterol levels were detected. A meta-analysis of 11 studies (27,394 subjects) 
presented in the same paper
39
 showed that SNPs related to elevated plasma plant 
sterol levels were associated with increased CHD risk whereas SNPs related to 
decreased plasma plant sterol levels were associated with reduced risk. Plasma 
plant sterol concentrations may however reflect cholesterol absorption 
efficiency
40,41
. In another genetic study
42
, the same SNPs were associated with 
increases in the cholestanol-to-cholesterol ratio, a measure of cholesterol 
absorption that is independent of plasma plant sterols. This high cholestanol-to-
cholesterol ratio was significantly related to increased CVD risk
42
. The association 
between plasma plant sterols and CVD risk may thus, at least partly, be explained 
by increased absorption of cholesterol and not by plant sterols per se.  
 
Several potential mechanisms have been suggested why circulating plant sterols 
might be atherogenic. These include: 1) plant sterols are susceptible to oxidation
43
 
and it can be hypothesized that oxyphytosterols, like oxycholesterol
44
 are 
atherogenic; 2) plant sterols are taken up by human aortic tissue where they may 
relate to the degree of aortic valve stenosis
45
; and 3) circulating plant sterols have 
been shown to be correlated with worsening of endothelial function in mice
46
. 
These observations have so far not been confirmed in individuals that consume 
plant sterol-enriched foods. Intake of such foods by healthy subjects did not 
significantly change blood levels of oxidized plant sterols
47
. Also, the ratio of plant 
sterols over cholesterol in aortic tissue after intake of phytosterol-enriched foods 
does not exceed this ratio in plasma. This suggests that plant sterols are not 
200 | Chapter 8 
 
preferentially taken up in these tissues 
48
. Furthermore, the intake of plant sterol-
enriched foods does not result in a worsening of endothelial function in humans
49
.   
 
Not only circulating plant sterols, but also plant stanol concentrations are increased 
in homozygous phytosterolemic patients
28
 and after intake of plant stanol-enriched 
foods
50,51
. In absolute terms, however, the increases in plant stanols are much 
smaller than the increases in plant sterols due to a lower absorption rate
52
. Also, 
plant stanols do not have a double bound in the steroid nucleus and can therefore 
not be oxidized. Epidemiological studies on blood plant stanol concentrations and 
CVD risk have so far not been performed. 
 
The effect of phytosterols on experimental atherosclerosis has extensively been 
studied in different animal models including chickens, rabbits, hamsters and 
genetically-modified mouse models of atherosclerosis, as recently summarized by 
Gylling et al.
53
 These studies with high doses of phytosterols (0.1-2.0% (w/w)) 
showed overall atheroprotective effects including attenuation of foam cells, 
inhibition of lesion formation and regression of existing lesions
46,54-56
. Although 
these observations in animals cannot directly be translated to humans, the findings 
suggest that phytosterol intake may induce atheroprotective effects despite 
increases (up to 10-fold) in blood levels of phytosterols. 
 
Phytosterols and CVD risk 
Whether dietary phytosterols can impact CVD risk has so far not been investigated 
in randomized trials. Only a few epidemiological studies with phytosterol intake 
and occurrence of CVD, including the study described in Chapter 7, have been 
performed. Our study showed no significant association between intakes of 
naturally occurring phytosterols and CVD risk. In a recent prospective analysis by 
Klingberg et al.
57
, a significant inverse association between intakes of naturally 
occurring phytosterols and risk of myocardial infarction was shown in men, but not 
in women. However, when adjusting for energy intake, the association in men was 
no longer significant, in line with our findings. As intakes of phytosterols from 
natural sources are low and limited in range (200-400 mg/d; Figure 2), the results 
from these two observational studies cannot be taken as strong evidence for 
absence of a relation between dietary phytosterol intake and CVD risk, and cannot 
merely be extrapolated to effects on CVD risk of supplemental phytosterol intake 
through enriched foods. Such foods contain much higher amounts of phytosterols, 
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e.g. 0.75 g per 10 g portion of phytosterol-enriched spread. In controlled trial 
settings, phytosterol intakes from enriched foods ranged overall between 1.5 and 
2.4 g/d. In free-living settings, however, users of such foods consume lower 
amounts of 1.0-1.3 g/d
4,5
. Furthermore, such foods are consumed by only a small 
part of the population
58
 as compared to the widespread intake of naturally 
occurring phytosterols with habitual diets (Figure 2). 
 
 
Figure 2. Intake of phytosterols in the general population and in populations with plant-
based diets vs. intake of phytosterols from enriched foods as tested in trials. 
 
In individuals with diets that emphasize plant-based foods, the intake of 
phytosterols is higher than in a general Western diet (Figure 2). Examples of such 
diets are the Mediterranean diet
59
 and the Dietary Approaches to Stop 
Hypertension (DASH) diet for lowering blood pressure
60
. With these diets, 
phytosterol intakes of 500-550 g/d can be achieved (Table 2). The Predimed study, 
a randomized trial with 7,447 persons at high cardiovascular risk
61
, showed a 28 to 
30% lower incidence of major CVD events for a Mediterranean diet with additional 
extra-virgin olive oil or nuts. The DASH diet was associated with an 18% lower 
estimated 10-year CHD risk (based on the Framingham risk equation) in individuals 
with (pre-)hypertension
62
. A lacto-vegetarian diet that emphasizes phytosterol-rich 
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foods (Table 2) may yield phytosterol intakes up to 1 g/d. Such types of vegetarian 
diets have been associated with a ~24% reduced risk in CHD mortality, which could 
partly be mediated through favorable effects on blood cholesterol
63
.  
 
Table 2. Estimated phytosterol intakes with various diets 
 Lacto-vegetarian diet Predimed diet DASH diet 
Concept A diet that excludes meat, fish, 
poultry and eggs 
A Mediterranean diet with 
addition of 50 mL extra-virgin 
olive oil or 30 g nuts 
A diet low in saturated fat, trans 
fat and sodium and high in 
potassium 
Hypothetical 
daily menu 
Breakfast 
¾ cup (50 g) bran flakes 
1 cup (200 mL) low-fat milk 
1 cup (150 g) fruit salad 
1 cup orange juice (200 mL) 
 
Lunch 
2 slices (70 g) whole-wheat 
bread 
2 tsp. (10 g) margarine 
1 ½ tbsp. (30g) peanut butter 
1 ¼ cup (250 mL) broccoli soup 
 
Dinner 
1 whole-wheat roll (50 g) 
2 tbsp. (40 g) hummus 
2 tbs. (10 g) canola oil 
½ cup (150 g) couscous 
1 avocado (150 g) 
½ cup (75 g) corn  
½ onion (30 g) 
½ tomato (50 g) 
½ carrot (50 g) 
2 tbsp. (30 g) feta cheese 
4 tsp. (20 g) corn oil 
2 tsp. (10 g) lemon juice 
20 g pine nuts 
½ cup (100 mL) fruit yogurt 
 
Snacks 
¼ cup (50 g) almonds 
¼ cup (50 g) pistachios 
1 bar (25 g) dark chocolate 
100 g grapes 
Breakfast 
150 g Greek yogurt  
75 g strawberries  
1 tsp. (5 g) honey 
1 slice (35 g) whole-wheat toast 
½ avocado (100 g) 
 
Lunch 
1 slice (35 g) whole-wheat toast 
2 tbsp. (40 g) hummus  
1 cup (20 g) lettuce  
½ tomato (50 g)  
1 cup (200 mL) minestrone soup 
1 medium orange (150 g) 
 
Dinner 
100 g salmon 
1 tsp. (5 g) mustard  
½ cup (150 g) couscous 
½ cup (100 g) egg plant 
4 asparagus (100 g) 
½ cup (10 g) rucola 
½ cup  (10 g) spinach 
1 tbsp. (15 g) parmesan cheese 
1 tbsp. (15 g) vinaigrette 
150 mL red wine 
100  g grapes 
½ cup (100 mL) lemon sorbet 
 
Snacks 
1/8 cup (25 g) almonds 
1/8 cup (25 g) peanuts 
 
Additional 
50 mL olive oil or 30 g nuts 
Breakfast 
¾ cup (50 g) bran flakes 
1 medium banana (100 g)  
1 cup (200 mL) low-fat milk  
1 slice (35 g) whole-wheat bread 
1 tsp. (5 g) unsalted margarine 
1 cup (200 mL) orange juice 
 
Lunch 
2 slices (70 g) whole-wheat 
bread 
¾ cup (50 g) chicken salad 
1 tsp. (5 g) mustard 
½ cup (50 g) fresh cucumber 
slices 
½ cup (50 g) tomato wedges 
1 tbsp. (15 g) sunflower seeds 
1 tsp. (5 g) dressing 
½ cup (75 g) fruit cocktail 
 
Dinner 
100 g beef 
2 tbsp. (30 g) fat-free beef gravy 
1 cup (150 g) green beans 
1 tsp. (5 g) canola oil 
1 small baked potato (75 g) 
1 tbsp. (15 g) fat-free sour cream 
1 tbsp. (15 g) cheddar cheese  
1 tbsp. (15 g) chopped scallions 
1 whole-wheat roll (50 g) 
1 tsp. (5 g) unsalted margarine 
1 small apple (100 g) 
1 cup low-fat milk (200 mL) 
 
Snacks 
¼ cup (50 g) almonds, unsalted 
¼ cup (50 g) raisins 
½ cup (100 mL)  fruit yogurt 
Phytosterol 
intakea (mg/d) 
±1000 500-550 ±500 
a Phytosterol intakes are estimated using the phytosterol database that was developed by Sioen et al.67  
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It should be noted that these plant-based diets not only contain phytosterols, but 
also a wide array of other nutrients (e.g. fiber, B-vitamins and vegetable protein) 
and bioactive compounds (e.g. flavonoids) that could exert a beneficial effect on 
cardiovascular health. An additional intake of phytosterols of 250-750 mg/d, 
attainable with a plant-based diet, is predicted to lower LDL-C by 2-5% based on 
the dose-response curve presented in Chapter 2. The effect of phytosterols on LDL-
C has been shown to be additive to that of a healthy diet
64-66
. To what extent the 2-
5% reduction in LDL-C by phytosterols, which is expected to lower CHD risk by ~2-
12%
9,16
, could contribute to the cardio protective effect of plant-based foods has 
not yet been investigated.  
 
Public health implications 
Opinions of regulatory authorities 
The LDL-C-lowering efficacy of phytosterols has been acknowledged by regulatory 
bodies. The European Food and Safety Authority (EFSA) approved a disease risk 
reduction health claim (article 14.1a) for phytosterols
68
. This health claim, 
authorized by the European Union (EU) in 2009, was formulated as follows
69,70
: 
“Plant sterols and plant stanol esters have been shown to lower/reduce blood 
cholesterol. High cholesterol is a risk factor in the development of coronary heart 
disease”. This positive opinion from the EFSA panel was based on the established 
efficacy of phytosterols in lowering LDL-C and the established relation between 
LDL-C and CHD risk. The conditions of use for the approved health claim specify 
that intakes of 1.5-2.4 g/d plant sterols or stanols, incorporated in yellow fat 
spreads, dairy products, mayonnaise or salad dressings, are required to lower LDL-C 
by 7-10% or intakes of 2.5-3.0 g/d plant sterols or stanols to lower LDL-C by 10-
12.5%, within 2-3 weeks
71
. In 2012, the EFSA delivered an opinion stating that plant 
sterols and stanols have similar cholesterol-lowering efficacy at intakes of 1.5-3.0 
g/d
72
. The United States Food and Drug Administration (US FDA)
73
 also approved 
the use of a health claim on phytosterols stating that plant sterol/stanol esters may 
reduce the risk of CHD provided that at least 1.3 g/d of plant sterol esters or 3.4 g/d 
of plant stanol esters is consumed as part of a diet low in saturated fat and 
cholesterol.  
 
The safety of phytosterols was assessed as part of the EU Novel Foods approval 
process. Overall, no safety issues with prolonged intakes of phytosterols were 
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noted by the Scientific Committee on Food (SCF); intakes up to 8% phytosterols per 
100 g spread were considered safe for human use
74
. Phytosterols may, however, 
interfere with the absorption of fat-soluble vitamins, particularly β-carotene
75
. This 
effect on β-carotene, a vitamin A precursor, is not expected by the SCF to have 
health consequences except in situations where vitamin A requirements are 
greater than normal such as in pregnancy, lactation or infancy. Phytosterol-
enriched foods are therefore not nutritionally appropriate for these groups as 
clarified in the EU labeling regulation
76
. Although no numerical upper level of total 
intake could be established, it was concluded by the SCF that a prudent upper level 
of 3 g/d phytosterols should be considered
75
. In a recent post-launch monitoring 
study
58
 in users of phytosterol-enriched foods, it was shown that the daily upper 
intake (95
th
 percentile) of phytosterols at the household level ranged from 1.1 g in 
France up to 3.7 g in the Netherlands. Mean intakes ranged from 0.4 to 0.9 g/d. In 
total, 75-85% of the volume of phytosterol-enriched products was purchased by 1-
2 person households whereas only 1.3-2.5% of the volume was purchased by 
households with children <5 years
58
.  
 
The French Agence nationale de sécurité sanitaire de l'alimentation, de 
l'environnement et du travail (ANSES) recently evaluated the benefits and risks 
relating to the consumption of foods with added phytosterols. In contrast with 
reports from other authoritative bodies, ANSES concluded that, based on the 
available evidence, foods enriched with phytosterols are not appropriate means for 
preventing heart disease
77
. Arguments that were used by ANSES to support their 
conclusion were the increase in blood phytosterol concentrations and the 
reduction in β-carotene concentrations with phytosterol-enriched food intake, the 
observation that some individuals fail to reduce LDL-C with such foods and the 
absence of data from endpoint trials
77
. 
 
Guidelines and recommendations 
The blood cholesterol-lowering properties of phytosterols have been 
acknowledged in recent guidelines by the European Society of Cardiology (ESC) and 
the European Atherosclerosis Society (EAS) for the management of dyslipidemia
78
. 
These guidelines recognize that there are no clinical trial data showing that 
cholesterol-lowering through phytosterol intake prevents CVD. The recent Joint 
British Societies’ guidelines
79
 mention that it is reasonable to postulate a beneficial 
effect on CVD outcomes based on the LDL-C-lowering hypothesis. In the United 
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States, recent guidelines by the American College of Cardiology (ACC) and the 
American Heart Association (AHA) do not explicitly mention the use of phytosterol-
enriched foods for lowering CVD risk
80,81
. These guidelines only considered dietary 
options that have supporting endpoint evidence with emphasize on dietary 
patterns rather than on individual dietary components. For example, for adults who 
would benefit from LDL-C-lowering, a diet that emphasizes vegetables, fruits, 
whole grains, low-fat dairy, lean meat, fish, legumes, nuts and vegetable oils is 
advised, as well as reduced saturated fat and trans fat intakes
80
. 
 
An EAS panel of experts in the field of cholesterol metabolism, phytosterol biology 
and CVD recently concluded that phytosterols may be a useful dietary adjunct for 
people with elevated cholesterol at intermediate or low CVD risk who do not yet 
qualify for drug treatment, for high risk patients who fail to achieve LDL-C targets 
while on drug treatment, and for people with familial hypercholesterolemia
53
. 
Foods with added phytosterols should not be used as a substitute for adopting a 
healthy dietary pattern. Rather, phytosterols may be incorporated in an overall 
healthy diet and lifestyle approach to manage hypercholesterolemia. 
 
For the general population, current dietary guidelines do not include specific 
recommendations on phytosterol intake. Nevertheless, most dietary guidelines 
include the advice to consume more foods of plant origin
82,83
. For example, in the 
Netherlands, consumption of ~200 g/d of vegetables, ~200 g (i.e., two pieces) of 
fruit, and fiber-rich foods are part of the dietary recommendations
84,85
. When 
adhering to these guidelines, the intake of phytosterols will increase up to 0.5-1.0 
g/d.  
 
Recommendations for future research 
Intervention studies 
High intakes of phytosterols lower LDL-C, an established risk factor for CVD, 
particularly CHD. The direct relation between increased phytosterol intake and CVD 
risk has so far not been assessed in randomized controlled trials. Such a trial would 
require a sample size of 36,000-76,000 hypercholesterolemic individuals in primary 
and secondary prevention settings with an expected annual CVD risk level of 3%, 
and follow-up of 6-10 years
53
. Because of challenging practical issues and high 
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costs, it is highly unlikely that such a trial on hard CVD endpoints will be conducted 
in the next decades.  
 
Alternatively, future randomized controlled trials may investigate the effect on CVD 
risk of phytosterol-enriched foods as part of a healthy diet. For example, a 
randomized trial with 7,447 subjects has recently shown that the Mediterranean 
diet reduces the risk of CVD by 30%
61
. Phytosterol-enriched foods have been shown 
to lower LDL-C on top of a healthy diet
65
. A follow-up study may investigate 
whether addition of phytosterol-enriched foods to this Mediterranean diet may 
further improve the health outcome of the subjects. Also, a combination of 
supplemental phytosterols with other LDL-C-lowering foods such as soluble fiber, 
nuts and soy protein could be tested in CVD endpoint studies. This combination, 
known as the Portfolio diet, has been shown to lower LDL-C to a similar extent 
(~30%) as statins
86
. The contribution of phytosterol-enriched foods to this LDL-C-
lowering effect is over one third
87
. As the expected effect on LDL-C and 
subsequently on CVD risk with this diet is ~3 times higher as compared to the effect 
of phytosterols alone, it is expected that such a study would require less than half 
of the subjects as estimated for a randomized controlled trial with phytosterols 
alone
53
. Trials with phytosterols may furthermore focus on markers for CVD risk 
beyond LDL-C-lowering such as measuring progression of intima-media thickness, 
using advanced techniques.  
 
Epidemiological studies 
Future epidemiological studies of long-term CVD risk may focus on populations 
with higher levels and a wider distribution of natural phytosterol intake from 
dietary sources. These studies may include, for example, cohorts with a large 
number of vegetarians or vegans who consume a predominantly plant-based diet, 
or individuals consuming Mediterranean diets. To enable these epidemiological 
studies, food composition tables with extensive information on phytosterol content 
of foods are needed. Only a few food composition tables, e.g. in Finland
88
 and the 
US
89
, contain such detailed information on phytosterol content. To date, the Dutch 
NEVO table is lacking this information
90
. 
 
Other suggestions for epidemiological studies include the prospective investigation 
of CVD events in regular users of foods with added phytosterols compared to non-
users. Such foods have been on the market in Europe and in the US for almost 15 
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years now. Exposure to phytosterol-enriched foods is around 2-6% in the 
Netherlands
4,5,91
. To enable this type of investigation, questions that allow accurate 
assessment of intake of phytosterol-enriched foods need to be incorporated in 
food frequency questionnaires. In cohorts with dietary assessments performed 
before the year 2000, including the EPIC-NL cohort (Chapter 7), this information is 
not available. Investigating phytosterol-enriched food intake in CVD cases vs. 
controls may also provide useful evidence.  
 
Concluding remarks 
In the current thesis, a high intake of phytosterols (i.e., plant sterols and plant 
stanols) with enriched foods was shown to lower LDL-C in a dose-dependent 
manner. Furthermore, a high intake of plant sterols with enriched foods modestly 
lowered TG concentrations and increased plasma plant sterol concentrations. A low 
intake of naturally occurring phytosterols in the general population did not show a 
clear association with CVD risk. Based on these findings, we conclude that the 
intake of phytosterols may be considered in the management of 
hypercholesterolemia. Whether a high intake of phytosterols can play a role in CVD 
prevention in the population at large remains to be established.  
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 Thesis overview 
What was known 
 Dietary plant sterols and plant stanols lower blood LDL-C, but the dose-response relationship for 
this effect has not yet been extensively studied. 
 The maximal LDL-C-lowering effect may be larger for plant stanols than for plant sterols. 
 The intake of plant stanols modestly lowers blood TG concentrations; studies with plant sterols 
were mostly underpowered to detect effects on TGs. 
 The intake of high doses of omega-3 fish fatty acids (2-4 g/d) lowers TG concentrations. 
 The intake of plant sterols results in increased blood concentrations of plant sterols; the size of 
this increase has not yet been systematically investigated. 
 Observational studies with intake of plant sterols or plant stanols and long-term risk of CVD are 
lacking. 
What this thesis adds 
 The LDL-C-lowering effect of plant sterols and stanols is dose-dependent and reaches a plateau at 
doses around 3 g/d. 
 Plant sterols and plant stanols at doses up to 3 g/d are equally effective in lowering blood LDL-C. 
 Not only plant stanols, but also plant sterols modestly lower fasting TG concentrations. 
 Low doses (<2 g/d) of omega-3 fish fatty acids incorporated in a low-fat plant sterol-enriched 
spread lower blood TGs and LDL-C. 
 The intake of foods with added plant sterols increases plasma plant sterol concentrations but 
these remain below 1% of total sterols circulating in the blood. 
 The intakes of plant sterols and stanols from a regular Dutch diet is ~300 mg/d; these low intakes 
are associated with lower LDL-C, but not with a reduced CVD risk.  
Recommendations for future research 
 Randomized controlled trials of supplemental phytosterol intake and hard CVD endpoints are 
lacking and it is uncertain whether such trials will be conducted in the near future; trials on 
surrogate CVD endpoints such as carotid intima-media thickness are warranted. 
 Randomized controlled trials of phytosterol intake as part of the healthy diet or the Portfolio diet 
in relation to CVD risk factors and (surrogate) CVD endpoints are needed. 
 There is a need for long-term epidemiological studies on CVD risk in populations with higher 
levels and wider distributions of phytosterol intake. 
 Dietary assessment methods in epidemiological studies should be adapted to enable studies on 
the association of long-term intake of phytosterol-enriched foods and CVD risk in the general 
population.  
CVD, cardiovascular disease; LDL-C, low-density lipoprotein cholesterol; TG, triglyceride 
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English summary 
Cardiovascular disease (CVD) is the leading cause of morbidity and mortality 
worldwide. Lifestyle improvements including dietary changes are important for 
CVD prevention. This thesis aimed to advance insights in the role of phytosterols, 
lipid-like compounds present in foods or plant origin, in the management of blood 
lipid risk factors for CVD. Phytosterols include plant sterols and their saturated 
form, plant stanols. These compounds resemble cholesterol in both structure and 
function, but cannot be produced by the human body. The intake of phytosterols 
occurs through plant-based foods and/or enriched foods like margarine. 
 
Elevated blood low-density lipoprotein cholesterol (LDL-C) is a major risk factor for 
CVD, especially for coronary heart disease (CHD) resulting from atherosclerosis. We 
studied the dose-response relationship between dietary phytosterols and blood 
LDL-C in two meta-analyses (Chapters 2 and 3). A meta-analysis of 81 randomized 
controlled trials (Chapter 2) demonstrated a non-linear, continuous dose-response 
relationship for the LDL-C-lowering effect of phytosterols. Based on this dose-
response curve, it may be predicted that phytosterols at a dose of 2 g/d lower LDL-
C by 0.35 mmol/L or 9%. The dose-response curve reached a plateau at phytosterol 
doses of ~3 g/d, above which there is limited additional LDL-C-lowering effect. In 
another meta-analysis of 124 randomized controlled trials (Chapter 3), we showed 
that plant sterols and plant stanols up to ~3 g/d are equally effective in lowering 
LDL-C by a maximum of 12%. No conclusions could be drawn for phytosterol doses 
exceeding 4 g/d because of the limited number of studies. 
 
Elevated blood triglycerides (TGs) may also be involved in the onset of CVD, 
although its role is less established than for LDL-C. The effect of plant sterols on 
blood TG concentrations was assessed in a meta-analysis of individual subject data 
from 12 randomized controlled trials (Chapter 4). We showed that plant sterols, at 
a dose of ~2 g/d, modestly reduce TG concentrations by on average 0.12 mmol/L or 
6%. The TG-lowering effect of plant sterols was larger in subjects with higher initial 
TG concentrations. Our double-blind, placebo-controlled, randomized trial with 332 
subjects (Chapter 5) showed more pronounced TG-lowering effects of 9-16% when 
plant sterols (2.5 g/d) were combined with low doses of omega-3 fish fatty acids 
(0.9 to 1.8 g/d).  
 
Dietary phytosterols are, after initial absorption by intestinal cells, actively excreted 
back into the intestinal lumen. Nevertheless, small amounts reach the circulation. 
218 | Summary 
 
We assessed the effect of plant sterol intake on blood plant sterol concentrations 
in a meta-analysis of 41 randomized controlled trials (Chapter 6). The intake of 
plant sterols, at a dose of ~1.6 g/d, increased blood sitosterol concentrations by on 
average 2 µmol/L (31%) and campesterol concentrations by 5 µmol/L (37%). At the 
same time, total cholesterol and LDL-C concentrations were reduced by on average 
0.36 mmol/L (6%) and 0.33 mmol/L (9%), respectively. After supplemental intake, 
plant sterol concentrations remained below 1% of total sterols circulating in the 
blood. 
 
Whether phytosterols, due to their LDL-C-lowering properties, affect the risk of 
CVD events is at present unknown. The relation between phytosterol intake from 
natural sources (e.g. vegetables, cereals, nuts) and CVD risk in the population was 
examined in a large prospective cohort of 35,597 Dutch men and women with 12 
years of follow-up (Chapter 7). The intake of phytosterols from natural sources 
(~300 mg/d) was not related to risk of CVD (total of 3,047 events) with a relative 
risk ranging from 0.90 to 0.99 across quintiles of phytosterol intake. Also, no 
association with incident CHD and myocardial infarction were found. In a cross-
sectional analysis using baseline data of this cohort, phytosterol intake was 
associated with lower blood LDL-C in men (-0.18 mmol/L per 50 mg/d; 95% CI:         
-0.29; -0.08) but not in women (-0.03 mmol/L; 95% CI: -0.08; 0.03).  
 
Most randomized trials with enriched foods have tested phytosterol doses 
between 1.5 and 2.4 g/d. In practice, however, users of such foods consume much 
lower amounts (~1 g/d), which is about 3 times higher than obtained from a regular 
Western diet. Individuals who consume diets with emphasis on plant-based foods 
(e.g. vegetarians) may reach phytosterol intakes between 0.5 and 1 g/d. Health 
authorities recommend various types of diets for CVD prevention, almost all rich in 
plant-based foods and, consequently, relatively rich in phytosterols.  
 
In conclusion, a high intake of phytosterols with enriched foods was shown to 
lower LDL-C in a dose-dependent manner. Furthermore, a high intake of plant 
sterols with enriched foods modestly lowered TG concentrations and increased 
plasma plant sterol concentrations. A low intake of naturally occurring phytosterols 
in the general population did not show a clear association with CVD risk. Based on 
these findings, the intake of phytosterols may be considered in the management of 
hypercholesterolemia. Whether a high intake of phytosterols can play a role in CVD 
prevention in the population at large remains to be established. 
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Hart- en vaatziekten (HVZ) vormen de belangrijkste oorzaak van morbiditeit en 
mortaliteit wereldwijd. Verbeteringen in de levensstijl waaronder veranderingen in 
eetgewoonten, zijn belangrijk voor de preventie van HVZ. Het doel van dit 
proefschrift was om inzicht te verkrijgen in de rol die fytosterolen spelen in het 
beïnvloeden van bepaalde vetten in het bloed die een risico (kunnen) vormen op 
het krijgen van HVZ. Fytosterolen zijn vetachtige verbindingen die aanwezig zijn in 
plantaardig voedsel. Onder de fytosterolen vallen de plantensterolen en hun 
verzadigde vorm, de plantenstanolen. Deze verbindingen lijken op cholesterol in 
zowel structuur als functie, maar kunnen niet worden geproduceerd door het 
menselijk lichaam. Fytosterolen worden geconsumeerd in lage doseringen via 
plantaardig voedsel en/of in hoge doseringen via verrijkte producten zoals in 
sommige margarines. 
 
Een verhoogd cholesterol in lage-dichtheids lipoproteÏnes (LDL-C) is een belangrijke 
risicofactor voor HVZ, in het bijzonder voor coronaire hartziekten, als gevolg van 
aderverkalking. We bestudeerden de dosis-effectrelatie tussen fytosterolen en LDL-
C in het bloed in twee meta-analyses (Hoofdstukken 2 en 3). In een meta-analyse 
van 81 gerandomiseerde, gecontroleerde studies (Hoofdstuk 2) werd er een niet-
lineair, dosisafhankelijk verband gevonden tussen fytosterolinname en LDL-C. Op 
basis van deze relatie kan worden voorspeld dat 2 g/dag fytosterolen het LDL-C-
gehalte met gemiddeld 0,35 mmol/L of 9% verlaagt. Deze dosis-effectrelatie liet 
verder zien dat een inname van meer dan 3 g/dag weinig extra effect geeft. In een 
andere meta-analyse van 124 gerandomiseerde, gecontroleerde studies (Hoofdstuk 
3) werd aangetoond dat plantensterolen en plantenstanolen tot een inname van ~3 
g/dag even effectief zijn in het verlagen van LDL-C. Er konden geen conclusies 
getrokken worden over innamen boven de 4 g/dag omdat er slechts een beperkt 
aantal studies is uitgevoerd met dergelijke hoge innamen. 
 
Een verhoogd triglyceriden (TG)-gehalte in het bloed is mogelijk ook een 
risicofactor voor HVZ. Het effect van plantensterolen op het TG-gehalte in het 
bloed werd onderzocht in een meta-analyse van 12 gerandomiseerde, 
gecontroleerde studies waarvan data van individuele proefpersonen beschikbaar 
waren (Hoofdstuk 4). We toonden aan dat een inname van ~2 g/dag 
plantensterolen het TG-gehalte met gemiddeld 0,12 mmol/L of 6% verlaagt. Het 
TG-verlagende effect van plantensterolen bleek groter bij proefpersonen met een 
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hoger initieel TG-gehalte. In een dubbelblinde, placebogecontroleerde, 
gerandomiseerde studie met 332 patiënten (Hoofdstuk 5) toonden we aan dat 
grotere verlagingen in TG (9-16%) bereikt kunnen worden als plantensterolen (2.5 
g/dag) worden gecombineerd met omega-3 visvetzuren variërend in doseringen 
tussen de 0.9 en 1.8 g/dag. 
 
Fytosterolen worden over het algemeen, na opname via de darmwand, weer 
uitgescheiden in het darmkanaal. Toch komen er kleine hoeveelheden in de 
bloedsomloop terecht. De mate waarin het gehalte van plantensterolen in het 
bloed toeneemt na inneming van plantensterolen werd onderzocht in een meta-
analyse van 41 gerandomiseerde, gecontroleerde studies (Hoofdstuk 6). De inname 
van ~1.6 g/dag plantensterolen bleek het sitosterolgehalte in het bloed te verhogen 
met gemiddeld 2 µmol/L (31%) en het campesterolgehalte met gemiddeld 5 µmol/L 
(37%). Tegelijkertijd werden de gehaltes van totaal cholesterol en LDL-C verlaagd 
met respectievelijk 0.36 mmol/L (6%) en 0.33 mmol/L (9%). Na hoge inname van 
plantensterolen bedroegen de plantensterolgehaltes minder dan 1% van alle 
sterolen die in het bloed circuleren. 
 
Het is niet zeker of fytosterolen het risico op HVZ kunnen beïnvloeden. De relatie 
tussen fytosterolinname uit natuurlijke bronnen (zoals groenten, granen en noten) 
en het risico op HVZ werd onderzocht in een populatie van 35.597 Nederlandse 
mannen en vrouwen die 12 jaar werden gevolgd (Hoofdstuk 7). In totaal werden er 
3.047 nieuwe gevallen van HVZ geconstateerd. De inname van fytosterolen uit 
natuurlijke bronnen (gemiddeld 300 mg/dag) hield geen verband met het risico op 
HVZ. Het risico van groepen met toenemende innamen van fytosterolen ten 
opzichte van de groep met de laagste fytosterolinname varieerde tussen 0.90 en 
0.99. Ook werd er geen significant verband gevonden met coronaire hartziekten of 
acute hartinfarcten. In een cross-sectionele analyse werd een omgekeerd verband 
waargenomen tussen fytosterolinname en LDL-C voor mannen (-0.18 mmol/L per 
50 mg/dag) maar niet voor vrouwen (-0.03 mmol/L per 50 mg/dag). 
 
In de meeste gerandomiseerde studies met fytosterolen van verrijkte 
voedingsmiddelen zijn doseringen getest tussen de 1.5 en 2.4 g/dag. In de praktijk 
consumeren de gebruikers van dit soort voedingsmiddelen echter lagere 
hoeveelheden (~1 g/dag fytosterolen). Dit is ongeveer drie keer de hoeveelheid die 
van nature in onze dagelijkse voeding aanwezig is. Mensen die voornamelijk 
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plantaardige voeding eten (bijvoorbeeld vegetariërs) kunnen over het algemeen 
hogere fytosterolinnamen van 0.5 tot 1.0 g/dag bereiken. Gezondheidsautoriteiten 
adviseren over het algemeen diëten die rijk zijn aan plantaardig voedsel, waarin 
ook veel fytosterolen voorkomen, ten behoeve van HVZ preventie. 
 
Samengevat kan gesteld worden dat een hoge inname van fytosterolen via verrijkte 
voedingsmiddelen het LDL-C-gehalte in het bloed verlaagt. Verder kan een hoge 
inname van plantensterolen het TG gehalte iets verlagen en het gehalte 
plantensterolen in het bloed verhogen. Een lage inname van fytosterolen uit 
natuurlijke bronnen blijkt vooralsnog niet geassocieerd te zijn met het risico op 
HVZ. Of fytosterolen daadwerkelijk een rol kunnen spelen in de preventie van HVZ 
in de algemene bevolking moet nog definitief worden vastgesteld.  
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